Copyright    GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on:     November  2, 2005, 09:35:31 ; Search time 164 Seconds
                                        (without alignments)
                                        10.196 Million cell updates/sec

Title:              US-10-618-856-1
Perfect score:      24
Sequence:           1 EFRH 4

Scoring table:      BLOSUM62
                    Gapop 10.0 , Gapext 0.5

Searched:           165214 seqs, 41804040 residues

Total number of hits satisfying chosen parameters:        230398

Minimum DB seq length: 4
Maximum DB seq length: 10

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 100 summaries

Database :    Published Applications AA:*
         1:  /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
         2:  /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*
         3:  /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
         4:  /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*
         5:  /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
         6:  /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*
         7:  /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
         8:  /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
         9:  /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:*
        10:  /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:*
        11:  /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*
        12:  /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
        13:  /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*
        14:  /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*
        15:  /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*
        16:  /cgn2_6/ptodata/2/pubpaa/US10D_PUBCOMB.pep:*
        17:  /cgn2_6/ptodata/2/pubpaa/US10E_PUBCOMB.pep:*
        18:  /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
        19:  /cgn2_6/ptodata/2/pubpaa/US11A_PUBCOMB.pep:*
        20:  /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep:*
        21:  /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
        22:  /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

SUMMARIES

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

| Result No. | Score | % Query Match | Length | DB | ID | Description |
|---|---|---|---|---|---|---|
| 1 | 24 | 100.0 | 4 | 9 | US-09-808-037-1 | Sequence 1, Appli |
| 2 | 24 | 100.0 | 4 | 9 | US-09-975-932-8 | Sequence 8, Appli |
| 3 | 24 | 100.0 | 4 | 14 | US-10-084-380A-8 | Sequence 8, Appli |
| 4 | 24 | 100.0 | 4 | 14 | US-10-162-889-1 | Sequence 1, Appli |
| 5 | 24 | 100.0 | 4 | 15 | US-10-384-788-1 | Sequence 1, Appli |
| 6 | 24 | 100.0 | 4 | 15 | US-10-618-856-1 | Sequence 1, Appli |
| 7 | 24 | 100.0 | 4 | 17 | US-10-481-642-5 | Sequence 5, Appli |
| 8 | 24 | 100.0 | 4 | 17 | US-10-749-522-1 | Sequence 1, Appli |
| 9 | 24 | 100.0 | 4 | 18 | US-10-625-854-27 | Sequence 27, Appli |
| 10 | 24 | 100.0 | 4 | 20 | US-11-073-526-1 | Sequence 1, Appli |
| 11 | 24 | 100.0 | 5 | 18 | US-10-505-313-287 | Sequence 287, App |

| | Score | % | DB length | ID | Seq | | Description |
|---|---|---|---|---|---|---|---|
| 12 | 24 | 100.0 | 18 | US-10-625-854-15 | 5 | | Sequence 15, Appl |
| 13 | 24 | 100.0 | 18 | US-10-625-854-28 | 5 | | Sequence 28, Appl |
| 14 | 24 | 100.0 | 9 | US-09-808-037-7 | 6 | | Sequence 7, Appli |
| 15 | 24 | 100.0 | 9 | US-09-975-932-6 | 6 | | Sequence 6, Appli |
| 16 | 24 | 100.0 | 14 | US-10-084-380A-6 | 6 | | Sequence 6, Appli |
| 17 | 24 | 100.0 | 15 | US-10-162-889-7 | 6 | | Sequence 7, Appli |
| 18 | 24 | 100.0 | 15 | US-10-384-788-7 | 6 | | Sequence 7, Appli |
| 19 | 24 | 100.0 | 16 | US-10-618-856-7 | 6 | | Sequence 7, Appli |
| 20 | 24 | 100.0 | 16 | US-10-622-087-75 | 6 | | Sequence 75, Appl |
| 21 | 24 | 100.0 | 16 | US-10-622-087-84 | 6 | | Sequence 84, Appl |
| 22 | 24 | 100.0 | 16 | US-10-622-087-85 | 6 | | Sequence 85, Appl |
| 23 | 24 | 100.0 | 16 | US-10-622-087-88 | 6 | | Sequence 88, Appl |
| 24 | 24 | 100.0 | 16 | US-10-622-087-90 | 6 | | Sequence 90, Appl |
| 25 | 24 | 100.0 | 17 | US-10-749-522-7 | 6 | | Sequence 7, Appli |
| 26 | 24 | 100.0 | 18 | US-10-810-881A-101 | 6 | | Sequence 101, App |
| 27 | 24 | 100.0 | 18 | US-10-810-881A-111 | 6 | | Sequence 111, App |
| 28 | 24 | 100.0 | 18 | US-10-505-313-285 | 6 | | Sequence 285, App |
| 29 | 24 | 100.0 | 18 | US-10-625-854-3 | 6 | | Sequence 3, Appli |
| 30 | 24 | 100.0 | 18 | US-10-625-854-16 | 6 | | Sequence 16, Appl |
| 31 | 24 | 100.0 | 18 | US-10-625-854-29 | 6 | | Sequence 29, Appl |
| 32 | 24 | 100.0 | 18 | US-10-625-854-41 | 6 | | Sequence 41, Appl |
| 33 | 24 | 100.0 | 20 | US-11-073-526-7 | 6 | | Sequence 7, Appli |
| 34 | 24 | 100.0 | 9 | US-09-867-847-5 | 7 | | Sequence 5, Appli |
| 35 | 24 | 100.0 | 14 | US-10-337-970-8 | 7 | | Sequence 8, Appli |
| 36 | 24 | 100.0 | 16 | US-10-481-954-4 | 7 | | Sequence 4, Appli |
| 37 | 24 | 100.0 | 17 | US-10-825-958-5 | 7 | | Sequence 5, Appli |
| 38 | 24 | 100.0 | 18 | US-10-810-881A-100 | 7 | | Sequence 100, App |
| 39 | 24 | 100.0 | 18 | US-10-505-313-256 | 7 | | Sequence 256, App |
| 40 | 24 | 100.0 | 18 | US-10-505-313-257 | 7 | | Sequence 257, App |
| 41 | 24 | 100.0 | 18 | US-10-505-313-286 | 7 | | Sequence 286, App |
| 42 | 24 | 100.0 | 18 | US-10-625-854-4 | 7 | | Sequence 4, Appli |
| 43 | 24 | 100.0 | 18 | US-10-625-854-17 | 7 | | Sequence 17, Appl |
| 44 | 24 | 100.0 | 18 | US-10-625-854-30 | 7 | | Sequence 30, Appl |
| 45 | 24 | 100.0 | 18 | US-10-625-854-42 | 7 | | Sequence 42, Appl |
| 46 | 24 | 100.0 | 18 | US-10-625-854-228 | 7 | | Sequence 228, App |
| 47 | 24 | 100.0 | 9 | US-09-975-932-3 | 8 | | Sequence 3, Appli |
| 48 | 24 | 100.0 | 14 | US-10-084-380A-3 | 8 | | Sequence 3, Appli |
| 49 | 24 | 100.0 | 16 | US-10-343-389A-23 | 8 | | Sequence 23, Appl |
| 50 | 24 | 100.0 | 17 | US-10-481-642-1 | 8 | | Sequence 1, Appli |
| 51 | 24 | 100.0 | 18 | US-10-810-881A-99 | 8 | | Sequence 99, Appl |
| 52 | 24 | 100.0 | 18 | US-10-810-881A-109 | 8 | | Sequence 109, App |
| 53 | 24 | 100.0 | 18 | US-10-625-854-5 | 8 | | Sequence 5, Appli |
| 54 | 24 | 100.0 | 18 | US-10-625-854-18 | 8 | | Sequence 18, Appl |
| 55 | 24 | 100.0 | 18 | US-10-625-854-31 | 8 | | Sequence 31, Appl |
| 56 | 24 | 100.0 | 18 | US-10-625-854-43 | 8 | | Sequence 43, Appl |
| 57 | 24 | 100.0 | 18 | US-10-625-854-229 | 8 | | Sequence 229, App |
| 58 | 24 | 100.0 | 18 | US-10-625-854-238 | 8 | | Sequence 238, App |
| 59 | 24 | 100.0 | 15 | US-10-619-454-16 | 9 | | Sequence 16, Appl |
| 60 | 24 | 100.0 | 15 | US-10-619-454-33 | 9 | | Sequence 33, Appl |
| 61 | 24 | 100.0 | 15 | US-10-619-454-39 | 9 | | Sequence 39, Appl |
| 62 | 24 | 100.0 | 15 | US-10-619-454-44 | 9 | | Sequence 44, Appl |
| 63 | 24 | 100.0 | 15 | US-10-619-454-49 | 9 | | Sequence 49, Appl |
| 64 | 24 | 100.0 | 15 | US-10-619-454-54 | 9 | | Sequence 54, Appl |
| 65 | 24 | 100.0 | 15 | US-10-619-454-63 | 9 | | Sequence 63, Appl |
| 66 | 24 | 100.0 | 15 | US-10-619-454-68 | 9 | | Sequence 68, Appl |
| 67 | 24 | 100.0 | 15 | US-10-619-454-74 | 9 | | Sequence 74, Appl |
| 68 | 24 | 100.0 | 15 | US-10-619-454-75 | 9 | | Sequence 75, Appl |
| 69 | 24 | 100.0 | 15 | US-10-619-454-79 | 9 | | Sequence 79, Appl |
| 70 | 24 | 100.0 | 15 | US-10-619-454-81 | 9 | | Sequence 81, Appl |
| 71 | 24 | 100.0 | 15 | US-10-619-454-85 | 9 | | Sequence 85, Appl |
| 72 | 24 | 100.0 | 15 | US-10-619-454-97 | 9 | | Sequence 97, Appl |
| 73 | 24 | 100.0 | 15 | US-10-619-454-100 | 9 | | Sequence 100, App |
| 74 | 24 | 100.0 | 15 | US-10-619-454-103 | 9 | | Sequence 103, App |
| 75 | 24 | 100.0 | 15 | US-10-619-454-112 | 9 | | Sequence 112, App |
| 76 | 24 | 100.0 | 15 | US-10-619-454-114 | 9 | | Sequence 114, App |
| 77 | 24 | 100.0 | 15 | US-10-619-454-122 | 9 | | Sequence 122, App |
| 78 | 24 | 100.0 | 15 | US-10-619-454-125 | 9 | | Sequence 125, App |
| 79 | 24 | 100.0 | 15 | US-10-619-454-136 | 9 | | Sequence 136, App |
| 80 | 24 | 100.0 | 15 | US-10-619-454-153 | 9 | | Sequence 153, App |
| 81 | 24 | 100.0 | 15 | US-10-619-454-166 | 9 | | Sequence 166, App |
| 82 | 24 | 100.0 | 15 | US-10-619-454-174 | 9 | | Sequence 174, App |
| 83 | 24 | 100.0 | 16 | US-10-622-087-77 | 9 | | Sequence 77, Appl |
| 84 | 24 | 100.0 | 17 | US-10-481-642-2 | 9 | | Sequence 2, Appli |

| | | | | | | |
|---|---|---|---|---|---|---|
| 85 | 24 | 100.0 | 9 | 18 | US-10-810-881A-98 | Sequence 98, Appl |
| 86 | 24 | 100.0 | 9 | 18 | US-10-810-881A-108 | Sequence 108, App |
| 87 | 24 | 100.0 | 9 | 18 | US-10-810-881A-110 | Sequence 110, App |
| 88 | 24 | 100.0 | 9 | 18 | US-10-505-313-1 | Sequence 1, Appli |
| 89 | 24 | 100.0 | 9 | 18 | US-10-625-854-6 | Sequence 6, Appli |
| 90 | 24 | 100.0 | 9 | 18 | US-10-625-854-19 | Sequence 19, Appl |
| 91 | 24 | 100.0 | 9 | 18 | US-10-625-854-32 | Sequence 32, Appl |
| 92 | 24 | 100.0 | 9 | 18 | US-10-625-854-44 | Sequence 44, Appl |
| 93 | 24 | 100.0 | 9 | 18 | US-10-625-854-230 | Sequence 230, App |
| 94 | 24 | 100.0 | 9 | 18 | US-10-625-854-239 | Sequence 239, App |
| 95 | 24 | 100.0 | 9 | 18 | US-10-625-854-247 | Sequence 247, App |
| 96 | 24 | 100.0 | 10 | 18 | US-09-865-294-69 | Sequence 69, Appl |
| 97 | 24 | 100.0 | 10 | 14 | US-10-010-942B-33 | Sequence 33, Appl |
| 98 | 24 | 100.0 | 10 | 15 | US-10-411-544-24 | Sequence 24, Appl |
| 99 | 24 | 100.0 | 10 | 15 | US-10-388-389-33 | Sequence 33, Appl |
| 100 | 24 | 100.0 | 10 | 16 | US-10-703-713-33 | Sequence 33, Appl |

ALIGNMENTS

RESULT 1
US-09-808-037-1
; Sequence 1, Application US/09808037
; Patent No. US20020052311A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR DIAGNOSIS OF
; TITLE OF INVENTION: NEUROLOGICAL DISEASES AND DISORDERS
; FILE REFERENCE: SOLOMON=2D
; CURRENT APPLICATION NUMBER: US/09/808,037
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-09-808-037-1

Query Match             100.0%;  Score 24;  DB 9;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              |||
Db          1 EFRH 4

RESULT 2
US-09-975-932-8
; Sequence 8, Application US/09975932
; Publication No. US20020086847A1
; GENERAL INFORMATION:
; APPLICANT: CHAIN, Daniel G.
; TITLE OF INVENTION: RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,
; TITLE OF INVENTION: DNA ENCODING AND METHODS OF USE THEREOF
; FILE REFERENCE: CHAIN1B
; CURRENT APPLICATION NUMBER: US/09/975,932
; CURRENT FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 09/402,820
; PRIOR FILING DATE: 1999-10-12
; PRIOR APPLICATION NUMBER: PCT/US98/06900
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/041,850
; PRIOR FILING DATE: 1997-04-09
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-975-932-8

Query Match             100.0%;  Score 24;  DB 9;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              |||
Db          1 EFRH 4

RESULT 3
US-10-084-380A-8
; Sequence 8, Application US/10084380A
; Publication No. US20030073655A1
; GENERAL INFORMATION:
; APPLICANT: Mindset Biopharmaceutical Inc.
; APPLICANT: Chain, Daniel G.
; TITLE OF INVENTION: specific antibodies to amyloid beta peptide, pharmaceutical compo
; TITLE OF INVENTION: and methods of use thereof
; FILE REFERENCE: P-4815-US1
; CURRENT APPLICATION NUMBER: US/10/084,380A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/041,850
; PRIOR FILING DATE: 1997-04-09
; PRIOR APPLICATION NUMBER: 09/402,820
; PRIOR FILING DATE: 1999-10-12
; PRIOR APPLICATION NUMBER: pct/us98/06900
; PRIOR FILING DATE: 1998-04-09
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 4
; TYPE: PRT
; ORGANISM: human
US-10-084-380A-8

Query Match             100.0%;  Score 24;  DB 14;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              |||
Db          1 EFRH 4

RESULT 4
US-10-162-889-1
; Sequence 1, Application US/10162889
; Publication No. US20030077252A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME
; TITLE OF INVENTION: USEFUL IN DIAGNOSING
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
; FILE REFERENCE: SOLOMON-2B
; CURRENT APPLICATION NUMBER: US/10/162,889
; CURRENT FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US/09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03

; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-162-889-1

Query Match       100.0%;     Score 24;  DB 14;  Length 4;
Best Local Similarity   100.0%;   Pred. No. 1.7e+06;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    1 EFRH 4

RESULT 5
US-10-384-788-1
; Sequence 1, Application US/10384788
; Publication No. US20040013647A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING A PLAQUE-FORMING DISEASE
; FILE REFERENCE: SOLOMON=2D.2
; CURRENT APPLICATION NUMBER: US/10/384,788
; CURRENT FILING DATE: 2003-03-11
; PRIOR APPLICATION NUMBER: 60/371,735
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 09/808,037
; PRIOR FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/830,954
; PRIOR FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: 10/162,889
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: 60/152,417
; PRIOR FILING DATE: 1999-09-03
; PRIOR APPLICATION NUMBER: PCT/IL00/00518
; PRIOR FILING DATE: 2000-08-31
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-384-788-1

Query Match       100.0%;     Score 24;  DB 15;  Length 4;
Best Local Similarity   100.0%;   Pred. No. 1.7e+06;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    1 EFRH 4

RESULT 6
US-10-618-856-1
; Sequence 1, Application US/10618856
; Publication No. US20040025766A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; TITLE OF INVENTION: IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY TECHNOLOGY

; FILE REFERENCE: SOLOMON=2A
; CURRENT APPLICATION NUMBER: US/10/618,856
; CURRENT FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: US/09/473,653A
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-618-856-1

Query Match       100.0%;     Score 24;  DB 15;  Length 4;
Best Local Similarity   100.0%;   Pred. No. 1.7e+06;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    1 EFRH 4

RESULT 7
US-10-481-642-5
; Sequence 5, Application US/10481642
; Publication No. US2005005375A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; TITLE OF INVENTION: ANTIGENIC PRODUCT DISPLAYING MULTIPLE COPIES OF AN EPITOPE OF A L
; TITLE OF INVENTION: FORMING POLYPEPTIDE INVOLVED IN PLAQUE-FORMING DISEASES AND METH
; TITLE OF INVENTION: USING SAME
; FILE REFERENCE: SOLOMON=4.1A PCT
; CURRENT APPLICATION NUMBER: US/10/481,642
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-481-642-5

Query Match       100.0%;     Score 24;  DB 17;  Length 4;
Best Local Similarity   100.0%;   Pred. No. 1.7e+06;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    1 EFRH 4

RESULT 8
US-10-749-522-1
; Sequence 1, Application US/10749522
; Publication No. US2005008951OA1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIA
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
; FILE REFERENCE: SOLOMON=2B
; CURRENT APPLICATION NUMBER: US/10/749,522
; CURRENT FILING DATE: 2004-01-02
; PRIOR APPLICATION NUMBER: US/09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29

; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-749-522-1

Query Match             100.0%;  Score 24;  DB 17;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 9
US-10-625-854-27
; Sequence 27, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 27
; LENGTH: 4
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-27

Query Match             100.0%;  Score 24;  DB 18;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 10
US-11-073-526-1
; Sequence 1, Application US/11073526
; Publication No. US20050152878A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIAG
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
; FILE REFERENCE: SOLOMON-2C
; CURRENT APPLICATION NUMBER: US/11/073,526
; CURRENT FILING DATE: 2005-03-08
; PRIOR APPLICATION NUMBER: US/09/830,954
; PRIOR FILING DATE: 2001-08-07
; PRIOR APPLICATION NUMBER: PCT/IL00/00518
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31

; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-11-073-526-1

Query Match             100.0%;  Score 24;  DB 20;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 11
US-10-505-313-287
; Sequence 287, Application US/10505313
; Publication No. US20050169925A1
; GENERAL INFORMATION:
; APPLICANT: F. Hoffmann-La Roche AG
; APPLICANT: MorphoSys AG
; TITLE OF INVENTION: Anti A-beta antibodies and their use
; FILE REFERENCE: F 2842 PCT
; CURRENT APPLICATION NUMBER: US/10/505,313
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: EP 02003844.4
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 414
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 287
; LENGTH: 5
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct; peptide 3 A beta
US-10-505-313-287

Query Match             100.0%;  Score 24;  DB 18;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 12
US-10-625-854-15
; Sequence 15, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2

```
; SEQ ID NO 15
; LENGTH: 5
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-15

Query Match    100.0%;   Score 24;   DB 18;   Length 5;
Best Local Similarity   100.0%;   Pred. No. 1.7e+06;
Matches   4;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy    1 EFRH 4
        ||||
Db    2 EFRH 5


RESULT 13
US-10-625-854-28
; Sequence 28, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28
; LENGTH: 5
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-28

Query Match    100.0%;   Score 24;   DB 18;   Length 5;
Best Local Similarity   100.0%;   Pred. No. 1.7e+06;
Matches   4;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy    1 EFRH 4
        ||||
Db    1 EFRH 4


RESULT 14
US-09-808-037-7
; Sequence 7, Application US/09808037
; Patent No. US20020052311A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR DIAGNOSIS OF
; TITLE OF INVENTION: NEUROLOGICAL DISEASES AND DISORDERS
; FILE REFERENCE: SOLOMON=2D
; CURRENT APPLICATION NUMBER: US/09/808,037
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: synthetic peptide
US-09-808-037-7

Query Match    100.0%;   Score 24;   DB 9;   Length 6;
Best Local Similarity   100.0%;   Pred. No. 1.7e+06;
Matches   4;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy    1 EFRH 4
        ||||
Db    3 EFRH 6


RESULT 15
US-09-975-932-6
; Sequence 6, Application US/09975932
; Publication No. US20020086847A1
; GENERAL INFORMATION:
; APPLICANT: CHAIN, Daniel G.
; TITLE OF INVENTION: RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,
; TITLE OF INVENTION: DNA ENCODING AND METHODS OF USE THEREOF
; FILE REFERENCE: CHAIN1B
; CURRENT APPLICATION NUMBER: US/09/975,932
; CURRENT FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 09/402,820
; PRIOR FILING DATE: 1999-10-12
; PRIOR APPLICATION NUMBER: PCT/US98/06900
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/041,850
; PRIOR FILING DATE: 1997-04-09
; NUMBER OF SEQ ID NOS: 8
; SEQ ID NO 6
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-975-932-6

Query Match    100.0%;   Score 24;   DB 9;   Length 6;
Best Local Similarity   100.0%;   Pred. No. 1.7e+06;
Matches   4;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy    1 EFRH 4
        ||||
Db    3 EFRH 6


RESULT 16
US-10-084-380A-6
; Sequence 6, Application US/10084380A
; Publication No. US20030073655A1
; GENERAL INFORMATION:
; APPLICANT: Mindset Biopharmaceutical Inc.
; APPLICANT: Chain, Daniel G.
; TITLE OF INVENTION: specific antibodies to amyloid beta peptide, pharmaceutical compo
; TITLE OF INVENTION: and methods of use thereof
; FILE REFERENCE: P-4815-US1
; CURRENT APPLICATION NUMBER: US/10/084,380A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/041,850
; PRIOR FILING DATE: 1997-04-09
; PRIOR APPLICATION NUMBER: 09/402,820
; PRIOR FILING DATE: 1999-10-12
; PRIOR APPLICATION NUMBER: pct/us98/06900
; PRIOR FILING DATE: 1998-04-09
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 6
; TYPE: PRT
; ORGANISM: human
US-10-084-380A-6

Query Match    100.0%;   Score 24;   DB 14;   Length 6;
```

```
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;  Indels  0;  Gaps  0;
Matches  4;  Conservative  0;  Mismatches  0;

Qy    1 EFRH 4
        ||||
Db    3 EFRH 6

RESULT 17
US-10-162-889-7
; Sequence 7, Application US/10162889
; Publication No. US20030077252A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME
; TITLE OF INVENTION: USEFUL IN DIAGNOSING
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
; FILE REFERENCE: SOLOMON=2B
; CURRENT APPLICATION NUMBER: US/10/162,889
; CURRENT FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US/09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-162-889-7

Query Match        100.0%;  Score 24;  DB 14;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;  Indels  0;  Gaps  0;
Matches  4;  Conservative  0;  Mismatches  0;

Qy    1 EFRH 4
        ||||
Db    3 EFRH 6

RESULT 18
US-10-384-788-7
; Sequence 7, Application US/10384788
; Publication No. US20040013647A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING A PLAQUE-FORMING DISEASE
; FILE REFERENCE: SOLOMON=2D.2
; CURRENT APPLICATION NUMBER: US/10/384,788
; CURRENT FILING DATE: 2003-03-11
; PRIOR APPLICATION NUMBER: 60/371,735
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 09/808,037
; PRIOR FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/830,954
; PRIOR FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: 10/162,889
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: 60/152,417
; PRIOR FILING DATE: 1999-09-03
; PRIOR APPLICATION NUMBER: PCT/IL00/00518
; PRIOR FILING DATE: 2000-08-31

; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-384-788-7

Query Match        100.0%;  Score 24;  DB 15;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;  Indels  0;  Gaps  0;
Matches  4;  Conservative  0;  Mismatches  0;

Qy    1 EFRH 4
        ||||
Db    3 EFRH 6

RESULT 19
US-10-618-856-7
; Sequence 7, Application US/10618856
; Publication No. US20040052766A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; TITLE OF INVENTION: IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY TECHNOLOGY
; FILE REFERENCE: SOLOMON=2A
; CURRENT APPLICATION NUMBER: US/10/618,856
; CURRENT FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: US/09/473,653A
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-618-856-7

Query Match        100.0%;  Score 24;  DB 15;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;  Indels  0;  Gaps  0;
Matches  4;  Conservative  0;  Mismatches  0;

Qy    1 EFRH 4
        ||||
Db    3 EFRH 6

RESULT 20
US-10-622-087-75
; Sequence 75, Application US/10622087
; Publication No. US20040141984A1
; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin F
; APPLICANT: Tissot, Alain
; APPLICANT: Ortmann, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenbiel, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
; FILE REFERENCE: 1700.0350002
; CURRENT APPLICATION NUMBER: US/10/622,087
; CURRENT FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US 60/396,639
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/470,432
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 93
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 75
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-622-087-75

Query Match    100.0%;  Score 24;  DB 16;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy       1 EFRH 4
           |||
Db       3 EFRH 6

RESULT 21
US-10-622-087-84
; Sequence 84, Application US/10622087
; Publication No. US20040141984A1
; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin F
; APPLICANT: Tissot, Alain
; APPLICANT: Ortmann, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenbiel, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
; FILE REFERENCE: 1700.0350002
; CURRENT APPLICATION NUMBER: US/10/622,087
; CURRENT FILING DATE:  2003-07-18
; PRIOR APPLICATION NUMBER: US 60/396,639
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/470,432
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 84
; LENGTH: 6
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-622-087-84

Query Match    100.0%;  Score 24;  DB 16;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy       1 EFRH 4
           |||
Db       3 EFRH 6

RESULT 22
US-10-622-087-85
; Sequence 85, Application US/10622087
; Publication No. US20040141984A1
; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin F
; APPLICANT: Tissot, Alain
; APPLICANT: Ortmann, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenbiel, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
; FILE REFERENCE: 1700.0350002
; CURRENT APPLICATION NUMBER: US/10/622,087
; CURRENT FILING DATE:  2003-07-18
; PRIOR APPLICATION NUMBER: US 60/396,639
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/470,432
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn version 3.2


; SEQ ID NO 85
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Oryctolagus cuniculus
US-10-622-087-85

Query Match    100.0%;  Score 24;  DB 16;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy       1 EFRH 4
           |||
Db       3 EFRH 6

RESULT 23
US-10-622-087-88
; Sequence 88, Application US/10622087
; Publication No. US20040141984A1
; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin F
; APPLICANT: Tissot, Alain
; APPLICANT: Ortmann, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenbiel, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
; FILE REFERENCE: 1700.0350002
; CURRENT APPLICATION NUMBER: US/10/622,087
; CURRENT FILING DATE:  2003-07-18
; PRIOR APPLICATION NUMBER: US 60/396,639
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/470,432
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 88
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Cavia porcellus
US-10-622-087-88

Query Match    100.0%;  Score 24;  DB 16;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy       1 EFRH 4
           |||
Db       3 EFRH 6

RESULT 24
US-10-622-087-90
; Sequence 90, Application US/10622087
; Publication No. US20040141984A1
; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin F
; APPLICANT: Tissot, Alain
; APPLICANT: Ortmann, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenbiel, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
; FILE REFERENCE: 1700.0350002
; CURRENT APPLICATION NUMBER: US/10/622,087
; CURRENT FILING DATE:  2003-07-18
-CURRENT FILING DATE:  2003-07-18
; PRIOR APPLICATION NUMBER: US 60/396,639
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/470,432
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 90
```

; LENGTH: 6
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-622-087-90

Query Match    100.0%;  Score 24;  DB 16;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches  4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    3 EFRH 6

RESULT 25
US-10-749-522-7
; Sequence 7, Application US/10749522
; Publication No. US20050089510A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIAG
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
; FILE REFERENCE: SOLOMON=2B
; CURRENT APPLICATION NUMBER: US/10/749,522
; CURRENT FILING DATE: 2004-01-02
; PRIOR APPLICATION NUMBER: US/09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-749-522-7

Query Match    100.0%;  Score 24;  DB 17;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches  4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    3 EFRH 6

RESULT 26
US-10-810-881A-101
; Sequence 101, Application US/10810881A
; Publication No. US2005012969SA1
; GENERAL INFORMATION:
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
; FILE REFERENCE: CEN5021 NP
; CURRENT APPLICATION NUMBER: US/10/810,881A
; CURRENT FILING DATE: 2004-03-26
; PRIOR APPLICATION NUMBER: US 60/458,474
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,469
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,509
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,510
; PRIOR FILING DATE: 2003-03-28
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 101
; LENGTH: 6

; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PEPTIDE
US-10-810-881A-101

Query Match    100.0%;  Score 24;  DB 18;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches  4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    1 EFRH 4

RESULT 27
US-10-810-881A-111
; Sequence 111, Application US/10810881A
; Publication No. US2005012969SA1
; GENERAL INFORMATION:
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
; FILE REFERENCE: CEN5021 NP
; CURRENT APPLICATION NUMBER: US/10/810,881A
; CURRENT FILING DATE: 2004-03-26
; PRIOR APPLICATION NUMBER: US 60/458,474
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,469
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,509
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,510
; PRIOR FILING DATE: 2003-03-28
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 111
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PEPTIDE
US-10-810-881A-111

Query Match    100.0%;  Score 24;  DB 18;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches  4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    2 EFRH 5

RESULT 28
US-10-505-313-285
; Sequence 285, Application US/10505313
; Publication No. US2005016992SA1
; GENERAL INFORMATION:
; APPLICANT: F. Hoffmann-La Roche AG
; APPLICANT: MorphoSys AG
; TITLE OF INVENTION: Anti A-beta antibodies and their use
; FILE REFERENCE: F 2842 PCT
; CURRENT APPLICATION NUMBER: US/10/505,313
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: EP 02003844.4
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 414
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 285
; LENGTH: 6
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct; peptide 1 A beta

```
US-10-505-313-285

Query Match             100.0%;  Score 24;  DB 18;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 29
US-10-625-854-3
; Sequence 3, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
;   APPLICANT: Delacourte, Andr
;   APPLICANT: Sergeant, Nicolas
;   TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;   TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;   FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;   CURRENT APPLICATION NUMBER: US/10/625,854
;   CURRENT FILING DATE: 2003-07-23
;   PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;   PRIOR FILING DATE: 2002-07-24
;   PRIOR APPLICATION NUMBER: 60/401,497
;   PRIOR FILING DATE: 2002-08-06
;   NUMBER OF SEQ ID NOS: 261
;   SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: homo sapiens
US-10-625-854-3

Query Match             100.0%;  Score 24;  DB 18;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 30
US-10-625-854-16
; Sequence 16, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
;   APPLICANT: Delacourte, Andr
;   APPLICANT: Sergeant, Nicolas
;   TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;   TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;   FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;   CURRENT APPLICATION NUMBER: US/10/625,854
;   CURRENT FILING DATE: 2003-07-23
;   PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;   PRIOR FILING DATE: 2002-07-24
;   PRIOR APPLICATION NUMBER: 60/401,497
;   PRIOR FILING DATE: 2002-08-06
;   NUMBER OF SEQ ID NOS: 261
;   SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: homo sapiens
US-10-625-854-16

Query Match             100.0%;  Score 24;  DB 18;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
```

```
Db          2 EFRH 5

RESULT 31
US-10-625-854-29
; Sequence 29, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
;   APPLICANT: Delacourte, Andr
;   APPLICANT: Sergeant, Nicolas
;   TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;   TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;   FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;   CURRENT APPLICATION NUMBER: US/10/625,854
;   CURRENT FILING DATE: 2003-07-23
;   PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;   PRIOR FILING DATE: 2002-07-24
;   PRIOR APPLICATION NUMBER: 60/401,497
;   PRIOR FILING DATE: 2002-08-06
;   NUMBER OF SEQ ID NOS: 261
;   SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: homo sapiens
US-10-625-854-29

Query Match             100.0%;  Score 24;  DB 18;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 32
US-10-625-854-41
; Sequence 41, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
;   APPLICANT: Delacourte, Andr
;   APPLICANT: Sergeant, Nicolas
;   TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;   TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;   FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;   CURRENT APPLICATION NUMBER: US/10/625,854
;   CURRENT FILING DATE: 2003-07-23
;   PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;   PRIOR FILING DATE: 2002-07-24
;   PRIOR APPLICATION NUMBER: 60/401,497
;   PRIOR FILING DATE: 2002-08-06
;   NUMBER OF SEQ ID NOS: 261
;   SOFTWARE: PatentIn version 3.2
; SEQ ID NO 41
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: homo sapiens
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: Xaa represents pyroglutamate
US-10-625-854-41

Query Match             100.0%;  Score 24;  DB 18;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5
```

RESULT 33
US-11-073-526-7
; Sequence 7, Application US/11073526
; Publication No. US2005152878A1
; GENERAL INFORMATION:
;   APPLICANT: SOLOMON, Beka
;   APPLICANT: FRENKEL, Dan
;   APPLICANT: HANAN, Eilat
;   TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIAG
;   TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
;   FILE REFERENCE: SOLOMON=2C
;   CURRENT APPLICATION NUMBER: US/11/073,526
;   CURRENT FILING DATE: 2005-03-08
;   PRIOR APPLICATION NUMBER: US/09/830,954
;   PRIOR FILING DATE: 2001-08-07
;   PRIOR APPLICATION NUMBER: PCT/IL00/00518
;   PRIOR FILING DATE: 2000-08-31
;   PRIOR APPLICATION NUMBER: 09/629,971
;   PRIOR FILING DATE: 2000-07-31
;   PRIOR APPLICATION NUMBER: US 09/473,653
;   PRIOR FILING DATE: 1999-12-29
;   PRIOR APPLICATION NUMBER: US 60/152,417
;   PRIOR FILING DATE: 1999-09-03
;   NUMBER OF SEQ ID NOS: 29
;   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic peptide
US-11-073-526-7

  Query Match             100.0%;  Score 24;  DB 20;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 34
US-09-867-847-5
; Sequence 5, Application US/09867847
; Patent No. US2002009435A1
; GENERAL INFORMATION:
;   APPLICANT: Chalifour, Robert
;   APPLICANT: Hebert, Lise
;   APPLICANT: Kong, Xianqi
;   APPLICANT: Gervais, Francine
;   TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S
;   TITLE OF INVENTION: AND AMYLOID RELATED DISEASES
;   FILE REFERENCE: 14445-501 CIP
;   CURRENT APPLICATION NUMBER: US/09/867,847
;   CURRENT FILING DATE: 2001-09-20
;   PRIOR APPLICATION NUMBER: 60/168,594
;   PRIOR FILING DATE: 1999-11-29
;   PRIOR APPLICATION NUMBER: 09/724,842
;   PRIOR FILING DATE: 2000-11-28
;   NUMBER OF SEQ ID NOS: 65
;   SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: All D peptides
;   OTHER INFORMATION: or peptidomimetics
US-09-867-847-5

  Query Match             100.0%;  Score 24;  DB 9;  Length 7;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 35
US-10-337-970-8
; Sequence 8, Application US/10337970
; Publication No. US2003014835A1
; GENERAL INFORMATION:
;   APPLICANT: Cruts, Marc
;   APPLICANT: De Jonghe, Chris
;   APPLICANT: Singh, Samir Kumar
;   APPLICANT: Van Broeckhoven, Christine Kumar
;   TITLE OF INVENTION: A NOVEL APP MUTATION ASSOCIATED WITH AN UNUSUAL ALZHEIMER'S DISEA
;   TITLE OF INVENTION: PATHOLOGY
;   FILE REFERENCE: 2183-5642US
;   CURRENT APPLICATION NUMBER: US/10/337,970
;   CURRENT FILING DATE: 2003-01-06
;   NUMBER OF SEQ ID NOS: 8
;   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic peptide corresponding to amyloid beta peptide residues
;   OTHER INFORMATION: 1-7
US-10-337-970-8

  Query Match             100.0%;  Score 24;  DB 14;  Length 7;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 36
US-10-481-954-4
; Sequence 4, Application US/10481954
; Publication No. US2004025364A1
; GENERAL INFORMATION:
;   APPLICANT: New York State Office of Mental Health
;   TITLE OF INVENTION: Cell-based High Throughput Screening Methods
;   FILE REFERENCE: 1079-4014PC
;   CURRENT APPLICATION NUMBER: US/10/481,954
;   CURRENT FILING DATE: 2003-12-23
;   PRIOR APPLICATION NUMBER: US 60/300,959
;   PRIOR FILING DATE: 2001-06-26
;   NUMBER OF SEQ ID NOS: 5
;   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic peptide containing epitope for JRF/ABN/25 antibody.
US-10-481-954-4

  Query Match             100.0%;  Score 24;  DB 16;  Length 7;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 37
US-10-825-958-5
; Sequence 5, Application US/10825958
; Publication No. US2005090439A1
; GENERAL INFORMATION:
; APPLICANT: Chalifour, Robert
; APPLICANT: Hebert, Lise
; APPLICANT: Kong, Xianqi
; APPLICANT: Gervais, Francine
; TITLE OF INVENTION: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S
; TITLE OF INVENTION: AND AMYLOID RELATED DISEASES
; FILE REFERENCE: 50291/004002
; CURRENT APPLICATION NUMBER: US/10/825,958
; CURRENT FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: 09/724,842
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 60/168,594
; PRIOR FILING DATE: 1999-11-29
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: All D peptides
; OTHER INFORMATION: or peptidomimetics
US-10-825-958-5

Query Match        100.0%;  Score 24;  DB 17;  Length 7;
Best Local Similarity 100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            ||||
Db        3 EFRH 6

RESULT 38
US-10-810-881A-100
; Sequence 100, Application US/10810881A
; Publication No. US2005012965A1
; GENERAL INFORMATION:
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
; FILE REFERENCE: CEN5021 NP
; CURRENT APPLICATION NUMBER: US/10/810,881A
; CURRENT FILING DATE: 2004-03-26
; PRIOR APPLICATION NUMBER: US 60/458,474
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,469
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,509
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,510
; PRIOR FILING DATE: 2003-03-28
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 100
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PEPTIDE
US-10-810-881A-100

Query Match        100.0%;  Score 24;  DB 18;  Length 7;
Best Local Similarity 100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            ||||
Db        1 EFRH 4

RESULT 39
US-10-505-313-256
; Sequence 256, Application US/10505313
; Publication No. US2005016992SA1
; GENERAL INFORMATION:
; APPLICANT: F. Hoffmann-La Roche AG
; APPLICANT: MorphoSys AG
; TITLE OF INVENTION: Anti A-beta antibodies and their use
; FILE REFERENCE: F 2842 PCT
; CURRENT APPLICATION NUMBER: US/10/505,313
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: EP 02003844.4
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 414
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 256
; LENGTH: 7
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct
US-10-505-313-256

Query Match        100.0%;  Score 24;  DB 18;  Length 7;
Best Local Similarity 100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            ||||
Db        2 EFRH 5

RESULT 40
US-10-505-313-257
; Sequence 257, Application US/10505313
; Publication No. US2005016992SA1
; GENERAL INFORMATION:
; APPLICANT: F. Hoffmann-La Roche AG
; APPLICANT: MorphoSys AG
; TITLE OF INVENTION: Anti A-beta antibodies and their use
; FILE REFERENCE: F 2842 PCT
; CURRENT APPLICATION NUMBER: US/10/505,313
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: EP 02003844.4
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 414
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 257
; LENGTH: 7
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct
US-10-505-313-257

Query Match        100.0%;  Score 24;  DB 18;  Length 7;
Best Local Similarity 100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            ||||
Db        1 EFRH 4

RESULT 41
US-10-505-313-286
; Sequence 286, Application US/10505313
; Publication No. US2005016992SA1
; GENERAL INFORMATION:
; APPLICANT: F. Hoffmann-La Roche AG
; APPLICANT: MorphoSys AG

```
;    TITLE OF INVENTION: Anti A-beta antibodies and their use
;    FILE REFERENCE: F 2842 PCT
;    CURRENT APPLICATION NUMBER: US/10/505,313
;    CURRENT FILING DATE: 2004-08-20
;    PRIOR APPLICATION NUMBER: EP 02003844.4
;    PRIOR FILING DATE: 2002-02-20
;    NUMBER OF SEQ ID NOS: 414
;    SOFTWARE: PatentIn version 3.1
;    SEQ ID NO 286
;    LENGTH: 7
;    TYPE: PRT
;    ORGANISM: artificial sequence
;    FEATURE:
;    OTHER INFORMATION: synthetic construct; peptide 2 A beta
US-10-505-313-286

Query Match             100.0%;  Score 24;  DB 18;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4


RESULT 42
US-10-625-854-4
;  Sequence 4, Application US/10625854
;  Publication No. US20050175626A1
;  GENERAL INFORMATION:
;    APPLICANT: Delacourte, Andr
;    APPLICANT:  Sergeant, Nicolas
;    TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;    TITLE OF INVENTION:  beta-amyloid formation and/or aggregation
;    FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;    CURRENT APPLICATION NUMBER: US/10/625,854
;    CURRENT FILING DATE: 2003-07-23
;    PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;    PRIOR FILING DATE: 2002-07-24
;    PRIOR APPLICATION NUMBER: 60/401,497
;    PRIOR FILING DATE: 2002-08-06
;    NUMBER OF SEQ ID NOS: 261
;    SOFTWARE: PatentIn version 3.2
;    SEQ ID NO 4
;    LENGTH: 7
;    TYPE: PRT
;    ORGANISM: homo sapiens
US-10-625-854-4

Query Match             100.0%;  Score 24;  DB 18;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6


RESULT 43
US-10-625-854-17
;  Sequence 17, Application US/10625854
;  Publication No. US20050175626A1
;  GENERAL INFORMATION:
;    APPLICANT: Delacourte, Andr
;    APPLICANT:  Sergeant, Nicolas
;    TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;    TITLE OF INVENTION:  beta-amyloid formation and/or aggregation
;    FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;    CURRENT APPLICATION NUMBER: US/10/625,854
;    CURRENT FILING DATE: 2003-07-23
;    PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;    PRIOR FILING DATE: 2002-07-24
;    PRIOR APPLICATION NUMBER: 60/401,497
```

```
;    PRIOR FILING DATE: 2002-08-06
;    NUMBER OF SEQ ID NOS: 261
;    SOFTWARE: PatentIn version 3.2
;    SEQ ID NO 17
;    LENGTH: 7
;    TYPE: PRT
;    ORGANISM: homo sapiens
US-10-625-854-17

Query Match             100.0%;  Score 24;  DB 18;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5


RESULT 44
US-10-625-854-30
;  Sequence 30, Application US/10625854
;  Publication No. US20050175626A1
;  GENERAL INFORMATION:
;    APPLICANT: Delacourte, Andr
;    APPLICANT:  Sergeant, Nicolas
;    TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;    TITLE OF INVENTION:  beta-amyloid formation and/or aggregation
;    FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;    CURRENT APPLICATION NUMBER: US/10/625,854
;    CURRENT FILING DATE: 2003-07-23
;    PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;    PRIOR FILING DATE: 2002-07-24
;    PRIOR APPLICATION NUMBER: 60/401,497
;    PRIOR FILING DATE: 2002-08-06
;    NUMBER OF SEQ ID NOS: 261
;    SOFTWARE: PatentIn version 3.2
;    SEQ ID NO 30
;    LENGTH: 7
;    TYPE: PRT
;    ORGANISM: homo sapiens
US-10-625-854-30

Query Match             100.0%;  Score 24;  DB 18;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4


RESULT 45
US-10-625-854-42
;  Sequence 42, Application US/10625854
;  Publication No. US20050175626A1
;  GENERAL INFORMATION:
;    APPLICANT: Delacourte, Andr
;    APPLICANT:  Sergeant, Nicolas
;    TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;    TITLE OF INVENTION:  beta-amyloid formation and/or aggregation
;    FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;    CURRENT APPLICATION NUMBER: US/10/625,854
;    CURRENT FILING DATE: 2003-07-23
;    PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;    PRIOR FILING DATE: 2002-07-24
;    PRIOR APPLICATION NUMBER: 60/401,497
;    PRIOR FILING DATE: 2002-08-06
;    NUMBER OF SEQ ID NOS: 261
;    SOFTWARE: PatentIn version 3.2
;    SEQ ID NO 42
;    LENGTH: 7
;    TYPE: PRT
;    ORGANISM: homo sapiens
```

```
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: Xaa represents pyroglutamate
US-10-625-854-42

  Query Match       100.0%;  Score 24;  DB 18;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5


RESULT 46
US-10-625-854-228
;   Sequence 228, Application US/10625854
;   Publication No. US2005017562GA1
;   GENERAL INFORMATION:
;   APPLICANT: Delacourte, Andr
;   APPLICANT: Sergeant, Nicolas
;   TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;   TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;   FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;   CURRENT APPLICATION NUMBER: US/10/625,854
;   CURRENT FILING DATE:  2003-07-24
;   PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;   PRIOR FILING DATE: 2002-07-24
;   PRIOR APPLICATION NUMBER: 60/401,497
;   PRIOR FILING DATE: 2002-08-06
;   NUMBER OF SEQ ID NOS: 261
;   SOFTWARE: PatentIn version 3.2
;   SEQ ID NO 228
;     LENGTH: 7
;     TYPE: PRT
;     ORGANISM: homo sapiens
US-10-625-854-228

  Query Match       100.0%;  Score 24;  DB 18;  Length 7;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          4 EFRH 7


RESULT 47
US-09-975-932-3
;   Sequence 3, Application US/09975932
;   Publication No. US2002008647A1
;   GENERAL INFORMATION:
;   APPLICANT: CHAIN, Daniel G.
;   TITLE OF INVENTION: RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,
;   TITLE OF INVENTION: DNA ENCODING AND METHODS OF USE THEREOF
;   FILE REFERENCE: CHAIN1B
;   CURRENT APPLICATION NUMBER: US/09/975,932
;   CURRENT FILING DATE:  2001-10-15
;   PRIOR APPLICATION NUMBER: 09/402,820
;   PRIOR FILING DATE: 1999-10-12
;   PRIOR APPLICATION NUMBER: PCT/US98/06900
;   PRIOR FILING DATE: 1998-04-09
;   PRIOR APPLICATION NUMBER: 60/041,850
;   PRIOR FILING DATE: 1997-04-09
;   NUMBER OF SEQ ID NOS: 8
;   SOFTWARE: PatentIn Ver. 2.0
;   SEQ ID NO 3
;     LENGTH: 8
;     TYPE: PRT
;     ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: HUMAN PEPTIDE
```

```
;   OTHER INFORMATION: WITH ARTIFICIAL TERMINAL CYSTEINE RESIDUE
US-09-975-932-3

  Query Match       100.0%;  Score 24;  DB 9;  Length 8;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6


RESULT 48
US-10-084-380A-3
;   Sequence 3, Application US/10084380A
;   Publication No. US20030073655A1
;   GENERAL INFORMATION:
;   APPLICANT: Mindset Biopharmaceutical Inc.
;   APPLICANT: Chain, Daniel G.
;   TITLE OF INVENTION: specific antibodies to amyloid beta peptide, pharmaceutical compo
;   TITLE OF INVENTION: and methods of use thereof
;   FILE REFERENCE: P-4815-US1
;   CURRENT APPLICATION NUMBER: US/10/084,380A
;   CURRENT FILING DATE:  2002-02-28
;   PRIOR APPLICATION NUMBER: 60/041,850
;   PRIOR FILING DATE: 1997-04-09
;   PRIOR APPLICATION NUMBER: 09/402,820
;   PRIOR FILING DATE: 1999-10-12
;   PRIOR APPLICATION NUMBER: pct/us98/06900
;   PRIOR FILING DATE: 1998-04-09
;   NUMBER OF SEQ ID NOS: 13
;   SOFTWARE: PatentIn version 3.1
;   SEQ ID NO 3
;     LENGTH: 8
;     TYPE: PRT
;     ORGANISM: human
US-10-084-380A-3

  Query Match       100.0%;  Score 24;  DB 14;  Length 8;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6


RESULT 49
US-10-343-389A-23
;   Sequence 23, Application US/10343389A
;   Publication No. US2004180417A1
;   GENERAL INFORMATION:
;   APPLICANT: SEIDAH, NABIL G.
;   APPLICANT: CHRETIEN, MICHEL
;   APPLICANT: CROMLISH, JAMES A.
;   TITLE OF INVENTION: SECRETASE/SHEDDASE WITH ASP-ASE ACTIVITY ON THE
;   TITLE OF INVENTION: BETA-SITE APP CLEAVING ENZYME (BACE, ASP2, MEMEPSIN 2)
;   FILE REFERENCE: GOUD:027US
;   CURRENT APPLICATION NUMBER: US/10/343,389A
;   CURRENT FILING DATE:  2003-01-30
;   NUMBER OF SEQ ID NOS: 28
;   SOFTWARE: PatentIn Ver. 2.1
;   SEQ ID NO 23
;     LENGTH: 8
;     TYPE: PRT
;     ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Synthetic
;   OTHER INFORMATION: Peptide
US-10-343-389A-23

  Query Match       100.0%;  Score 24;  DB 16;  Length 8;
  Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
```

Matches        4;  Conservative        0;  Mismatches        0;  Indels        0;  Gaps        0;

Qy      1 EFRH 4
          |||
Db      3 EFRH 6

RESULT 50
US-10-481-642-1
; Sequence 1, Application US/10481642
; Publication No. US2005005375A1
; GENERAL INFORMATION:
;   APPLICANT: SOLOMON, Beka
;   TITLE OF INVENTION: ANTIGENIC PRODUCT DISPLAYING MULTIPLE COPIES OF AN EPITOPE OF A D
;   TITLE OF INVENTION:  FORMING POLYPEPTIDE INVOLVED IN PLAQUE-FORMING DISEASES AND METH
;   TITLE OF INVENTION: USING SAME
;   FILE REFERENCE: SOLOMON=4.1A PCT
;   CURRENT APPLICATION NUMBER: US/10/481,642
;   CURRENT FILING DATE: 2003-12-22
;   NUMBER OF SEQ ID NOS: 7
;   SOFTWARE: PatentIn version 3.1
;   SEQ ID NO 1
;     LENGTH: 8
;     TYPE: PRT
;     ORGANISM: Artificial Sequence
;     FEATURE:
;     OTHER INFORMATION: Synthetic
US-10-481-642-1

Query Match             100.0%;  Score 24;  DB 17;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches        4;  Conservative        0;  Mismatches        0;  Indels        0;  Gaps        0;

Qy      1 EFRH 4
          |||
Db      3 EFRH 6

RESULT 51
US-10-810-881A-99
; Sequence 99, Application US/10810881A
; Publication No. US2005012969SA1
; GENERAL INFORMATION:
;   APPLICANT: Mercken, Marc; Benson, Jacqueline M.
;   TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
;   FILE REFERENCE: CEN5021 NP
;   CURRENT APPLICATION NUMBER: US/10/810,881A
;   CURRENT FILING DATE: 2004-03-26
;   PRIOR APPLICATION NUMBER: US 60/458,474
;   PRIOR FILING DATE: 2003-03-28
;   PRIOR APPLICATION NUMBER: US 60/458,469
;   PRIOR FILING DATE: 2003-03-28
;   PRIOR APPLICATION NUMBER: US 60/458,509
;   PRIOR FILING DATE: 2003-03-28
;   PRIOR APPLICATION NUMBER: US 60/458,510
;   PRIOR FILING DATE: 2003-03-28
;   NUMBER OF SEQ ID NOS: 131
;   SOFTWARE: PatentIn version 3.3
;   SEQ ID NO 99
;     LENGTH: 8
;     TYPE: PRT
;     ORGANISM: Artificial
;     FEATURE:
;     OTHER INFORMATION: PEPTIDE
US-10-810-881A-99

Query Match             100.0%;  Score 24;  DB 18;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches        4;  Conservative        0;  Mismatches        0;  Indels        0;  Gaps        0;

Qy      1 EFRH 4
          |||
Db      2 EFRH 5

RESULT 52
US-10-810-881A-109
; Sequence 109, Application US/10810881A
; Publication No. US2005012969SA1
; GENERAL INFORMATION:
;   APPLICANT: Mercken, Marc; Benson, Jacqueline M.
;   TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
;   FILE REFERENCE: CEN5021 NP
;   CURRENT APPLICATION NUMBER: US/10/810,881A
;   CURRENT FILING DATE: 2004-03-26
;   PRIOR APPLICATION NUMBER: US 60/458,474
;   PRIOR FILING DATE: 2003-03-28
;   PRIOR APPLICATION NUMBER: US 60/458,469
;   PRIOR FILING DATE: 2003-03-28
;   PRIOR APPLICATION NUMBER: US 60/458,509
;   PRIOR FILING DATE: 2003-03-28
;   PRIOR APPLICATION NUMBER: US 60/458,510
;   PRIOR FILING DATE: 2003-03-28
;   NUMBER OF SEQ ID NOS: 131
;   SOFTWARE: PatentIn version 3.3
;   SEQ ID NO 109
;     LENGTH: 8
;     TYPE: PRT
;     ORGANISM: Artificial
;     FEATURE:
;     OTHER INFORMATION: PEPTIDE
US-10-810-881A-109

Query Match             100.0%;  Score 24;  DB 18;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches        4;  Conservative        0;  Mismatches        0;  Indels        0;  Gaps        0;

Qy      1 EFRH 4
          |||
Db      2 EFRH 5

RESULT 53
US-10-625-854-5
; Sequence 5, Application US/10625854
; Publication No. US2005017562SA1
; GENERAL INFORMATION:
;   APPLICANT: Delacourte, Andr
;   APPLICANT: Sergeant, Nicolas
;   TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;   TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;   FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;   CURRENT APPLICATION NUMBER: US/10/625,854
;   CURRENT FILING DATE: 2003-07-23
;   PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;   PRIOR FILING DATE: 2002-07-24
;   PRIOR APPLICATION NUMBER: 60/401,497
;   PRIOR FILING DATE: 2002-08-06
;   NUMBER OF SEQ ID NOS: 261
;   SOFTWARE: PatentIn version 3.2
;   SEQ ID NO 5
;     LENGTH: 8
;     TYPE: PRT
;     ORGANISM: homo sapiens
US-10-625-854-5

Query Match             100.0%;  Score 24;  DB 18;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches        4;  Conservative        0;  Mismatches        0;  Indels        0;  Gaps        0;

Qy      1 EFRH 4
          |||
Db      3 EFRH 6

RESULT 54

US-10-625-854-18
; Sequence 18, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
;  APPLICANT: Delacourte, Andr
;  APPLICANT: Sergeant, Nicolas
;  TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;  TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;  FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;  CURRENT APPLICATION NUMBER: US/10/625,854
;  CURRENT FILING DATE: 2003-07-23
;  PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;  PRIOR FILING DATE: 2002-07-24
;  PRIOR APPLICATION NUMBER: 60/401,497
;  PRIOR FILING DATE: 2002-08-06
;  NUMBER OF SEQ ID NOS: 261
;  SOFTWARE: PatentIn version 3.2
;  SEQ ID NO 18
;  LENGTH: 8
;  TYPE: PRT
;  ORGANISM: homo sapiens
US-10-625-854-18

Query Match             100.0%;  Score 24;  DB 18;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 55
US-10-625-854-31
; Sequence 31, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
;  APPLICANT: Delacourte, Andr
;  APPLICANT: Sergeant, Nicolas
;  TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;  TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;  FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;  CURRENT APPLICATION NUMBER: US/10/625,854
;  CURRENT FILING DATE: 2003-07-23
;  PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;  PRIOR FILING DATE: 2002-07-24
;  PRIOR APPLICATION NUMBER: 60/401,497
;  PRIOR FILING DATE: 2002-08-06
;  NUMBER OF SEQ ID NOS: 261
;  SOFTWARE: PatentIn version 3.2
;  SEQ ID NO 31
;  LENGTH: 8
;  TYPE: PRT
;  ORGANISM: homo sapiens
US-10-625-854-31

Query Match             100.0%;  Score 24;  DB 18;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 56
US-10-625-854-43
; Sequence 43, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
;  APPLICANT: Delacourte, Andr
;  APPLICANT: Sergeant, Nicolas
;  TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with

;  TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;  FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;  CURRENT APPLICATION NUMBER: US/10/625,854
;  CURRENT FILING DATE: 2003-07-23
;  PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;  PRIOR FILING DATE: 2002-07-24
;  PRIOR APPLICATION NUMBER: 60/401,497
;  PRIOR FILING DATE: 2002-08-06
;  NUMBER OF SEQ ID NOS: 261
;  SOFTWARE: PatentIn version 3.2
;  SEQ ID NO 43
;  LENGTH: 8
;  TYPE: PRT
;  ORGANISM: homo sapiens
;  FEATURE:
;  NAME/KEY: MISC_FEATURE
;  LOCATION: (1)..(1)
;  OTHER INFORMATION: Xaa represents pyroglutamate
US-10-625-854-43

Query Match             100.0%;  Score 24;  DB 18;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 57
US-10-625-854-229
; Sequence 229, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
;  APPLICANT: Delacourte, Andr
;  APPLICANT: Sergeant, Nicolas
;  TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;  TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;  FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;  CURRENT APPLICATION NUMBER: US/10/625,854
;  CURRENT FILING DATE: 2003-07-23
;  PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;  PRIOR FILING DATE: 2002-07-24
;  PRIOR APPLICATION NUMBER: 60/401,497
;  PRIOR FILING DATE: 2002-08-06
;  NUMBER OF SEQ ID NOS: 261
;  SOFTWARE: PatentIn version 3.2
;  SEQ ID NO 229
;  LENGTH: 8
;  TYPE: PRT
;  ORGANISM: homo sapiens
US-10-625-854-229

Query Match             100.0%;  Score 24;  DB 18;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          5 EFRH 8

RESULT 58
US-10-625-854-238
; Sequence 238, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
;  APPLICANT: Delacourte, Andr
;  APPLICANT: Sergeant, Nicolas
;  TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;  TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;  FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;  CURRENT APPLICATION NUMBER: US/10/625,854

```
    ;   CURRENT FILING DATE:  2003-07-23
    ;   PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
    ;   PRIOR FILING DATE: 2002-07-24
    ;   PRIOR APPLICATION NUMBER: 60/401,497
    ;   PRIOR FILING DATE: 2002-08-06
    ;   NUMBER OF SEQ ID NOS: 261
    ;   SOFTWARE: PatentIn version 3.2
    ;   SEQ ID NO 238
    ;   LENGTH: 8
    ;   TYPE: PRT
    ;   ORGANISM: homo sapiens
US-10-625-854-238

Query Match             100.0%;  Score 24;  DB 18;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          4 EFRH 7

RESULT 59
US-10-619-454-16, Application US/10619454
    ;   Sequence 16, Application US/10619454
    ;   Publication No. US20040091945A1
    ;   GENERAL INFORMATION:
    ;   APPLICANT: Mindset
    ;   APPLICANT:  Fitzer Attas, Cheryl
    ;   APPLICANT:  Chain, Daniel
    ;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
    ;   TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
    ;   FILE REFERENCE: P-5202-US
    ;   CURRENT APPLICATION NUMBER: US/10/619,454
    ;   CURRENT FILING DATE:  2003-07-16
    ;   PRIOR APPLICATION NUMBER: US 60/396,245
    ;   PRIOR FILING DATE: 2002-07-17
    ;   NUMBER OF SEQ ID NOS: 187
    ;   SOFTWARE: PatentIn version 3.1
    ;   SEQ ID NO 16
    ;   LENGTH: 9
    ;   TYPE: PRT
    ;   ORGANISM: artificial sequence
    ;   FEATURE:
    ;   OTHER INFORMATION: algorithm generated
US-10-619-454-16

Query Match             100.0%;  Score 24;  DB 15;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 60
US-10-619-454-33, Application US/10619454
    ;   Sequence 33, Application US/10619454
    ;   Publication No. US20040091945A1
    ;   GENERAL INFORMATION:
    ;   APPLICANT: Mindset
    ;   APPLICANT:  Fitzer Attas, Cheryl
    ;   APPLICANT:  Chain, Daniel
    ;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES ARE REDUCED
    ;   TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
    ;   FILE REFERENCE: P-5202-US
    ;   CURRENT APPLICATION NUMBER: US/10/619,454
    ;   CURRENT FILING DATE:  2003-07-16
    ;   PRIOR APPLICATION NUMBER: US 60/396,245
    ;   PRIOR FILING DATE: 2002-07-17
    ;   NUMBER OF SEQ ID NOS: 187
    ;   SOFTWARE: PatentIn version 3.1
```

```
    ;   SEQ ID NO 33
    ;   LENGTH: 9
    ;   TYPE: PRT
    ;   ORGANISM: artificial sequence
    ;   FEATURE:
    ;   OTHER INFORMATION: algorithm generated
US-10-619-454-33

Query Match             100.0%;  Score 24;  DB 15;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 61
US-10-619-454-39
    ;   Sequence 39, Application US/10619454
    ;   Publication No. US20040091945A1
    ;   GENERAL INFORMATION:
    ;   APPLICANT: Mindset
    ;   APPLICANT:  Fitzer Attas, Cheryl
    ;   APPLICANT:  Chain, Daniel
    ;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
    ;   TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
    ;   FILE REFERENCE: P-5202-US
    ;   CURRENT APPLICATION NUMBER: US/10/619,454
    ;   CURRENT FILING DATE:  2003-07-16
    ;   PRIOR APPLICATION NUMBER: US 60/396,245
    ;   PRIOR FILING DATE: 2002-07-17
    ;   NUMBER OF SEQ ID NOS: 187
    ;   SOFTWARE: PatentIn version 3.1
    ;   SEQ ID NO 39
    ;   LENGTH: 9
    ;   TYPE: PRT
    ;   ORGANISM: artificial sequence
    ;   FEATURE:
    ;   OTHER INFORMATION: algorithm generated
US-10-619-454-39

Query Match             100.0%;  Score 24;  DB 15;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 62
US-10-619-454-44
    ;   Sequence 44, Application US/10619454
    ;   Publication No. US20040091945A1
    ;   GENERAL INFORMATION:
    ;   APPLICANT: Mindset
    ;   APPLICANT:  Fitzer Attas, Cheryl
    ;   APPLICANT:  Chain, Daniel
    ;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
    ;   TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
    ;   FILE REFERENCE: P-5202-US
    ;   CURRENT APPLICATION NUMBER: US/10/619,454
    ;   CURRENT FILING DATE:  2003-07-16
    ;   PRIOR APPLICATION NUMBER: US 60/396,245
    ;   PRIOR FILING DATE: 2002-07-17
    ;   NUMBER OF SEQ ID NOS: 187
    ;   SOFTWARE: PatentIn version 3.1
    ;   SEQ ID NO 44
    ;   LENGTH: 9
    ;   TYPE: PRT
    ;   ORGANISM: artificial sequence
    ;   FEATURE:
```

; OTHER INFORMATION: algorithm generated
US-10-619-454-44

Query Match      100.0%;    Score 24;    DB 15;    Length 9;
Best Local Similarity   100.0%;    Pred. No. 1.7e+06;
Matches      4;    Conservative     0;    Mismatches     0;    Indels     0;    Gaps     0;

Qy        1 EFRH 4
            ||||
Db        2 EFRH 5

RESULT 63
US-10-619-454-49
; Sequence 49, Application US/10619454
; Publication No.US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 49
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-49

Query Match      100.0%;    Score 24;    DB 15;    Length 9;
Best Local Similarity   100.0%;    Pred. No. 1.7e+06;
Matches      4;    Conservative     0;    Mismatches     0;    Indels     0;    Gaps     0;

Qy        1 EFRH 4
            ||||
Db        2 EFRH 5

RESULT 64
US-10-619-454-54
; Sequence 54, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT: Fitzer Attas, Cheryl
; APPLICANT: Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE: 2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 54
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-54

Query Match      100.0%;    Score 24;    DB 15;    Length 9;
Best Local Similarity   100.0%;    Pred. No. 1.7e+06;

Matches      4;    Conservative     0;    Mismatches     0;    Indels     0;    Gaps     0:

Qy        1 EFRH 4
            ||||
Db        2 EFRH 5

RESULT 65
US-10-619-454-63
; Sequence 63, Application US/10619454
; Publication No.US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT:   Fitzer Attas, Cheryl
; APPLICANT:   Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE:  2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 63
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-63

Query Match      100.0%;    Score 24;    DB 15;    Length 9;
Best Local Similarity   100.0%;    Pred. No. 1.7e+06;
Matches      4;    Conservative     0;    Mismatches     0;    Indels     0;    Gaps     0;

Qy        1 EFRH 4
            ||||
Db        2 EFRH 5

RESULT 66
US-10-619-454-68
; Sequence 68, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
; APPLICANT: Mindset
; APPLICANT:   Fitzer Attas, Cheryl
; APPLICANT:   Chain, Daniel
; TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
; TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
; FILE REFERENCE: P-5202-US
; CURRENT APPLICATION NUMBER: US/10/619,454
; CURRENT FILING DATE:  2003-07-16
; PRIOR APPLICATION NUMBER: US 60/396,245
; PRIOR FILING DATE: 2002-07-17
; NUMBER OF SEQ ID NOS: 187
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 68
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: algorithm generated
US-10-619-454-68

Query Match      100.0%;    Score 24;    DB 15;    Length 9;
Best Local Similarity   100.0%;    Pred. No. 1.7e+06;
Matches      4;    Conservative     0;    Mismatches     0;    Indels     0;    Gaps     0;

Qy        1 EFRH 4
            ||||
Db        3 EFRH 6

RESULT 67
US-10-619-454-74
; Sequence 74, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT: Fitzer Attas, Cheryl
;   APPLICANT: Chain, Daniel
;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
;   TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
;   FILE REFERENCE: P-5202-US
;   CURRENT APPLICATION NUMBER: US/10/619,454
;   CURRENT FILING DATE: 2003-07-16
;   PRIOR APPLICATION NUMBER: US 60/396,245
;   PRIOR FILING DATE: 2002-07-17
;   NUMBER OF SEQ ID NOS: 187
;   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 74
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-74

Query Match             100.0%;  Score 24;  DB 15;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          4 EFRH 7

RESULT 68
US-10-619-454-75
; Sequence 75, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT: Fitzer Attas, Cheryl
;   APPLICANT: Chain, Daniel
;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
;   TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
;   FILE REFERENCE: P-5202-US
;   CURRENT APPLICATION NUMBER: US/10/619,454
;   CURRENT FILING DATE: 2003-07-16
;   PRIOR APPLICATION NUMBER: US 60/396,245
;   PRIOR FILING DATE: 2002-07-17
;   NUMBER OF SEQ ID NOS: 187
;   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 75
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-75

Query Match             100.0%;  Score 24;  DB 15;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 69
US-10-619-454-79
; Sequence 79, Application US/10619454

; Publication NO. US20040091945A1
; GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT: Fitzer Attas, Cheryl
;   APPLICANT: Chain, Daniel
;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
;   TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
;   FILE REFERENCE: P-5202-US
;   CURRENT APPLICATION NUMBER: US/10/619,454
;   CURRENT FILING DATE: 2003-07-16
;   PRIOR APPLICATION NUMBER: US 60/396,245
;   PRIOR FILING DATE: 2002-07-17
;   NUMBER OF SEQ ID NOS: 187
;   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 79
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-79

Query Match             100.0%;  Score 24;  DB 15;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 70
US-10-619-454-81
; Sequence 81, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT: Fitzer Attas, Cheryl
;   APPLICANT: Chain, Daniel
;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
;   TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
;   FILE REFERENCE: P-5202-US
;   CURRENT APPLICATION NUMBER: US/10/619,454
;   CURRENT FILING DATE: 2003-07-16
;   PRIOR APPLICATION NUMBER: US 60/396,245
;   PRIOR FILING DATE: 2002-07-17
;   NUMBER OF SEQ ID NOS: 187
;   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 81
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-81

Query Match             100.0%;  Score 24;  DB 15;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          4 EFRH 7

RESULT 71
US-10-619-454-85
; Sequence 85, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT: Fitzer Attas, Cheryl
;   APPLICANT: Chain, Daniel

```
          TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
          TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
          FILE REFERENCE: P-5202-US
          CURRENT APPLICATION NUMBER: US/10/619,454
          CURRENT FILING DATE: 2003-07-16
          PRIOR APPLICATION NUMBER: US 60/396,245
          PRIOR FILING DATE: 2002-07-17
          NUMBER OF SEQ ID NOS: 187
          SOFTWARE: PatentIn version 3.1
          SEQ ID NO 85
          LENGTH: 9
          TYPE: PRT
          ORGANISM: artificial sequence
          FEATURE:
          OTHER INFORMATION: algorithm generated
US-10-619-454-85

Query Match          100.0%;   Score 24;  DB 15;   Length 9;
Best Local Similarity  100.0%;   Pred. No. 1.7e+06;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy   1 EFRH 4
       ||||
Db   2 EFRH 5

RESULT 72
US-10-619-454-97
; Sequence 97, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT: Fitzer Attas, Cheryl
;   APPLICANT: Chain, Daniel
;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
;   TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
;   FILE REFERENCE: P-5202-US
;   CURRENT APPLICATION NUMBER: US/10/619,454
;   CURRENT FILING DATE: 2003-07-16
;   PRIOR APPLICATION NUMBER: US 60/396,245
;   PRIOR FILING DATE: 2002-07-17
;   NUMBER OF SEQ ID NOS: 187
;   SOFTWARE: PatentIn version 3.1
;   SEQ ID NO 97
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-97

Query Match          100.0%;   Score 24;  DB 15;   Length 9;
Best Local Similarity  100.0%;   Pred. No. 1.7e+06;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy   1 EFRH 4
       ||||
Db   2 EFRH 5

RESULT 73
US-10-619-454-100
; Sequence 100, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT: Fitzer Attas, Cheryl
;   APPLICANT: Chain, Daniel
;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
;   TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
;   FILE REFERENCE: P-5202-US
;   CURRENT APPLICATION NUMBER: US/10/619,454
;   CURRENT FILING DATE: 2003-07-16


;   PRIOR APPLICATION NUMBER: US 60/396,245
;   PRIOR FILING DATE: 2002-07-17
;   NUMBER OF SEQ ID NOS: 187
;   SOFTWARE: PatentIn version 3.1
;   SEQ ID NO 100
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-100

Query Match          100.0%;   Score 24;  DB 15;   Length 9;
Best Local Similarity  100.0%;   Pred. No. 1.7e+06;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy   1 EFRH 4
       ||||
Db   2 EFRH 5

RESULT 74
US-10-619-454-103
; Sequence 103, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT: Fitzer Attas, Cheryl
;   APPLICANT: Chain, Daniel
;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
;   TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
;   FILE REFERENCE: P-5202-US
;   CURRENT APPLICATION NUMBER: US/10/619,454
;   CURRENT FILING DATE: 2003-07-16
;   PRIOR APPLICATION NUMBER: US 60/396,245
;   PRIOR FILING DATE: 2002-07-17
;   NUMBER OF SEQ ID NOS: 187
;   SOFTWARE: PatentIn version 3.1
;   SEQ ID NO 103
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-103

Query Match          100.0%;   Score 24;  DB 15;   Length 9;
Best Local Similarity  100.0%;   Pred. No. 1.7e+06;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy   1 EFRH 4
       ||||
Db   3 EFRH 6

RESULT 75
US-10-619-454-112
; Sequence 112, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT: Fitzer Attas, Cheryl
;   APPLICANT: Chain, Daniel
;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
;   TITLE OF INVENTION: AD IN WHICH T-CELL EPITOPES ARE REDUCED
;   FILE REFERENCE: P-5202-US
;   CURRENT APPLICATION NUMBER: US/10/619,454
;   CURRENT FILING DATE: 2003-07-16
;   PRIOR APPLICATION NUMBER: US 60/396,245
;   PRIOR FILING DATE: 2002-07-17
;   NUMBER OF SEQ ID NOS: 187
;   SOFTWARE: PatentIn version 3.1
;   SEQ ID NO 112
```

```
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-112

    Query Match             100.0%;  Score 24;  DB 15;  Length 9;
    Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
    Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5


RESULT 78
US-10-619-454-125
;   Sequence 125, Application US/10619454
;   Publication No. US20040091945A1
;   GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT:  Fitzer Attas, Cheryl
;   APPLICANT:  Chain, Daniel
;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A(
;   TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
;   FILE REFERENCE: P-5202-US
;   CURRENT APPLICATION NUMBER: US/10/619,454
;   CURRENT FILING DATE:  2003-07-16
;   PRIOR APPLICATION NUMBER: US 60/396,245
;   PRIOR FILING DATE: 2002-07-17
;   NUMBER OF SEQ ID NOS: 187
;   SOFTWARE: PatentIn version 3.1
;   SEQ ID NO 125
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-125

    Query Match             100.0%;  Score 24;  DB 15;  Length 9;
    Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
    Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5


RESULT 79
US-10-619-454-136
;   Sequence 136, Application US/10619454
;   Publication No. US20040091945A1
;   GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT:  Fitzer Attas, Cheryl
;   APPLICANT:  Chain, Daniel
;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A(
;   TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
;   FILE REFERENCE: P-5202-US
;   CURRENT APPLICATION NUMBER: US/10/619,454
;   CURRENT FILING DATE:  2003-07-16
;   PRIOR APPLICATION NUMBER: US 60/396,245
;   PRIOR FILING DATE: 2002-07-17
;   NUMBER OF SEQ ID NOS: 187
;   SOFTWARE: PatentIn version 3.1
;   SEQ ID NO 136
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-136

    Query Match             100.0%;  Score 24;  DB 15;  Length 9;
    Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
    Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-112

    Query Match             100.0%;  Score 24;  DB 15;  Length 9;
    Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
    Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6


RESULT 76
US-10-619-454-114
;   Sequence 114, Application US/10619454
;   Publication No. US20040091945A1
;   GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT:  Fitzer Attas, Cheryl
;   APPLICANT:  Chain, Daniel
;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
;   TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
;   FILE REFERENCE: P-5202-US
;   CURRENT APPLICATION NUMBER: US/10/619,454
;   CURRENT FILING DATE:  2003-07-16
;   PRIOR APPLICATION NUMBER: US 60/396,245
;   PRIOR FILING DATE: 2002-07-17
;   NUMBER OF SEQ ID NOS: 187
;   SOFTWARE: PatentIn version 3.1
;   SEQ ID NO 114
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-114

    Query Match             100.0%;  Score 24;  DB 15;  Length 9;
    Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
    Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6


RESULT 77
US-10-619-454-122
;   Sequence 122, Application US/10619454
;   Publication No. US20040091945A1
;   GENERAL INFORMATION:
;   APPLICANT: Mindset
;   APPLICANT:  Fitzer Attas, Cheryl
;   APPLICANT:  Chain, Daniel
;   TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
;   TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
;   FILE REFERENCE: P-5202-US
;   CURRENT APPLICATION NUMBER: US/10/619,454
;   CURRENT FILING DATE:  2003-07-16
;   PRIOR APPLICATION NUMBER: US 60/396,245
;   PRIOR FILING DATE: 2002-07-17
;   NUMBER OF SEQ ID NOS: 187
;   SOFTWARE: PatentIn version 3.1
;   SEQ ID NO 122
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
```

RESULT 80
US-10-619-454-153
; Sequence 153, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
;  APPLICANT: Mindset
;  APPLICANT:  Fitzer Attas, Cheryl
;  APPLICANT:  Chain, Daniel
;  TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
;  TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
;  FILE REFERENCE: P-5202-US
;  CURRENT APPLICATION NUMBER: US/10/619,454
;  CURRENT FILING DATE:  2003-07-16
;  PRIOR APPLICATION NUMBER: US 60/396,245
;  PRIOR FILING DATE: 2002-07-17
;  NUMBER OF SEQ ID NOS: 187
;  SOFTWARE: PatentIn version 3.1
;  SEQ ID NO 153
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-153

Query Match          100.0%;  Score 24;  DB 15;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            ||||
Db        1 EFRH 4

RESULT 81
US-10-619-454-166
; Sequence 166, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
;  APPLICANT: Mindset
;  APPLICANT:  Fitzer Attas, Cheryl
;  APPLICANT:  Chain, Daniel
;  TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES A
;  TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
;  FILE REFERENCE: P-5202-US
;  CURRENT APPLICATION NUMBER: US/10/619,454
;  CURRENT FILING DATE:  2003-07-16
;  PRIOR APPLICATION NUMBER: US 60/396,245
;  PRIOR FILING DATE: 2002-07-17
;  NUMBER OF SEQ ID NOS: 187
;  SOFTWARE: PatentIn version 3.1
;  SEQ ID NO 166
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-166

Query Match          100.0%;  Score 24;  DB 15;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            ||||
Db        2 EFRH 5

RESULT 82
US-10-619-454-174
; Sequence 174, Application US/10619454
; Publication No. US20040091945A1
; GENERAL INFORMATION:
;  APPLICANT: Mindset
;  APPLICANT:  Fitzer Attas, Cheryl
;  APPLICANT:  Chain, Daniel
;  TITLE OF INVENTION: PEPTIDES AND METHODS FOR SCREENING IMMUNOGENIC PEPTIDE VACCINES J
;  TITLE OF INVENTION:  AD IN WHICH T-CELL EPITOPES ARE REDUCED
;  FILE REFERENCE: P-5202-US
;  CURRENT APPLICATION NUMBER: US/10/619,454
;  CURRENT FILING DATE:  2003-07-16
;  PRIOR APPLICATION NUMBER: US 60/396,245
;  PRIOR FILING DATE: 2002-07-17
;  NUMBER OF SEQ ID NOS: 187
;  SOFTWARE: PatentIn version 3.1
;  SEQ ID NO 174
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: algorithm generated
US-10-619-454-174

Query Match          100.0%;  Score 24;  DB 15;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            ||||
Db        6 EFRH 9

RESULT 83
US-10-622-087-77
; Sequence 77, Application US/10622087
; Publication No. US20040141984A1
; GENERAL INFORMATION:
;  APPLICANT: Bachmann, Martin F
;  APPLICANT:  Tissot, Alain
;  APPLICANT:  Ortmann, Rainer
;  APPLICANT:  Luond, Rainer
;  APPLICANT:  Staufenbiel, Matthias
;  APPLICANT:  Frey, Peter
;  TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
;  FILE REFERENCE: 1700.0350002
;  CURRENT APPLICATION NUMBER: US/10/622,087
;  CURRENT FILING DATE:  2003-07-18
;  PRIOR APPLICATION NUMBER: US 60/396,639
;  PRIOR FILING DATE: 2002-07-19
;  PRIOR APPLICATION NUMBER: US 60/470,432
;  PRIOR FILING DATE: 2003-05-15
;  NUMBER OF SEQ ID NOS: 93
;  SOFTWARE: PatentIn version 3.2
;  SEQ ID NO 77
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Abeta 1-6 GGC
US-10-622-087-77

Query Match          100.0%;  Score 24;  DB 16;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            ||||
Db        3 EFRH 6

RESULT 84
US-10-481-642-2
; Sequence 2, Application US/10481642
; Publication No. US20050053575A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; TITLE OF INVENTION: ANTIGENIC PRODUCT DISPLAYING MULTIPLE COPIES OF AN EPITOPE OF A L
; TITLE OF INVENTION: FORMING POLYPEPTIDE INVOLVED IN PLAQUE-FORMING DISEASES AND METH
; TITLE OF INVENTION: USING SAME
; FILE REFERENCE: SOLOMON=4.1A PCT
; CURRENT APPLICATION NUMBER: US/10/481,642
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-481-642-2

Query Match             100.0%;  Score 24;  DB 17;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 85
US-10-810-881A-98
; Sequence 98, Application US/10810881A
; Publication No. US20050129695A1
; GENERAL INFORMATION:
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
; FILE REFERENCE: CEN5021 NP
; CURRENT APPLICATION NUMBER: US/10/810,881A
; CURRENT FILING DATE: 2004-03-26
; PRIOR APPLICATION NUMBER: US 60/458,474
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,469
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,509
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,510
; PRIOR FILING DATE: 2003-03-28
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 98
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PEPTIDE
US-10-810-881A-98

Query Match             100.0%;  Score 24;  DB 18;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 86
US-10-810-881A-108
; Sequence 108, Application US/10810881A
; Publication No. US20050129695A1
; GENERAL INFORMATION:
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
; FILE REFERENCE: CEN5021 NP
; CURRENT APPLICATION NUMBER: US/10/810,881A
; CURRENT FILING DATE: 2004-03-26
; PRIOR APPLICATION NUMBER: US 60/458,474
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,469
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,509
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,510
; PRIOR FILING DATE: 2003-03-28
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 108
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PEPTIDE
US-10-810-881A-108

Query Match             100.0%;  Score 24;  DB 18;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 87
US-10-810-881A-110
; Sequence 110, Application US/10810881A
; Publication No. US20050129695A1
; GENERAL INFORMATION:
; APPLICANT: Mercken, Marc; Benson, Jacqueline M.
; TITLE OF INVENTION: ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
; FILE REFERENCE: CEN5021 NP
; CURRENT APPLICATION NUMBER: US/10/810,881A
; CURRENT FILING DATE: 2004-03-26
; PRIOR APPLICATION NUMBER: US 60/458,474
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,469
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,509
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: US 60/458,510
; PRIOR FILING DATE: 2003-03-28
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 110
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PEPTIDE
US-10-810-881A-110

Query Match             100.0%;  Score 24;  DB 18;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 88
US-10-505-313-1
; Sequence 1, Application US/10505313
; Publication No. US20050169925A1

; GENERAL INFORMATION:
; APPLICANT: F. Hoffmann-La Roche AG
; APPLICANT: MorphoSys AG
; TITLE OF INVENTION: Anti A-beta antibodies and their use
; FILE REFERENCE: F 2842 PCT
; CURRENT APPLICATION NUMBER: US/10/505,313
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: EP 02003844.4
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 414
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic construct; first region of beta-A4 peptide
US-10-505-313-1

Query Match        100.0%;   Score 24;   DB 18;   Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches     4;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5


RESULT 89
US-10-625-854-6
; Sequence 6, Application US/10625854
; Publication No. US2005017S626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION:  beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: homo sapiens
US-10-625-854-6

Query Match        100.0%;   Score 24;   DB 18;   Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches     4;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6


RESULT 90
US-10-625-854-19
; Sequence 19, Application US/10625854
; Publication No. US2005017S626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION:  beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23

---

; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: homo sapiens
US-10-625-854-19

Query Match        100.0%;   Score 24;   DB 18;   Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches     4;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5


RESULT 91
US-10-625-854-32
; Sequence 32, Application US/10625854
; Publication No. US2005017S626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION:  beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: homo sapiens
US-10-625-854-32

Query Match        100.0%;   Score 24;   DB 18;   Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches     4;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4


RESULT 92
US-10-625-854-44
; Sequence 44, Application US/10625854
; Publication No. US2005017S626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION:  beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44

```
;  LENGTH: 9
;  TYPE: PRT
;  ORGANISM: homo sapiens
;  FEATURE:
;  NAME/KEY: MISC_FEATURE
;  LOCATION: (1)..(1)
;  OTHER INFORMATION: Xaa represents pyroglutamate
US-10-625-854-44

Query Match             100.0%;  Score 24;  DB 18;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db      2 EFRH 5

RESULT 93
US-10-625-854-230
;  Sequence 230, Application US/10625854
;  Publication No. US20050175626A1
;  GENERAL INFORMATION:
;  APPLICANT:  Delacourte, Andr
;  APPLICANT:  Sergeant, Nicolas
;  TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;  TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;  FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;  CURRENT APPLICATION NUMBER: US/10/625,854
;  CURRENT FILING DATE: 2003-07-23
;  PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;  PRIOR FILING DATE: 2002-07-24
;  PRIOR APPLICATION NUMBER: 60/401,497
;  PRIOR FILING DATE: 2002-08-06
;  NUMBER OF SEQ ID NOS: 261
;  SOFTWARE: PatentIn version 3.2
;  SEQ ID NO 230
;  LENGTH: 9
;  TYPE: PRT
;  ORGANISM: homo sapiens
US-10-625-854-230

Query Match             100.0%;  Score 24;  DB 18;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db      6 EFRH 9

RESULT 94
US-10-625-854-239
;  Sequence 239, Application US/10625854
;  Publication No. US20050175626A1
;  GENERAL INFORMATION:
;  APPLICANT:  Delacourte, Andr
;  APPLICANT:  Sergeant, Nicolas
;  TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;  TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;  FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;  CURRENT APPLICATION NUMBER: US/10/625,854
;  CURRENT FILING DATE: 2003-07-23
;  PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;  PRIOR FILING DATE: 2002-07-24
;  PRIOR APPLICATION NUMBER: 60/401,497
;  PRIOR FILING DATE: 2002-08-06
;  NUMBER OF SEQ ID NOS: 261
;  SOFTWARE: PatentIn version 3.2
;  SEQ ID NO 239
;  LENGTH: 9
;  TYPE: PRT
;  ORGANISM: homo sapiens

US-10-625-854-239

Query Match             100.0%;  Score 24;  DB 18;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db      5 EFRH 8

RESULT 95
US-10-625-854-247
;  Sequence 247, Application US/10625854
;  Publication No. US20050175626A1
;  GENERAL INFORMATION:
;  APPLICANT:  Delacourte, Andr
;  APPLICANT:  Sergeant, Nicolas
;  TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
;  TITLE OF INVENTION: beta-amyloid formation and/or aggregation
;  FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
;  CURRENT APPLICATION NUMBER: US/10/625,854
;  CURRENT FILING DATE: 2003-07-23
;  PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
;  PRIOR FILING DATE: 2002-07-24
;  PRIOR APPLICATION NUMBER: 60/401,497
;  PRIOR FILING DATE: 2002-08-06
;  NUMBER OF SEQ ID NOS: 261
;  SOFTWARE: PatentIn version 3.2
;  SEQ ID NO 247
;  LENGTH: 9
;  TYPE: PRT
;  ORGANISM: homo sapiens
US-10-625-854-247

Query Match             100.0%;  Score 24;  DB 18;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db      4 EFRH 7

RESULT 96
US-09-865-294-69
;  Sequence 69, Application US/09865294
;  Publication No. US20030068325A1
;  GENERAL INFORMATION:
;  APPLICANT:  Wang, Chang Yi
;  TITLE OF INVENTION: Immunogenic peptide composition as vaccines for the
;  TITLE OF INVENTION: prevention and treatment of Alzheimer's Disease
;  FILE REFERENCE: 1151-4167
;  CURRENT APPLICATION NUMBER: US/09/865,294
;  CURRENT FILING DATE: 2001-05-25
;  NUMBER OF SEQ ID NOS: 76
;  SOFTWARE: PatentIn Ver. 2.0
;  SEQ ID NO 69
;  LENGTH: 10
;  TYPE: PRT
;  ORGANISM: Homo sapiens
US-09-865-294-69

Query Match             100.0%;  Score 24;  DB 10;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 80;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db      3 EFRH 6

RESULT 97
```

US-10-010-942B-33
; Sequence 33, Application US/10010942B
; Publication No. US20030165496A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Guriq
; APPLICANT: Saldanha, Jose
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
; TITLE OF INVENTION: BETA AMYLOID PEPTIDE
; FILE REFERENCE: ELN-002
; CURRENT APPLICATION NUMBER: US/10/010,942B
; CURRENT FILING DATE: 2002-12-06
; PRIOR APPLICATION NUMBER: US 60/251,892
; PRIOR FILING DATE: 2000-12-06
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: native ABeta peptide
US-10-010-942B-33

Query Match 100.0%; Score 24; DB 14; Length 10;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
            ||||
Db      3 EFRH 6

RESULT 98
US-10-411-544-24
; Sequence 24, Application US/10411544
; Publication No. US20030232758A1
; GENERAL INFORMATION:
; APPLICANT: St. George-Hyslop, Peter
; APPLICANT: McLaurin, JoAnne
; TITLE OF INVENTION: Immunological Methods and Compositions for the Treatment of Alzhe
; TITLE OF INVENTION: Disease
; FILE REFERENCE: LI01547
; CURRENT APPLICATION NUMBER: US/10/411,544
; CURRENT FILING DATE: 2003-04-10
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-411-544-24

Query Match 100.0%; Score 24; DB 15; Length 10;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
            ||||
Db      3 EFRH 6

RESULT 99
US-10-388-389-33
; Sequence 33, Application US/10388389
; Publication No. US20040087777A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Guriq
; APPLICANT: Saldanha, Jose
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
; TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
; FILE REFERENCE: ELN-002CP
; CURRENT APPLICATION NUMBER: US/10/388,389
; CURRENT FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/010,942
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: US 60/251,892
; PRIOR FILING DATE: 2000-12-06
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: native ABeta peptide
US-10-388-389-33

Query Match 100.0%; Score 24; DB 15; Length 10;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
            ||||
Db      3 EFRH 6

RESULT 100
US-10-703-713-33
; Sequence 33, Application US/10703713
; Publication No. US20040171815A1
; GENERAL INFORMATION:
; APPLICANT: Basi, Guriq
; APPLICANT: Saldanha, Jose
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: HUMANIZED ANTIBODIES THAT RECOGNIZE
; TITLE OF INVENTION: BETA-AMYLOID PEPTIDE
; FILE REFERENCE: ELN-002CP
; CURRENT APPLICATION NUMBER: US/10/703,713
; CURRENT FILING DATE: 2003-11-07
; PRIOR APPLICATION NUMBER: US/10/388,389
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/010,942
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: US 60/251,892
; PRIOR FILING DATE: 2000-12-06
; NUMBER OF SEQ ID NOS: 63
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: native ABeta peptide
US-10-703-713-33

Query Match 100.0%; Score 24; DB 16; Length 10;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 EFRH 4
            ||||
Db      3 EFRH 6

Search completed: November 2, 2005, 09:45:23
Job time : 166 secs

OM protein - protein search, using sw model

```
             GenCore version 5.1.6
Copyright (c) 1993 - 2005  Compugen Ltd.
```

Run on:    November  2, 2005, 09:27:59 ; Search time 161 Seconds
              (without alignments)
              9.609 Million cell updates/sec

Title:     US-10-618-856-1
Perfect score:  24
Sequence:  1 EFRH 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched:  2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters:      463897

Minimum DB seq length: 4
Maximum DB seq length: 10

Post-processing: Minimum Match 0%
        Maximum Match 100%
        Listing first 100 summaries

Database : A_Geneseq_16Dec04:*
   1: geneseqp1980s:*
   2: geneseqp1990s:*
   3: geneseqp2000s:*
   4: geneseqp2001s:*
   5: geneseqp2002s:*
   6: geneseqp2003as:*
   7: geneseqp2003bs:*
   8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | % Match | Query Length | Length | DB | ID | Description |
|---|---|---|---|---|---|---|---|
| 1 | 24 | 100.0 | 24 | 4 | 2 | AAW70870 | Aaw70870 Beta-amyl |
| 2 | 24 | 100.0 | 24 | 4 | 6 | AAO16062 | Aao16062 Neurologi |
| 3 | 24 | 100.0 | 24 | 4 | 6 | ABP70744 | Abp70744 Antigenic |
| 4 | 24 | 100.0 | 24 | 4 | 7 | ADB75167 | Adb75167 Human amy |
| 5 | 24 | 100.0 | 24 | 4 | 7 | ADE36574 | Ade36574 Beta-amyl |
| 6 | 24 | 100.0 | 24 | 4 | 8 | ADJ88108 | Adj88108 Human bet |
| 7 | 24 | 100.0 | 24 | 4 | 8 | ADJ71364 | Adj71364 N-termina |
| 8 | 24 | 100.0 | 24 | 4 | 8 | ADJ71377 | Adj71377 N-termina |
| 9 | 24 | 100.0 | 24 | 4 | 8 | ADP90808 | Adp90808 Protein/p |
| 10 | 24 | 100.0 | 24 | 5 | 6 | ADA90172 | Ada90172 Anti-Abet |
| 11 | 24 | 100.0 | 24 | 5 | 8 | ADJ71378 | Adj71378 N-termina |
| 12 | 24 | 100.0 | 24 | 5 | 8 | ADJ71365 | Adj71365 N-termina |
| 13 | 24 | 100.0 | 24 | 5 | 8 | ADJ71352 | Adj71352 N-termina |
| 14 | 24 | 100.0 | 24 | 5 | 2 | AAW70868 | Aaw70868 Beta-amyl |
| 15 | 24 | 100.0 | 24 | 6 | 4 | AAB47109 | Aab47109 Epitope # |
| 16 | 24 | 100.0 | 24 | 6 | 6 | AAO16067 | Aao16067 Neurologi |
| 17 | 24 | 100.0 | 24 | 6 | 6 | ADA90170 | Ada90170 Anti-Abet |
| 18 | 24 | 100.0 | 24 | 6 | 7 | ADB75165 | Adb75165 Human amy |
| 19 | 24 | 100.0 | 24 | 6 | 8 | ADJ88114 | Adj88114 fd phage |
| 20 | 24 | 100.0 | 24 | 6 | 8 | ADJ71366 | Adj71366 N-termina |
| 21 | 24 | 100.0 | 24 | 6 | 8 | ADJ71379 | Adj71379 N-termina |
| 22 | 24 | 100.0 | 24 | 6 | 8 | ADJ71340 | Adj71340 N-termina |
| 23 | 24 | 100.0 | 24 | 6 | 8 | ADJ71353 | Adj71353 N-termina |
| 24 | 24 | 100.0 | 24 | 6 | 8 | ADK52251 | Adk52251 Human amy |
| 25 | 24 | 100.0 | 24 | 6 | 8 | ADK52264 | Adk52264 Guinea pi |
| 26 | 24 | 100.0 | 24 | 6 | 8 | ADK52261 | Adk52261 Rabbit am |
| 27 | 24 | 100.0 | 24 | 6 | 8 | ADK52260 | Adk52260 Primate a |
| 28 | 24 | 100.0 | 24 | 6 | 8 | ADK52266 | Adk52266 Amyloid b |
| 29 | 24 | 100.0 | 24 | 6 | 8 | ADQ82427 | Adq82427 N-termina |
| 30 | 24 | 100.0 | 24 | 6 | 8 | ADQ82432 | Adq82432 N-termina |
| 31 | 24 | 100.0 | 24 | 6 | 8 | ADQ82430 | Adq82430 N-termina |
| 32 | 24 | 100.0 | 24 | 6 | 8 | ADQ82433 | Adq82433 N-termina |
| 33 | 24 | 100.0 | 24 | 6 | 8 | ADQ82434 | Adq82434 N-termina |
| 34 | 24 | 100.0 | 24 | 6 | 8 | ADQ82436 | Adq82436 N-termina |
| 35 | 24 | 100.0 | 24 | 6 | 8 | ADQ82431 | Adq82431 N-termina |
| 36 | 24 | 100.0 | 24 | 6 | 8 | ADQ82423 | Adq82423 N-termina |
| 37 | 24 | 100.0 | 24 | 6 | 8 | ADQ82424 | Adq82424 N-termina |
| 38 | 24 | 100.0 | 24 | 6 | 8 | ADQ82428 | Adq82428 N-termina |
| 39 | 24 | 100.0 | 24 | 6 | 8 | ADQ82435 | Adq82435 N-termina |
| 40 | 24 | 100.0 | 24 | 6 | 8 | ADQ82429 | Adq82429 N-termina |
| 41 | 24 | 100.0 | 24 | 6 | 8 | ADQ82425 | Adq82425 N-termina |
| 42 | 24 | 100.0 | 24 | 6 | 8 | ADQ82422 | Adq82422 N-termina |
| 43 | 24 | 100.0 | 24 | 6 | 8 | ADQ82421 | Adq82421 N-termina |
| 44 | 24 | 100.0 | 24 | 6 | 8 | ADQ82437 | Adq82437 N-termina |
| 45 | 24 | 100.0 | 24 | 6 | 8 | ADQ82386 | Adq82386 Natural N |
| 46 | 24 | 100.0 | 24 | 6 | 8 | ADQ82426 | Adq82426 N-termina |
| 47 | 24 | 100.0 | 24 | 7 | 4 | AAB46202 | Aab46202 Human APP |
| 48 | 24 | 100.0 | 24 | 7 | 5 | AAO14421 | Aao14421 Synthetic |
| 49 | 24 | 100.0 | 24 | 7 | 6 | AAO19884 | Aao19884 Human amy |
| 50 | 24 | 100.0 | 24 | 7 | 6 | AAE35432 | Aae35432 Abeta pep |
| 51 | 24 | 100.0 | 24 | 7 | 6 | ADA90925 | Ada90925 Solid-pha |
| 52 | 24 | 100.0 | 24 | 7 | 6 | ADA90142 | Ada90142 Anti-Abet |
| 53 | 24 | 100.0 | 24 | 7 | 6 | ADA90141 | Ada90141 Anti-Abet |
| 54 | 24 | 100.0 | 24 | 7 | 6 | ADA90924 | Ada90924 Solid-pha |
| 55 | 24 | 100.0 | 24 | 7 | 6 | ADA90171 | Ada90171 Anti-Abet |
| 56 | 24 | 100.0 | 24 | 7 | 8 | ADJ71565 | Adj71565 N-termina |
| 57 | 24 | 100.0 | 24 | 7 | 8 | ADJ71380 | Adj71380 N-termina |
| 58 | 24 | 100.0 | 24 | 7 | 8 | ADJ71341 | Adj71341 N-termina |
| 59 | 24 | 100.0 | 24 | 7 | 8 | ADJ71367 | Adj71367 N-termina |
| 60 | 24 | 100.0 | 24 | 7 | 8 | ADJ71354 | Adj71354 N-termina |
| 61 | 24 | 100.0 | 24 | 7 | 8 | ADQ37256 | Adq37256 Vaccine a |
| 62 | 24 | 100.0 | 24 | 7 | 8 | ADQ82412 | Adq82412 Natural N |
| 63 | 24 | 100.0 | 24 | 7 | 8 | ADS09217 | Ads09217 Amyloid b |
| 64 | 24 | 100.0 | 24 | 8 | 2 | AAW70865 | Aaw70865 Beta-amyl |
| 65 | 24 | 100.0 | 24 | 8 | 5 | AAU78518 | Aau78518 N-terminu |
| 66 | 24 | 100.0 | 24 | 8 | 6 | ABP70740 | Abp70740 Antigenic |
| 67 | 24 | 100.0 | 24 | 8 | 7 | ADB75162 | Adb75162 Human amy |
| 68 | 24 | 100.0 | 24 | 8 | 7 | ADB75174 | Adb75174 Amyloid b |
| 69 | 24 | 100.0 | 24 | 8 | 8 | ADJ71355 | Adj71355 N-termina |
| 70 | 24 | 100.0 | 24 | 8 | 8 | ADJ71368 | Adj71368 N-termina |
| 71 | 24 | 100.0 | 24 | 8 | 8 | ADJ71575 | Adj71575 N-termina |
| 72 | 24 | 100.0 | 24 | 8 | 8 | ADJ71181 | Adj71181 N-termina |
| 73 | 24 | 100.0 | 24 | 8 | 8 | ADJ71342 | Adj71342 N-termina |
| 74 | 24 | 100.0 | 24 | 8 | 8 | ADJ71566 | Adj71566 N-termina |
| 75 | 24 | 100.0 | 24 | 8 | 8 | ADQ82413 | Adq82413 Natural N |
| 76 | 24 | 100.0 | 24 | 9 | 6 | ABP70741 | Abp70741 Antigenic |
| 77 | 24 | 100.0 | 24 | 9 | 7 | ADA89986 | Ada89986 Beta-A4 f |
| 78 | 24 | 100.0 | 24 | 9 | 7 | ADE36577 | Ade36577 APP epito |
| 79 | 24 | 100.0 | 24 | 9 | 7 | ADE36575 | Ade36575 Beta-amyl |
| 80 | 24 | 100.0 | 24 | 9 | 8 | ADI35862 | Adi35862 Amyloid b |
| 81 | 24 | 100.0 | 24 | 9 | 8 | ADI35931 | Adi35931 Amyloid b |
| 82 | 24 | 100.0 | 24 | 9 | 8 | ADI35943 | Adi35943 Amyloid b |
| 83 | 24 | 100.0 | 24 | 9 | 8 | ADI36020 | Adi36020 Amyloid b |
| 84 | 24 | 100.0 | 24 | 9 | 8 | ADI35949 | Adi35949 Amyloid b |
| 85 | 24 | 100.0 | 24 | 9 | 8 | ADI36012 | Adi36012 Amyloid b |
| 86 | 24 | 100.0 | 24 | 9 | 8 | ADI35946 | Adi35946 Amyloid b |
| 87 | 24 | 100.0 | 24 | 9 | 8 | ADI35890 | Adi35890 Amyloid b |
| 88 | 24 | 100.0 | 24 | 9 | 8 | ADI35900 | Adi35900 Amyloid b |
| 89 | 24 | 100.0 | 24 | 9 | 8 | ADI35960 | Adi35960 Amyloid b |
| 90 | 24 | 100.0 | 24 | 9 | 8 | ADI35921 | Adi35921 Amyloid b |
| 91 | 24 | 100.0 | 24 | 9 | 8 | ADI35958 | Adi35958 Amyloid b |
| 92 | 24 | 100.0 | 24 | 9 | 8 | ADI35925 | Adi35925 Amyloid b |
| 93 | 24 | 100.0 | 24 | 9 | 8 | ADI35968 | Adi35968 Amyloid b |
| 94 | 24 | 100.0 | 24 | 9 | 8 | ADI35999 | Adi35999 Amyloid b |
| 95 | 24 | 100.0 | 24 | 9 | 8 | ADI35895 | Adi35895 Amyloid b |
| 96 | 24 | 100.0 | 24 | 9 | 8 | ADI35982 | Adi35982 Amyloid b |
| 97 | 24 | 100.0 | 24 | 9 | 8 | ADI35885 | Adi35885 Amyloid b |
| 98 | 24 | 100.0 | 24 | 9 | 8 | ADI35920 | Adi35920 Amyloid b |

```
        99   24  100.0   9  8   ADI35879    Adi35879 Amyloid b
       100   24  100.0   9  8   ADI35971    Adi35971 Amyloid b


                    ALIGNMENTS

RESULT 1
AAW70870
ID  AAW70870 standard; peptide; 4 AA.
XX
AC  AAW70870;
XX
DT  04-FEB-1999  (first entry)
XX
DE  Beta-amyloid peptide epitope.
XX
KW  Beta-amyloid precursor protein; beta-APP; beta-amyloid peptide; antibody;
KW  amyloid deposit; Alzheimer's disease.
XX
OS  Synthetic.
OS  Homo sapiens.
XX
PN  WO9844955-A1.
XX
PD  15-OCT-1998.
XX
PF  09-APR-1998;  98WO-US006900.
XX
PR  09-APR-1997;  97US-0041850P.
XX
PA  (MIND-) MINDSET LTD.
PA  (MCIN/) MCINNIS P A.
XX
PI  Chain DG;
XX
DR  WPI; 1998-594476/50.
XX
PT  Preventing or inhibiting progression of Alzheimer's Disease - comprises
PT  use of recombinant DNA encoding an antibody specific for the N- or C-
PT  terminus of an amyloid-beta peptide.
XX
PS  Example 1; Page 47; 58pp; English.
XX
CC  The present sequence represents a peptide epitope derived from beta-
CC  amyloid precursor protein peptide. The specification describes a method
CC  for prevention or inhibition of progression of Alzheimer's disease. The
CC  method comprises administering a composition comprising a recombinant DNA
CC  molecule containing a gene encoding a recombinant antibody end-specific
CC  for the N-terminus or the C-terminus of an amyloid-beta peptide, operably
CC  linked to a promoter which is expressed in the central nervous system.
CC  The recombinant antibody molecules prevent the accumulation of beta-
CC  amyloid peptides in the extracellular space, interstitial fluid and
CC  cerebrospinal fluid and the aggregation of such peptides into amyloid
CC  deposits in the brain. They also inhibit the progression of Alzheimer's
CC  disease by inhibiting the interaction of beta-amyloid peptides mediating
CC  Alzheimer's disease induced neurotoxicity and inhibiting the Alzheimer's
CC  disease induced complement activation and cytokine release involved in
CC  the inflammatory process
XX
SQ  Sequence 4 AA;

Query Match             100.0%;  Score 24; DB 2; Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 2
AAO16062
ID  AAO16062 standard; peptide; 4 AA.
XX
AC  AAO16062;
XX
DT  27-FEB-2003  (first entry)
XX
DE  Neurological/CNS disease treatment method-related peptide #1.
XX
KW  Vaccine; gene therapy; neurological disease; CNS disorder;
KW  central nervous system disorder; olfactory system; Alzheimer's disease;
KW  Creutzfeld-Jakob disease; Huntington's chorea; Parkinson's disease;
KW  viral infection of the brain; brain tumour; lysosomal storage disease;
KW  multiple sclerosis.
XX
OS  Unidentified.
XX
PN  WO200274243-A2.
XX
PD  26-SEP-2002.
XX
PF  15-MAR-2002;  2002WO-US008042.
XX
PR  15-MAR-2001;  2001US-00808037.
XX
PA  (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
PA  (MCIN/) MCINNIS P.
XX
PI  Solomon B,  Frenkel D;
XX
DR  WPI; 2003-040542/03.
XX
PT  Treating or diagnosing neurological diseases of the central nervous
PT  system, e.g. Alzheimer's disease, comprises displaying a polypeptide or
PT  diagnostic agent on viral display vehicle and introducing or detecting
PT  the display vehicle.
XX
PS  Example 9; Page 138; 214pp; English.
XX
CC  The invention comprises a method for treating a neurological disease or a
CC  central nervous system (CNS) disorder. The method involves displaying a
CC  therapeutic molecule capable of treating the neurological disease or CNS
CC  disorder on a viral display vehicle. The viral display vehicle is then
CC  introduced into the olfactory system of a subject to treat the disease or
CC  disorder. The method of the invention is useful for preventing, treating
CC  and diagnosing neurological diseases or CNS disorders, such as:
CC  Alzheimer's disease; Creutzfeld-Jakob disease; Huntington's chorea; viral
CC  infections of the brain; brain tumours; lysosomal storage diseases;
CC  Parkinson's disease; and multiple sclerosis. The present amino acid
CC  sequence represents a peptide which was used in the invention
XX
SQ  Sequence 4 AA;

Query Match             100.0%;  Score 24; DB 6; Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 3
ABP70744
ID  ABP70744 standard; peptide; 4 AA.
XX
AC  ABP70744;
XX
DT  15-MAY-2003  (first entry)
XX
DE  Antigenic peptide, SEQ ID 5.
XX
KW  Nootropic; neuroprotective; antiinflammatory; vaccine; antigenic product;
KW  plaque-forming disease; Alzheimer's disease; SAA amyloidosis;
```

KW   hereditary Icelandic syndrome; senility; multiple myeloma;
KW   Creutzfeldt-Jakob disease; Kuru; Gerstmann-Straussler-Scheinker disease;
KW   fatal familial insomnia; scrapie; bovine spongiform encephalitis;
KW   antigenic; multiantigen.
XX
OS   Synthetic.
XX
PN   WO2003000719-A2.
XX
PD   03-JAN-2003.
XX
PF   20-JUN-2002; 2002WO-US019567.
XX
PR   20-JUN-2001; 2001US-0299201P.
PR   12-APR-2002; 2002US-0371717P.
XX
PA   (UYRA-) UNIV RAMOT.
PA   (MCIN/) MCINNIS P.
XX
PI   Mcinnis P, Solomon B;
XX
DR   WPI; 2003-239139/23.
XX
PT   Antigenic product has dendritic polymer built on core molecule having
PT   terminal functional groups to which antigenic peptide that has epitope of
PT   deposit-forming polypeptide involved in plaque-forming disease is joined.
XX
PS   Claim 6; Page 44; 70pp; English.
XX
CC   The present invention relates to antigenic products (A), comprising a
CC   dendritic polymer built on a core molecule which is at least difunctional
CC   to provide branching and containing up to 16 terminal functional groups
CC   to which an antigenic peptide, that comprises an epitope of a deposit-
CC   forming polypeptide involved in plaque-forming disease, is joined by
CC   covalent bonds. The antigenic products are useful for eliciting an immune
CC   response against a deposit-forming polypeptide involved in a plaque-
CC   forming disease or disorder, e.g. Alzheimer's disease, SAA amyloidosis,
CC   hereditary Icelandic syndrome, senility, multiple myeloma, Creutzfeldt-
CC   Jakob disease, Kuru, Gerstmann-Straussler-Scheinker disease, fatal
CC   familial insomnia, scrapie or bovine spongiform encephalitis, by
CC   administering the antigenic product to a subject in need of it. The
CC   present sequence is one such antigenic peptide, which was used to
CC   illustrate the invention
XX
SQ   Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 6;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 4
ADB75167
ID   ADB75167 standard; peptide; 4 AA.
XX
AC   ADB75167;
XX
DT   04-DEC-2003 (first entry)
XX
DE   Human amyloid beta peptide SEQ ID NO:8.
XX
KW   antibody; amyloid beta peptide; amyloid beta; nootropic; neuroprotective;
KW   antibody therapy; Alzheimer's disease; mild cognitive impairment;
KW   cerebral amyloid angiopathy; congiophylic angiopathy; Down's syndrome;
KW   inclusion body myositis; neurotoxicity; beta amyloid precursor protein;
KW   APP; human.
XX
OS   Homo sapiens.
XX

PN   WO2003074081-A1.
XX
PD   12-SEP-2003.
XX
PF   21-OCT-2002; 2002WO-US031590.
XX
PR   28-FEB-2002; 2002US-00084380.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS USA INC.
XX
PI   Chain DG;
XX
DR   WPI; 2003-731651/69.
XX
PT   New antibody that is targeted to amyloid beta peptide, or its fragment,
PT   useful for treating a subject having Alzheimer's disease, or a disease or
PT   disorder characterized by amyloid beta deposition, e.g. cognitive
PT   impairment or dementia.
XX
PS   Disclosure; Page 60; 63pp; English.
XX
CC   The present invention describes an antibody that is targeted to amyloid
CC   beta peptide, or its fragment. Also described: (1) an antibody that is
CC   free-end specific and is targeted to: (a) the free N-terminus of amyloid
CC   beta-peptide; (b) the free N-terminus of amyloid beta-peptide, where the
CC   first amino acid of amyloid beta-peptide is aspartate; (c) the free N-
CC   terminus of N- and/or C-terminus-truncated amyloid beta-peptide fragment;
CC   (d) the free C-terminus of the amyloid beta-peptide Abetal-39, Abetal-40,
CC   Abetal-41 or Abetal-43; or (e) to the free C-terminus of N- and/or C-
CC   terminus-truncated amyloid beta-peptide fragment; (2) a single chain or
CC   artificial antibody that is free-end specific and is targeted to the free
CC   C-terminus of the amyloid beta-peptide Abetal-42, and (3) a
CC   pharmaceutical composition comprising the antibody, and a carrier. The
CC   antibody targeted to amyloid beta peptide has nootropic and
CC   neuroprotective activities, and can be used in antibody therapy. The
CC   antibody or its fragment is useful for manufacturing a medicament for
CC   treating a subject having Alzheimer's disease, or a disease or disorder
CC   characterised by amyloid beta deposition (e.g. mild cognitive impairment,
CC   cerebral amyloid angiopathy or congiophylic angiopathy, Alzheimer's
CC   disease associated with Down's syndrome, or inclusion body myositis), or
CC   for delaying, inhibiting or suppressing accumulation of amyloid beta
CC   peptide, or the neurotoxicity of amyloid beta peptide or its fragment.
CC   Amyloid beta peptide are derived from beta amyloid precursor protein
CC   (APP). The present sequence represents an amyloid beta peptide which is
CC   used in the exemplification of the present invention
XX
SQ   Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 7;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 5
ADE36574
ID   ADE36574 standard; peptide; 4 AA.
XX
AC   ADE36574;
XX
DT   29-JAN-2004 (first entry)
XX
DE   Beta-amyloid (Abeta) peptide 3-6 SEQ ID NO:2.
XX
KW   immune response; beta-secretase cleavage site; amyloid precursor protein;
KW   APP; nootropic; neuroprotective; vaccine; passive immunisation;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX

**Left column**

```
PN   WO2003076455-A2.
XX
PD   18-SEP-2003.
XX
PF   04-MAR-2003; 2003WO-US006388.
XX
PR   05-MAR-2002; 2002US-0361344P.
XX
PA   (UYRA-) UNIV RAMOT AT TEL AVIV LTD.
PA   (MCIN/) MCINNIS P.
XX
PI   Solomon B;
XX
DR   WPI; 2003-865017/80.
XX
PT   Immunizing composition, useful for treating Alzheimer's disease by
PT   inhibiting processing of amyloid precursor protein, also antibodies for
PT   passive immunization.
XX
PS   Disclosure; SEQ ID NO 2; 76pp; English.
XX
CC   The present invention describes an immunising composition (A) comprising:
CC   (a) an antigenic product (I) which induces an immune response against the
CC   beta-secretase cleavage site of amyloid precursor protein (APP); and (b)
CC   a carrier, diluent, excipient, adjuvant or auxiliary. Also described: (1)
CC   a molecule (II) comprising the antigen-binding part of an antibody (Ab)
CC   directed against the beta secretase cleavage site of APP; (2) a
CC   filamentous bacteriophage (FB) that displays (II), where this is a single
CC   -chain Ab, on its surface; and (3) a composition containing FB. (A) has
CC   nootropic and neuroprotective activities, and can be used in vaccines or
CC   passive immunisation. (A) inhibits the cleavage of APP and so prevents
CC   the formation of beta-amyloid. (A) can be used to induce an immune
CC   response against the beta-secretase cleavage site of APP, specifically
CC   for treatment and prevention of Alzheimer's disease. The molecule (II)
CC   that contains the antigen-binding part of an Ab directed against the
CC   cleavage site, or a filamentous phage that displays an Ab (as a
CC   single-chain molecule) can be used similarly, for passive immunisation.
CC   The present sequence represents a beta-amyloid (Abeta) peptide which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 7;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 6
ADJ88108
ID   ADJ88108 standard; peptide; 4 AA.
XX
AC   ADJ88108;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human beta amyloid peptide anti-aggregating epitope.
XX
KW   Neurological disease; central nervous system; CNS disorder;
KW   plaque-forming disease; Alzheimer's disease; SAA amyloidosis;
KW   hereditary Icelandic syndrome; senility; multiple myeloma; scrapie;
KW   bovine spongiform encephalopathy; BSE; kuru; Creutzfeldt-Jakob disease;
KW   CJD; Gerstmann-Streussler-Sheinker disease; kuru; GSS; fatal familial insomnia;
KW   FFI; non-plaque-forming disease; Huntington's chorea; viral infection;
KW   brain tumour; lysosomal storage disease; neurodegeneration;
KW   multiple sclerosis; vaccine; beta amyloid peptide; epitope; beta AP;
KW   human.
XX
OS   Homo sapiens.
XX
```

**Right column**

```
PN   US2004013647-A1.
XX
PD   22-JAN-2004.
XX
PF   11-MAR-2003; 2003US-00384788.
XX
PR   03-SEP-1999;  99US-0152417P.
PR   29-DEC-1999;  99US-00473653.
PR   31-JUL-2000;  2000US-00629971.
PR   31-AUG-2000;  2000WO-IL000518.
PR   15-MAR-2001;  2001US-00808037.
PR   07-AUG-2001;  2001US-00830954.
PR   12-APR-2002;  2002US-0371735P.
PR   06-JUN-2002;  2002US-0162889.
XX
PA   (UYRA-) UNIV RAMOT AT TEL AVIV LTD.
XX
PI   Solomon B, Frenkel D;
XX
DR   WPI; 2004-108188/11.
XX
PT   Treating neurological disease CNS e.g., Alzheimer's disease, by
PT   displaying therapeutic molecule capable of treating the disease on viral
PT   display vehicle which is then administered to subject through olfactory
PT   system.
XX
PS   Example 10; SEQ ID NO 1; 68pp; English.
XX
CC   The invention relates to a method of treating a neurological disease or
CC   disorder of the central nervous system (CNS). The method involves
CC   displaying a therapeutic molecule capable of treating the neurological
CC   disease or disorder of the CNS on a viral display vehicle and introducing
CC   viral display vehicle into a subject by applying an effective amount of
CC   the viral display vehicle displaying the therapeutic molecule to an
CC   olfactory system of the subject. The method is useful for treating a
CC   neurological disease or disorder of CNS such as a plaque-forming disease
CC   such as Alzheimer's disease, late onset Alzheimer's disease,
CC   presymptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic
CC   syndrome, senility, multiple myeloma, scrapie, bovine spongiform
CC   encephalopathy (BSE), kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-
CC   Streussler-Sheinker disease (GSS) or fatal familial insomnia (FFI). The
CC   method is also useful for treating a non plaque forming disease or
CC   disorder e.g. Huntington's chorea, viral infections of the brain, brain
CC   tumours, lysosomal storage diseases which cause neurodegeneration and are
CC   manifested by enzyme deficiencies and multiple sclerosis. The invention
CC   is also used in the preparation of vaccines. The present sequence is
CC   human beta amyloid peptide (beta AP) anti-aggregating epitope. This
CC   sequence is used to illustrate the method of the invention.
XX
SQ   Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 7
ADJ71364
ID   ADJ71364 standard; peptide; 4 AA.
XX
AC   ADJ71364;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 27.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
```

OS   Homo sapiens.
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 8
ADJ71377
ID   ADJ71377 standard; peptide; 4 AA.
XX
AC   ADJ71377;
XX
DT   06-MAY-2004 (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 40.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "Pyroglutamic acid"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.

XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 62; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 9
ADP90808
ID   ADP90808 standard; peptide; 4 AA.
XX
AC   ADP90808;
XX
DT   09-SEP-2004 (first entry)
XX
DE   Protein/peptide labelling method-related affinity tag peptide #3.
XX
KW   protein labelling; peptide labelling;
KW   irreversible affinity tagging residue;
KW   reversible affinity tagging residue; high throughput screening assay;
KW   pharmaceutical agent; affinity tag.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   4
FT                   /note= "C-terminal amide"
XX
PN   WO2004051270-A2.
XX
PD   17-JUN-2004.
XX
PF   04-DEC-2003; 2003WO-EP013715.
XX
PR   05-DEC-2002; 2002GB-00028429.
XX
PA   (NOVS ) NOVARTIS AG.
PA   (NOVS ) NOVARTIS PHARMA GMBH.
XX
PI   Auer M, Meisner N, Seifert J;
XX
DR   WPI; 2004-480677/45.
XX
PT   Providing labeled target protein or target peptide by contacting chemical
PT   compound with affinity support, removing impurities in reaction mixture
PT   surrounding affinity support, cleaving or eluting chemical molecule from
PT   affinity support.
XX

PS   Claim 4; Page 70; 81pp; English.
XX
CC   The invention comprises a method for providing a labelled target
CC   protein/peptide. The method involves contacting a chemical compound with
CC   affinity support, removing impurities in the reaction mixture surrounding
CC   the affinity support to which the chemical molecule is bound, and
CC   cleaving or eluting the molecule from the affinity support to obtain
CC   irreversible or reversible affinity tagging residue, labelled target
CC   protein or labelled peptide. The method of the invention is useful for
CC   labelling a target protein/peptide or high throughput screening assay.
CC   The method of the invention is useful for identifying agents that
CC   modulate the activity or characteristics of a target protein/peptide -
CC   such agents are useful as pharmaceuticals. The present amino acid
CC   sequence represents an affinity tag peptide of the invention.
XX
SQ   Sequence 4 AA;

Query Match       100.0%;    Score 24;   DB 8;  Length 4;
Best Local Similarity  100.0%;  Pred. No. 1.8e+06;
Matches     4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy     1 EFRH 4
          ||||
Db     1 EFRH 4

RESULT 10
ADA90172
ID   ADA90172 standard; peptide; 5 AA.
XX
AC   ADA90172;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Anti-Abeta antibody related amino acid sequence SEQ ID NO:287.
XX
KW   antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;
KW   nootropic; antiparkinsonian; gene therapy; amyloidogenesis;
KW   amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;
KW   Alzheimer's disease; motor neuropathy; Down's syndrome;
KW   Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;
KW   Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;
KW   neuronal disorder; aging.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO200307060-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-EP001759.
XX
PR   20-FEB-2002; 2002EP-00003844.
XX
PA   (HOFF ) HOFFMANN LA ROCHE & CO AG F.
PA   (MORP-) MORPHOSYS AG.
XX
PI   Bardroff M,  Bohrmann B,  Brockhaus M,  Huber W,  Kretzschmar T;
PI   Loehning C,  Loetscher H,  Nordstedt C,  Rothe C;
XX
DR   WPI; 2003-663848/62.
XX
PT   New antibody molecule capable of specifically recognizing two regions of
PT   the beta-A4 peptide, useful for diagnosing, preventing or treating
PT   diseases associated with amyloidogenesis or amyloid-plaque formation
PT   (e.g. dementia).
XX
PS   Disclosure; Page 265; 312pp; English.
XX
CC   The present invention describes an antibody molecule (I) capable of
CC   specifically recognising two regions of the beta-A4 peptide/Abeta4. The
CC   first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-

CC   Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the
CC   amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-
CC   Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule
CC   encoding (I); (2) a vector comprising the nucleic acid of (1); (3) a host
CC   cell comprising the vector of (2); (4) preparing (I), comprising
CC   culturing the host cell of (3) under conditions that allow synthesis of
CC   (I) and recovering (I) from the culture; (5) a composition comprising (I)
CC   or an antibody molecule produced by method (4);  (6) a kit comprising (I)
CC   nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising
CC   (I); (8) testing the resulting Fab optimisation library by panning
CC   against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing
CC   of selected, optimised clones; (11) preparing a pharmaceutical
CC   composition, comprising optimisation of (I), and formulating the
CC   optimised antibody/antibody molecule with a carrier; and (12) a
CC   pharmaceutical composition prepared by method (8). (I) has
CC   neuroprotective, nootropic and antiparkinsonian activities, and can be
CC   used in gene therapy. The antibody molecule (I), nucleic acid molecule,
CC   vector or host is useful in preparing a pharmaceutical composition for
CC   the prevention and/or treatment of a disease associated with
CC   amyloidogenesis and/or amyloid-plaque formation. The antibody molecule
CC   may also be used in preparing a diagnostic composition for the detection
CC   of the disease mentioned above. The antibody is used for the
CC   disintegration of beta-amyloid plaques or for passive immunisation
CC   against beta-amyloid plaque formation. In particular, the disease is
CC   dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,
CC   Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with
CC   amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,
CC   amyotrophic lateral sclerosis or neuronal disorders related to aging. The
CC   present sequence is used in the exemplification of the present invention.
XX
SQ   Sequence 5 AA;

Query Match       100.0%;    Score 24;   DB 6;  Length 5;
Best Local Similarity  100.0%;  Pred. No. 1.8e+06;
Matches     4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy     1 EFRH 4
          ||||
Db     1 EFRH 4

RESULT 11
ADJ71378
ID   ADJ71378 standard; peptide; 5 AA.
XX
AC   ADJ71378;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 41.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key            Location/Qualifiers
FT   Modified-site  1
FT                  /note= "Pyroglutamic acid"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A,  Sergeant N;
XX

DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 62; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 5 AA;

Query Match        100.0%;   Score 24;   DB 8;   Length 5;
Best Local Similarity  100.0%;   Pred. No. 1.8e+06;
Matches    4;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

```
Qy   1 EFRH 4
       ||||
Db   1 EFRH 4
```

RESULT 12
ADJ71365
ID   ADJ71365 standard; peptide; 5 AA.
XX
AC   ADJ71365;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 28.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 5 AA;

Query Match        100.0%;   Score 24;   DB 8;   Length 5;
Best Local Similarity  100.0%;   Pred. No. 1.8e+06;
Matches    4;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

```
Qy   1 EFRH 4
       ||||
Db   1 EFRH 4
```

RESULT 13
ADJ71352
ID   ADJ71352 standard; peptide; 5 AA.
XX
AC   ADJ71352;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 15.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "Optionally methylated"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 5 AA;

Query Match        100.0%;   Score 24;   DB 8;   Length 5;
Best Local Similarity  100.0%;   Pred. No. 1.8e+06;
Matches    4;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

```
Qy   1 EFRH 4
       ||||
Db   2 EFRH 5
```

RESULT 14
AAW70868
ID   AAW70868 standard; peptide; 6 AA.
XX
AC   AAW70868;
XX
DT   04-FEB-1999  (first entry)
XX
DE   Beta-amyloid peptide to create a monoclonal antibody.
XX
KW   Beta-amyloid precursor protein; beta-APP; beta-amyloid peptide; antibody;
KW   amyloid deposit; Alzheimer's disease.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9844955-A1.
XX
PD   15-OCT-1998.
XX
PF   09-APR-1998;   98WO-US006900.
XX
PR   09-APR-1997;   97US-0041850P.
XX
PA   (MIND-) MINDSET LTD.
PA   (MCIN/) MCINNIS P A.
XX
PI   Chain DG;
XX
DR   WPI; 1998-594476/50.
XX
PT   Preventing or inhibiting progression of Alzheimer's Disease - comprises
PT   use of recombinant DNA encoding an antibody specific for the N- or C-
PT   terminus of an amyloid-beta peptide.
XX
PS   Example 1; Page 47; 58pp; English.
XX
CC   The present sequence represents a peptide derived from beta-amyloid
CC   precursor protein (beta-APP, see AAW70863). The peptide is a beta-amyloid
CC   peptide and is used to produce a monoclonal antibody. The specification
CC   describes a method for prevention or inhibition of progression of
CC   Alzheimer's disease. The method comprises administering a composition
CC   comprising a recombinant DNA molecule containing a gene encoding a
CC   recombinant antibody end-specific for the N-terminus or the C-terminus of
CC   an amyloid-beta peptide, operably linked to a promoter which is expressed
CC   in the central nervous system. The recombinant antibody molecules prevent
CC   the accumulation of beta-amyloid peptides in the extracellular space,
CC   interstitial fluid and cerebrospinal fluid and the aggregation of such
CC   peptides into amyloid deposits in the brain. They also inhibit the
CC   progression of Alzheimer's disease by inhibiting the interaction of beta-
CC   amyloid peptides mediating Alzheimer's disease induced neurotoxicity and
CC   inhibiting the Alzheimer's disease induced complement activation and
CC   cytokine release involved in the inflammatory process
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24; DB 2; Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 15
AAB47109
ID   AAB47109 standard; peptide; 6 AA.
XX
AC   AAB47109;
XX
DT   04-JUN-2001  (first entry)

XX
DE   Epitope #1 used in treatment of plaque forming disease.
XX
KW   Human; prion protein; plaque forming disease; display vehicle; kuru;
KW   aggregating protein; amyloid plaque; brain; early onset; senility;
KW   Alzheimer's disease; late onset; pre-symptomatic; SAA amyloidosis;
KW   hereditary Icelandic syndrome; multiple myeloma; scrapie; BSE; CJD;
KW   bovine spongiform encephalopathy; Creutzfeldt-Jakob Disease; FFI;
KW   Gerstmann-Streussler-Sheinker Disease; GSS; fatal familial insomnia.
XX
OS   Synthetic.
XX
PN   WO20018169-A2.
XX
PD   15-MAR-2001.
XX
PF   31-AUG-2000; 2000WO-IL000518.
XX
PR   03-SEP-1999;   99US-0152417P.
PR   29-DEC-1999;   99US-00473653.
PR   31-JUL-2000; 2000US-00629971.
XX
PA   (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
XX
PI   Solomon B, Frenkel D, Hanan E;
XX
DR   WPI; 2001-244564/25.
XX
PT   Treating amyloidgenic disease such as Alzheimer's disease, BSE or CJD
PT   comprises presentation of plaque derived antigens or epitopes on a
PT   display vehicle, and introducing the vehicle into the recipient.
XX
PS   Example; Page 50; 120pp; English.
XX
CC   This peptide is based on the N-terminal fragment of beta-amyloid peptide
CC   (beta-AP) and was fused to the minor coat protein of fd phage. This
CC   peptide may be used in the method of the invention. The invention
CC   provides an agent for treating a plaque forming disease. The polypeptide
CC   is displayed on a display vehicle and is capable of eliciting antibodies
CC   capable of disaggregating the aggregating protein and/or of preventing
CC   aggregation of the aggregating protein. This reduces formation of amyloid
CC   plaques in the brain of victims of plaque forming diseases, e.g. early
CC   onset Alzheimer's disease, late onset Alzheimer's disease, pre-
CC   symptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic
CC   syndrome, senility, multiple myeloma, scrapie, bovine spongiform
CC   encephalopathy (BSE), kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann-
CC   Streussler-Sheinker Disease (GSS) and fatal familial insomnia (FFI)
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24; DB 4; Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 16
AAO16067
ID   AAO16067 standard; peptide; 6 AA.
XX
AC   AAO16067;
XX
DT   27-FEB-2003  (first entry)
XX
DE   Neurological/CNS disease treatment method-related peptide #4.
XX
KW   Vaccine; gene therapy; neurological disease; CNS disorder;
KW   central nervous system disorder; olfactory system; Alzheimer's disease;
KW   Creutzfeld-Jakob disease; Huntington's chorea; Parkinson's disease;
KW   viral infection of the brain; brain tumour; lysosomal storage disease;

```
KW   multiple sclerosis.
OS   Unidentified.
XX
PN   WO20027243-A2.
XX
PD   26-SEP-2002.
XX
PA   (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
PA   (MCIN/) MCINNIS P.
XX
PI   Solomon B, Frenkel D;
XX
DR   WPI; 2003-040542/03.
XX
PT   Treating or diagnosing neurological diseases of the central nervous
PT   system, e.g. Alzheimer's disease, comprises displaying a polypeptide or
PT   diagnostic agent on viral display vehicle and introducing or detecting
PT   the display vehicle.
XX
PS   Example 9; Page 138; 214pp; English.
XX
CC   The invention comprises a method for treating a neurological disease or a
CC   central nervous system (CNS) disorder. The method involves displaying a
CC   therapeutic molecule capable of treating the neurological disease or CNS
CC   disorder on a viral display vehicle. The viral display vehicle is then
CC   introduced into the olfactory system of a subject to treat the disease or
CC   disorder. The method of the invention is useful for preventing, treating
CC   and diagnosing neurological diseases or CNS disorders, such as:
CC   Alzheimer's disease; Creutzfeld-Jakob disease; Huntington's chorea; viral
CC   infections of the brain; brain tumours; lysosomal storage diseases;
CC   Parkinson's disease; and multiple sclerosis. The present amino acid
CC   sequence represents a peptide which was used in the invention
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 6;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 17
ADA90170
ID   ADA90170 standard; peptide; 6 AA.
XX
AC   ADA90170;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Anti-Abeta antibody related amino acid sequence SEQ ID NO:285.
XX
KW   antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;
KW   nootropic; antiparkinsonian; gene therapy; amyloidogenesis;
KW   amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;
KW   Alzheimer's disease; motor neuropathy; Down's syndrome;
KW   Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;
KW   Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;
KW   neuronal disorder; aging.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070760-A2.
XX
PD   28-AUG-2003.


XX
PF   20-FEB-2003; 2003WO-EP001759.
XX
PR   20-FEB-2002; 2002EP-00003844.
XX
PA   (HOFF ) HOFFMANN LA ROCHE & CO AG F.
PA   (MORP-) MORPHOSYS AG.
XX
PI   Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;
PI   Loehning C, Loetscher H, Nordstedt C, Roche C;
XX
DR   WPI; 2003-663848/62.
XX
PT   New antibody molecule capable of specifically recognizing two regions of
PT   the beta-A4 peptide, useful for diagnosing, preventing or treating
PT   diseases associated with amyloidogenesis or amyloid-plaque formation
PT   (e.g. dementia).
XX
PS   Disclosure; Page 264; 312pp; English.
XX
CC   The present invention describes an antibody molecule (I) capable of
CC   specifically recognising two regions of the beta-A4 peptide/Abeta4. The
CC   first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-
CC   Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the
CC   amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-
CC   Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule
CC   encoding (I); (2) a vector comprising the nucleic acid of (1); (3) a host
CC   cell comprising the vector of (2); (4) preparing (I), comprising
CC   culturing the host cell of (3) under conditions that allow synthesis of
CC   (I) and recovering (I) from the culture; (5) a composition comprising (I),
CC   or an antibody molecule produced by method (4); (6) a kit comprising (I),
CC   nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising
CC   (I); (8) testing the resulting Fab optimisation library by panning
CC   against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing
CC   of selected, optimised clones; (11) preparing a pharmaceutical
CC   composition, comprising optimisation of (I), and formulating the
CC   optimised antibody/antibody molecule with a carrier; and (12) a
CC   pharmaceutical composition prepared by method (8). (I) has
CC   neuroprotective, nootropic and antiparkinsonian activities, and can be
CC   used in gene therapy. The antibody molecule (I), nucleic acid molecule,
CC   vector or host is useful in preparing a pharmaceutical composition for
CC   the prevention and/or treatment of a disease associated with
CC   amyloidogenesis and/or amyloid-plaque formation. The antibody molecule
CC   may also be used in preparing a diagnostic composition for the detection
CC   of the disease mentioned above. The antibody is used for the
CC   disintegration of beta-amyloid plaques or for passive immunisation
CC   against beta-amyloid plaque formation. In particular, the disease is
CC   dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,
CC   Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with
CC   amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,
CC   amyotrophic lateral sclerosis or neuronal disorders related to aging. The
CC   present sequence is used in the exemplification of the present invention.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 6;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 18
ADB75165
ID   ADB75165 standard; peptide; 6 AA.
XX
AC   ADB75165;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Human amyloid beta peptide SEQ ID NO:6.
```

XX
KW  antibody; amyloid beta peptide; amyloid beta; nootropic; neuroprotective;
KW  antibody therapy; Alzheimer's disease; mild cognitive impairment;
KW  cerebral amyloid angiopathy; congiophylic angiopathy; Down's syndrome;
KW  inclusion body myositis; neurotoxicity; beta amyloid precursor protein;
KW  APP; human.
XX
OS  Homo sapiens.
XX
PN  WO200307408l-Al.
XX
PD  12-SEP-2003.
XX
PF  21-OCT-2002; 2002WO-US031590.
XX
PR  28-FEB-2002; 2002US-00084380.
XX
PA  (MIND-) MINDSET BIOPHARMACEUTICALS USA INC.
XX
PI  Chain DG;
XX
DR  WPI; 2003-731651/69.
XX
PT  New antibody that is targeted to amyloid beta peptide, or its fragment,
PT  useful for treating a subject having Alzheimer's disease, or a disease or
PT  disorder characterized by amyloid beta deposition, e.g. cognitive
PT  impairment or dementia.
XX
PS  Example 2; Page 29; 63pp; English.
XX
CC  The present invention describes an antibody that is targeted to amyloid
CC  beta peptide, or its fragment. Also described: (1) an antibody that is
CC  free-end specific and is targeted to: (a) the free N-terminus of amyloid
CC  beta-peptide; (b) the free N-terminus of amyloid beta-peptide, where the
CC  first amino acid of amyloid beta-peptide is aspartate; (c) the free N-
CC  terminus of N- and/or C-terminus-truncated amyloid beta-peptide fragment;
CC  (d) the free C-terminus of the amyloid beta-peptide Abetal-39, Abetal-40,
CC  Abetal-41 or Abetal-43; or (e) to the free C-terminus of N- and/or C-
CC  terminus-truncated amyloid beta-peptide fragment; (2) a single chain or
CC  artificial antibody that is free-end specific and is targeted to the free
CC  C-terminus of the amyloid beta-peptide Abetal-42; and (3) a
CC  pharmaceutical composition comprising the antibody, and a carrier. The
CC  antibody targeted to amyloid beta peptide has nootropic and
CC  neuroprotective activities, and can be used in antibody therapy. The
CC  antibody or its fragment is useful for manufacturing a medicament for
CC  treating a subject having Alzheimer's disease, or a disease or disorder
CC  characterised by amyloid beta deposition (e.g. mild cognitive impairment,
CC  cerebral amyloid angiopathy or congiophylic angiopathy, Alzheimer's
CC  disease associated with Down's syndrome, or inclusion body myositis), or
CC  for delaying, inhibiting or suppressing accumulation of amyloid beta
CC  peptide, or the neurotoxicity of amyloid beta peptide or its fragment.
CC  Amyloid beta peptide are derived from beta amyloid precursor protein
CC  (APP). The present sequence represents an amyloid beta peptide which is
CC  used in the exemplification of the present invention.
XX
SQ  Sequence 6 AA;

Query Match        100.0%;   Score 24;   DB 7;   Length 6;
Best Local Similarity 100.0%;   Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 EFRH 4
          ||||
Db      3 EFRH 6

RESULT 19
ADJ88114
ID  ADJ88114 standard; peptide; 6 AA.
XX
AC  ADJ88114;
XX
DT  06-MAY-2004  (first entry)

XX
DE  fd phage peptide #1 used to raise non-aggregating beta AP antibody.
XX
KW  Neurological disease; central nervous system; CNS disorder;
KW  plaque-forming disease; Alzheimer's disease; SAA amyloidosis;
KW  hereditary Icelandic syndrome; senility; multiple myeloma; scrapie;
KW  bovine spongiform encephalopathy; BSE; kuru; Creutzfeldt-Jakob disease;
KW  CJD; Gerstmann-Streussler-Sheinker disease; GSS; fatal familial insomnia;
KW  FFI; non-plaque-forming disease; Huntington's chorea; viral infection;
KW  brain tumour; lysosomal storage disease; neurodegeneration;
KW  multiple sclerosis; vaccine; beta amyloid peptide; beta AP.
XX
OS  Enterobacteria phage fd.
XX
PN  US2004013647-Al.
XX
PD  22-JAN-2004.
XX
PF  11-MAR-2003; 2003US-00384788.
XX
PR  03-SEP-1999;   99US-0152417P.
PR  29-DEC-1999;   99US-0473653.
PR  31-JUL-2000;   2000US-00629971.
PR  31-AUG-2000;   2000WO-IL000518.
PR  15-MAR-2001;   2001US-00800807.
PR  07-AUG-2001;   2001US-00830954.
PR  12-APR-2002;   2002US-0371735P.
PR  06-JUN-2002;   2002US-0162889.
XX
PA  (UYRA-) UNIV RAMOT AT TEL AVIV LTD.
XX
PI  Solomon B, Frenkel D;
XX
DR  WPI; 2004-108188/11.
XX
PT  Treating neurological disease CNS e.g., Alzheimer's disease, by
PT  displaying therapeutic molecule capable of treating the disease on viral
PT  display vehicle which is then administered to subject through olfactory
PT  system.
XX
PS  Example 9; SEQ ID NO 7; 68pp; English.
XX
CC  The invention relates to a method of treating a neurological disease or
CC  disorder of the central nervous system (CNS). The method involves
CC  displaying a therapeutic molecule capable of treating the neurological
CC  disease or disorder of the CNS on a viral display vehicle and introducing
CC  viral display vehicle into a subject by applying an effective amount of
CC  the viral display vehicle displaying the therapeutic molecule to an
CC  olfactory system of the subject. The method is useful for treating a
CC  neurological disease or disorder of CNS such as a plaque-forming disease
CC  such as Alzheimer's disease, late onset Alzheimer's disease,
CC  presymptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic
CC  syndrome, senility, multiple myeloma, scrapie, bovine spongiform
CC  encephalopathy (BSE), kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-
CC  Streussler-Sheinker disease (GSS) or fatal familial insomnia (FFI). The
CC  method is also useful for treating a non plaque forming disease or
CC  disorder e.g. Huntington's chorea, viral infections of the brain, brain
CC  tumours, lysosomal storage diseases which cause neurodegeneration and are
CC  manifested by enzyme deficiencies and multiple sclerosis. The invention
CC  is also used in the preparation of vaccines. The present sequence is fd
CC  phage peptide used to raise non-aggregating beta AP (beta amyloid
CC  peptide) antibody. This sequence is used to illustrate the method of the
CC  invention.
XX
SQ  Sequence 6 AA;

Query Match        100.0%;   Score 24;   DB 8;   Length 6;
Best Local Similarity 100.0%;   Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 EFRH 4
          ||||
Db      3 EFRH 6

```
RESULT 20
ADJ71366
ID   ADJ71366 standard; peptide; 6 AA.
XX
AC   ADJ71366;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 29.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 21
ADJ71379
ID   ADJ71379 standard; peptide; 6 AA.
XX
AC   ADJ71379;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 42.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "Pyroglutamic acid"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 62; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 22
ADJ71340
ID   ADJ71340 standard; peptide; 6 AA.
XX
AC   ADJ71340;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 3.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "Methylated"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
```

PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 23
ADJ71353
ID   ADJ71353 standard; peptide; 6 AA.
XX
AC   ADJ71353;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 16.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key            Location/Qualifiers
FT   Modified-site  1
FT                  /note= "Optionally methylated"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.

XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              |||
Db          2 EFRH 5

RESULT 24
ADK52251
ID   ADK52251 standard; peptide; 6 AA.
XX
AC   ADK52251;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human amyloid beta (Abeta) 1-6 peptide seqid 75.
XX
KW   neuroprotective; nootropic; vaccine; amyloid beta 1-6 peptide;
KW   core particle; antigen array; Alzheimer's disease; human.
XX
OS   Homo sapiens.
XX
PN   WO2004016282-A1.
XX
PD   26-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007864.
XX
PR   19-JUL-2002; 2002US-0396639P.
PR   15-MAY-2003; 2003US-0470432P.
XX
PA   (CYTO-) CYTOS BIOTECHNOLOGY AG.
PA   (NOVS ) NOVARTIS PHARMA AG.
XX
PI   Bachmann MF, Tissot A, Ortmann R, Lueoend R, Staufenbiel M;
PI   Frey P;
XX
DR   WPI; 2004-203731/19.
XX
PT   Composition comprising a core particle with at least one attachment site,
PT   and an antigenic amyloid beta 1-6 peptide, useful for treating diseases
PT   such as Alzheimer's disease.
XX
PS   Claim 22; SEQ ID NO 75; 184pp; English.
XX
CC   The invention describes a novel composition comprising a core particle
CC   with at least one attachment site, and an antigenic amyloid beta 1-6
CC   peptide. The new composition comprises: a core particle with at least one
CC   first attachment site; and at least one antigen or antigenic determinant
CC   with at least one second attachment site, where the antigen or antigenic
CC   determinant is a Amyloid beta 1-6 peptide, and where the second
CC   attachment site comprises: an attachment site not naturally occurring
CC   with the antigen or antigenic determinant; or an attachment site
CC   naturally occurring with the antigen or antigenic determinant. The second
CC   attachment site is capable of association to the first attachment site
CC   and the beta 1-6 peptide and the core particle interact through the
CC   association to form an ordered and repetitive antigen array. The

**Left column:**

```
CC   composition is useful for the manufacture of a medicament for treating
CC   Alzheimer's disease and related diseases. This is the amino acid sequence
CC   of an amyloid beta (Abeta) 1-6 peptide that can be used in the creation
CC   of the compositions and vaccines of the invention.
XX
SQ   Sequence 6 AA;

Query Match          100.0%;   Score 24;   DB 8;   Length 6;
Best Local Similarity  100.0%;   Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy         1 EFRH 4
             |||
Db         3 EFRH 6

RESULT 25
ADK52264
ID   ADK52264 standard; peptide; 6 AA.
XX
AC   ADK52264;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Guinea pig amyloid beta (Abeta) 1-6 peptide.
XX
KW   neuroprotective; nootropic; vaccine; amyloid beta 1-6 peptide;
KW   core particle; antigen array; Alzheimer's disease; guinea pig.
XX
OS   Cavia porcellus.
XX
PN   WO2004016282-A1.
XX
PD   26-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007864.
XX
PR   19-JUL-2002; 2002US-0396639P.
PR   15-MAY-2003; 2003US-0470432P.
XX
PA   (CYTO-) CYTOS BIOTECHNOLOGY AG.
PA   (NOVS ) NOVARTIS PHARMA AG.
XX
PI   Bachmann MF, Tissot A, Ortmann R, Lueoend R, Staufenbiel M;
PI   Frey P;
XX
DR   WPI; 2004-203731/19.
XX
PT   Composition comprising a core particle with at least one attachment site,
PT   and an antigenic amyloid beta 1-6 peptide, useful for treating diseases
PT   such as Alzheimer's disease.
XX
PS   Claim 22; SEQ ID NO 88; 184pp; English.
XX
CC   The invention describes a novel composition comprising a core particle
CC   with at least one attachment site, and an antigenic amyloid beta 1-6
CC   peptide. The new composition comprises: a core particle with at least one
CC   first attachment site; and at least one antigen or antigenic determinant
CC   with at least one second attachment site, where the antigen or antigenic
CC   determinant is a Amyloid beta 1-6 peptide, and where the second
CC   attachment site comprises: an attachment site not naturally occurring
CC   with the antigen or antigenic determinant; or an attachment site
CC   naturally occurring with the antigen or antigenic determinant. The second
CC   attachment site is capable of association to the first attachment site
CC   and the beta 1-6 peptide and the core particle interact through the
CC   association to form an ordered and repetitive antigen array. The
CC   composition is useful for the manufacture of a medicament for treating
CC   Alzheimer's disease and related diseases. This is the amino acid sequence
CC   of an amyloid beta (Abeta) 1-6 peptide that can be used as an alternative
CC   to the human sequence in the compositions and vaccines of the invention.
XX
SQ   Sequence 6 AA;
```

**Right column:**

```
Query Match          100.0%;   Score 24;   DB 8;   Length 6;
Best Local Similarity  100.0%;   Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy         1 EFRH 4
             |||
Db         3 EFRH 6

RESULT 26
ADK52261
ID   ADK52261 standard; peptide; 6 AA.
XX
AC   ADK52261;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Rabbit amyloid beta (Abeta) 1-6 peptide.
XX
KW   neuroprotective; nootropic; vaccine; amyloid beta 1-6 peptide;
KW   core particle; antigen array; Alzheimer's disease; rabbit.
XX
OS   Oryctolagus cuniculus.
XX
PN   WO2004016282-A1.
XX
PD   26-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007864.
XX
PR   19-JUL-2002; 2002US-0396639P.
PR   15-MAY-2003; 2003US-0470432P.
XX
PA   (CYTO-) CYTOS BIOTECHNOLOGY AG.
PA   (NOVS ) NOVARTIS PHARMA AG.
XX
PI   Bachmann MF, Tissot A, Ortmann R, Lueoend R, Staufenbiel M;
PI   Frey P;
XX
DR   WPI; 2004-203731/19.
XX
PT   Composition comprising a core particle with at least one attachment site,
PT   and an antigenic amyloid beta 1-6 peptide, useful for treating diseases
PT   such as Alzheimer's disease.
XX
PS   Claim 22; SEQ ID NO 85; 184pp; English.
XX
CC   The invention describes a novel composition comprising a core particle
CC   with at least one attachment site, and an antigenic amyloid beta 1-6
CC   peptide. The new composition comprises: a core particle with at least one
CC   first attachment site; and at least one antigen or antigenic determinant
CC   with at least one second attachment site, where the antigen or antigenic
CC   determinant is a Amyloid beta 1-6 peptide, and where the second
CC   attachment site comprises: an attachment site not naturally occurring
CC   with the antigen or antigenic determinant; or an attachment site
CC   naturally occurring with the antigen or antigenic determinant. The second
CC   attachment site is capable of association to the first attachment site
CC   and the beta 1-6 peptide and the core particle interact through the
CC   association to form an ordered and repetitive antigen array. The
CC   composition is useful for the manufacture of a medicament for treating
CC   Alzheimer's disease and related diseases. This is the amino acid sequence
CC   of an amyloid beta (Abeta) 1-6 peptide that can be used as an alternative
CC   to the human sequence in the compostions and vaccines of the invention.
XX
SQ   Sequence 6 AA;

Query Match          100.0%;   Score 24;   DB 8;   Length 6;
Best Local Similarity  100.0%;   Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy         1 EFRH 4
             |||
Db         3 EFRH 6
```

RESULT 27
ADK52260
ID   ADK52260 standard; peptide; 6 AA.
XX
AC   ADK52260;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Primate amyloid beta (Abeta) 1-6 peptide.
XX
KW   neuroprotective; nootropic; vaccine; amyloid beta 1-6 peptide;
KW   core particle; antigen array; Alzheimer's disease; primate.
XX
OS   Primates.
XX
PN   WO2004016282-A1.
XX
PD   26-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007864.
XX
PR   19-JUL-2002; 2002US-0396639P.
PR   15-MAY-2003; 2003US-0470432P.
XX
PA   (CYTO-) CYTOS BIOTECHNOLOGY AG.
PA   (NOVS ) NOVARTIS PHARMA AG.
XX
PI   Bachmann MF, Tissot A,  Ortmann R,  Lueoend R,  Staufenbiel M;
PI   Frey P;
XX
DR   WPI; 2004-203731/19.
XX
PT   Composition comprising a core particle with at least one attachment site,
PT   and an antigenic amyloid beta 1-6 peptide, useful for treating diseases
PT   such as Alzheimer's disease.
XX
PS   Claim 22; SEQ ID NO 84; 184pp; English.
XX
CC   The invention describes a novel composition comprising a core particle
CC   with at least one attachment site, and an antigenic amyloid beta 1-6
CC   peptide. The new composition comprises: a core particle with at least one
CC   first attachment site; and at least one antigen or antigenic determinant
CC   with at least one second attachment site, where the antigen or antigenic
CC   determinant is a Amyloid beta 1-6 peptide, and where the second
CC   attachment site comprises: an attachment site not naturally occurring
CC   with the antigen or antigenic determinant; or an attachment site
CC   naturally occurring with the antigen or antigenic determinant. The second
CC   attachment site is capable of association to the first attachment site
CC   and the beta 1-6 peptide and the core particle interact through the
CC   association to form an ordered and repetitive antigen array. The
CC   composition is useful for the manufacture of a medicament for treating
CC   Alzheimer's disease and related diseases. This is the amino acid sequence
CC   of an amyloid beta (Abeta) 1-6 peptide that can be used as an alternative
CC   to the human sequence in the compositions and vaccines of the invention.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 28
ADK52266
ID   ADK52266 standard; peptide; 6 AA.
XX
AC   ADK52266;

RESULT 27
ADK52260
ID   ADK52260 standard; peptide; 6 AA.
XX
AC   ADK52260;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Amyloid beta (Abeta) immunogen.
XX
KW   neuroprotective; nootropic; vaccine; amyloid beta 1-6 peptide;
KW   core particle; antigen array; Alzheimer's disease; immunogen.
XX
OS   Unidentified.
XX
PN   WO2004016282-A1.
XX
PD   26-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007864.
XX
PR   19-JUL-2002; 2002US-0396639P.
PR   15-MAY-2003; 2003US-0470432P.
XX
PA   (CYTO-) CYTOS BIOTECHNOLOGY AG.
PA   (NOVS ) NOVARTIS PHARMA AG.
XX
PI   Bachmann MF,  Tissot A,  Ortmann R,  Lueoend R,  Staufenbiel M;
PI   Frey P;
XX
DR   WPI; 2004-203731/19.
XX
PT   Composition comprising a core particle with at least one attachment site,
PT   and an antigenic amyloid beta 1-6 peptide, useful for treating diseases
PT   such as Alzheimer's disease.
XX
PS   Disclosure; SEQ ID NO 90; 184pp; English.
XX
CC   The invention describes a novel composition comprising a core particle
CC   with at least one attachment site, and an antigenic amyloid beta 1-6
CC   peptide. The new composition comprises: a core particle with at least one
CC   first attachment site; and at least one antigen or antigenic determinant
CC   with at least one second attachment site, where the antigen or antigenic
CC   determinant is a Amyloid beta 1-6 peptide, and where the second
CC   attachment site comprises: an attachment site not naturally occurring
CC   with the antigen or antigenic determinant; or an attachment site
CC   naturally occurring with the antigen or antigenic determinant. The second
CC   attachment site is capable of association to the first attachment site
CC   and the beta 1-6 peptide and the core particle interact through the
CC   association to form an ordered and repetitive antigen array. The
CC   composition is useful for the manufacture of a medicament for treating
CC   Alzheimer's disease and related diseases. This is the amino acid sequence
CC   of an amyloid beta (Abeta) 1-6 peptide that can be used as an immunogen
CC   to create anti-amyloid beta-antibodies.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 29
ADQ82427
ID   ADQ82427 standard; peptide; 6 AA.
XX
AC   ADQ82427;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #38.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.

XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match        100.0%;   Score 24;  DB 8;  Length 6;
Best Local Similarity  100.0%;   Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 30
ADQ82432
ID   ADQ82432 standard; peptide; 6 AA.
XX
AC   ADQ82432;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #43.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX

PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match        100.0%;   Score 24;  DB 8;  Length 6;
Best Local Similarity  100.0%;   Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 31
ADQ82430
ID   ADQ82430 standard; peptide; 6 AA.
XX
AC   ADQ82430;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #41.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match        100.0%;   Score 24;  DB 8;  Length 6;
Best Local Similarity  100.0%;   Pred. No. 1.8e+06;

```
Matches    4; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

Qy    1 EFRH 4
         |||
Db    3 EFRH 6

RESULT 32
ADQ82433
ID   ADQ82433 standard; peptide; 6 AA.
XX
AC   ADQ82433;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #44.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

Qy    1 EFRH 4
         |||
Db    3 EFRH 6

RESULT 33
ADQ82434
ID   ADQ82434 standard; peptide; 6 AA.
XX
AC   ADQ82434;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #45.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

Qy    1 EFRH 4
         |||
Db    3 EFRH 6

RESULT 34
ADQ82436
ID   ADQ82436 standard; peptide; 6 AA.
XX
AC   ADQ82436;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #47.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
```

XX
PT  Use of a compound having a binding capacity to an antibody specific for
PT  the natural N-terminal AB42 sequence, for preparing a vaccine for
PT  preventing and treating Alzheimer's disease.
XX
PS  Example 2.4; Fig 1B; 29pp; English.
XX
CC  The invention comprises peptides which mimic the N-terminal region of
CC  amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC  the invention have the capacity to bind to an antibody which is specific
CC  for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC  of the invention are useful in the preparation of a vaccine for
CC  Alzheimer's disease. The present amino acid sequence represents an N-
CC  terminal AB42 peptide mimotope of the invention.
XX
SQ  Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 35
ADQ82431
ID   ADQ82431 standard; peptide; 6 AA.
XX
AC   ADQ82431;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #42.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;

---

Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 36
ADQ82423
ID   ADQ82423 standard; peptide; 6 AA.
XX
AC   ADQ82423;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #34.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 37
ADQ82424
ID   ADQ82424 standard; peptide; 6 AA.
XX
AC   ADQ82424;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #35.
XX

RESULT 38
ADQ82428
ID   ADQ82428 standard; peptide; 6 AA.
XX
AC   ADQ82428;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #39.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6


RESULT 39
ADQ82435
ID   ADQ82435 standard; peptide; 6 AA.
XX
AC   ADQ82435;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #46.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

```
Query Match        100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.8e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy     1 EFRH 4
         ||||
Db     3 EFRH 6

RESULT 40
ADQ82429
ID  ADQ82429 standard; peptide; 6 AA.
XX
AC  ADQ82429;
XX
DT  21-OCT-2004 (first entry)
XX
DE  N-terminal amyloid-beta (AB42) peptide mimotope #40.
XX
KW  amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW  Alzheimer's disease.
XX
OS  Synthetic.
XX
PN  WO2004062556-A2.
XX
PD  29-JUL-2004.
XX
PF  13-JAN-2004; 2004WO-EP000162.
XX
PR  14-JAN-2003; 2003AT-00000036.
PR  17-SEP-2003; 2003AT-00001464.
XX
PA  (MATT/) MATTNER F.
XX
PI  Mattner F;
XX
DR  WPI; 2004-561715/54.
XX
PT  Use of a compound having a binding capacity to an antibody specific for
PT  the natural N-terminal AB42 sequence, for preparing a vaccine for
PT  preventing and treating Alzheimer's disease.
XX
PS  Example 2.4; Fig 1B; 29pp; English.
XX
CC  The invention comprises peptides which mimic the N-terminal region of
CC  amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC  the invention have the capacity to bind to an antibody which is specific
CC  for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC  of the invention are useful in the preparation of a vaccine for
CC  Alzheimer's disease. The present amino acid sequence represents an N-
CC  terminal AB42 peptide mimotope of the invention.
XX
SQ  Sequence 6 AA;

Query Match        100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.8e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy     1 EFRH 4
         ||||
Db     3 EFRH 6

RESULT 41
ADQ82425
ID  ADQ82425 standard; peptide; 6 AA.
XX
AC  ADQ82425;
XX
DT  21-OCT-2004 (first entry)
XX
DE  N-terminal amyloid-beta (AB42) peptide mimotope #36.
XX
KW  amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW  Alzheimer's disease.
XX
OS  Synthetic.
XX
PN  WO2004062556-A2.
XX
PD  29-JUL-2004.
XX
PF  13-JAN-2004; 2004WO-EP000162.
XX
PR  14-JAN-2003; 2003AT-00000036.
PR  17-SEP-2003; 2003AT-00001464.
XX
PA  (MATT/) MATTNER F.
XX
PI  Mattner F;
XX
DR  WPI; 2004-561715/54.
XX
PT  Use of a compound having a binding capacity to an antibody specific for
PT  the natural N-terminal AB42 sequence, for preparing a vaccine for
PT  preventing and treating Alzheimer's disease.
XX
PS  Example 2.4; Fig 1B; 29pp; English.
XX
CC  The invention comprises peptides which mimic the N-terminal region of
CC  amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC  the invention have the capacity to bind to an antibody which is specific
CC  for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC  of the invention are useful in the preparation of a vaccine for
CC  Alzheimer's disease. The present amino acid sequence represents an N-
CC  terminal AB42 peptide mimotope of the invention.
XX
SQ  Sequence 6 AA;

Query Match        100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 1.8e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy     1 EFRH 4
         ||||
Db     3 EFRH 6

RESULT 42
ADQ82422
ID  ADQ82422 standard; peptide; 6 AA.
XX
AC  ADQ82422;
XX
DT  21-OCT-2004 (first entry)
XX
DE  N-terminal amyloid-beta (AB42) peptide mimotope #33.
XX
KW  amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW  Alzheimer's disease.
XX
OS  Synthetic.
XX
PN  WO2004062556-A2.
XX
PD  29-JUL-2004.
XX
PF  13-JAN-2004; 2004WO-EP000162.
XX
PR  14-JAN-2003; 2003AT-00000036.
PR  17-SEP-2003; 2003AT-00001464.
XX
PA  (MATT/) MATTNER F.
XX
PI  Mattner F;
```

```
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 43
ADQ82421
ID   ADQ82421 standard; peptide; 6 AA.
XX
AC   ADQ82421;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #32.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 44
ADQ82437
ID   ADQ82437 standard; peptide; 6 AA.
XX
AC   ADQ82437;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #48.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 45
ADQ82386
ID   ADQ82386 standard; peptide; 6 AA.
XX
AC   ADQ82386;
XX
DT   21-OCT-2004  (first entry)
XX
```

```
DE   Natural N-terminal amyloid-beta (AB42) peptide #1.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Unidentified.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Claim 1; Page 22; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents the
CC   natural N-terminal AB42 peptide.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;     Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;     Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 46
ADQ82426
ID   ADQ82426 standard; peptide; 6 AA.
XX
AC   ADQ82426;
XX
DT   21-OCT-2004  (first entry)
XX
DE   N-terminal amyloid-beta (AB42) peptide mimotope #37.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
```

```
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2.4; Fig 1B; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents an N-
CC   terminal AB42 peptide mimotope of the invention.
XX
SQ   Sequence 6 AA;

Query Match             100.0%;     Score 24;  DB 8;  Length 6;
Best Local Similarity   100.0%;     Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 47
AAB46202
ID   AAB46202 standard; peptide; 7 AA.
XX
AC   AAB46202;
XX
DT   04-APR-2001  (first entry)
XX
DE   Human APP A-beta protein N-terminal fragment.
XX
KW   Amyloid deposit; APP; Abeta; brain; human; clearing response; nootropic;
KW   Fc receptor mediated phagocytosis; immunogenic response; neuroprotective;
KW   amyloid precursor protein; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   WO200072880-A2.
XX
PD   07-DEC-2000.
XX
PF   26-MAY-2000; 2000WO-US014810.
XX
PR   28-MAY-1999;  99US-00322289.
XX
PA   (NEUR-) NEURALAB LTD.
XX
PI   Schenk DB,  Bard F,  Vasquez NJ,  Yednock T;
XX
DR   WPI; 2001-032104/04.
XX
PT   Preventing or treating a disease associated with amyloid deposits,
PT   especially Alzheimer's disease, comprises administering amyloid specific
PT   antibody.
XX
PS   Claim 59; Page 119; 143pp; English.
XX
CC   This invention describes a novel method of preventing or treating a
CC   disease associated with amyloid deposits of amyloid precursor protein
CC   (APP) Abeta fragments in the brain of a patient, which comprises
CC   administering to the patient: (a) an antibody that binds to Abeta, the
CC   antibody binds to an amyloid deposit and induces a clearing response (Fc
CC   receptor mediated phagocytosis) against it (b) a polypeptide containing
CC   an N-terminal segment of at least residues 1-5 of Abeta; or (c) an agent
CC   that induces an immunogenic response against residues 1-3 to 7-11 of
```

CC   Abeta. The products of the invention have nootropic and neuroprotective
CC   activity. The method is also useful for monitoring a course of treatment
CC   being administered to a patient e.g. active and passive immunization. The
CC   methods are useful for prophylactic and therapeutic treatment of
CC   Alzheimer's disease
XX
SQ   Sequence 7 AA;

Query Match             100.0%;  Score 24;  DB 4;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
  Matches    4;  Conservative    0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 48
AAO14421
ID   AAO14421 standard; peptide; 7 AA.
XX
AC   AAO14421;
XX
DT   02-MAY-2002  (first entry)
XX
DE   Synthetic peptide of A-Beta residues 1-7 (DAEFRHD).
XX
KW   Neurodegenerative disorder; Alzheimer's disease; AD; T714I; APP; APP714;
KW   amyloid precursor protein; amyloid Beta peptide; A-Beta; A-Beta40; brain;
KW   A-Beta42; plaque pathology; pre-amyloid; cerebral amyloid angiopathy;
KW   Dense-cored plaque; CAA; senile plaque core; amyloid cascade; murine;
KW   mouse; DAEFRHD; monoclonal antibody.
XX
OS   Mus sp.
OS   Synthetic.
XX
PN   WO20202769-A1.
XX
PD   10-JAN-2002.
XX
PF   06-JUL-2001; 2001WO-EP007830.
PR   06-JUL-2000; 2000EP-00202362.
XX
PA   (VLAA-) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
XX
PI   Cruts M,  De Jonghe C,  Kumar Singh S,  Van Broeckhoven C;
XX
DR   WPI; 2002-15474/20.
XX
PT   Novel polynucleotide sequence encoding a mutant of amyloid precursor
PT   protein 70, useful for screening for a molecule capable of reducing the
PT   formation of beta amyloid 42 peptide.
XX
PS   Disclosure; Page 21; 42pp; English.
XX
CC   The invention relates to the field of the neurodegenerative disorder of
CC   Alzheimer's disease (AD). In particular, the invention provides a novel
CC   mutation (T714I) identified in the amyloid precursor protein (APP),
CC   APP714, which leads to a very aggressive form of AD. The mutation
CC   involves the 43rd codon of the amyloid Beta peptide (A-Beta)
CC   corresponding to the putative gamma 42-secretase cleavage site. The novel
CC   mutation alters both A-Beta40 and A-Beta42 secretion elevating the A-
CC   Beta42/A-Beta40 ratio by 10-fold in vitro. Furthermore, the main amyloid
CC   plaque pathology in brains of these patients is of the diffuse 'pre-
CC   amyloid' type composed primarily of N-truncated A-Beta42. Dense- cored
CC   plaques although not absent, were significantly reduced. Also, the usual
CC   sites in brain where A-Beta40 is predominantly deposited, for instance,
CC   in vessels as cerebral amyloid angiopathy (CAA) or senile plaque cores,
CC   were composed entirely of A-Beta42 form. Together, these indicate that
CC   deposition of N-truncated A-Beta42 in one of the earliest amyloid
CC   deposited in the brain, the diffuse plaques, is fully competent of
CC   inciting AD either through the well-established 'amyloid cascade' or by a

CC   yet unknown mechanism(s). This sequence represents a synthetic peptide of
CC   A-Beta, residues 1-7 (DAEFRHD). This sequence was used for raising a
CC   monoclonal antibody specific for the N-terminus of A-Beta40 and A-Beta42
CC   by immunising mice with the synthetic peptide
XX
SQ   Sequence 7 AA;

Query Match             100.0%;  Score 24;  DB 5;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
  Matches    4;  Conservative    0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 49
AAO19884
ID   AAO19884 standard; peptide; 7 AA.
XX
AC   AAO19884;
XX
DT   11-AUG-2003  (first entry)
XX
DE   Human amyloid precursor protein APP immunogenic peptide #4.
XX
KW   Human; APP; amyloid precursor protein; immunogen; Alzheimer's disease;
KW   high-throughput screening; neuroprotective; nootropic; antiparkinsonian.
XX
OS   Homo sapiens.
XX
PN   WO2003001881-A2.
XX
PD   09-JAN-2003.
XX
PF   26-JUN-2002; 2002WO-US02267.
PR   26-JUN-2001; 2001US-0300959P.
XX
PA   (NYME-) NEW YORK STATE OFFICE MENTAL HEALTH.
XX
PI   Mathews PM,  Nixon RA,  Schmidt SD,  Jiang Y;
XX
DR   WPI; 2003-210182/20.
XX
PT   Identifying compounds that modulates the generation of metabolites
PT   associated with a disease or disorder, for treating e.g. Alzheimer's
PT   disease by determining levels of a cellular component protein, or its
PT   conformation state.
XX
PS   Example 1; Page 29; 69pp; English.
XX
CC   The present invention relates to a method of identifying compounds that
CC   modulate the generation of one or more metabolites associated with a
CC   disease or disorder comprising determining levels of a cellular component
CC   protein or a conformation state of a cellular precursor protein. In
CC   particular, the method can be used to determine levels of amyloid
CC   precursor protein (APP), which is associated with Alzheimer's disease. It
CC   is also useful for identifying compounds as drugs for treating diseases
CC   or disorders associated with metabolic and/or proteolytic pathways, e.g.
CC   Alzheimer's disease, Parkinson's disease, Huntington's disease, lysosomal
CC   storage disorders, prion diseases, the tau-based neurodegenerative
CC   disorders, and other non-AD amyloidoses. The present sequence is an
CC   immunogenic portion of human APP
XX
SQ   Sequence 7 AA;

Query Match             100.0%;  Score 24;  DB 6;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
  Matches    4;  Conservative    0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||

```
Db        3 EFRH 6

RESULT 50
AAE35432
ID   AAE35432 standard; peptide; 7 AA.
XX
AC   AAE35432;
XX
DT   17-JUN-2003  (first entry)
XX
DE   Abeta peptide #3.
XX
KW   All-D-amyloid-beta peptide; Alzheimer's disease; rheumatoid arthritis;
KW   cerebral amyloid angiopathy; amyloid disease; ankylosing spondylitis;
KW   psoriasis; Reiter's syndrome; Adult Still's disease; Bechet's syndrome;
KW   Crohn's disease; infection; leprosy; tuberculosis; carcinoma; nootropic;
KW   chronic pyelonephritis; osteomyelitis; Whipple's disease; vasotropic;
KW   Hodgkin's lymphoma; neuroprotective; bronchiectasis; ophthalmological;
KW   ulcer; antiinflammatory; cytostatic; uropathic; therapy.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1..7
FT                   /note= "D-form residues"
XX
PN   WO200296937-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-CA000763.
XX
PR   29-MAY-2001; 2001US-00867847.
XX
PA   (NEUR-) NEUROCHEM INC.
XX
PI   Gervais F, Hebert L, Chalifour RJ, Kong X;
XX
DR   WPI; 2003-201269/19.
XX
PT   Prevention and/or treatment of an amyloid-related disease e.g.
PT   Alzheimer's disease, comprises use of all-D-amyloid-beta peptides.
XX
PS   Claim 1; Page 58; 44pp; English.
XX
CC   The invention relates to a method for prevention and/or treatment of an
CC   amyloid-related disease which comprises administration of an all-D -
CC   amyloid-beta peptide. The method is used for preventing and/or treating
CC   Alzheimer's and other amyloid related disease e.g. cerebral amyloid
CC   angiopathy; for altering serum levels of amyloid-beta in a mammal and
CC   favours the clearance of soluble amyloid-beta or fibril amyloid-beta from
CC   the mammal; and reducing or inhibiting the formation of plaques. It is
CC   also used for treating AA (reactive) amyloid diseases including
CC   inflammatory diseases e.g. rheumatoid arthritis, juvenile chronic
CC   arthritis, ankylosing spondylitis, psoriasis, psoriatic arthropathy,
CC   Reiter's syndrome, Adult Still's disease, Bechet's syndrome and Crohn's
CC   disease. AA deposits are also produced as a result of chronic microbial
CC   infections (preferably leprosy, tuberculosis, bronchiectasis, decubitus
CC   ulcers, chronic pyelonephritis, osteomyelitis and Whipple's disease).
CC   Certain malignant neoplasms can also result in AA fibril amyloid deposits
CC   including Hodgkin's lymphoma, renal carcinoma, carcinomas of gut, lung
CC   and urogenital tract, basal cell carcinoma and hairy cell leukaemia. The
CC   present sequence is an Abeta peptide used to illustrate the method of the
CC   invention
XX
SQ   Sequence 7 AA;

Query Match             100.0%;  Score 24;  DB 6;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
```

```
Db        3 EFRH 6
          ||||

RESULT 51
ADA90925
ID   ADA90925 standard; peptide; 7 AA.
XX
AC   ADA90925;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Solid-phase synthesis heptapeptide #2.
XX
KW   antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;
KW   nootropic; antiparkinsonian; gene therapy; amyloidogenesis;
KW   amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;
KW   Alzheimer's disease; motor neuropathy; Down's syndrome;
KW   Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;
KW   Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;
KW   neuronal disorder; aging.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO200307076O-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-EP001759.
XX
PR   20-FEB-2002; 2002EP-00003844.
XX
PA   (HOFF ) HOFFMANN LA ROCHE & CO AG F.
PA   (MORP-) MORPHOSYS AG.
XX
PI   Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;
PI   Loehning C, Loetscher H, Nordstedt C, Rothe C;
XX
DR   WPI; 2003-663848/62.
XX
PT   New antibody molecule capable of specifically recognizing two regions of
PT   the beta-A4 peptide, useful for diagnosing, preventing or treating
PT   diseases associated with amyloidogenesis or amyloid-plaque formation
PT   (e.g. dementia).
XX
PS   Example 12; Page 82; 312pp; English.
XX
CC   The present invention describes an antibody molecule (I) capable of
CC   specifically recognising two regions of the beta-A4 peptide/Abeta4. The
CC   first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-
CC   Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the
CC   amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-
CC   Gly ADA89987 or its fragment. Also described: (1) a nucleic acid molecule
CC   encoding (I); (2) a vector comprising the nucleic acid of (1); (3) a host
CC   cell comprising the vector of (2); (4) preparing (I), comprising
CC   culturing the host cell of (3) under conditions that allow synthesis of
CC   (I) and recovering (I) from the culture; (5) a composition comprising (I),
CC   or an antibody molecule produced by method (4); (6) a kit comprising (1),
CC   nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising
CC   (I); (8) testing the resulting Fab optimisation library by panning
CC   against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing
CC   of selected, optimised clones; (11) preparing a pharmaceutical
CC   composition, comprising optimisation of (I), and formulating the
CC   optimised antibody/antibody molecule with a carrier; and (12) a
CC   pharmaceutical composition prepared by method (8). (I) has
CC   neuroprotective, nootropic and antiparkinsonian activities, and can be
CC   used in gene therapy. The antibody molecule (I), nucleic acid molecule,
CC   vector or host is useful in preparing a pharmaceutical composition for
CC   the prevention and/or treatment of a disease associated with
CC   amyloidogenesis and/or amyloid-plaque formation. The antibody molecule
CC   may also be used in preparing a diagnostic composition for the detection
CC   of the disease mentioned above. The antibody is used for the
```

```
CC   disintegration of beta-amyloid plaques or for passive immunisation
CC   against beta-amyloid plaque formation. In particular, the disease is
CC   dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,
CC   Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with
CC   amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,
CC   amyotrophic lateral sclerosis or neuronal disorders related to aging. The
CC   present sequence is used in the exemplification of the present invention.
XX
SQ   Sequence 7 AA;

Query Match             100.0%;  Score 24;  DB 6;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         1 EFRH 4
             ||||
Db         1 EFRH 4

RESULT 52
ADA90142
ID   ADA90142 standard; peptide; 7 AA.
XX
AC   ADA90142;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Anti-Abeta antibody related amino acid sequence SEQ ID NO:257.
XX
KW   antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;
KW   nootropic; antiparkinsonian; gene therapy; amyloidogenesis;
KW   amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;
KW   Alzheimer's disease; motor neuropathy; Down's syndrome;
KW   Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;
KW   Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;
KW   neuronal disorder; aging.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070760-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-EP001759.
XX
PR   20-FEB-2002; 2002EP-00003844.
XX
PA   (HOFF ) HOFFMANN LA ROCHE & CO AG F.
PA   (MORP-) MORPHOSYS AG.
XX
PI   Bardroff M,  Bohrmann B,  Brockhaus M,  Huber W,  Kretzschmar T;
PI   Loehning C,  Loetscher H,  Nordstedt C,  Rothe C;
XX
DR   WPI; 2003-663848/62.
XX
PT   New antibody molecule capable of specifically recognizing two regions of
PT   the beta-A4 peptide, useful for diagnosing, preventing or treating
PT   diseases associated with amyloidogenesis or amyloid-plaque formation
PT   (e.g. dementia).
XX
PS   Disclosure; Page 258; 312pp; English.
XX
CC   The present invention describes an antibody molecule (I) capable of
CC   specifically recognising two regions of the beta-A4 peptide/Abeta4. The
CC   first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-
CC   Ser-Gly-Tyr ADA9886 or its fragment, and the second region comprises the
CC   amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-
CC   Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule
CC   encoding (I); (2) a vector comprising the nucleic acid of (1); (3) a host
CC   cell comprising the vector of (2); (4) preparing (I), comprising
CC   culturing the host cell of (3) under conditions that allow synthesis of
CC   (I) and recovering (I) from the culture; (5) a composition comprising (I)

CC   or an antibody molecule produced by method (4); (6) a kit comprising (I),
CC   nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising
CC   (I); (8) testing the resulting Fab optimisation library by panning
CC   against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing
CC   of selected, optimised clones; (11) preparing a pharmaceutical
CC   composition, comprising optimisation of (I), and formulating the
CC   optimised antibody/antibody molecule with a carrier; and (12) a
CC   pharmaceutical composition prepared by method (8). (I) has
CC   neuroprotective, nootropic and antiparkinsonian activities, and can be
CC   used in gene therapy. The antibody molecule (I), nucleic acid molecule,
CC   vector or host is useful in preparing a pharmaceutical composition for
CC   the prevention and/or treatment of a disease associated with
CC   amyloidogenesis and/or amyloid-plaque formation. The antibody molecule
CC   may also be used in preparing a diagnostic composition for the detection
CC   of the disease mentioned above. The antibody is used for the
CC   disintegration of beta-amyloid plaques or for passive immunisation
CC   against beta-amyloid plaque formation. In particular, the disease is
CC   dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,
CC   Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with
CC   amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,
CC   amyotrophic lateral sclerosis or neuronal disorders related to aging. The
CC   present sequence is used in the exemplification of the present invention.
XX
SQ   Sequence 7 AA;

Query Match             100.0%;  Score 24;  DB 6;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         1 EFRH 4
             ||||
Db         1 EFRH 4

RESULT 53
ADA90141
ID   ADA90141 standard; peptide; 7 AA.
XX
AC   ADA90141;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Anti-Abeta antibody related amino acid sequence SEQ ID NO:256.
XX
KW   antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;
KW   nootropic; antiparkinsonian; gene therapy; amyloidogenesis;
KW   amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;
KW   Alzheimer's disease; motor neuropathy; Down's syndrome;
KW   Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;
KW   Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;
KW   neuronal disorder; aging.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070760-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-EP001759.
XX
PR   20-FEB-2002; 2002EP-00003844.
XX
PA   (HOFF ) HOFFMANN LA ROCHE & CO AG F.
PA   (MORP-) MORPHOSYS AG.
XX
PI   Bardroff M,  Bohrmann B,  Brockhaus M,  Huber W,  Kretzschmar T;
PI   Loehning C,  Loetscher H,  Nordstedt C,  Rothe C;
XX
DR   WPI; 2003-663848/62.
XX
PT   New antibody molecule capable of specifically recognizing two regions of
PT   the beta-A4 peptide, useful for diagnosing, preventing or treating
```

PT   diseases associated with amyloidogenesis or amyloid-plaque formation
PT   (e.g. dementia).
XX
PS   Disclosure; Page 257; 312pp; English.
XX
CC   The present invention describes an antibody molecule (I) capable of
CC   specifically recognising two regions of the beta-A4 peptide/Abeta4. The
CC   first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-
CC   Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the
CC   amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-
CC   Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule
CC   encoding (I); (2) a vector comprising the nucleic acid of (1); (3) a host
CC   cell comprising the vector of (2); (4) preparing (I), comprising
CC   culturing the host cell of (3) under conditions that allow synthesis of
CC   (I) and recovering (I) from the culture; (5) a composition comprising (I)
CC   or an antibody molecule produced by method (4); (6) a kit comprising (I),
CC   nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising
CC   (I); (8) testing the resulting Fab optimisation library by panning
CC   against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing
CC   of selected, optimised clones; (11) preparing a pharmaceutical
CC   composition, comprising optimisation of (I), and formulating the
CC   optimised antibody/antibody molecule with a carrier; and (12) a
CC   pharmaceutical composition prepared by method (8). (I) has
CC   neuroprotective, nootropic and antiparkinsonian activities, and can be
CC   used in gene therapy. The antibody molecule (I), nucleic acid molecule,
CC   vector or host is useful in preparing a pharmaceutical composition for
CC   the prevention and/or treatment of a disease associated with
CC   amyloidogenesis and/or amyloid-plaque formation. The antibody molecule
CC   may also be used in preparing a diagnostic composition for the detection
CC   of the disease mentioned above. The antibody is used for the
CC   disintegration of beta-amyloid plaques or for passive immunisation
CC   against beta-amyloid plaque formation. In particular, the disease is
CC   dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,
CC   Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with
CC   amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,
CC   amyotrophic lateral sclerosis or neuronal disorders related to aging. The
CC   present sequence is used in the exemplification of the present invention.
XX
SQ   Sequence 7 AA;

Query Match     100.0%;   Score 24;   DB 6;   Length 7;
Best Local Similarity   100.0%;   Pred. No. 1.8e+06;
Matches    4;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

Qy    1 EFRH 4
       ||||
Db    2 EFRH 5

RESULT 54
ADA90924
ID   ADA90924 standard; peptide; 7 AA.
XX
AC   ADA90924;
XX
DT   20-NOV-2003 (first entry)
XX
DE   Solid-phase synthesis heptapeptide #1.
XX
KW   antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;
KW   nootropic; antiparkinsonian; gene therapy; amyloidogenesis;
KW   amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;
KW   Alzheimer's disease; motor neuropathy; Down's syndrome;
KW   Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;
KW   Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;
KW   neuronal disorder; aging.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO200307O760-A2.
XX
PD   28-AUG-2003.

---

XX
PF   20-FEB-2003; 2003WO-EP001759.
XX
PR   20-FEB-2002; 2002EP-00003844.
XX
PA   (HOFF ) HOFFMANN LA ROCHE & CO AG F.
PA   (MORP-) MORPHOSYS AG.
XX
PI   Bardroff M,   Bohrmann B,   Brockhaus M,   Huber W,   Kretzschmar T;
PI   Loehning C,   Loetscher H,   Nordstedt C,   Rothe C;
XX
DR   WPI; 2003-663848/62.
XX
PT   New antibody molecule capable of specifically recognizing two regions of
PT   the beta-A4 peptide, useful for diagnosing, preventing or treating
PT   diseases associated with amyloidogenesis or amyloid-plaque formation
PT   (e.g. dementia).
XX
PS   Example 12; Page 82; 312pp; English.
XX
CC   The present invention describes an antibody molecule (I) capable of
CC   specifically recognising two regions of the beta-A4 peptide/Abeta4. The
CC   first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-
CC   Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the
CC   amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-
CC   Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule
CC   encoding (I); (2) a vector comprising the nucleic acid of (1); (3) a host
CC   cell comprising the vector of (2); (4) preparing (I), comprising
CC   culturing the host cell of (3) under conditions that allow synthesis of
CC   (I) and recovering (I) from the culture; (5) a composition comprising (I)
CC   or an antibody molecule produced by method (4); (6) a kit comprising (I),
CC   nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising
CC   (I); (8) testing the resulting Fab optimisation library by panning
CC   against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing
CC   of selected, optimised clones; (11) preparing a pharmaceutical
CC   composition, comprising optimisation of (I), and formulating the
CC   optimised antibody/antibody molecule with a carrier; and (12) a
CC   pharmaceutical composition prepared by method (8). (I) has
CC   neuroprotective, nootropic and antiparkinsonian activities, and can be
CC   used in gene therapy. The antibody molecule (I), nucleic acid molecule,
CC   vector or host is useful in preparing a pharmaceutical composition for
CC   the prevention and/or treatment of a disease associated with
CC   amyloidogenesis and/or amyloid-plaque formation. The antibody molecule
CC   may also be used in preparing a diagnostic composition for the detection
CC   of the disease mentioned above. The antibody is used for the
CC   disintegration of beta-amyloid plaques or for passive immunisation
CC   against beta-amyloid plaque formation. In particular, the disease is
CC   dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,
CC   Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with
CC   amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,
CC   amyotrophic lateral sclerosis or neuronal disorders related to aging. The
CC   present sequence is used in the exemplification of the present invention.
XX
SQ   Sequence 7 AA;

Query Match     100.0%;   Score 24;   DB 6;   Length 7;
Best Local Similarity   100.0%;   Pred. No. 1.8e+06;
Matches    4;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

Qy    1 EFRH 4
       ||||
Db    2 EFRH 5

RESULT 55
ADA90171
ID   ADA90171 standard; peptide; 7 AA.
XX
AC   ADA90171;
XX
DT   20-NOV-2003 (first entry)
XX
DE   Anti-Abeta antibody related amino acid sequence SEQ ID NO:286.

```
XX
KW   antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;
KW   nootropic; antiparkinsonian; gene therapy; amyloidogenesis;
KW   amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;
KW   Alzheimer's disease; motor neuropathy; Down's syndrome;
KW   Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;
KW   Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;
KW   neuronal disorder; aging.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070760-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-EP001759.
XX
PR   20-FEB-2002; 2002EP-00003844.
XX
PA   (HOFF ) HOFFMANN LA ROCHE & CO AG F.
PA   (MORP-) MORPHOSYS AG.
XX
PI   Bardroff M,  Bohrmann B,  Brockhaus M,  Huber W,  Kretzschmar T;
PI   Loehning C,  Loetscher H,  Nordstedt C,  Rothe C;
XX
DR   WPI; 2003-663848/62.
XX
PT   New antibody molecule capable of specifically recognizing two regions of
PT   the beta-A4 peptide, useful for diagnosing, preventing or treating
PT   diseases associated with amyloidogenesis or amyloid-plaque formation
PT   (e.g. dementia).
XX
PS   Disclosure; Page 264; 312pp; English.
XX
CC   The present invention describes an antibody molecule (I) capable of
CC   specifically recognising two regions of the beta-A4 peptide/Abeta4. The
CC   first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-
CC   Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the
CC   amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-
CC   Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule
CC   encoding (I); (2) a vector comprising the nucleic acid of (1); (3) a host
CC   cell comprising the vector of (2); (4) preparing (I), comprising
CC   culturing the host cell of (3) under conditions that allow synthesis of
CC   (I) and recovering (I) from the culture; (5) a composition comprising (I)
CC   or an antibody molecule produced by method (4); (6) a kit comprising (I),
CC   nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising
CC   (I); (8) testing the resulting Fab optimisation library by panning
CC   against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing
CC   of selected, optimised clones; (11) preparing a pharmaceutical
CC   composition, comprising optimisation of (I), and formulating the
CC   optimised antibody/antibody molecule with a carrier; and (12) a
CC   pharmaceutical composition prepared by method (8). (I) has
CC   neuroprotective, nootropic and antiparkinsonian activities, and can be
CC   used in gene therapy. The antibody molecule (I), nucleic acid molecule,
CC   vector or host is useful in preparing a pharmaceutical composition for
CC   the prevention and/or treatment of a disease associated with
CC   amyloidogenesis and/or amyloid-plaque formation. The antibody molecule
CC   may also be used in preparing a diagnostic composition for the detection
CC   of the disease mentioned above. The antibody is used for the
CC   disintegration of beta-amyloid plaques or for passive immunisation
CC   against beta-amyloid plaque formation. In particular, the disease is
CC   dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,
CC   Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with
CC   amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,
CC   amyotrophic lateral sclerosis or neuronal disorders related to aging. The
CC   present sequence is used in the exemplification of the present invention.
XX
SQ   Sequence 7 AA;

Query Match             100.0%;  Score 24;  DB 6;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 56
ADJ71565
ID   ADJ71565 standard; peptide; 7 AA.
XX
AC   ADJ71565;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal APP peptide C-terminal fragment, SEQ ID 228.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A,  Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 7; Page 67; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 7 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          4 EFRH 7

RESULT 57
ADJ71380
ID   ADJ71380 standard; peptide; 7 AA.
XX
AC   ADJ71380;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 43.
XX
```

```
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "Pyroglutamic acid"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 62; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 7 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 58
ADJ71341
ID   ADJ71341 standard; peptide; 7 AA.
XX
AC   ADJ71341;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 4.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "Methylated"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 7 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 59
ADJ71367
ID   ADJ71367 standard; peptide; 7 AA.
XX
AC   ADJ71367;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 30.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
```

XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 7 AA;

Query Match             100.0%;   Score 24;  DB 8;  Length 7;
Best Local Similarity   100.0%;   Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db      1 EFRH 4

RESULT 60
ADJ71354
ID   ADJ71354 standard; peptide; 7 AA.
XX
AC   ADJ71354;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 17.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key            Location/Qualifiers
FT   Modified-site  1
FT                  /note= "Optionally methylated"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX

SQ   Sequence 7 AA;

Query Match             100.0%;   Score 24;  DB 8;  Length 7;
Best Local Similarity   100.0%;   Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db      2 EFRH 5

RESULT 61
ADQ37256
ID   ADQ37256 standard; peptide; 7 AA.
XX
AC   ADQ37256;
XX
DT   07-OCT-2004  (first entry)
XX
DE   Vaccine antigen amyloid-beta related amino acid sequence.
XX
KW   amyloid-beta; amyloid-beta related disease;
KW   amyloid-beta fibril formation; immune response; nootropic;
KW   neuroprotective; cerebroprotective; haemostatic; ophthalmological;
KW   antithyroid; vasotropic; cardiovascular; tranquilliser; uropathic;
KW   anticonvulsant; anti-HIV; antiparkinsonian; muscular; neuroleptic;
KW   cardiant; antidepressant; endocrine; hypnotic;
KW   amyloid-beta fibril formation modulator; immune system modulator;
KW   Alzheimer's disease; mild cognitive impairment;
KW   mild-to-moderate cognitive impairment; vascular dementia;
KW   cerebral amyloid angiopathy; hereditary cerebral haemorrhage;
KW   senile dementia; Down's syndrome; inclusion body myositis;
KW   age-related macular degeneration; hypothyroidism;
KW   cerebrovascular disease; cardiovascular disease; memory loss; anxiety;
KW   behavioural dysfunction; neurological condition; psychological condition;
KW   vaccine antigen.
XX
OS   Synthetic.
XX
FH   Key            Location/Qualifiers
FT   Misc-difference 1..7
FT                  /note= "D-form residues"
XX
PN   WO2004058239-A1.
XX
PD   15-JUL-2004.
XX
PF   24-DEC-2003; 2003WO-CA002021.
XX
PR   24-DEC-2002; 2002US-0436379P.
PR   23-JUN-2003; 2003US-0482214P.
XX
PA   (NEUR-) NEUROCHEM INT LTD.
XX
PI   Gervais F, Bellini F;
XX
DR   WPI; 2004-543342/52.
XX
PT   Composition for treating e.g. Alzheimer's disease comprises first agent
PT   that prevents or treats amyloid-beta related disease and second agent
PT   that is either a peptide or peptidomimetic or an immune system modulator.
XX
PS   Disclosure; Page 67; 143pp; English.
XX
CC   The present invention describes compositions (C) comprising: (a) a first
CC   agent (a1) that prevents or treats amyloid-beta related disease; and (b)
CC   a second agent (a2) that is: (i) a peptide or peptidomimetic that
CC   modulates amyloid-beta fibril formation or induces a prophylactic or
CC   therapeutic immune response against amyloid-beta fibril formation; or
CC   (ii) an immune system modulator that prevents or inhibits amyloid-beta
CC   fibril formation. Also described is a kit comprising (C). (C) have
CC   nootropic, neuroprotective, cerebroprotective, haemostatic,
CC   ophthalmological, antithyroid, vasotropic, cardiovascular, tranquilliser,
XX

CC uropathic, anticonvulsant, anti-HIV, antiparkinsonian, muscular,
CC neuroleptic, cardiant, antidepressant, endocrine and hypnotic activities,
CC and can be used as amyloid-beta fibril formation modulators, and as
CC immune system modulators. (C) can be used for preventing or treating an
CC amyloid-beta related disease e.g. Alzheimer's disease (including sporadic
CC (non-hereditary) or familial (hereditary)), mild cognitive impairment,
CC mild-to-moderate cognitive impairment, vascular dementia, cerebral
CC amyloid angiopathy, hereditary cerebral haemorrhage, senile dementia,
CC Down's syndrome, inclusion body myositis, age-related macular
CC degeneration, or a condition associated with Alzheimer's disease
CC (including hypothyroidism, cerebrovascular disease, cardiovascular
CC disease, memory loss, anxiety, a behavioural dysfunction (e.g. apathy,
CC aggression, or incontinence), a neurological condition (e.g. Huntington's
CC disease, amyotrophic lateral sclerosis, acquired immunodeficiency,
CC Parkinson's disease, aphasia, apraxia, agnosia, Pick disease, dementia
CC with Lewy bodies, altered muscle tone, seizures, sensory loss, visual
CC field deficits, incoordination, gait disturbance, transient ischaemic
CC attack or stroke, transient alertness, attention deficit, frequent falls,
CC syncope, neuroleptic sensitivity, normal pressure hydrocephalus, subdural
CC haematoma, brain tumour, posttraumatic brain injury, or posthypoxic
CC damage), or a psychological condition (e.g. depression, delusions,
CC illusion, hallucination, sexual disorder, weight loss, psychosis, a sleep
CC disturbance, insomnia, behavioural disinhibition, poor insight, suicidal
CC ideation, depressed mood, irritability, anhedonia, social withdrawal, or
CC excessive guilt)) in a subject e.g. human having a genomic mutation in an
CC amyloid precursor protein gene, an ApoE gene, or a presenilin gene;
CC having amyloid-beta deposits. The present sequence represents a peptide
CC that can be used as a vaccine antigen in the exemplification of the
CC present invention.
XX
SQ Sequence 7 AA;

Query Match      100.0%;    Score 24;   DB 8;   Length 7;
Best Local Similarity   100.0%;   Pred. No. 1.8e+06;
Matches    4;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

```
Qy   1 EFRH 4
        ||||
Db   3 EFRH 6
```

RESULT 62
ADQ82412
ID ADQ82412 standard; peptide; 7 AA.
XX
AC ADQ82412;
XX
DT 21-OCT-2004 (first entry)
XX
DE Natural N-terminal amyloid-beta (AB42) peptide.
XX
KW amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW Alzheimer's disease.
XX
OS Unidentified.
XX
PN WO200406556-A2.
XX
PD 29-JUL-2004.
XX
PF 13-JAN-2004; 2004WO-EP000162.
XX
PR 14-JAN-2003; 2003AT-00000036.
PR 17-SEP-2003; 2003AT-00001464.
XX
PA (MATT/) MATTNER F.
XX
PI Mattner F;
XX
DR WPI; 2004-561715/54.
XX
PT Use of a compound having a binding capacity to an antibody specific for
PT the natural N-terminal AB42 sequence, for preparing a vaccine for
PT preventing and treating Alzheimer's disease.
XX
PS Example 2; Page 12; 29pp; English.
XX
CC The invention comprises peptides which mimic the N-terminal region of
CC amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC the invention have the capacity to bind to an antibody which is specific
CC for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC of the invention are useful in the preparation of a vaccine for
CC Alzheimer's disease. The present amino acid sequence represents the
CC natural N-terminal AB42 peptide.
XX
SQ Sequence 7 AA;

Query Match      100.0%;    Score 24;   DB 8;   Length 7;
Best Local Similarity   100.0%;   Pred. No. 1.8e+06;
Matches    4;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

```
Qy   1 EFRH 4
        ||||
Db   4 EFRH 7
```

RESULT 63
ADS09217
ID ADS09217 standard; peptide; 7 AA.
XX
AC ADS09217;
XX
DT 16-DEC-2004 (first entry)
XX
DE Amyloid beta 1-7 peptide.
XX
KW antibacterial; vaccine; immunogenic composition; cholera holotoxin; CT;
KW immunogenicity; heat labile toxin; pertussis toxin; A sub-unit;
KW amyloid beta; human.
XX
OS Homo sapiens.
XX
PN WO2004083251-A2.
XX
PD 30-SEP-2004.
XX
PF 11-MAR-2004; 2004WO-US007673.
XX
PR 17-MAR-2003; 2003US-0455214P.
XX
PA (AMHP ) WYETH HOLDINGS CORP.
XX
PI Hagen M;
XX
DR WPI; 2004-699805/68.
XX
PT Immunogenic composition for immunizing mammalian host against cholera,
PT Escherichia coli and pertussis,comprises a mutated cholera holotoxin
PT subunit, Escherichia coli heat labile toxin, pertussis toxin and their
PT covalent antigens.
XX
PS Example 5; SEQ ID NO 8; 82pp; English.
XX
CC The invention describes an immunogenic composition (I) comprising a
CC cholera holotoxin (CT) and an antigen covalently associated with CT. CT
CC comprises A subunit (CT-A) having a mutation at amino acid residue 29 of
CC a sequence (S1) of 240 amino acids fully defined in the specification,
CC where the mutation is not aspartic acid, where CT increases
CC immunogenicity of the antigen, (b) CT and an antigen covalently
CC associated with CT, where CT comprises one or more mutations in CT-A,
CC where CT increases immunogenicity of the antigen, (c) Escherichia coli
CC heat labile toxin (LT) and an antigen covalently associated with LT,
CC where LT increases immunogenicity of the antigen, or (d) a pertussis
CC toxin (PT) and an antigen covalently associated with PT, where PT
CC increases immunogenicity of the antigen. Isolated and purified CT, LT and
CC PT polynucleotides and polypeptides, are also disclosed. (I) is useful

CC    for immunising a mammalian host against cholera, Escherichia coli,
CC    Bordetella pertussis, which involves administering (I) to the host. (I)
CC    has reduced or minimal toxicity. This is the amino acid sequence of an
CC    amyloid beta 1-7 peptide used in the creation of holotoxin conjugates.
XX
SQ    Sequence 7 AA;

Query Match            100.0%;  Score 24;  DB 8;  Length 7;
Best Local Similarity  100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         1 EFRH 4
             ||||
Db         3 EFRH 6

RESULT 64
AAW70865
ID    AAW70865 standard; peptide; 8 AA.
XX
AC    AAW70865;
XX
DT    04-FEB-1999  (first entry)
XX
DE    Beta-amyloid peptide to create a monoclonal antibody.
XX
KW    Beta-amyloid precursor protein; beta-APP; beta-amyloid peptide; antibody;
KW    amyloid deposit; Alzheimer's disease.
XX
OS    Synthetic.
OS    Homo sapiens.
XX
PN    WO9844955-A1.
XX
PD    15-OCT-1998.
XX
PF    09-APR-1998;  98WO-US006900.
XX
PR    09-APR-1997;  97US-0041850P.
XX
PA    (MIND-) MINDSET LTD.
PA    (MCIN/) MCINNIS P A.
XX
PI    Chain DG;
XX
DR    WPI; 1998-594476/50.
XX
PT    Preventing or inhibiting progression of Alzheimer's Disease - comprises
PT    use of recombinant DNA encoding an antibody specific for the N- or C-
PT    terminus of an amyloid-beta peptide.
XX
PS    Example 1; Page 46; 58pp; English.
XX
CC    The present sequence represents a peptide derived from beta-amyloid
CC    precursor protein (beta-APP, see AAW70863). The peptide is a beta-amyloid
CC    peptide and is used to produce a monoclonal antibody designated
CC    antisenilin N1/7. The specification describes a method for prevention or
CC    inhibition of progression of Alzheimer's disease. The method comprises
CC    administering a composition comprising a recombinant DNA molecule
CC    containing a gene encoding a recombinant antibody end-specific for the N-
CC    terminus or the C-terminus of an amyloid-beta peptide, operably linked to
CC    a promoter which is expressed in the central nervous system. The
CC    recombinant antibody molecules prevent the accumulation of beta-amyloid
CC    peptides in the extracellular space, interstitial fluid and cerebrospinal
CC    fluid and the aggregation of such peptides into amyloid deposits in the
CC    brain. They also inhibit the progression of Alzheimer's disease by
CC    inhibiting the interaction of beta-amyloid peptides mediating Alzheimer's
CC    disease induced neurotoxicity and inhibiting the Alzheimer's disease
CC    induced complement activation and cytokine release involved in the
CC    inflammatory process
XX
SQ    Sequence 8 AA;

Query Match            100.0%;  Score 24;  DB 2;  Length 8;
Best Local Similarity  100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         1 EFRH 4
             ||||
Db         3 EFRH 6

RESULT 65
AAU78518
ID    AAU78518 standard; peptide; 8 AA.
XX
AC    AAU78518;
XX
DT    18-JUN-2002  (first entry)
XX
DE    N terminus of beta amyloid.
XX
KW    Alzheimer's disease; beta amyloid precursor protein; mouse; BACE;
KW    beta-site APP cleaving enzyme; nootropic; neuroprotective;
KW    beta-site amyloid precursor protein (APP)-cleaving enzyme; APP;
KW    BACE secretase/sheddase; neurodegenerative disorder.
XX
OS    Mus sp.
XX
PN    WO200210354-A2.
XX
PD    07-FEB-2002.
XX
PF    01-AUG-2001;  2001WO-CA001118.
XX
PR    01-AUG-2000;  2000CA-0231B828.
XX
PA    (RECL-) INST RECH CLINIQUES MONTREAL.
XX
PI    Seidah NG,  Chretien M,  Cromlish JA;
XX
DR    WPI; 2002-280632/32.
XX
PT    Modulating activity of beta-site amyloid precursor protein-cleaving
PT    enzyme secretase/sheddase for treatment of neurodegenerative disorder
PT    characterized by generation of Abeta protein, by preventing cleavage of
PT    enzyme.
XX
PS    Disclosure; Page 28; 64pp; English.
XX
CC    This invention relates to a novel method for modulating activity of beta-
CC    site amyloid precursor protein (APP)-cleaving enzyme (BACE)
CC    secretase/sheddase. Cleavage of BACE by this enzyme results in the
CC    generation of a soluble BACE which enhances the production of the
CC    amyloidogenic peptide Abeta which has been shown to be involved in the
CC    aetiology of Alzheimer's disease. Inhibition of BACE secretase can be
CC    achieved by administration of an antisense nucleotide molecule capable of
CC    hybridising with BACE mRNA, by using a ribozyme that targets and degrades
CC    BACE secretase mRNA, with a peptide that can interfere with binding of
CC    the enzyme with BACE or using an antibody or antagonist that can function
CC    as an inhibitor of BACE secretase activation. The methods of the
CC    invention modulate the activity of BACE secretase/sheddase by preventing
CC    cleavage of BACE, which is useful for the treatment of a
CC    neurodegenerative disorder characterised by the generation of Abeta
CC    protein, especially Alzheimer's disease. The invention also comprises a
CC    method for identification of an agent that can alter the ability of BACE
CC    secretase to associate with and process a known substrate, this method
CC    can be used for high throughput screening of candidate molecules. The
CC    invention also comprises a method for determining whether an individual
CC    is at risk of developing a neurodegenerative disorder characterised by
CC    the generation of Abeta protein by measuring the levels of BACE C
CC    terminal cleavage products in a sample or tissue where an increase in
CC    cleavage products indicates a person at risk. The present sequence
CC    represents the N terminal of a beta amyloid protein of the invention
XX
SQ    Sequence 8 AA;

```
Query Match          100.0%;   Score 24;  DB 5;  Length 8;
Best Local Similarity 100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 66
ABP70740
ID   ABP70740 standard; peptide; 8 AA.
XX
AC   ABP70740;
XX
DT   15-MAY-2003  (first entry)
XX
DE   Antigenic peptide, SEQ ID 1.
XX
KW   Nootropic; neuroprotective; antiinflammatory; vaccine; antigenic product;
KW   plaque-forming disease; Alzheimer's disease; SAA amyloidosis;
KW   hereditary Icelandic syndrome; senility; multiple myeloma;
KW   Creutzfeldt-Jakob disease; Kuru; Gerstmann-Straussler-Scheinker disease;
KW   fatal familial insomnia; scrapie; bovine spongiform encephalitis;
KW   antigenic; multiantigen.
XX
OS   Synthetic.
XX
PN   WO2003000719-A2.
XX
PD   03-JAN-2003.
XX
PF   20-JUN-2002; 2002WO-US019567.
XX
PR   20-JUN-2001; 2001US-0299201P.
PR   12-APR-2002; 2002US-0371717P.
XX
PA   (UYRA-) UNIV RAMOT.
PA   (MCIN/) MCINNIS P.
XX
PI   McInnis P, Solomon B;
XX
DR   WPI; 2003-239139/23.
XX
PT   Antigenic product has dendritic polymer built on core molecule having
PT   terminal functional groups to which antigenic peptide that has epitope of
PT   deposit-forming polypeptide involved in plaque-forming disease is joined.
XX
PS   Claim 7; Page 42; 70pp; English.
XX
CC   The present invention relates to antigenic products (A), comprising a
CC   dendritic polymer built on a core molecule which is at least difunctional
CC   to provide branching and containing up to 16 terminal functional groups
CC   to which an antigenic peptide, that comprises an epitope of a deposit-
CC   forming polypeptide involved in plaque-forming disease, is joined by
CC   covalent bonds. The antigenic products are useful for eliciting an immune
CC   response against a deposit-forming polypeptide involved in a plaque-
CC   forming disease or disorder, e.g. Alzheimer's disease, SAA amyloidosis,
CC   hereditary Icelandic syndrome, senility, multiple myeloma, Creutzfeldt-
CC   Jakob disease, Kuru, Gerstmann-Straussler-Scheinker disease, fatal
CC   familial insomnia, scrapie or bovine spongiform encephalitis, by
CC   administering the antigenic product to a subject in need of it. The
CC   present sequence is one such antigenic peptide, which can be used in the
CC   antigenic product of the invention (see ABP70747)
XX
SQ   Sequence 8 AA;

Query Match          100.0%;   Score 24;  DB 6;  Length 8;
Best Local Similarity 100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy          1 EFRH 4
```

```
Db          3 EFRH 6
              ||||
Db          3 EFRH 6

RESULT 67
ADB75162
ID   ADB75162 standard; peptide; 8 AA.
XX
AC   ADB75162;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Human amyloid beta peptide SEQ ID NO:3.
XX
KW   antibody; amyloid beta peptide; amyloid beta; nootropic; neuroprotective;
KW   antibody therapy; Alzheimer's disease; mild cognitive impairment;
KW   cerebral amyloid angiopathy; congiophylic angiopathy; Down's syndrome;
KW   inclusion body myositis; neurotoxicity; beta amyloid precursor protein;
KW   APP; human.
XX
OS   Homo sapiens.
XX
PN   WO200374081-A1.
XX
PD   12-SEP-2003.
XX
PF   21-OCT-2002; 2002WO-US031590.
XX
PR   28-FEB-2002; 2002US-00084380.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS USA INC.
XX
PI   Chain DG;
XX
DR   WPI; 2003-731651/69.
XX
PT   New antibody that is targeted to amyloid beta peptide, or its fragment,
PT   useful for treating a subject having Alzheimer's disease, or a disease or
PT   disorder characterized by amyloid beta deposition, e.g. cognitive
PT   impairment or dementia.
XX
PS   Disclosure; Page 18; 63pp; English.
XX
CC   The present invention describes an antibody that is targeted to amyloid
CC   beta peptide, or its fragment. Also described: (1) an antibody that is
CC   free-end specific and is targeted to: (a) the free N-terminus of amyloid
CC   beta-peptide; (b) the free N-terminus of amyloid beta-peptide, where the
CC   first amino acid of amyloid beta-peptide is aspartate; (c) the free N-
CC   terminus of N- and/or C-terminus-truncated amyloid beta-peptide fragment;
CC   (d) the free C-terminus of the amyloid beta-peptide Abetal-39, Abetal-40,
CC   Abetal-41 or Abetal-43; or (e) to the free C-terminus of N- and/or C-
CC   terminus-truncated amyloid beta-peptide fragment; (2) a single chain or
CC   artificial antibody that is free-end specific and is targeted to the free
CC   C-terminus of the amyloid beta-peptide Abetal-42; and (3) a
CC   pharmaceutical composition comprising the antibody, and a carrier. The
CC   antibody targeted to amyloid beta peptide has nootropic and
CC   neuroprotective activities, and can be used in antibody therapy. The
CC   antibody or its fragment is useful for manufacturing a medicament for
CC   treating a subject having Alzheimer's disease, or a disease or disorder
CC   characterised by amyloid beta deposition (e.g. mild cognitive impairment,
CC   cerebral amyloid angiopathy or congiophylic angiopathy, Alzheimer's
CC   disease associated with Down's syndrome, or inclusion body myositis), or
CC   for delaying, inhibiting or suppressing accumulation of amyloid beta
CC   peptide, or the neurotoxicity of amyloid beta peptide or its fragment.
CC   Amyloid beta peptide are derived from beta amyloid precursor protein
CC   (APP). The present sequence represents an amyloid beta peptide which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 8 AA;

Query Match          100.0%;   Score 24;  DB 7;  Length 8;
Best Local Similarity 100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;
```

```
Qy    1 EFRH 4
        ||||
Db    3 EFRH 6

RESULT 68
ADB75174
ID   ADB75174 standard; peptide; 8 AA.
XX
AC   ADB75174;
XX
DT   04-DEC-2003 (first entry)
XX
DE   Amyloid beta peptide related peptide.
XX
KW   antibody; amyloid beta peptide; amyloid beta; nootropic; neuroprotective;
KW   antibody therapy; Alzheimer's disease; mild cognitive impairment;
KW   cerebral amyloid angiopathy; congiophylic angiopathy; Down's syndrome;
KW   inclusion body myositis; neurotoxicity; beta amyloid precursor protein;
KW   APP; human.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
FH   Key            Location/Qualifiers
FT   Modified-site  7
FT                  /note= "aminohexanoate"
FT   Modified-site  8
FT                  /label= amidated
XX
PN   WO2003074081-A1.
XX
PD   12-SEP-2003.
XX
PF   21-OCT-2002; 2002WO-US031590.
XX
PR   28-FEB-2002; 2002US-00084380.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS USA INC.
XX
PI   Chain DG;
XX
DR   WPI; 2003-71651/69.
XX
PT   New antibody that is targeted to amyloid beta peptide, or its fragment,
PT   useful for treating a subject having Alzheimer's disease, or a disease or
PT   disorder characterized by amyloid beta deposition, e.g. cognitive
PT   impairment or dementia.
XX
PS   Example 2; Page 29; 63pp; English.
XX
CC   The present invention describes an antibody that is targeted to amyloid
CC   beta peptide, or its fragment. Also described: (1) an antibody that is
CC   free-end specific and is targeted to: (a) the free N-terminus of amyloid
CC   beta-peptide; (b) the free N-terminus of amyloid beta-peptide, where the
CC   first amino acid of amyloid beta-peptide is aspartate; (c) the free N-
CC   terminus of N- and/or C-terminus-truncated amyloid beta-peptide fragment;
CC   (d) the free C-terminus of the amyloid beta-peptide Abeta1-39, Abeta1-40,
CC   Abeta1-41 or Abeta1-43; or (e) to the free C-terminus of N- and/or C-
CC   terminus-truncated amyloid beta-peptide fragment; (2) a single chain or
CC   artificial antibody that is free-end specific and is targeted to the free
CC   C-terminus of the amyloid beta-peptide Abeta1-42; and (3) a
CC   pharmaceutical composition comprising the antibody, and a carrier. The
CC   antibody targeted to amyloid beta peptide has nootropic and
CC   neuroprotective activities, and can be used in antibody therapy. The
CC   antibody or its fragment is useful for manufacturing a medicament for
CC   treating a subject having Alzheimer's disease, or a disease or disorder
CC   characterised by amyloid beta deposition (e.g. mild cognitive impairment,
CC   cerebral amyloid angiopathy or congiophylic angiopathy, Alzheimer's
CC   disease associated with Down's syndrome, or inclusion body myositis), or
CC   for delaying, inhibiting or suppressing accumulation of amyloid beta
CC   peptide, or the neurotoxicity of amyloid beta peptide or its fragment.
CC   Amyloid beta peptides are derived from beta amyloid precursor protein
CC   (APP). The present sequence represents an amyloid beta peptide related
CC   peptide, which is used in an example from the present invention.
XX
SQ   Sequence 8 AA;

Query Match             100.0%;  Score 24;  DB 7;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    1 EFRH 4
        ||||
Db    3 EFRH 6

RESULT 69
ADJ71355
ID   ADJ71355 standard; peptide; 8 AA.
XX
AC   ADJ71355;
XX
DT   06-MAY-2004 (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 18.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key            Location/Qualifiers
FT   Modified-site  1
FT                  /note= "Optionally methylated"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 8 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    1 EFRH 4
        ||||
```

```
Db         2 EFRH 5

RESULT 70
ADJ71368
ID   ADJ71368 standard; peptide; 8 AA.
XX
AC   ADJ71368;
XX
DT   06-MAY-2004 (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 31.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 7; Page 67; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 8 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          4 EFRH 7
```

```
Db         1 EFRH 4

RESULT 71
ADJ71575
ID   ADJ71575 standard; peptide; 8 AA.
XX
AC   ADJ71575;
XX
DT   06-MAY-2004 (first entry)
XX
DE   N-terminal APP peptide C-terminal fragment, SEQ ID 238.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 8 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4
```

```
RESULT 72
ADJ71381
ID   ADJ71381 standard; peptide; 8 AA.
XX
AC   ADJ71381;
XX
DT   06-MAY-2004 (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 44.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "Pyroglutamic acid"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
```

XX
PI Delacourte A, Sergeant N;
XX
DR WPI; 2004-180423/17.
XX
PT New beta-amyloid or amyloid precursor protein preparation, useful as a
PT prophylactic vaccine or a therapeutic for preventing or treating a
PT disease associated with beta-amyloid formation and/or aggregation, e.g.
PT Alzheimer's disease.
XX
PS Claim 4; Page 62; 104pp; English.
XX
CC The present invention relates to preparations (I) comprising a beta-
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC fragment. The beta-amyloid or APP preparations are useful for
CC manufacturing a prophylactic vaccine or a therapeutic, or as a
CC prophylactic vaccine for the prevention, or as a therapeutic for the
CC treatment of a disease associated with beta-amyloid formation and/or
CC aggregation, such as Alzheimer's disease.
XX
SQ Sequence 8 AA;

Query Match          100.0%;    Score 24;    DB 8;    Length 8;
Best Local Similarity 100.0%;   Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    1 EFRH 4

RESULT 73
ADJ71342
ID  ADJ71342 standard; peptide; 8 AA.
XX
AC  ADJ71342;
XX
DT  06-MAY-2004 (first entry)
XX
DE  N-terminal truncated beta-amyloid peptide, SEQ ID 5.
XX
KW  Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW  amyloid precursor protein; APP; Alzheimer's disease.
XX
OS  Homo sapiens.
XX
FH  Key             Location/Qualifiers
FT  Modified-site   1
FT                  /note= "Methylated"
XX
PN  WO2004013172-A2.
XX
PD  12-FEB-2004.
XX
PF  18-JUL-2003; 2003WO-EP007833.
XX
PR  24-JUL-2002; 2002EP-00447147.
PR  06-AUG-2002; 2002US-0401497P.
PA  (INNO-) INNOGENETICS NV.
XX
PI  Delacourte A, Sergeant N;
XX
DR  WPI; 2004-180423/17.
XX
PT  New beta-amyloid or amyloid precursor protein preparation, useful as a
PT  prophylactic vaccine or a therapeutic for preventing or treating a
PT  disease associated with beta-amyloid formation and/or aggregation, e.g.
PT  Alzheimer's disease.
XX
PS  Claim 4; Page 61; 104pp; English.
XX

CC The present invention relates to preparations (I) comprising a beta-
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC fragment. The beta-amyloid or APP preparations are useful for
CC manufacturing a prophylactic vaccine or a therapeutic, or as a
CC prophylactic vaccine for the prevention, or as a therapeutic for the
CC treatment of a disease associated with beta-amyloid formation and/or
CC aggregation, such as Alzheimer's disease.
XX
SQ Sequence 8 AA;

Query Match          100.0%;    Score 24;    DB 8;    Length 8;
Best Local Similarity 100.0%;   Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    3 EFRH 6

RESULT 74
ADJ71556
ID  ADJ71556 standard; peptide; 8 AA.
XX
AC  ADJ71556;
XX
DT  06-MAY-2004 (first entry)
XX
DE  N-terminal APP peptide C-terminal fragment, SEQ ID 229.
XX
KW  Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW  amyloid precursor protein; APP; Alzheimer's disease.
XX
OS  Homo sapiens.
XX
PN  WO2004013172-A2.
XX
PD  12-FEB-2004.
XX
PF  18-JUL-2003; 2003WO-EP007833.
XX
PR  24-JUL-2002; 2002EP-00447147.
PR  06-AUG-2002; 2002US-0401497P.
PA  (INNO-) INNOGENETICS NV.
XX
PI  Delacourte A, Sergeant N;
XX
DR  WPI; 2004-180423/17.
XX
PT  New beta-amyloid or amyloid precursor protein preparation, useful as a
PT  prophylactic vaccine or a therapeutic for preventing or treating a
PT  disease associated with beta-amyloid formation and/or aggregation, e.g.
PT  Alzheimer's disease.
XX
PS  Claim 7; Page 67; 104pp; English.
XX
CC The present invention relates to preparations (I) comprising a beta-
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC fragment. The beta-amyloid or APP preparations are useful for
CC manufacturing a prophylactic vaccine or a therapeutic, or as a
CC prophylactic vaccine for the prevention, or as a therapeutic for the
CC treatment of a disease associated with beta-amyloid formation and/or
CC aggregation, such as Alzheimer's disease.
XX
SQ Sequence 8 AA;

Query Match          100.0%;    Score 24;    DB 8;    Length 8;
Best Local Similarity 100.0%;   Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4

```
           ||||
Db   5 EFRH 8

RESULT 75
ADQ82413
ID   ADQ82413 standard; peptide; 8 AA.
XX
AC   ADQ82413;
XX
DT   21-OCT-2004  (first entry)
XX
DE   Natural N-terminal amyloid-beta (AB42) peptide #3.
XX
KW   amyloid-beta peptide; AB42 peptide; mimotope; vaccine;
KW   Alzheimer's disease.
XX
OS   Unidentified.
XX
PN   WO2004062556-A2.
XX
PD   29-JUL-2004.
XX
PF   13-JAN-2004; 2004WO-EP000162.
XX
PR   14-JAN-2003; 2003AT-00000036.
PR   17-SEP-2003; 2003AT-00001464.
XX
PA   (MATT/) MATTNER F.
XX
PI   Mattner F;
XX
DR   WPI; 2004-561715/54.
XX
PT   Use of a compound having a binding capacity to an antibody specific for
PT   the natural N-terminal AB42 sequence, for preparing a vaccine for
PT   preventing and treating Alzheimer's disease.
XX
PS   Example 2; Page 12; 29pp; English.
XX
CC   The invention comprises peptides which mimic the N-terminal region of
CC   amyloid-beta (AB42) peptide (Asp-Ala-Glu-Phe-Arg-His). The peptides of
CC   the invention have the capacity to bind to an antibody which is specific
CC   for the N-terminal region of the AB42 peptide. The peptides (mimotopes)
CC   of the invention are useful in the preparation of a vaccine for
CC   Alzheimer's disease. The present amino acid sequence represents the
CC   natural N-terminal AB42 peptide.
XX
SQ   Sequence 8 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy   1 EFRH 4
       ||||
Db   5 EFRH 8

RESULT 76
ABP70741
ID   ABP70741 standard; peptide; 9 AA.
XX
AC   ABP70741;
XX
DT   15-MAY-2003  (first entry)
XX
DE   Antigenic peptide, SEQ ID 2.
XX
KW   Nootropic; neuroprotective; antiinflammatory; vaccine; antigenic product;
KW   plaque-forming disease; Alzheimer's disease; SAA amyloidosis;
KW   hereditary Icelandic syndrome; senility; multiple myeloma;
KW   Creutzfeldt-Jakob disease; Kuru; Gerstmann-Straussler-Scheinker disease;
KW   fatal familial insomnia; scrapie; bovine spongiform encephalitis;
KW   antigenic; multiantigen.
XX
OS   Synthetic.
XX
PN   WO2003000719-A2.
XX
PD   03-JAN-2003.
XX
PF   20-JUN-2002; 2002WO-US019567.
XX
PR   20-JUN-2001; 2001US-0299201P.
PR   12-APR-2002; 2002US-0371717P.
XX
PA   (UYRA-) UNIV RAMOT.
PA   (MCIN/) MCINNIS P.
XX
PI   Mcinnis P,  Solomon B;
XX
DR   WPI; 2003-239139/23.
XX
PT   Antigenic product has dendritic polymer built on core molecule having
PT   terminal functional groups to which antigenic peptide that has epitope of
PT   deposit-forming polypeptide involved in plaque-forming disease is joined.
XX
PS   Disclosure; Page 8; 70pp; English.
XX
CC   The present invention relates to antigenic products (A), comprising a
CC   dendritic polymer built on a core molecule which is at least difunctional
CC   to provide branching and containing up to 16 terminal functional groups
CC   to which an antigenic peptide, that comprises an epitope of a deposit-
CC   forming polypeptide involved in plaque-forming disease, is joined by
CC   covalent bonds. The antigenic products are useful for eliciting an immune
CC   response against a deposit-forming polypeptide involved in a plaque-
CC   forming disease or disorder, e.g. Alzheimer's disease, SAA amyloidosis,
CC   hereditary Icelandic syndrome, senility, multiple myeloma, Creutzfeldt-
CC   Jakob disease, Kuru, Gerstmann-Straussler-Scheinker disease, fatal
CC   familial insomnia, scrapie or bovine spongiform encephalitis, by
CC   administering the antigenic product to a subject in need of it. The
CC   present sequence is one such antigenic peptide, which was used to
CC   illustrate the invention
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 6;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy   1 EFRH 4
       ||||
Db   3 EFRH 6

RESULT 77
ADA89886
ID   ADA89886 standard; peptide; 9 AA.
XX
AC   ADA89886;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Beta-A4 first region peptide SEQ ID NO:1.
XX
KW   antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;
KW   nootropic; antiparkinsonian; gene therapy; amyloidogenesis;
KW   amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;
KW   Alzheimer's disease; motor neuropathy; Down's syndrome;
KW   Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;
KW   Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;
KW   neuronal disorder; aging.
XX
OS   Synthetic.
OS   Homo sapiens.
```

XX
PN  WO2003070760-A2.
XX
PD  28-AUG-2003.
XX
PF  20-FEB-2003; 2003WO-EP001759.
XX
PR  20-FEB-2002; 2002EP-00003844.
XX
PA  (HOFF ) HOFFMANN LA ROCHE & CO AG F.
PA  (MORP-) MORPHOSYS AG.
XX
PI  Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;
PI  Loehning C, Loetscher H, Nordstedt C, Rothe C;
XX
DR  WPI; 2003-663848/62.
XX
PT  New antibody molecule capable of specifically recognizing two regions of
PT  the beta-A4 peptide, useful for diagnosing, preventing or treating
PT  diseases associated with amyloidogenesis or amyloid-plaque formation
PT  (e.g. dementia).
XX
PS  Claim 1; Page 99; 312pp; English.
XX
CC  The present invention describes an antibody molecule (I) capable of
CC  specifically recognising two regions of the beta-A4 peptide/Abeta4. The
CC  first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-
CC  Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the
CC  amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-
CC  Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule
CC  encoding (I); (2) a vector comprising the nucleic acid of (1); (3) a host
CC  cell comprising the vector of (2); (4) preparing (I), comprising
CC  culturing the host cell of (3) under conditions that allow synthesis of
CC  (I) and recovering (I) from the culture; (5) a composition comprising (I)
CC  or an antibody molecule produced by method (4); (6) a kit comprising (I,
CC  nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising
CC  (I); (8) testing the resulting Fab optimisation library by panning
CC  against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing
CC  of selected, optimised clones; (11) preparing a pharmaceutical
CC  composition, comprising optimisation of (I), and formulating the
CC  optimised antibody/antibody molecule with a carrier; and (12) a
CC  pharmaceutical composition prepared by method (8). (I) has
CC  neuroprotective, nootropic and antiparkinsonian activities, and can be
CC  used in gene therapy. The antibody molecule (I), nucleic acid molecule,
CC  vector or host is useful in preparing a pharmaceutical composition for
CC  the prevention and/or treatment of a disease associated with
CC  amyloidogenesis and/or amyloid-plaque formation. The antibody molecule
CC  may also be used in preparing a diagnostic composition for the detection
CC  of the disease mentioned above. The antibody is used for the
CC  disintegration of beta-amyloid plaques or for passive immunisation
CC  against beta-amyloid plaque formation. In particular, the disease is
CC  dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,
CC  Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with
CC  amyloidosis Dutch type, Parkinson's disease, HIV-related dementia. The
CC  amyotrophic lateral sclerosis or neuronal disorders related to aging. The
CC  present sequence is used in the exemplification of the present invention.
XX
SQ  Sequence 9 AA;

Query Match           100.0%;  Score 24;  DB 6;  Length 9;
Best Local Similarity 100.0%;  Pred. No. 1.8e+06;  Indels 0;  Gaps 0;
Matches    4;  Conservative    0;  Mismatches    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 78
ADE36577
ID  ADE36577 standard; peptide; 9 AA.
XX
AC  ADE36577;

XX
DT  29-JAN-2004 (first entry)
XX
DE  APP epitope spanning the beta-secretase cleavage site SEQ ID NO:5.
XX
KW  immune response; beta-secretase cleavage site; amyloid precursor protein;
KW  APP; nootropic; neuroprotective; vaccine; passive immunisation;
KW  Alzheimer's disease.
XX
OS  Synthetic.
OS  Homo sapiens.
XX
PN  WO2003076455-A2.
XX
PD  18-SEP-2003.
XX
PF  04-MAR-2003; 2003WO-US006388.
XX
PR  05-MAR-2002; 2002US-0361344P.
XX
PA  (UYRA-) UNIV RAMOT AT TEL AVIV LTD.
PA  (MCIN/) MCINNIS P.
XX
PI  Solomon B;
XX
DR  WPI; 2003-865017/80.
XX
PT  Immunizing composition, useful for treating Alzheimer's disease by
PT  inhibiting processing of amyloid precursor protein, also antibodies for
PT  passive immunization.
XX
PS  Claim 5; SEQ ID NO 5; 76pp; English.
XX
CC  The present invention describes an immunising composition (A) comprising:
CC  (a) an antigenic product (I) which induces an immune response against the
CC  beta-secretase cleavage site of amyloid precursor protein (APP); and (b)
CC  a carrier, diluent, excipient, adjuvant or auxiliary. Also described: (1)
CC  a molecule (II) comprising the antigen-binding part of an antibody (Ab)
CC  directed against the beta-secretase cleavage site of APP; (2) a
CC  filamentous bacteriophage (FB) that displays (II), where this is a single
CC  -chain Ab, on its surface; and (3) a composition containing FB. (A) has
CC  nootropic and neuroprotective activities, and can be used in vaccines or
CC  passive immunisation. (A) inhibits the cleavage of APP and so prevents
CC  the formation of beta-amyloid. (A) can be used to induce an immune
CC  response against the beta-secretase cleavage site of APP, specifically
CC  for treatment and prevention of Alzheimer's disease. The molecule (II)
CC  that contains the antigen-binding part of an Ab directed against the
CC  cleavage site, or a filamentous phage that displays such an Ab (as a
CC  single-chain molecule) can be used similarly, for passive immunisation.
CC  The present sequence represents an APP epitope spanning the beta-
CC  secretase cleavage site, which is used in the exemplification of the
CC  present invention.
XX
SQ  Sequence 9 AA;

Query Match           100.0%;  Score 24;  DB 7;  Length 9;
Best Local Similarity 100.0%;  Pred. No. 1.8e+06;  Indels 0;  Gaps 0;
Matches    4;  Conservative    0;  Mismatches    0;

Qy          1 EFRH 4
              ||||
Db          6 EFRH 9

RESULT 79
ADE36575
ID  ADE36575 standard; peptide; 9 AA.
XX
AC  ADE36575;
XX
DT  29-JAN-2004 (first entry)
XX
DE  Beta-amyloid (Abeta) peptide 1-9 SEQ ID NO:3.

```
XX
KW   immune response; beta-secretase cleavage site; amyloid precursor protein;
KW   APP; nootropic; neuroprotective; vaccine; passive immunisation;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2003076455-A2.
XX
PD   18-SEP-2003.
XX
PP   04-MAR-2003; 2003WO-US006388.
XX
PR   05-MAR-2002; 2002US-0361344P.
XX
PA   (UYRA-) UNIV RAMOT AT TEL AVIV LTD.
PA   (MCIN/) MCINNIS P.
XX
PI   Solomon B;
XX
DR   WPI; 2003-865017/80.
XX
PT   Immunizing composition, useful for treating Alzheimer's disease by
PT   inhibiting processing of amyloid precursor protein, also antibodies for
PT   passive immunization.
XX
PS   Disclosure; SEQ ID NO 3; 76pp; English.
XX
CC   The present invention describes an immunising composition (A) comprising:
CC   (a) an antigenic product (I) which induces an immune response against the
CC   beta-secretase cleavage site of amyloid precursor protein (APP); and (b)
CC   a carrier, diluent, excipient, adjuvant or auxiliary. Also described: (1)
CC   a molecule (II) comprising the antigen-binding part of an antibody (Ab)
CC   directed against the beta-secretase cleavage site of APP; (2) a
CC   filamentous bacteriophage (FB) that displays (II), where this is a single
CC   -chain Ab, on its surface; and (3) a composition containing FB. (A) has
CC   nootropic and neuroprotective activities, and can be used in vaccines or
CC   passive immunisation. (A) inhibits the cleavage of APP and so prevents
CC   the formation of beta-amyloid. (A) can be used to induce an immune
CC   response against the beta-secretase cleavage site of APP, specifically
CC   for treatment and prevention of Alzheimer's disease. The molecule (II)
CC   that contains the antigen-binding part of an Ab directed against the
CC   cleavage site, or a filamentous phage that displays such an Ab (as a
CC   single-chain molecule) can be used similarly, for passive immunisation.
CC   The present sequence represents a beta-amyloid (Abeta) peptide which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 7;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 80
ADI35862
ID   ADI35862 standard; peptide; 9 AA.
XX
AC   ADI35862;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta peptide SEQ ID NO:16.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
```

```
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG, Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 1; SEQ ID NO 16; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining the T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 81
ADI35931
ID   ADI35931 standard; peptide; 9 AA.
XX
AC   ADI35931;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:85.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease; epitope.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
```

```
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG, Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 4; SEQ ID NO 85; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 82
ADI35943
ID   ADI35943 standard; peptide; 9 AA.
XX
AC   ADI35943;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:97.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease; epitope.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX


PI   Chain DG, Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 5; SEQ ID NO 97; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 83
ADI36020
ID   ADI36020 standard; peptide; 9 AA.
XX
AC   ADI36020;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta peptide SEQ ID NO:174.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG, Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
```

```
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 6; SEQ ID NO 174; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          6 EFRH 9

RESULT 84
ADI35949
ID   ADI35949 standard; peptide; 9 AA.
XX
AC   ADI35949;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:103.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease; epitope.
XX
OS   Synthetic.
XX
PN   WO200406861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG,  Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PS   Example 5; SEQ ID NO 103; 69pp; English.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
```

```
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 85
ADI36012
ID   ADI36012 standard; peptide; 9 AA.
XX
AC   ADI36012;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta peptide SEQ ID NO:166.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO200406861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG,  Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PS   Example 6; SEQ ID NO 166; 69pp; English.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
```

CC based on the binding value of each amino acids obtained in step (1); and
CC (c) comparing the resulting score to a preselected value. Also described:
CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC vaccine comprising a beta amyloid or homologue peptide to an individual,
CC for immunisation of an individual based on the HLA haplotype of the
CC individual; (5) a kit for matching a vaccine comprising amyloid beta
CC peptide to an individual based on the HLA haplotype of the individual;
CC and (6) preventing the formation or progression of amyloid plaques. The
CC amyloid beta peptide has neuroprotective activity, and can be used in
CC vaccines. The amyloid beta peptide is useful for preparing a composition
CC for preventing the formation or progression of amyloid plaques for
CC preventing or treating Alzheimer's disease. The present sequence
CC represents an amyloid beta (Abeta) peptide, which is used in an example
CC from the present invention.
XX
SQ Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 86
ADI35946
ID   ADI35946 standard; peptide; 9 AA.
XX
AC   ADI35946;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:100.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease; epitope.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG, Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 5; SEQ ID NO 100; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a

CC vaccine comprising a beta amyloid or homologue peptide to an individual,
CC for immunisation of an individual based on the HLA haplotype of the
CC individual; (5) a kit for matching a vaccine comprising amyloid beta
CC peptide to an individual based on the HLA haplotype of the individual;
CC and (6) preventing the formation or progression of amyloid plaques. The
CC amyloid beta peptide has neuroprotective activity, and can be used in
CC vaccines. The amyloid beta peptide is useful for preparing a composition
CC for preventing the formation or progression of amyloid plaques for
CC preventing or treating Alzheimer's disease. The present sequence
CC represents an amyloid beta (Abeta) peptide, which is used in an example
CC from the present invention.
XX
SQ Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 87
ADI35890
ID   ADI35890 standard; peptide; 9 AA.
XX
AC   ADI35890;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta LV/KK modification peptide SEQ ID NO:44.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG, Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 2; SEQ ID NO 44; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The

```
CC    amyloid beta peptide has neuroprotective activity, and can be used in
CC    vaccines. The amyloid beta peptide is useful for preparing a composition
CC    for preventing the formation or progression of amyloid plaques for
CC    preventing or treating Alzheimer's disease. The present sequence
CC    represents an amyloid beta (Abeta) peptide, which is used in an example
CC    from the present invention.
XX
SQ    Sequence 9 AA;

Query Match         100.0%;    Score 24;   DB 8;   Length 9;
Best Local Similarity   100.0%;    Pred. No. 1.8e+06;
Matches    4;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 88
ADI35900
ID   ADI35900 standard; peptide; 9 AA.
XX
AC   ADI35900;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta LVF/EDD modification peptide SEQ ID NO:54.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO200406861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG,  Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 2; SEQ ID NO 54; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example

CC    from the present invention.
XX
SQ    Sequence 9 AA;

Query Match         100.0%;    Score 24;   DB 8;   Length 9;
Best Local Similarity   100.0%;    Pred. No. 1.8e+06;
Matches    4;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 89
ADI35960
ID   ADI35960 standard; peptide; 9 AA.
XX
AC   ADI35960;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:114.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease; epitope.
XX
OS   Synthetic.
XX
PN   WO200406861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG,  Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 5; SEQ ID NO 114; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match         100.0%;    Score 24;   DB 8;   Length 9;
```

Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
        |||
Db 3 EFRH 6

RESULT 90
ADI35921
ID ADI35921 standard; peptide; 9 AA.
XX
AC ADI35921;
XX
DT 22-APR-2004 (first entry)
XX
DE Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:75.
XX
KW amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW Alzheimer's disease; epitope.
XX
OS Synthetic.
XX
PN WO2004006861-A2.
XX
PD 22-JAN-2004.
XX
PF 16-JUL-2003; 2003WO-US022280.
XX
PR 17-JUL-2002; 2002US-0396245P.
XX
PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI Chain DG, Fitzer-Attas C;
XX
DR WPI; 2004-122759/12.
XX
PT New amyloid beta peptide, useful for preparing a composition for
PT preventing the formation or progression of amyloid plaques for preventing
PT or treating Alzheimer's disease.
XX
PS Example 4; SEQ ID NO 75; 69pp; English.
XX
CC The present invention describes an isolated amyloid beta peptide or its
CC homologue which is selected by a method comprising: (a) determining the
CC binding value of each amino acid of a subsequence of amyloid beta peptide
CC upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC determining the resulting score of all amino acids of the subsequence,
CC based on the binding value of each amino acids obtained in step (1); and
CC (c) comparing the resulting score to a preselected value. Also described:
CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC vaccine comprising a beta amyloid or homologue peptide to an individual,
CC for immunisation of an individual based on the HLA haplotype of the
CC individual; (5) a kit for matching a vaccine comprising amyloid beta
CC peptide to an individual based on the HLA haplotype of the individual;
CC and (6) preventing the formation or progression of amyloid plaques. The
CC amyloid beta peptide has neuroprotective activity, and can be used in
CC vaccines. The amyloid beta peptide is useful for preparing a composition
CC for preventing the formation or progression of amyloid plaques for
CC preventing or treating Alzheimer's disease. The present sequence
CC represents an amyloid beta (Abeta) peptide, which is used in an example
CC from the present invention.
XX
SQ Sequence 9 AA;

Query Match 100.0%; Score 24; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
        ||||

---

Db 2 EFRH 5

RESULT 91
ADI35958
ID ADI35958 standard; peptide; 9 AA.
XX
AC ADI35958;
XX
DT 22-APR-2004 (first entry)
XX
DE Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:112.
XX
KW amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW Alzheimer's disease; epitope.
XX
OS Synthetic.
XX
PN WO2004006861-A2.
XX
PD 22-JAN-2004.
XX
PF 16-JUL-2003; 2003WO-US022280.
XX
PR 17-JUL-2002; 2002US-0396245P.
XX
PA (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI Chain DG, Fitzer-Attas C;
XX
DR WPI; 2004-122759/12.
XX
PT New amyloid beta peptide, useful for preparing a composition for
PT preventing the formation or progression of amyloid plaques for preventing
PT or treating Alzheimer's disease.
XX
PS Example 5; SEQ ID NO 112; 69pp; English.
XX
CC The present invention describes an isolated amyloid beta peptide or its
CC homologue which is selected by a method comprising: (a) determining the
CC binding value of each amino acid of a subsequence of amyloid beta peptide
CC upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC determining the resulting score of all amino acids of the subsequence,
CC based on the binding value of each amino acids obtained in step (1); and
CC (c) comparing the resulting score to a preselected value. Also described:
CC (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC vaccine comprising a beta amyloid or homologue peptide to an individual,
CC for immunisation of an individual based on the HLA haplotype of the
CC individual; (5) a kit for matching a vaccine comprising amyloid beta
CC peptide to an individual based on the HLA haplotype of the individual;
CC and (6) preventing the formation or progression of amyloid plaques. The
CC amyloid beta peptide has neuroprotective activity, and can be used in
CC vaccines. The amyloid beta peptide is useful for preparing a composition
CC for preventing the formation or progression of amyloid plaques for
CC preventing or treating Alzheimer's disease. The present sequence
CC represents an amyloid beta (Abeta) peptide, which is used in an example
CC from the present invention.
XX
SQ Sequence 9 AA;

Query Match 100.0%; Score 24; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.8e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
        |||
Db 3 EFRH 6

RESULT 92
ADI35925

```
ID   ADI35925 standard; peptide; 9 AA.
XX
AC   ADI35925;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:79.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease; epitope.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG, Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 4; SEQ ID NO 79; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8; Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches   0;  Indels   0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 93
ADI35968
ID   ADI35968 standard; peptide; 9 AA.
XX
AC   ADI35968;
XX
DT   22-APR-2004  (first entry)
```

```
XX
DE   Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:122.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease; epitope.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG, Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 5; SEQ ID NO 122; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class II and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8; Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches   0;  Indels   0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 94
ADI35999
ID   ADI35999 standard; peptide; 9 AA.
XX
AC   ADI35999;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta peptide SEQ ID NO:153.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease.
```

```
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG,  Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 6; SEQ ID NO 153; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 95
ADI35895
ID   ADI35895 standard; peptide; 9 AA.
XX
AC   ADI35895;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta LVF/EEE modification peptide SEQ ID NO:49.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
```

```
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG,  Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 2; SEQ ID NO 49; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 96
ADI35982
ID   ADI35982 standard; peptide; 9 AA.
XX
AC   ADI35982;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta peptide SEQ ID NO:136.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
```

RESULT 97
ADI35885
ID   ADI35885 standard; peptide; 9 AA.
XX
AC   ADI35885;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta LV/DD modification peptide SEQ ID NO:39.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG, Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 6; SEQ ID NO 136; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8; Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 98
ADI35920
ID   ADI35920 standard; peptide; 9 AA.
XX
AC   ADI35920;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:74.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease; epitope.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG, Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 2; SEQ ID NO 39; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual.
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match             100.0%;  Score 24;  DB 8; Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

```
XX
PS   Example 4; SEQ ID NO 74; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match         100.0%;      Score 24;   DB 8;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    1 EFRH 4
        ||||
Db    4 EFRH 7

RESULT 99
ADI35879
ID   ADI35879 standard; peptide; 9 AA.
XX
AC   ADI35879;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta LV/EE modification peptide SEQ ID NO:33.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG,  Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 2; SEQ ID NO 33; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
CC   (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC   or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC   (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC   vaccine comprising a beta amyloid or homologue peptide to an individual,
CC   for immunisation of an individual based on the HLA haplotype of the
CC   individual; (5) a kit for matching a vaccine comprising amyloid beta
CC   peptide to an individual based on the HLA haplotype of the individual;
CC   and (6) preventing the formation or progression of amyloid plaques. The
CC   amyloid beta peptide has neuroprotective activity, and can be used in
CC   vaccines. The amyloid beta peptide is useful for preparing a composition
CC   for preventing the formation or progression of amyloid plaques for
CC   preventing or treating Alzheimer's disease. The present sequence
CC   represents an amyloid beta (Abeta) peptide, which is used in an example
CC   from the present invention.
XX
SQ   Sequence 9 AA;

Query Match         100.0%;      Score 24;   DB 8;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    1 EFRH 4
        |||
Db    2 EFRH 5

RESULT 100
ADI35971
ID   ADI35971 standard; peptide; 9 AA.
XX
AC   ADI35971;
XX
DT   22-APR-2004  (first entry)
XX
DE   Amyloid beta homologue K6-1-30-LV/EE epitope SEQ ID NO:125.
XX
KW   amyloid beta peptide; vaccine; immunisation; neuroprotective;
KW   Alzheimer's disease; epitope.
XX
OS   Synthetic.
XX
PN   WO2004006861-A2.
XX
PD   22-JAN-2004.
XX
PF   16-JUL-2003; 2003WO-US022280.
XX
PR   17-JUL-2002; 2002US-0396245P.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS INC.
XX
PI   Chain DG,  Fitzer-Attas C;
XX
DR   WPI; 2004-122759/12.
XX
PT   New amyloid beta peptide, useful for preparing a composition for
PT   preventing the formation or progression of amyloid plaques for preventing
PT   or treating Alzheimer's disease.
XX
PS   Example 5; SEQ ID NO 125; 69pp; English.
XX
CC   The present invention describes an isolated amyloid beta peptide or its
CC   homologue which is selected by a method comprising: (a) determining the
CC   binding value of each amino acid of a subsequence of amyloid beta peptide
CC   upon binding to a HLA class 1 and/or class II molecule of interest; (b)
CC   determining the resulting score of all amino acids of the subsequence,
CC   based on the binding value of each amino acids obtained in step (1); and
CC   (c) comparing the resulting score to a preselected value. Also described:
```

CC      (1) a vaccine comprising the isolated amyloid beta peptide and a carrier
CC      or diluent; (2) determining T-cell epitopes within amyloid beta peptide;
CC      (3) predicting the reaction of an individual to a vaccine; (4) matching a
CC      vaccine comprising a beta amyloid or homologue peptide to an individual,
CC      for immunisation of an individual based on the HLA haplotype of the
CC      individual; (5) a kit for matching a vaccine comprising amyloid beta
CC      peptide to an individual based on the HLA haplotype of the individual;
CC      and (6) preventing the formation or progression of amyloid plaques. The
CC      amyloid beta peptide has neuroprotective activity, and can be used in
CC      vaccines. The amyloid beta peptide is useful for preparing a composition
CC      for preventing the formation or progression of amyloid plaques for
CC      preventing or treating Alzheimer's disease. The present sequence
CC      represents an amyloid beta (Abeta) peptide, which is used in an example
CC      from the present invention.
XX
SQ      Sequence 9 AA;

Query Match             100.0%;    Score 24;   DB 8;   Length 9;
Best Local Similarity   100.0%;    Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

Search completed: November  2, 2005, 09:38:09
Job time : 164 secs

```
OM protein - protein search, using sw model

                 GenCore version 5.1.6
                 Copyright (c) 1993 - 2005  Compugen Ltd.

Run on:    November  2, 2005, 09:32:35 ; Search time 41 Seconds
                                           (without alignments)
                                           7.283 Million cell updates/sec

Title:           US-10-618-856-1
Perfect score:   24
Sequence:        1 EFRH 4

Scoring table:   BLOSUM62
                 Gapop 10.0 , Gapext 0.5

Searched:        513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters:        114581

Minimum DB seq length: 4
Maximum DB seq length: 10

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 100 summaries

Database :       Issued Patents AA:*
        1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*
        2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*
        3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*
        4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*
        5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*
        6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.
```

SUMMARIES

| Result No. | Score | % Match | Query Match Length | DB Length | DB | ID | Description |
|---|---|---|---|---|---|---|---|
| 1 | 24 | 100.0 | 24 | 4 | 4 | US-09-579-012-24 | Sequence 24, Appl |
| 2 | 24 | 100.0 | 24 | 7 | 4 | US-09-579-012-25 | Sequence 25, Appl |
| 3 | 24 | 100.0 | 24 | 10 | 1 | US-08-371-930-12 | Sequence 12, Appl |
| 4 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-961-5 | Sequence 5, Appli |
| 5 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-961-6 | Sequence 6, Appli |
| 6 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-961-7 | Sequence 7, Appli |
| 7 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-961-8 | Sequence 8, Appli |
| 8 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-961-9 | Sequence 9, Appli |
| 9 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-961-10 | Sequence 10, Appl |
| 10 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-961-11 | Sequence 11, Appl |
| 11 | 24 | 100.0 | 24 | 10 | 4 | US-09-580-018-5 | Sequence 5, Appli |
| 12 | 24 | 100.0 | 24 | 10 | 4 | US-09-580-018-6 | Sequence 6, Appli |
| 13 | 24 | 100.0 | 24 | 10 | 4 | US-09-580-018-7 | Sequence 7, Appli |
| 14 | 24 | 100.0 | 24 | 10 | 4 | US-09-580-018-8 | Sequence 8, Appli |
| 15 | 24 | 100.0 | 24 | 10 | 4 | US-09-580-018-9 | Sequence 9, Appli |
| 16 | 24 | 100.0 | 24 | 10 | 4 | US-09-580-018-10 | Sequence 10, Appl |
| 17 | 24 | 100.0 | 24 | 10 | 4 | US-09-580-018-11 | Sequence 11, Appl |
| 18 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-551-5 | Sequence 5, Appli |
| 19 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-551-6 | Sequence 6, Appli |
| 20 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-551-7 | Sequence 7, Appli |
| 21 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-551-8 | Sequence 8, Appli |
| 22 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-551-9 | Sequence 9, Appli |
| 23 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-551-10 | Sequence 10, Appl |
| 24 | 24 | 100.0 | 24 | 10 | 4 | US-09-724-551-11 | Sequence 11, Appl |
| 25 | 24 | 100.0 | 24 | 10 | 5 | PCT-US94-01712-12 | Sequence 12, Appl |
| 26 | 21 | 87.5 | 21 | 9 | 3 | US-08-159-339A-76 | Sequence 76, Appl |
| 27 | 21 | 87.5 | 21 | 9 | 3 | US-08-159-339A-134 | Sequence 134, App |
| 28 | 21 | 87.5 | 21 | 9 | 3 | US-08-159-339A-234 | Sequence 234, App |
| 29 | 21 | 87.5 | 21 | 9 | 3 | US-08-159-339A-247 | Sequence 247, App |
| 30 | 21 | 87.5 | 21 | 9 | 4 | US-09-601-729-277 | Sequence 277, App |
| 31 | 21 | 87.5 | 21 | 10 | 2 | US-08-764-640-113 | Sequence 113, App |
| 32 | 21 | 87.5 | 21 | 10 | 3 | US-08-159-339A-75 | Sequence 75, Appl |
| 33 | 21 | 87.5 | 21 | 10 | 3 | US-08-973-225-113 | Sequence 113, App |
| 34 | 21 | 87.5 | 21 | 10 | 3 | US-09-244-298A-113 | Sequence 113, App |
| 35 | 21 | 87.5 | 21 | 10 | 4 | US-09-516-704-113 | Sequence 113, App |
| 36 | 20 | 83.3 | 20 | 10 | 4 | US-09-549-090-113 | Sequence 113, App |
| 37 | 19 | 79.2 | 19 | 10 | 4 | US-09-832-230A-113 | Sequence 113, App |
| 38 | 19 | 79.2 | 19 | 7 | 4 | US-09-526-738A-5 | Sequence 5, Appli |
| 39 | 19 | 79.2 | 19 | 5 | 2 | US-08-637-759B-303 | Sequence 303, App |
| 40 | 19 | 79.2 | 19 | 5 | 3 | US-08-871-355A-303 | Sequence 303, App |
| 41 | 19 | 79.2 | 19 | 6 | 3 | US-09-201-945-303 | Sequence 303, App |
| 42 | 19 | 79.2 | 19 | 6 | 1 | US-08-014-979-78 | Sequence 78, Appl |
| 43 | 19 | 79.2 | 19 | 6 | 2 | US-08-478-386A-52 | Sequence 52, Appl |
| 44 | 19 | 79.2 | 19 | 6 | 2 | US-08-292-597-52 | Sequence 52, Appl |
| 45 | 19 | 79.2 | 19 | 6 | 2 | US-08-388-653-52 | Sequence 52, Appl |
| 46 | 19 | 79.2 | 19 | 6 | 3 | US-08-473-985-52 | Sequence 52, Appl |
| 47 | 19 | 79.2 | 19 | 6 | 3 | US-08-483-898-52 | Sequence 52, Appl |
| 48 | 19 | 79.2 | 19 | 6 | 3 | US-09-087-716-52 | Sequence 52, Appl |
| 49 | 19 | 79.2 | 19 | 6 | 3 | US-09-157-753-52 | Sequence 52, Appl |
| 50 | 19 | 79.2 | 19 | 6 | 3 | US-09-157-230-52 | Sequence 52, Appl |
| 51 | 19 | 79.2 | 19 | 6 | 3 | US-09-087-811-52 | Sequence 52, Appl |
| 52 | 19 | 79.2 | 19 | 6 | 3 | US-09-156-855-52 | Sequence 52, Appl |
| 53 | 19 | 79.2 | 19 | 6 | 3 | US-09-158-010-52 | Sequence 52, Appl |
| 54 | 19 | 79.2 | 19 | 6 | 3 | US-09-087-647-52 | Sequence 52, Appl |
| 55 | 19 | 79.2 | 19 | 6 | 3 | US-09-302-629-52 | Sequence 52, Appl |
| 56 | 19 | 79.2 | 19 | 6 | 4 | US-09-526-738A-8 | Sequence 8, Appli |
| 57 | 19 | 79.2 | 19 | 8 | 3 | US-08-875-533-57 | Sequence 57, Appl |
| 58 | 19 | 79.2 | 19 | 8 | 4 | US-09-464-152A-14 | Sequence 14, Appl |
| 59 | 19 | 79.2 | 19 | 8 | 3 | US-09-589-483-28 | Sequence 28, Appl |
| 60 | 19 | 79.2 | 19 | 9 | 3 | US-08-134-198E-12 | Sequence 12, Appl |
| 61 | 19 | 79.2 | 19 | 9 | 4 | US-09-502-600-117 | Sequence 117, App |
| 62 | 19 | 79.2 | 19 | 9 | 3 | US-09-149-476-663 | Sequence 663, App |
| 63 | 19 | 79.2 | 19 | 9 | 4 | US-09-918-243-117 | Sequence 117, App |
| 64 | 19 | 79.2 | 19 | 9 | 4 | US-09-601-729-103 | Sequence 103, App |
| 65 | 19 | 79.2 | 19 | 9 | 5 | PCT-US95-16415-30 | Sequence 30, Appl |
| 66 | 19 | 79.2 | 19 | 9 | 6 | 5514558-10 | Patent No. 5514558 |
| 67 | 19 | 79.2 | 19 | 9 | 6 | 5514558-10 | Patent No. 5514558 |
| 68 | 19 | 79.2 | 19 | 10 | 1 | US-08-338-634-19 | Sequence 19, Appl |
| 69 | 19 | 79.2 | 19 | 10 | 2 | US-08-637-759B-417 | Sequence 417, App |
| 70 | 19 | 79.2 | 19 | 10 | 2 | US-08-556-597-171 | Sequence 171, App |
| 71 | 19 | 79.2 | 19 | 10 | 2 | US-08-434-664-1 | Sequence 1, Appli |
| 72 | 19 | 79.2 | 19 | 10 | 2 | US-08-239-428A-1 | Sequence 1, Appli |
| 73 | 19 | 79.2 | 19 | 10 | 3 | US-08-871-355A-417 | Sequence 417, App |
| 74 | 19 | 79.2 | 19 | 10 | 4 | US-09-201-945-417 | Sequence 417, App |
| 75 | 19 | 79.2 | 19 | 10 | 4 | US-09-103-671-1 | Sequence 1, Appli |
| 76 | 19 | 79.2 | 19 | 10 | 4 | US-09-724-961-12 | Sequence 12, Appl |
| 77 | 19 | 79.2 | 19 | 10 | 4 | US-09-580-018-12 | Sequence 12, Appl |
| 78 | 19 | 79.2 | 19 | 10 | 4 | US-09-724-551-12 | Sequence 12, Appl |
| 79 | 19 | 79.2 | 19 | 10 | 5 | PCT-US95-05787-1 | Sequence 1, Appli |
| 80 | 18 | 75.0 | 18 | 9 | 4 | US-09-020-065A-13 | Sequence 13, Appl |
| 81 | 18 | 75.0 | 18 | 9 | 4 | US-09-809-517A-5 | Sequence 5, Appli |
| 82 | 18 | 75.0 | 18 | 10 | 1 | US-08-555-579-2 | Sequence 2, Appli |
| 83 | 18 | 75.0 | 18 | 10 | 3 | US-08-159-339A-88 | Sequence 88, Appl |
| 84 | 18 | 75.0 | 18 | 10 | 3 | US-09-406-781-2 | Sequence 2, Appli |
| 85 | 18 | 75.0 | 18 | 10 | 3 | US-09-468-738A-5 | Sequence 5, Appli |
| 86 | 18 | 75.0 | 18 | 10 | 4 | US-09-020-065A-30 | Sequence 30, Appl |
| 87 | 18 | 75.0 | 18 | 10 | 4 | US-09-940-019-5 | Sequence 5, Appli |
| 88 | 18 | 75.0 | 18 | 10 | 4 | US-09-940-037A-5 | Sequence 5, Appli |
| 89 | 17 | 70.8 | 17 | 5 | 4 | US-08-880-132-2 | Sequence 2, Appli |
| 90 | 17 | 70.8 | 17 | 5 | 4 | US-08-134-231C-37 | Sequence 37, Appl |
| 91 | 17 | 70.8 | 17 | 5 | 1 | US-08-728-160-37 | Sequence 37, Appl |
| 92 | 17 | 70.8 | 17 | 10 | 3 | US-09-460-676B-3 | Sequence 3, Appli |
| 93 | 16 | 66.7 | 16 | 4 | 5 | US-08-199-508-57 | Sequence 57, Appl |
| 94 | 16 | 66.7 | 16 | 5 | 3 | US-08-441-871-2 | Sequence 2, Appli |
| 95 | 16 | 66.7 | 16 | 5 | 4 | PCT-US93-01669-16 | Sequence 16, Appl |
| 96 | 16 | 66.7 | 16 | 5 | 4 | US-09-260-190-2 | Sequence 2, Appli |
| 97 | 16 | 66.7 | 16 | 5 | 3 | US-09-029-267-15 | Sequence 15, Appl |
| 98 | 16 | 66.7 | 16 | 5 | 5 | US-09-794-927A-72 | Sequence 72, Appl |
| 99 | 16 | 66.7 | 16 | 5 | 4 | US-09-795-847B-72 | Sequence 72, Appl |
| 100 | 16 | 66.7 | 16 | 5 | 4 | US-09-869-414-72 | Sequence 72, Appl |

ALIGNMENTS

RESULT 1
US-09-579-012-24
; Sequence 24, Application US/09579012
; Patent No. 6670195
; GENERAL INFORMATION:
; APPLICANT: Jorge GHISO
; APPLICANT: Ruben VIDAL
; APPLICANT: Blas FRANGIONE
; TITLE OF INVENTION: New Mutant Genes in Familial British Dementia and Familial Danish
; TITLE OF INVENTION: Dementia
; FILE REFERENCE: 32004-16277
; CURRENT APPLICATION NUMBER: US/09/579,012
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/136238
; PRIOR FILING DATE: 1999-05-26
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: consensus sequence
US-09-579-012-24

Query Match     100.0%;   Score 24; DB 4; Length 4;
Best Local Similarity   100.0%;   Pred. No. 4.1e+05;
Matches   4;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy     1 EFRH 4
        ||||
Db     1 EFRH 4

RESULT 2
US-09-579-012-25
; Sequence 25, Application US/09579012
; Patent No. 6670195
; GENERAL INFORMATION:
; APPLICANT: Jorge GHISO
; APPLICANT: Ruben VIDAL
; APPLICANT: Blas FRANGIONE
; TITLE OF INVENTION: New Mutant Genes in Familial British Dementia and Familial Danish
; TITLE OF INVENTION: Dementia
; FILE REFERENCE: 32004-16277
; CURRENT APPLICATION NUMBER: US/09/579,012
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/136238
; PRIOR FILING DATE: 1999-05-26
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: epitope
US-09-579-012-25

Query Match     100.0%;   Score 24; DB 4; Length 7;
Best Local Similarity   100.0%;   Pred. No. 4.1e+05;
Matches   4;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy     1 EFRH 4
        ||||
Db     3 EFRH 6

RESULT 3
US-08-371-930-12
; Sequence 12, Application US/08371930
; Patent No. 5578451

GENERAL INFORMATION:
; APPLICANT: Nishimoto, Ikuo
; TITLE OF INVENTION: ALZHEIMER'S DISEASE THERAPEUTICS
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Fish & Richardson
;   STREET: 225 Franklin Street
;   CITY: Boston
;   STATE: Massachusetts
;   COUNTRY: U.S.A.
;   ZIP: 02110-2804
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;   COMPUTER: IBM PS/2 Model 50Z or 55SX
;   OPERATING SYSTEM: MS-DOS (Version 5.0)
;   SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/08/371,930
;   FILING DATE:
;   CLASSIFICATION: 436
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: 08/019,208
;   FILING DATE: February 18, 1993
; ATTORNEY/AGENT INFORMATION:
;   NAME: Clark, Paul T.
;   REGISTRATION NUMBER: 30,162
;   REFERENCE/DOCKET NUMBER: 00786/154001
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (617) 542-5070
;   TELEFAX: (617) 542-8906
;   TELEX: 200154
; INFORMATION FOR SEQ ID NO: 12:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 10
;   TYPE: amino acid
;   STRANDEDNESS:
;   TOPOLOGY: linear
US-08-371-930-12

Query Match     100.0%;   Score 24; DB 1; Length 10;
Best Local Similarity   100.0%;   Pred. No. 19;
Matches   4;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy     1 EFRH 4
        |||
Db     3 EFRH 6

RESULT 4
US-09-724-961-5
; Sequence 5, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02

; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-5

Query Match       100.0%;  Score 24; DB 4;  Length 10;
Best Local Similarity  100.0%;  Pred. No. 19;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy       1 EFRH 4
           ||||
Db       7 EFRH 10

RESULT 5
US-09-724-961-6
; Sequence 6, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE:  2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-6

Query Match       100.0%;  Score 24; DB 4;  Length 10;
Best Local Similarity  100.0%;  Pred. No. 19;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy       1 EFRH 4
           ||||
Db       6 EFRH 9

RESULT 6
US-09-724-961-7
; Sequence 7, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.

; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE:  2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-7

Query Match       100.0%;  Score 24; DB 4;  Length 10;
Best Local Similarity  100.0%;  Pred. No. 19;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy       1 EFRH 4
           ||||
Db       5 EFRH 8

RESULT 7
US-09-724-961-8
; Sequence 8, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE:  2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide

```
;    OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;    OTHER INFORMATION: peptide)
US-09-724-961-8

Query Match             100.0%;    Score 24;    DB 4;    Length 10;
Best Local Similarity   100.0%;    Pred. No 19;
Matches    4;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;

Qy         1  EFRH  4
              ||||
Db         4  EFRH  7

RESULT 8
US-09-724-961-9
;   Sequence 9, Application US/09724961
;   Patent No. 6743427
;   GENERAL INFORMATION:
;   APPLICANT: Schenk, Dale B.
;   APPLICANT: Bard, Frederique
;   APPLICANT: Vasquez, Nicki
;   APPLICANT: Yednock, Ted
;   TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;   FILE REFERENCE: 15270J-004750UC
;   CURRENT APPLICATION NUMBER: US/09/724,961
;   CURRENT FILING DATE: 2000-11-28
;   PRIOR APPLICATION NUMBER: US 09/580,015
;   PRIOR FILING DATE: 2000-05-26
;   PRIOR APPLICATION NUMBER: US 09/322,289
;   PRIOR FILING DATE: 1999-05-28
;   PRIOR APPLICATION NUMBER: US 60/067,740
;   PRIOR FILING DATE: 1998-04-07
;   PRIOR FILING DATE: 1998-11-30
;   PRIOR APPLICATION NUMBER: WO PCT/US00/14810
;   PRIOR FILING DATE: 1998-11-30
;   PRIOR APPLICATION NUMBER: US 60/080,970
;   PRIOR FILING DATE: 1998-04-07
;   PRIOR APPLICATION NUMBER: US 60/067,740
;   PRIOR FILING DATE: 1997-12-02
;   NUMBER OF SEQ ID NOS: 77
;   SOFTWARE: PatentIn Ver. 2.1
;   SEQ ID NO 9
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-724-961-9

Query Match             100.0%;    Score 24;    DB 4;    Length 10;
Best Local Similarity   100.0%;    Pred. No. 19;
Matches    4;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;

Qy         1  EFRH  4
              ||||
Db         3  EFRH  6

RESULT 9
US-09-724-961-10
;   Sequence 10, Application US/09724961
;   Patent No. 6743427
;   GENERAL INFORMATION:
;   APPLICANT: Schenk, Dale B.
;   APPLICANT: Bard, Frederique
;   APPLICANT: Vasquez, Nicki
;   APPLICANT: Yednock, Ted
;   TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;   FILE REFERENCE: 15270J-004750UC
;   CURRENT APPLICATION NUMBER: US/09/724,961
;   CURRENT FILING DATE: 2000-11-28
;   PRIOR APPLICATION NUMBER: US 09/580,015
```

```
;    PRIOR FILING DATE: 2000-05-26
;    PRIOR APPLICATION NUMBER: US 09/322,289
;    PRIOR FILING DATE: 1999-05-28
;    PRIOR APPLICATION NUMBER: US 09/201,430
;    PRIOR FILING DATE: 1998-11-30
;    PRIOR APPLICATION NUMBER: WO PCT/US00/14810
;    PRIOR FILING DATE: 1998-11-30
;    PRIOR FILING DATE: 1998-04-07
;    PRIOR APPLICATION NUMBER: US 60/067,740
;    PRIOR FILING DATE: 1997-12-02
;    NUMBER OF SEQ ID NOS: 77
;    SOFTWARE: PatentIn Ver. 2.1
;    SEQ ID NO 10
;    LENGTH: 10
;    TYPE: PRT
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;    OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;    OTHER INFORMATION: peptide)
US-09-724-961-10

Query Match             100.0%;    Score 24;    DB 4;    Length 10;
Best Local Similarity   100.0%;    Pred. No. 19;
Matches    4;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;

Qy         1  EFRH  4
              ||||
Db         2  EFRH  5

RESULT 10
US-09-724-961-11
;   Sequence 11, Application US/09724961
;   Patent No. 6743427
;   GENERAL INFORMATION:
;   APPLICANT: Schenk, Dale B.
;   APPLICANT: Bard, Frederique
;   APPLICANT: Vasquez, Nicki
;   APPLICANT: Yednock, Ted
;   TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;   FILE REFERENCE: 15270J-004750UC
;   CURRENT APPLICATION NUMBER: US/09/724,961
;   CURRENT FILING DATE: 2000-11-28
;   PRIOR APPLICATION NUMBER: US 09/580,015
;   PRIOR FILING DATE: 2000-05-26
;   PRIOR APPLICATION NUMBER: US 09/322,289
;   PRIOR FILING DATE: 1999-05-28
;   PRIOR APPLICATION NUMBER: US 09/201,430
;   PRIOR FILING DATE: 1998-11-30
;   PRIOR APPLICATION NUMBER: WO PCT/US00/14810
;   PRIOR FILING DATE: 1998-11-30
;   PRIOR FILING DATE: 1998-04-07
;   PRIOR APPLICATION NUMBER: US 60/080,970
;   PRIOR APPLICATION NUMBER: US 60/067,740
;   PRIOR FILING DATE: 1997-12-02
;   NUMBER OF SEQ ID NOS: 77
;   SOFTWARE: PatentIn Ver. 2.1
;   SEQ ID NO 11
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-724-961-11

Query Match             100.0%;    Score 24;    DB 4;    Length 10;
Best Local Similarity   100.0%;    Pred. No. 19;
Matches    4;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;
```

Qy      1 EFRH 4
          ||||
Db      1 EFRH 4

RESULT 11
US-09-580-018-5
; Sequence 5, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
;   APPLICANT: Schenk, Dale B.
;   APPLICANT: Bard, Frederique
;   APPLICANT: Yednock, Ted
;   TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;   FILE REFERENCE: 15270J-004760US
;   CURRENT APPLICATION NUMBER: US/09/580,018
;   CURRENT FILING DATE: 2000-05-26
;   PRIOR APPLICATION NUMBER: US 09/322,289
;   PRIOR FILING DATE: 1999-05-28
;   NUMBER OF SEQ ID NOS: 77
;   SOFTWARE: PatentIn Ver. 2.1
;   SEQ ID NO 5
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-580-018-5

Query Match        100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches    4; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

Qy      1 EFRH 4
          ||||
Db      7 EFRH 10

RESULT 12
US-09-580-018-6
; Sequence 6, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
;   APPLICANT: Schenk, Dale B.
;   APPLICANT: Bard, Frederique
;   APPLICANT: Yednock, Ted
;   TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;   FILE REFERENCE: 15270J-004760US
;   CURRENT APPLICATION NUMBER: US/09/580,018
;   CURRENT FILING DATE: 2000-05-26
;   PRIOR APPLICATION NUMBER: US 09/322,289
;   PRIOR FILING DATE: 1999-05-28
;   NUMBER OF SEQ ID NOS: 77
;   SOFTWARE: PatentIn Ver. 2.1
;   SEQ ID NO 6
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-580-018-6

Query Match        100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches    4; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

Qy      1 EFRH 4
          ||||
Db      6 EFRH 9

RESULT 13
US-09-580-018-7
; Sequence 7, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
;   APPLICANT: Schenk, Dale B.
;   APPLICANT: Bard, Frederique
;   APPLICANT: Yednock, Ted
;   TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;   FILE REFERENCE: 15270J-004760US
;   CURRENT APPLICATION NUMBER: US/09/580,018
;   CURRENT FILING DATE: 2000-05-26
;   PRIOR APPLICATION NUMBER: US 09/322,289
;   PRIOR FILING DATE: 1999-05-28
;   NUMBER OF SEQ ID NOS: 77
;   SOFTWARE: PatentIn Ver. 2.1
;   SEQ ID NO 7
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-580-018-7

Query Match        100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches    4; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

Qy      1 EFRH 4
          ||||
Db      5 EFRH 8

RESULT 14
US-09-580-018-8
; Sequence 8, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
;   APPLICANT: Schenk, Dale B.
;   APPLICANT: Bard, Frederique
;   APPLICANT: Yednock, Ted
;   TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;   FILE REFERENCE: 15270J-004760US
;   CURRENT APPLICATION NUMBER: US/09/580,018
;   CURRENT FILING DATE: 2000-05-26
;   PRIOR APPLICATION NUMBER: US 09/322,289
;   PRIOR FILING DATE: 1999-05-28
;   NUMBER OF SEQ ID NOS: 77
;   SOFTWARE: PatentIn Ver. 2.1
;   SEQ ID NO 8
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-580-018-8

Query Match        100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 19;
Matches    4; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

Qy      1 EFRH 4
          ||||
Db      4 EFRH 7

RESULT 15

US-09-580-018-9
; Sequence 9, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-9

Query Match             100.0%;  Score 24;  DB 4;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 19;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6


RESULT 16
US-09-580-018-10
; Sequence 10, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-10

Query Match             100.0%;  Score 24;  DB 4;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 19;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5


RESULT 17
US-09-580-018-11
; Sequence 11, Application US/09580018
; Patent No. 6761888

; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-11

Query Match             100.0%;  Score 24;  DB 4;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 19;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4


RESULT 18
US-09-724-551-5
; Sequence 5, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-551-5

Query Match             100.0%;  Score 24;  DB 4;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 19;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          7 EFRH 10


RESULT 19
US-09-724-551-6
; Sequence 6, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:

```
;   APPLICANT: Schenk, Dale B.
;   APPLICANT: Bard, Frederique
;   APPLICANT: Yednock, Ted
;   TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;   FILE REFERENCE: 15270J-004760US
;   CURRENT APPLICATION NUMBER: US/09/724,551
;   CURRENT FILING DATE: 2000-11-28
;   PRIOR APPLICATION NUMBER: US/09/580,018
;   PRIOR FILING DATE: 2000-05-26
;   PRIOR APPLICATION NUMBER: US 09/322,289
;   PRIOR FILING DATE: 1999-05-28
;   NUMBER OF SEQ ID NOS: 77
;   SOFTWARE: PatentIn Ver. 2.1
;   SEQ ID NO 6
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-724-551-6

Query Match             100.0%;  Score 24;  DB 4;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 19;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db      6 EFRH 9

RESULT 20
US-09-724-551-7
; Sequence 7, Application US/09724551
; Patent No. 6787637
;   GENERAL INFORMATION:
;   APPLICANT: Schenk, Dale B.
;   APPLICANT: Bard, Frederique
;   APPLICANT: Yednock, Ted
;   TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;   FILE REFERENCE: 15270J-004760US
;   CURRENT APPLICATION NUMBER: US/09/724,551
;   CURRENT FILING DATE: 2000-11-28
;   PRIOR APPLICATION NUMBER: US/09/580,018
;   PRIOR FILING DATE: 2000-05-26
;   PRIOR APPLICATION NUMBER: US 09/322,289
;   PRIOR FILING DATE: 1999-05-28
;   NUMBER OF SEQ ID NOS: 77
;   SOFTWARE: PatentIn Ver. 2.1
;   SEQ ID NO 7
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-724-551-7

Query Match             100.0%;  Score 24;  DB 4;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 19;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db      5 EFRH 8

RESULT 21
US-09-724-551-8
; Sequence 8, Application US/09724551
; Patent No. 6787637
```

```
;   GENERAL INFORMATION:
;   APPLICANT: Schenk, Dale B.
;   APPLICANT: Bard, Frederique
;   APPLICANT: Yednock, Ted
;   TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;   FILE REFERENCE: 15270J-004760US
;   CURRENT APPLICATION NUMBER: US/09/724,551
;   CURRENT FILING DATE: 2000-11-28
;   PRIOR APPLICATION NUMBER: US/09/580,018
;   PRIOR FILING DATE: 2000-05-26
;   PRIOR APPLICATION NUMBER: US 09/322,289
;   PRIOR FILING DATE: 1999-05-28
;   NUMBER OF SEQ ID NOS: 77
;   SOFTWARE: PatentIn Ver. 2.1
;   SEQ ID NO 8
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-724-551-8

Query Match             100.0%;  Score 24;  DB 4;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 19;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db      4 EFRH 7

RESULT 22
US-09-724-551-9
; Sequence 9, Application US/09724551
; Patent No. 6787637
;   GENERAL INFORMATION:
;   APPLICANT: Schenk, Dale B.
;   APPLICANT: Bard, Frederique
;   APPLICANT: Yednock, Ted
;   TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;   FILE REFERENCE: 15270J-004760US
;   CURRENT APPLICATION NUMBER: US/09/724,551
;   CURRENT FILING DATE: 2000-11-28
;   PRIOR APPLICATION NUMBER: US/09/580,018
;   PRIOR FILING DATE: 2000-05-26
;   PRIOR APPLICATION NUMBER: US 09/322,289
;   PRIOR FILING DATE: 1999-05-28
;   NUMBER OF SEQ ID NOS: 77
;   SOFTWARE: PatentIn Ver. 2.1
;   SEQ ID NO 9
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-724-551-9

Query Match             100.0%;  Score 24;  DB 4;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 19;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db      3 EFRH 6

RESULT 23
US-09-724-551-10
; Sequence 10, Application US/09724551
```

```
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-724-551-10

Query Match        100.0%;    Score 24;  DB 4;  Length 10;
Best Local Similarity  100.0%;   Pred. No. 19;
Matches    4;   Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1  EFRH  4
             ||||
Db        2  EFRH  5


RESULT 24
US-09-724-551-11
; Sequence 11, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-724-551-11

Query Match        100.0%;    Score 24;  DB 4;  Length 10;
Best Local Similarity  100.0%;   Pred. No. 19;
Matches    4;   Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1  EFRH  4
             ||||
Db        1  EFRH  4


RESULT 25
PCT-US94-01712-12
```

```
; Sequence 12, Application PC/TUS9401712
; GENERAL INFORMATION:
; APPLICANT: Nishimoto, Ikuo
; TITLE OF INVENTION: ALZHEIMER'S DISEASE THERAPEUTICS
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Fish & Richardson
;   STREET: 225 Franklin Street
;   CITY: Boston
;   STATE: Massachusetts
;   COUNTRY: U.S.A.
;   ZIP: 02110-2804
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;   COMPUTER: IBM PS/2 Model 50Z or 55SX
;   OPERATING SYSTEM: MS-DOS (Version 5.0)
;   SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: PCT/US94/01712
;   FILING DATE:
;   CLASSIFICATION:
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: 08/019,208
;   FILING DATE: February 18, 1993
; ATTORNEY/AGENT INFORMATION:
;   NAME: Clark, Paul T.
;   REGISTRATION NUMBER:   30,162
;   REFERENCE/DOCKET NUMBER: 00786/154001
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (617) 542-5070
;   TELEFAX:   (617) 542-8906
;   TELEX:  200154
; INFORMATION FOR SEQ ID NO:  12:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 10
;     TYPE: amino acid
;     STRANDEDNESS:
;     TOPOLOGY: linear
PCT-US94-01712-12

Query Match        100.0%;    Score 24;  DB 5;  Length 10;
Best Local Similarity  100.0%;   Pred. No. 19;
Matches    4;   Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1  EFRH  4
             ||||
Db        3  EFRH  6


RESULT 26
US-08-159-339A-76
; Sequence 76, Application US/08159339A
; Patent No. 6037135
; GENERAL INFORMATION:
; APPLICANT: Kubo, Ralph T.
; APPLICANT: Grey, Howard M.
; APPLICANT: Sette, Alessandro
; APPLICANT: Celis, Esteban
; TITLE OF INVENTION: HLA Binding peptides and Their
; TITLE OF INVENTION: Uses
; NUMBER OF SEQUENCES: 1254
; CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Townsend and Townsend and Crew LLP
;   STREET: Two Embarcadero Center, Eighth Floor
;   CITY: San Francisco
;   STATE: CA
;   COUNTRY: USA
;   ZIP: 94111-3834
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: Diskette
;   COMPUTER: IBM Compatible
;   OPERATING SYSTEM: DOS
;   SOFTWARE: FastSEQ for Windows Version 2.0
```

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/159,339A
 FILING DATE: 29-NOV-1993
 CLASSIFICATION: 424
PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/926,666
 FILING DATE: 07-AUG-1992
 APPLICATION NUMBER: US 08/027,746
 FILING DATE: 05-MAR-1993
 APPLICATION NUMBER: US 08/103,396
 FILING DATE: 06-AUG-1993
ATTORNEY/AGENT INFORMATION:
 NAME: Weber, Ellen Lauver
 REGISTRATION NUMBER: 32,762
 REFERENCE/DOCKET NUMBER: 018623-005030US
TELECOMMUNICATION INFORMATION:
 TELEPHONE: (415) 576-0200
 TELEFAX: (415) 576-0300
 TELEX:
INFORMATION FOR SEQ ID NO: 76:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
US-08-159-339A-76

Query Match       87.5%;   Score 21;   DB 3;   Length 9;
Best Local Similarity   75.0%;   Pred. No. 4.1e+05;
Matches   3;   Conservative   1;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 EFRH 4
       |:||
Db   3 EYRH 6

RESULT 27
US-08-159-339A-134
; Sequence 134, Application US/08159339A
; Patent No. 6037135
; GENERAL INFORMATION:
; APPLICANT: Kubo, Ralph T.
; APPLICANT: Grey, Howard M.
; APPLICANT: Sette, Alessandro
; APPLICANT: Celis, Esteban
; TITLE OF INVENTION: HLA Binding peptides and Their
; TITLE OF INVENTION: Uses
; NUMBER OF SEQUENCES: 1254
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/159,339A
; FILING DATE: 29-NOV-1993
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/926,666
; FILING DATE: 07-AUG-1992
; APPLICATION NUMBER: US 08/027,746
; FILING DATE: 05-MAR-1993
; APPLICATION NUMBER: US 08/103,396
; FILING DATE: 06-AUG-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Ellen Lauver
; REGISTRATION NUMBER: 32,762
; REFERENCE/DOCKET NUMBER: 018623-005030US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; TELEX:
; INFORMATION FOR SEQ ID NO: 134:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-159-339A-134

Query Match       87.5%;   Score 21;   DB 3;   Length 9;
Best Local Similarity   75.0%;   Pred. No. 4.1e+05;
Matches   3;   Conservative   1;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 EFRH 4
       |:||
Db   3 EYRH 6

RESULT 28
US-08-159-339A-234
; Sequence 234, Application US/08159339A
; Patent No. 6037135
; GENERAL INFORMATION:
; APPLICANT: Kubo, Ralph T.
; APPLICANT: Grey, Howard M.
; APPLICANT: Sette, Alessandro
; APPLICANT: Celis, Esteban
; TITLE OF INVENTION: HLA Binding peptides and Their
; TITLE OF INVENTION: Uses
; NUMBER OF SEQUENCES: 1254
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/159,339A
; FILING DATE: 29-NOV-1993
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/926,666
; FILING DATE: 07-AUG-1992
; APPLICATION NUMBER: US 08/027,746
; FILING DATE: 05-MAR-1993
; APPLICATION NUMBER: US 08/103,396
; FILING DATE: 06-AUG-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Ellen Lauver
; REGISTRATION NUMBER: 32,762
; REFERENCE/DOCKET NUMBER: 018623-005030US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; TELEX:
; INFORMATION FOR SEQ ID NO: 234:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; STRANDEDNESS: single

```
;   TOPOLOGY: linear
;   MOLECULE TYPE: peptide
US-08-159-339A-234

Query Match             87.5%;  Score 21;  DB 3;  Length 9;
Best Local Similarity   75.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              |:||
Db          4 EYRH 7

RESULT 29
US-08-159-339A-247
;   Sequence 247, Application US/08159339A
;   Patent No. 6037135
;   GENERAL INFORMATION:
;      APPLICANT: Kubo, Ralph T.
;      APPLICANT: Grey, Howard M.
;      APPLICANT: Sette, Alessandro
;      APPLICANT: Celis, Esteban
;      TITLE OF INVENTION: HLA Binding peptides and Their
;      TITLE OF INVENTION: Uses
;      NUMBER OF SEQUENCES: 1254
;      CORRESPONDENCE ADDRESS:
;         ADDRESSEE: Townsend and Townsend and Crew LLP
;         STREET: Two Embarcadero Center, Eighth Floor
;         CITY: San Francisco
;         STATE: CA
;         COUNTRY: USA
;         ZIP: 94111-3834
;      COMPUTER READABLE FORM:
;         MEDIUM TYPE: Diskette
;         COMPUTER: IBM Compatible
;         OPERATING SYSTEM: DOS
;         SOFTWARE: FastSEQ for Windows Version 2.0
;      CURRENT APPLICATION DATA:
;         APPLICATION NUMBER: US/08/159,339A
;         FILING DATE: 29-NOV-1993
;         CLASSIFICATION: 424
;      PRIOR APPLICATION DATA:
;         APPLICATION NUMBER: US 07/926,666
;         FILING DATE: 07-AUG-1992
;         APPLICATION NUMBER: US 08/027,746
;         FILING DATE: 05-MAR-1993
;         APPLICATION NUMBER: US 08/103,396
;         FILING DATE: 06-AUG-1993
;      ATTORNEY/AGENT INFORMATION:
;         NAME: Weber, Ellen Lauver
;         REGISTRATION NUMBER: 32,762
;         REFERENCE/DOCKET NUMBER: 018623-005030US
;      TELECOMMUNICATION INFORMATION:
;         TELEPHONE: (415) 576-0200
;         TELEFAX: (415) 576-0300
;         TELEX:
;      INFORMATION FOR SEQ ID NO: 247:
;      SEQUENCE CHARACTERISTICS:
;         LENGTH: 9 amino acids
;         TYPE: amino acid
;         STRANDEDNESS: single
;         TOPOLOGY: linear
;      MOLECULE TYPE: peptide
US-08-159-339A-247

Query Match             87.5%;  Score 21;  DB 3;  Length 9;
Best Local Similarity   75.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              |:||
Db          1 EYRH 4
```

```
RESULT 30
US-09-601-729-277
;   Sequence 277, Application US/09601729
;   Patent No. 6683052
;   GENERAL INFORMATION:
;      APPLICANT: THIAM, KADER
;      APPLICANT: AURIAULT, CLAUDE
;      APPLICANT: GRAS-MASSE, HELENE
;      APPLICANT: LOING, ESTELLE
;      APPLICANT: VERWAERDE, CLAUDIE
;      APPLICANT: GUILLET, JEAN GERARD
;      TITLE OF INVENTION: LIPOPEPTIDES CONTAINING AN INTERFERON FRAGMENT AND USES
;      TITLE OF INVENTION: THEREOF IN PHARMACEUTICAL COMPOSITIONS
;      FILE REFERENCE: USB-97-AU-IN
;      CURRENT APPLICATION NUMBER: US/09/601,729
;      CURRENT FILING DATE: 2000-11-20
;      PRIOR APPLICATION NUMBER: PCT/FR99/00259
;      PRIOR FILING DATE: 1999-02-05
;      PRIOR APPLICATION NUMBER: 98 01439
;      PRIOR FILING DATE: 1998-02-06
;      NUMBER OF SEQ ID NOS: 281
;      SOFTWARE: PatentIn Ver. 2.1
;   SEQ ID NO 277
;      LENGTH: 9
;      TYPE: PRT
;      ORGANISM: Artificial Sequence
;      FEATURE:
;      OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;      OTHER INFORMATION: peptide
US-09-601-729-277

Query Match             87.5%;  Score 21;  DB 4;  Length 9;
Best Local Similarity   75.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              |:||
Db          3 EYRH 6

RESULT 31
US-08-764-640-113
;   Sequence 113, Application US/08764640
;   Patent No. 5869451
;   Patent No. 5869451 5837683
;   GENERAL INFORMATION:
;      APPLICANT: Dower, William J.
;      APPLICANT: Barrett, Ronald W.
;      APPLICANT: Cwirla, Steven E.
;      APPLICANT: Gates, Christian
;      APPLICANT: Schatz, Peter J.
;      APPLICANT: Balasubramanian, Palaniappan
;      APPLICANT: Wagstrom, Christopher R.
;      APPLICANT: Hendren, Richard W.
;      APPLICANT: Deprince, Randolph B.
;      APPLICANT: Podduturi, Surekha
;      APPLICANT: Yin, Qun
;      TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
;      TITLE OF INVENTION: RECEPTOR
;      NUMBER OF SEQUENCES: 244
;      CORRESPONDENCE ADDRESS:
;         ADDRESSEE: Glaxo Wellcome
;         STREET: Five Moore Drive, P.O. Box 13398
;         CITY: Research Triangle Park
;         STATE: NC
;         COUNTRY: USA
;         ZIP: 27709
;      COMPUTER READABLE FORM:
;         MEDIUM TYPE: Floppy disk
;         COMPUTER: IBM PC compatible
;         OPERATING SYSTEM: PC-DOS/MS-DOS
;         SOFTWARE: PatentIn Release #1.0, Version #1.30
```

CURRENT APPLICATION DATA:
  APPLICATION NUMBER: US/08/764,640
  FILING DATE: 11-DEC-1996
  CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
  NAME: Hrubiec, Robert T.
  REGISTRATION NUMBER: 36,392
  REFERENCE/DOCKET NUMBER: PK3281
TELECOMMUNICATION INFORMATION:
  TELEPHONE: 919-248-1000
INFORMATION FOR SEQ ID NO: 113:
  SEQUENCE CHARACTERISTICS:
  LENGTH: 10 amino acids
  TYPE: amino acid
  STRANDEDNESS:
  TOPOLOGY: linear
  MOLECULE TYPE: peptide
US-08-764-640-113

Query Match            87.5%;   Score 21; DB 2; Length 10;
Best Local Similarity  75.0%;   Pred. No. 91;
Matches  3;  Conservative  1;  Mismatches  1;  Indels  0;  Gaps  0;

Qy   1 EFRH 4
       |:|:|
Db   5 EFKH 8

RESULT 32
US-08-159-339A-75
; Sequence 75, Application US/08159339A
; Patent No. 6037135
GENERAL INFORMATION:
  APPLICANT:  Kubo, Ralph T.
  APPLICANT:  Grey, Howard M.
  APPLICANT:  Sette, Alessandro
  APPLICANT:  Celis, Esteban
  TITLE OF INVENTION: HLA Binding peptides and Their
  TITLE OF INVENTION: Uses
  NUMBER OF SEQUENCES: 1254
  CORRESPONDENCE ADDRESS:
  ADDRESSEE: Townsend and Townsend and Crew LLP
  STREET: Two Embarcadero Center, Eighth Floor
  CITY: San Francisco
  STATE: CA
  COUNTRY: USA
  ZIP: 94111-3834
  COMPUTER READABLE FORM:
  MEDIUM TYPE: Diskette
  COMPUTER: IBM Compatible
  OPERATING SYSTEM: DOS
  SOFTWARE: FastSEQ for Windows Version 2.0
  CURRENT APPLICATION DATA:
  APPLICATION NUMBER: US/08/159,339A
  FILING DATE: 29-NOV-1993
  CLASSIFICATION: 424
  PRIOR APPLICATION DATA:
  APPLICATION NUMBER: US 07/926,666
  FILING DATE: 07-AUG-1992
  APPLICATION NUMBER: US 08/027,746
  FILING DATE: 05-MAR-1993
  APPLICATION NUMBER: US 08/103,396
  FILING DATE: 06-AUG-1993
  ATTORNEY/AGENT INFORMATION:
  NAME: Weber, Ellen Lauver
  REGISTRATION NUMBER: 32,762
  REFERENCE/DOCKET NUMBER: 018623-005030US
  TELECOMMUNICATION INFORMATION:
  TELEPHONE: (415) 576-0200
  TELEFAX: (415) 576-0300
  TELEX:
INFORMATION FOR SEQ ID NO: 75:
  SEQUENCE CHARACTERISTICS:

  LENGTH: 10 amino acids
  TYPE: amino acid
  STRANDEDNESS: single
  TOPOLOGY: linear
  MOLECULE TYPE: peptide
US-08-159-339A-75

Query Match            87.5%;   Score 21; DB 3; Length 10;
Best Local Similarity  75.0%;   Pred. No. 91;
Matches  3;  Conservative  1;  Mismatches  1;  Indels  0;  Gaps  0;

Qy   1 EFRH 4
       |:|:|
Db   6 EYRH 9

RESULT 33
US-08-973-225-113
; Sequence 113, Application US/08973225A
; Patent No. 6083913
GENERAL INFORMATION:
  APPLICANT:  Dower, William J.
              Barrett, Ronald W.
              Cwirla, Steven E.
              Duffin, David J.
              Gates, Christian
              Haselden, Sherril S.
              Mattheakis, Larry C.
              Schatz, Peter J.
              Wagtrom, Christopher R.
              Wrighton, Nicholas C.
  TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
  THROMBOPOIETIN RECEPTOR
NUMBER OF SEQUENCES: 232
CORRESPONDENCE ADDRESS:
  ADDRESSEE: Glaxo Wellcome
  STREET: Five Moore Drive, P.O. Box 13398
  CITY: Research Triangle Park
  STATE: NC
  COUNTRY: USA
  ZIP: 27709
COMPUTER READABLE FORM:
  MEDIUM TYPE: Floppy disk
  COMPUTER: IBM PC compatible
  OPERATING SYSTEM: PC-DOS/MS-DOS
  SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
  APPLICATION NUMBER: US/08/973,225A
  FILING DATE: 04-Dec-1997
  ATTORNEY/AGENT INFORMATION:
  NAME: Hrubiec, Robert T.
  REGISTRATION NUMBER: 36,392
  REFERENCE/DOCKET NUMBER: PK3065USW
  TELECOMMUNICATION INFORMATION:
  TELEPHONE: 919-248-1000
INFORMATION FOR SEQ ID NO: 113:
  SEQUENCE CHARACTERISTICS:
  LENGTH: 10 amino acids
  TYPE: amino acid
  STRANDEDNESS: <Unknown>
  TOPOLOGY: linear
  MOLECULE TYPE: peptide
  SEQUENCE DESCRIPTION: SEQ ID NO: 113:
US-08-973-225-113

Query Match            87.5%;   Score 21; DB 3; Length 10;
Best Local Similarity  75.0%;   Pred. No. 91;
Matches  3;  Conservative  1;  Mismatches  1;  Indels  0;  Gaps  0;

Qy   1 EFRH 4
       |:|:|
Db   5 EFKH 8

RESULT 34
US-09-244-298A-113
; Sequence 113, Application US/09244298A
; Patent No. 6121238
; GENERAL INFORMATION:
;     APPLICANT: Dower, William J.
;     APPLICANT: Barrett, Ronald W.
;     APPLICANT: Cwirla, Steven E.
;     APPLICANT: Gates, Christian
;     APPLICANT: Schatz, Peter J.
;     APPLICANT: Balasubramanian, Palaniappan
;     APPLICANT: Wagstrom, Christopher R.
;     APPLICANT: Hendren, Richard W.
;     APPLICANT: Deprince, Randolph B.
;     APPLICANT: Podduturi, Surekha
;     APPLICANT: Yin, Qun
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
; TITLE OF INVENTION: RECEPTOR
; NUMBER OF SEQUENCES: 244
; CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Glaxo Wellcome
;     STREET: Five Moore Drive, P.O. Box 13398
;     CITY: Research Triangle Park
;     STATE: NC
;     COUNTRY: USA
;     ZIP: 27709
; COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/09/244,298A
;     FILING DATE: 11-DEC-1996
;     CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
;     NAME: Hrubiec, Robert T.
;     REGISTRATION NUMBER: 36,392
;     REFERENCE/DOCKET NUMBER: PK3281
; TELECOMMUNICATION INFORMATION:
;     TELEPHONE: 919-248-1000
; INFORMATION FOR SEQ ID NO: 113:
; SEQUENCE CHARACTERISTICS:
;     LENGTH: 10 amino acids
;     TYPE: amino acid
;     STRANDEDNESS:
;     TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-244-298A-113

Query Match          87.5%;   Score 21;   DB 3;   Length 10;
Best Local Similarity   75.0%;   Pred. No. 91;
Matches     3;   Conservative   1;   Mismatches   1;   Indels   0;   Gaps   0;

Qy      1 EFRH 4
          ||:|
Db      5 EFKH 8

RESULT 35
US-09-516-704-113
; Sequence 113, Application US/09516704
; Patent No. 6251864
; GENERAL INFORMATION:
;     APPLICANT: Dower, William J.
;     APPLICANT: Barrett, Ronald W.
;     APPLICANT: Cwirla, Steven E.
;     APPLICANT: Gates, Christian
;     APPLICANT: Schatz, Peter J.
;     APPLICANT: Balasubramanian, Palaniappan
;     APPLICANT: Wagstrom, Christopher R.
;     APPLICANT: Hendren, Richard W.
               Deprince, Randolph B.
               Podduturi, Surekha
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
                      RECEPTOR
; NUMBER OF SEQUENCES: 244
; CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Glaxo Wellcome
;     STREET: Five Moore Drive, P.O. Box 13398
;     CITY: Research Triangle Park
;     STATE: NC
;     COUNTRY: USA
;     ZIP: 27709
; COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/09/516,704
;     FILING DATE: 01-Mar-2000
;     CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
;     NAME: Hrubiec, Robert T.
;     REGISTRATION NUMBER: 36,392
;     REFERENCE/DOCKET NUMBER: PK3281
; TELECOMMUNICATION INFORMATION:
;     TELEPHONE: 919-248-1000
; INFORMATION FOR SEQ ID NO: 113:
; SEQUENCE CHARACTERISTICS:
;     LENGTH: 10 amino acids
;     TYPE: amino acid
;     STRANDEDNESS: <Unknown>
;     TOPOLOGY: linear
; MOLECULE TYPE: peptide
; SEQUENCE DESCRIPTION: SEQ ID NO: 113:
US-09-516-704-113

Query Match          87.5%;   Score 21;   DB 3;   Length 10;
Best Local Similarity   75.0%;   Pred. No. 91;
Matches     3;   Conservative   1;   Mismatches   1;   Indels   0;   Gaps   0;

Qy      1 EFRH 4
          ||:|
Db      5 EFKH 8

RESULT 36
US-09-549-090-113
; Sequence 113, Application US/09549090
; Patent No. 6465430
; GENERAL INFORMATION:
;     APPLICANT: Dower, William J.
;                Barrett, Ronald W.
;                Cwirla, Steven E.
;                Duffin, David J.
;                Gates, Christian
;                Haselden, Sherril S.
;                Mattheakis, Larry C.
;                Schatz, Peter J.
;                Wagstrom, Christopher R.
;                Wrighton, Nicholas C.
; TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
                      THROMBOPOIETIN RECEPTOR
; NUMBER OF SEQUENCES: 232
; CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Glaxo Wellcome
;     STREET: Five Moore Drive, P.O. Box 13398
;     CITY: Research Triangle Park
;     STATE: NC
;     COUNTRY: USA
;     ZIP: 27709
; COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk

```
            COMPUTER: IBM PC compatible
            OPERATING SYSTEM: PC-DOS/MS-DOS
            SOFTWARE: PatentIn Release #1.0, Version #1.30
       CURRENT APPLICATION DATA:
            APPLICATION NUMBER: US/09/549,090
            FILING DATE: 13-Apr-2000
       PRIOR APPLICATION DATA:
            APPLICATION NUMBER: US 08/973,225
            FILING DATE: <Unknown>
       ATTORNEY/AGENT INFORMATION:
            NAME: Hrubiec, Robert T.
            REGISTRATION NUMBER: 36,392
            REFERENCE/DOCKET NUMBER: PK3065USW
       TELECOMMUNICATION INFORMATION:
            TELEPHONE: 919-248-1000
  INFORMATION FOR SEQ ID NO: 113:
       SEQUENCE CHARACTERISTICS:
            LENGTH: 10 amino acids
            TYPE: amino acid
            STRANDEDNESS: <Unknown>
            TOPOLOGY: linear
       MOLECULE TYPE: peptide
       SEQUENCE DESCRIPTION: SEQ ID NO: 113:
US-09-549-090-113

Query Match             87.5%;  Score 21;  DB 4;  Length 10;
Best Local Similarity   75.0%;  Pred. No. 91;
Matches    3;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              |:|:|
Db          5 EFKH 8

RESULT 37
US-09-832-230A-113
; Sequence 113, Application US/09832230A
; Patent No. 6506362
; GENERAL INFORMATION:
;   APPLICANT: Dower, William J. et al
;   TITLE OF INVENTION: PEPTIDES AND COMPOUNDS THAT BIND TO A
                        RECEPTOR
;   NUMBER OF SEQUENCES: 244
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Glaxo Wellcome
;     STREET: Five Moore Drive, P.O. Box 13398
;     CITY: Research Triangle Park
;     STATE: NC
;     COUNTRY: USA
;     ZIP: 27709
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/09/832,230A
;     FILING DATE: 10-Apr-2001
;     CLASSIFICATION: <Unknown>
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Hrubiec, Robert T.
;     REGISTRATION NUMBER: 36,392
;     REFERENCE/DOCKET NUMBER: PK3281
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: 919-248-1000
; INFORMATION FOR SEQ ID NO: 113:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 10 amino acids
;     TYPE: amino acid
;     STRANDEDNESS: <Unknown>
;     TOPOLOGY: linear
;   MOLECULE TYPE: peptide
;   SEQUENCE DESCRIPTION: SEQ ID NO: 113:
```

```
US-09-832-230A-113

Query Match             87.5%;  Score 21;  DB 4;  Length 10;
Best Local Similarity   75.0%;  Pred. No. 91;
Matches    3;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              |:|:|
Db          5 EFKH 8

RESULT 38
US-09-526-738A-5
; Sequence 5, Application US/09526738A
; Patent No. 6630584
; GENERAL INFORMATION:
;   APPLICANT: RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DVELOPMENT
;   APPLICANT: LTD.
;   TITLE OF INVENTION: SINGLE CHAIN  ANTIBODY AGAINST MUTANT P53
;   FILE REFERENCE: 1196336
;   CURRENT APPLICATION NUMBER: US/09/526,738A
;   CURRENT FILING DATE: 2000-03-16
;   NUMBER OF SEQ ID NOS: 9
;   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: Humanus
US-09-526-738A-5

Query Match             83.3%;  Score 20;  DB 4;  Length 7;
Best Local Similarity   75.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              :|||
Db          1 KFRH 4

RESULT 39
US-08-637-759B-303
; Sequence 303, Application US/08637759B
; Patent No. 5876931
; GENERAL INFORMATION:
;   APPLICANT: David William Holden
;   TITLE OF INVENTION: Identification of Genes
;   NUMBER OF SEQUENCES: 501
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Patrea L. Pabst
;     STREET: 2800 One Atlantic Center
;     STREET: 1201 West Peachtree Street
;     CITY: Atlanta
;     STATE: Georgia
;     COUNTRY: USA
;     ZIP: 30309-3450
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/637,759B
;     FILING DATE: 03-MAY-1996
;     CLASSIFICATION: 435
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: PCT/GB95/02875
;     FILING DATE: 11-DEC-1995
;     CLASSIFICATION: 435
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Pabst, Patrea L.
;     REGISTRATION NUMBER: 31,284
;     REFERENCE/DOCKET NUMBER: RPMS 101
;   TELECOMMUNICATION INFORMATION:
```

;     TELEPHONE: (404) 873-8794
;     TELEFAX: (404) 873-8795
; INFORMATION FOR SEQ ID NO: 303:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 5 amino acids
;     TYPE: amino acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
;     MOLECULE TYPE: protein
;     HYPOTHETICAL: NO
US-08-637-759B-303

Query Match     79.2%;   Score 19;   DB 2;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 4.1e+05;
Matches   3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy   2 FRH 4
       |||
Db   1 FRH 3

RESULT 40
US-08-871-355A-303
; Sequence 303, Application US/08871355A
; Patent No. 615669
; GENERAL INFORMATION:
;   APPLICANT: David William Holden
;   TITLE OF INVENTION: Identification of Genes
;   NUMBER OF SEQUENCES: 501
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Patrea L. Pabst
;     STREET: 2800 One Atlantic Center
;     STREET: 1201 West Peachtree Street
;     CITY: Atlanta
;     STATE: Georgia
;     COUNTRY: USA
;     ZIP: 30309-3450
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/871,355A
;     FILING DATE: 09-JUN-1997
;     CLASSIFICATION: 435
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: PCT/GB95/02875
;     FILING DATE: 11-DEC-1995
;     CLASSIFICATION: 435
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Pabst, Patrea L.
;     REGISTRATION NUMBER: 31,284
;     REFERENCE/DOCKET NUMBER: RPMS 101 CON
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (404) 873-8794
;     TELEFAX: (404) 873-8795
; INFORMATION FOR SEQ ID NO: 303:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 5 amino acids
;     TYPE: amino acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
;     MOLECULE TYPE: protein
;     HYPOTHETICAL: NO
US-08-871-355A-303

Query Match     79.2%;   Score 19;   DB 2;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 4.1e+05;
Matches   3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy   2 FRH 4
       |||

Db   1 FRH 3

RESULT 41
US-09-201-945-303
; Sequence 303, Application US/09201945
; Patent No. 6342215
; GENERAL INFORMATION:
;   APPLICANT: David William Holden
;   TITLE OF INVENTION: Identification of Genes
;   NUMBER OF SEQUENCES: 501
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Patrea L. Pabst
;     STREET: 2800 One Atlantic Center
;     STREET: 1201 West Peachtree Street
;     CITY: Atlanta
;     STATE: Georgia
;     COUNTRY: USA
;     ZIP: 30309-3450
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/09/201,945
;     FILING DATE:
;     CLASSIFICATION:
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 08/637,759
;     FILING DATE:
;     CLASSIFICATION:
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Pabst, Patrea L.
;     REGISTRATION NUMBER: 31,284
;     REFERENCE/DOCKET NUMBER: RPMS 101
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (404) 873-8794
;     TELEFAX: (404) 873-8795
; INFORMATION FOR SEQ ID NO: 303:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 5 amino acids
;     TYPE: amino acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
;     MOLECULE TYPE: protein
;     HYPOTHETICAL: NO
US-09-201-945-303

Query Match     79.2%;   Score 19;   DB 3;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 4.1e+05;
Matches   3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy   2 FRH 4
       |||
Db   1 FRH 3

RESULT 42
US-08-014-979-78
; Sequence 78, Application US/08014979
; Patent No. 5510240
; GENERAL INFORMATION:
;   APPLICANT: Lam, Kit S. et al.
;   TITLE OF INVENTION: Random Bio-Oligomer Library, A Method of
;   TITLE OF INVENTION: Synthesis Thereof, and a Method of Use Thereof
;   NUMBER OF SEQUENCES: 121
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Pennie & Edmonds
;     STREET: 1155 Avenue of the Americas
;     CITY: New York
;     STATE: New York
;     COUNTRY: U.S.A.

```
                 ZIP: 10036-2711
         COMPUTER READABLE FORM:
             MEDIUM TYPE: Floppy disk
             COMPUTER: IBM PC compatible
             OPERATING SYSTEM: PC-DOS/MS-DOS
             SOFTWARE: PatentIn Release #1.0, Version #1.25
         CURRENT APPLICATION DATA:
             APPLICATION NUMBER: US/08/014,979
             FILING DATE: 19930208
             CLASSIFICATION: 435
         ATTORNEY/AGENT INFORMATION:
             NAME: Misrock, S. Leslie
             REGISTRATION NUMBER: 18,872
             REFERENCE/DOCKET NUMBER: 7156-041
         TELECOMMUNICATION INFORMATION:
             TELEPHONE: 212 790-9090
             TELEFAX: 212 869-8864/9741
             .TELEX: 66141 PENNIE
 INFORMATION FOR SEQ ID NO: 78:
         SEQUENCE CHARACTERISTICS:
             LENGTH: 6 amino acids
             TYPE: amino acid
             STRANDEDNESS: single
             TOPOLOGY: unknown
             MOLECULE TYPE: peptide
 US-08-014-979-78

 Query Match         79.2%;   Score 19;  DB 1;  Length 6;
 Best Local Similarity 100.0%;  Pred. No. 4.1e+05;
 Matches    3;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

 Qy       2 FRH 4
           |||
 Db       2 FRH 4


 RESULT 43
 US-08-478-386A-52
 ; Sequence 52, Application US/08478386A
 ; Patent No. 5830462
 ; GENERAL INFORMATION:
         APPLICANT: Crabtree, Gerald R.
         APPLICANT: Schreiber, Stuart L.
         APPLICANT: Spencer, David M.
         APPLICANT: Wandless, Thomas J.
         APPLICANT: Belshaw, Peter
         TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED
         TITLE OF INVENTION: GENES AND OTHER BIOLOGICAL EVENTS
         NUMBER OF SEQUENCES: 81
         CORRESPONDENCE ADDRESS:
             ADDRESSEE: ARIAD Pharmaceuticals, Inc.
             STREET: 26 Landsdowne Street
             CITY: Cambridge
             STATE: Massachusetts
             COUNTRY: USA
             ZIP: 02139
         COMPUTER READABLE FORM:
             MEDIUM TYPE: Floppy disk
             COMPUTER: IBM PC compatible
             OPERATING SYSTEM: PC/DOS/MS/DOS
             SOFTWARE: PatentIn Release #1.0, Version #1.25
         CURRENT APPLICATION DATA:
             APPLICATION NUMBER: US/08/478,386A
             FILING DATE: 07/JUN/1995
             CLASSIFICATION: 514
         ATTORNEY/AGENT INFORMATION:
             NAME: Figg, E. Anthony
             REGISTRATION NUMBER: 27,195
             REFERENCE/DOCKET NUMBER: 2054-114A
         TELECOMMUNICATION INFORMATION:
             TELEPHONE: (202) 783-6040
             TELEFAX: (202) 783-6031
 INFORMATION FOR SEQ ID NO: 52:


         SEQUENCE CHARACTERISTICS:
             LENGTH: 6 amino acids
             TYPE: amino acid
             TOPOLOGY: linear
             MOLECULE TYPE: protein
 US-08-478-386A-52

 Query Match         79.2%;   Score 19;  DB 2;  Length 6;
 Best Local Similarity 100.0%;  Pred. No. 4.1e+05;
 Matches    3;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

 Qy       2 FRH 4
           |||
 Db       2 FRH 4


 RESULT 44
 US-08-292-597-52
 ; Sequence 52, Application US/08292597
 ; Patent No. 5834266
 ; GENERAL INFORMATION:
         APPLICANT: Crabtree, Gerald R.
         APPLICANT: Schreiber, Stuart L.
         APPLICANT: Spencer, David M.
         APPLICANT: Wandless, Thomas J.
         APPLICANT: Belshaw, Peter
         TITLE OF INVENTION: Regulated Apoptosis
         NUMBER OF SEQUENCES: 81
         CORRESPONDENCE ADDRESS:
             ADDRESSEE: ARIAD Pharmaceuticals, Inc.
             STREET: 26 Landsdowne Street
             CITY: Cambridge
             STATE: Massachusetts
             COUNTRY: USA
             ZIP: 02139
         COMPUTER READABLE FORM:
             MEDIUM TYPE: Floppy disk
             COMPUTER: IBM PC compatible
             OPERATING SYSTEM: PC/DOS/MS/DOS
             SOFTWARE: PatentIn Release #1.0, Version #1.25
         CURRENT APPLICATION DATA:
             APPLICATION NUMBER: US/08/292,597
             FILING DATE: 18/AUG/1994
             CLASSIFICATION: 435
         PRIOR APPLICATION DATA:
             APPLICATION NUMBER:
             FILING DATE:
         ATTORNEY/AGENT INFORMATION:
             NAME: Figg, E. Anthony
             REGISTRATION NUMBER: 27,195
             REFERENCE/DOCKET NUMBER: 2054-108A
         TELECOMMUNICATION INFORMATION:
             TELEPHONE: (202) 783-6040
             TELEFAX: (202) 783-6031
 INFORMATION FOR SEQ ID NO: 52:
         SEQUENCE CHARACTERISTICS:
             LENGTH: 6 amino acids
             TYPE: amino acid
             TOPOLOGY: linear
             MOLECULE TYPE: protein
 US-08-292-597-52

 Query Match         79.2%;   Score 19;  DB 2;  Length 6;
 Best Local Similarity 100.0%;  Pred. No. 4.1e+05;
 Matches    3;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

 Qy       2 FRH 4
           |||
 Db       2 FRH 4


 RESULT 45
 US-08-388-653-52
```

```
; Sequence 52, Application US/08388653
; Patent No. 5869337
; GENERAL INFORMATION:
;    APPLICANT: Crabtree, Gerald R.
;    APPLICANT: Schreiber, Stuart L.
;    APPLICANT: Spencer, David M.
;    APPLICANT: Wandless, Thomas J.
;    APPLICANT: Belshaw, Peter
;    TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED
;    TITLE OF INVENTION: GENES AND OTHER BIOLOGICAL EVENTS
;    NUMBER OF SEQUENCES: 81
;    CORRESPONDENCE ADDRESS:
;       ADDRESSEE: ARIAD Pharmaceuticals, Inc.
;       STREET: 26 Landsdowne Street
;       CITY: Cambridge
;       STATE: Massachusetts
;       COUNTRY: USA
;       ZIP: 02139
;    COMPUTER READABLE FORM:
;       MEDIUM TYPE: Floppy disk
;       COMPUTER: IBM PC compatible
;       OPERATING SYSTEM: PC/DOS/MS/DOS
;       SOFTWARE: PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;       APPLICATION NUMBER: US/08/388,653
;       FILING DATE: 14-FEB-1995
;       CLASSIFICATION: 514
;    PRIOR APPLICATION DATA:
;       APPLICATION NUMBER: US 08/478,386
;       FILING DATE: 07-JUN-1995
;    ATTORNEY/AGENT INFORMATION:
;       NAME: Figg, E. Anthony
;       REGISTRATION NUMBER: 27,195
;       REFERENCE/DOCKET NUMBER: 2054-114A
;    TELECOMMUNICATION INFORMATION:
;       TELEPHONE: (202) 783-6040
;       TELEFAX: (202) 783-6031
; INFORMATION FOR SEQ ID NO: 52:
;    SEQUENCE CHARACTERISTICS:
;       LENGTH: 6 amino acids
;       TYPE: amino acid
;       TOPOLOGY: linear
;       MOLECULE TYPE: protein
US-08-388-653-52

Query Match        79.2%;  Score 19;  DB 2;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        2 FRH 4
            |||
Db        2 FRH 4


RESULT 46
US-08-473-985-52
; Sequence 52, Application US/08473985
; Patent No. 5871753
; GENERAL INFORMATION:
;    APPLICANT: Crabtree, Gerald R.
;    APPLICANT: Schreiber, Stuart L.
;    APPLICANT: Spencer, David M.
;    APPLICANT: Wandless, Thomas J.
;    APPLICANT: Belshaw, Peter
;    APPLICANT: Ho, Steffan
;    TITLE OF INVENTION: Regulated Transcription of Targeted Genes and
;    TITLE OF INVENTION: Other Biological Events
;    NUMBER OF SEQUENCES: 66
;    CORRESPONDENCE ADDRESS:
;       ADDRESSEE: Campbell and Flores
;       STREET: 4370 La Jolla Village Drive, Suite 700
;       CITY: San Diego
;       STATE: California
```

```
;       COUNTRY: USA
;       ZIP: 92122
;    COMPUTER READABLE FORM:
;       MEDIUM TYPE: Floppy disk
;       COMPUTER: IBM PC compatible
;       OPERATING SYSTEM: PC-DOS/MS-DOS
;       SOFTWARE: PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;       APPLICATION NUMBER: US/08/473,985
;       FILING DATE:
;       CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;       APPLICATION NUMBER: US 08/179,748
;       FILING DATE: 07-JAN-1994
;    ATTORNEY/AGENT INFORMATION:
;       NAME: Campbell, Cathryn A.
;       REGISTRATION NUMBER: 31,815
;       REFERENCE/DOCKET NUMBER: P-SU 9863
;    TELECOMMUNICATION INFORMATION:
;       TELEPHONE: (619) 535-9001
;       TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 52:
;    SEQUENCE CHARACTERISTICS:
;       LENGTH: 6 amino acids
;       TYPE: amino acid
;       TOPOLOGY: linear
;       MOLECULE TYPE: protein
US-08-473-985-52

Query Match        79.2%;  Score 19;  DB 2;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        2 FRH 4
            |||
Db        2 FRH 4


RESULT 47
US-08-483-898-52
; Sequence 52, Application US/08483898
; Patent No. 5994313
; GENERAL INFORMATION:
;    APPLICANT: Crabtree, Gerald R.
;    APPLICANT: Schreiber, Stuart L.
;    APPLICANT: Spencer, David M.
;    APPLICANT: Wandless, Thomas J.
;    APPLICANT: Belshaw, Peter
;    TITLE OF INVENTION: Regulated Apoptosis
;    NUMBER OF SEQUENCES: 81
;    CORRESPONDENCE ADDRESS:
;       ADDRESSEE: ARIAD Pharmaceuticals, Inc.
;       STREET: 26 Landsdowne Street
;       CITY: Cambridge
;       STATE: Massachusetts
;       COUNTRY: USA
;       ZIP: 02139
;    COMPUTER READABLE FORM:
;       MEDIUM TYPE: Floppy disk
;       COMPUTER: IBM PC compatible
;       OPERATING SYSTEM: PC/DOS/MS/DOS
;       SOFTWARE: PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;       APPLICATION NUMBER: US/08/483,898
;       FILING DATE: 07-JUN-1995
;       CLASSIFICATION: 435
;    PRIOR APPLICATION DATA:
;       APPLICATION NUMBER: US 08/292,597
;       FILING DATE: 18-AUG-1994
;    ATTORNEY/AGENT INFORMATION:
;       NAME: Figg, E. Anthony
;       REGISTRATION NUMBER: 27,195
;       REFERENCE/DOCKET NUMBER: 2054-108A
```

```
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE: (202) 783-6040
;       TELEFAX: (202) 783-6031
; INFORMATION FOR SEQ ID NO: 52:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 6 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
;   MOLECULE TYPE: protein
US-08-483-898-52

Query Match    79.2%;  Score 19;  DB 2;  Length 6;
Best Local Similarity 100.0%;  Pred. No. 4.1e+05;
Matches   3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy    2 FRH 4
        |||
Db    2 FRH 4


RESULT 48
US-09-087-716-52
; Sequence 52, Application US/09087716
; Patent No. 6011018
; GENERAL INFORMATION:
;   APPLICANT: Crabtree, Gerald R.
;   APPLICANT: Schreiber, Stuart L.
;   APPLICANT: Spencer, David M.
;   APPLICANT: Wandless, Thomas J.
;   APPLICANT: Belshaw, Peter
;   TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED
;   TITLE OF INVENTION: GENES AND OTHER BIOLOGICAL EVENTS
;   NUMBER OF SEQUENCES: 81
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: ARIAD Pharmaceuticals, Inc.
;     STREET: 26 Landsdowne Street
;     CITY: Cambridge
;     STATE: Massachusetts
;     COUNTRY: USA
;     ZIP: 02139
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC/DOS/MS/DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/09/087,716
;     FILING DATE:
;     CLASSIFICATION:
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 08/388,653
;     FILING DATE: 02/14/1995
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Figg, E. Anthony
;     REGISTRATION NUMBER: 27,195
;     REFERENCE/DOCKET NUMBER: 2054-114A
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (202) 783-6040
;     TELEFAX: (202) 783-6031
; INFORMATION FOR SEQ ID NO: 52:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 6 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
;   MOLECULE TYPE: protein
US-09-087-716-52

Query Match    79.2%;  Score 19;  DB 3;  Length 6;
Best Local Similarity 100.0%;  Pred. No. 4.1e+05;
Matches   3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy    2 FRH 4
        |||
Db    2 FRH 4


RESULT 49
US-09-157-753-52
; Sequence 52, Application US/09157753
; Patent No. 604308Z
; GENERAL INFORMATION:
;   APPLICANT: Crabtree, Gerald R.
;   APPLICANT: Schreiber, Stuart L.
;   APPLICANT: Spencer, David M.
;   APPLICANT: Wandless, Thomas J.
;   APPLICANT: Belshaw, Peter
;   TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED
;   TITLE OF INVENTION: GENES AND OTHER BIOLOGICAL EVENTS
;   NUMBER OF SEQUENCES: 81
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: ARIAD Pharmaceuticals, Inc.
;     STREET: 26 Landsdowne Street
;     CITY: Cambridge
;     STATE: Massachusetts
;     COUNTRY: USA
;     ZIP: 02139
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC/DOS/MS/DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/09/157,753
;     FILING DATE:
;     CLASSIFICATION:
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 08/388,653
;     FILING DATE: 14-FEB-1995
;     APPLICATION NUMBER: US 08/478,386
;     FILING DATE: 07-JUN-1995
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Figg, E. Anthony
;     REGISTRATION NUMBER: 27,195
;     REFERENCE/DOCKET NUMBER: 2054-114A
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (202) 783-6040
;     TELEFAX: (202) 783-6031
; INFORMATION FOR SEQ ID NO: 52:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 6 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
;   MOLECULE TYPE: protein
US-09-157-753-52

Query Match    79.2%;  Score 19;  DB 3;  Length 6;
Best Local Similarity 100.0%;  Pred. No. 4.1e+05;  Indels   0;  Gaps   0;
Matches   3;  Conservative   0;  Mismatches   0;

Qy    2 FRH 4
        |||
Db    2 FRH 4


RESULT 50
US-09-157-230-52
; Sequence 52, Application US/09157230
; Patent No. 6046047
; GENERAL INFORMATION:
;   APPLICANT: Crabtree, Gerald R.
;   APPLICANT: Schreiber, Stuart L.
;   APPLICANT: Spencer, David M.
;   APPLICANT: Wandless, Thomas J.
;   APPLICANT: Belshaw, Peter
;   TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED
;   TITLE OF INVENTION: GENES AND OTHER BIOLOGICAL EVENTS
```

NUMBER OF SEQUENCES: 81
CORRESPONDENCE ADDRESS:
  ADDRESSEE: ARIAD Pharmaceuticals, Inc.
  STREET: 26 Landsdowne Street
  CITY: Cambridge
  STATE: Massachusetts
  COUNTRY: USA
  ZIP: 02139
COMPUTER READABLE FORM:
  MEDIUM TYPE: Floppy disk
  COMPUTER: IBM PC compatible
  OPERATING SYSTEM: PC/DOS/MS/DOS
  SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
  APPLICATION NUMBER: US/09/157,230
  FILING DATE:
  CLASSIFICATION:
PRIOR APPLICATION DATA:
  APPLICATION NUMBER: US 08/478,386
  FILING DATE: 07/JUN/1995
ATTORNEY/AGENT INFORMATION:
  NAME: Figg, E. Anthony
  REGISTRATION NUMBER: 27,195
  REFERENCE/DOCKET NUMBER: 2054-114A
TELECOMMUNICATION INFORMATION:
  TELEPHONE: (202) 783-6040
  TELEFAX: (202) 783-6031
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
  LENGTH: 6 amino acids
  TYPE: amino acid
  TOPOLOGY: linear
  MOLECULE TYPE: protein
US-09-157-230-52

Query Match     79.2%;  Score 19;  DB 3;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 4.1e+05;
Matches  3;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy     2 FRH 4
         |||
Db     2 FRH 4

RESULT 51
US-09-087-811-52
; Sequence 52, Application US/09087811
; Patent No. 6054436
; GENERAL INFORMATION:
  APPLICANT: Gerald R. Crabtree
  APPLICANT: Schreiber, Stuart L.
  APPLICANT: Spencer, David M.
  APPLICANT: Wandless, Thomas J.
  APPLICANT: Belshaw, Peter
  TITLE OF INVENTION: Regulated Apoptosis
  NUMBER OF SEQUENCES: 81
  CORRESPONDENCE ADDRESS:
    ADDRESSEE: ARIAD Pharmaceuticals, Inc.
    STREET: 26 Landsdowne Street
    CITY: Cambridge
    STATE: Massachusetts
    COUNTRY: USA
    ZIP: 02139
  COMPUTER READABLE FORM:
    MEDIUM TYPE: Floppy disk
    COMPUTER: IBM PC compatible
    OPERATING SYSTEM: PC/DOS/MS/DOS
    SOFTWARE: PatentIn Release #1.0, Version #1.25
  CURRENT APPLICATION DATA:
    APPLICATION NUMBER: US/09/087,811
    FILING DATE:
    CLASSIFICATION:
  PRIOR APPLICATION DATA:
    APPLICATION NUMBER: US 08/292,597
    FILING DATE: 18-AUG-1994
  ATTORNEY/AGENT INFORMATION:
    NAME: Figg, E. Anthony
    REGISTRATION NUMBER: 27,195
    REFERENCE/DOCKET NUMBER: 2054-108A
  TELECOMMUNICATION INFORMATION:
    TELEPHONE: (202) 783-6040
    TELEFAX: (202) 783-6031
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
  LENGTH: 6 amino acids
  TYPE: amino acid
  TOPOLOGY: linear
  MOLECULE TYPE: protein
US-09-087-811-52

Query Match     79.2%;  Score 19;  DB 3;  Length 6;
Best Local Similarity  100.0%;  Pred. No. 4.1e+05;
Matches  3;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy     2 FRH 4
         |||
Db     2 FRH 4

RESULT 52
US-09-156-855-52
; Sequence 52, Application US/09156855
; Patent No. 6063625
; GENERAL INFORMATION:
  APPLICANT: Gerald R. Crabtree
  APPLICANT: Schreiber, Stuart L.
  APPLICANT: Spencer, David M.
  APPLICANT: Wandless, Thomas J.
  APPLICANT: Belshaw, Peter
  TITLE OF INVENTION: Regulated Transcription of Targeted
  TITLE OF INVENTION: Genes and Other Biological Events
  NUMBER OF SEQUENCES: 76
  CORRESPONDENCE ADDRESS:
    ADDRESSEE: ARIAD Pharmaceuticals, Inc.
    STREET: 26 Landsdowne Street
    CITY: Cambridge
    STATE: Massachusetts
    COUNTRY: USA
    ZIP: 02139
  COMPUTER READABLE FORM:
    MEDIUM TYPE: Floppy disk
    COMPUTER: IBM PC compatible
    OPERATING SYSTEM: PCDOS/MSDOS
    SOFTWARE: PatentIn Release #1.0, Version #1.25
  CURRENT APPLICATION DATA:
    APPLICATION NUMBER: US/09/156,855
    FILING DATE:
    CLASSIFICATION:
  PRIOR APPLICATION DATA:
    APPLICATION NUMBER: US 08/196,043
    FILING DATE: 11-FEB-1994
  ATTORNEY/AGENT INFORMATION:
    NAME: Berstein, David L.
    REGISTRATION NUMBER: 31,235
    REFERENCE/DOCKET NUMBER: ARIAD 316C
  TELECOMMUNICATION INFORMATION:
    TELEPHONE: (617) 494-0400
    TELEFAX: (617) 494-8144
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
  LENGTH: 6 amino acids
  TYPE: amino acid
  TOPOLOGY: linear
  MOLECULE TYPE: protein
US-09-156-855-52

Query Match          79.2%;  Score 19;  DB 3;  Length 6;
Best Local Similarity 100.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          2 FRH 4
              |||
Db          2 FRH 4

RESULT 53
US-09-158-010-52
; Sequence 52, Application US/09158010
; Patent No. 6140120
; GENERAL INFORMATION:
; APPLICANT: Gerald R. Crabtree
; APPLICANT: Schreiber, Stuart L.
; APPLICANT: Spencer, David M.
; APPLICANT: Wandless, Thomas J.
; APPLICANT: Belshaw, Peter
; TITLE OF INVENTION: Regulated Transcription of Targeted
; TITLE OF INVENTION: Genes and Other Biological Events
; NUMBER OF SEQUENCES: 76
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.
; STREET: 26 Landsdowne Street
; CITY: Cambridge
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02139
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PCDOS/MSDOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/158,010
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/196,043
; FILING DATE: 11-FEB-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Berstein, David L.
; REGISTRATION NUMBER: 31,235
; REFERENCE/DOCKET NUMBER: ARIAD 316C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 494-0400
; TELEFAX: (617) 494-8144
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-158-010-52

Query Match          79.2%;  Score 19;  DB 3;  Length 6;
Best Local Similarity 100.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          2 FRH 4
              |||
Db          2 FRH 4

RESULT 54
US-09-087-647-52
; Sequence 52, Application US/09087647
; Patent No. 6165787
; GENERAL INFORMATION:
; APPLICANT: Crabtree, Gerald R.
; APPLICANT: Schreiber, Stuart L.
; APPLICANT: Spencer, David M.
; APPLICANT: Wandless, Thomas J.
; APPLICANT: Belshaw, Peter
; TITLE OF INVENTION: REGULATED TRANSCRIPTION OF TARGETED
; TITLE OF INVENTION: GENES AND OTHER BIOLOGICAL EVENTS
; NUMBER OF SEQUENCES: 81
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.
; STREET: 26 Landsdowne Street
; CITY: Cambridge
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02139
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC/DOS/MS/DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/087,647
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/478,386
; FILING DATE: 07/JUN/1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Figg, E. Anthony
; REGISTRATION NUMBER: 27,195
; REFERENCE/DOCKET NUMBER: 2054-114A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 783-6040
; TELEFAX: (202) 783-6031
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-087-647-52

Query Match          79.2%;  Score 19;  DB 3;  Length 6;
Best Local Similarity 100.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          2 FRH 4
              |||
Db          2 FRH 4

RESULT 55
US-09-302-629-52
; Sequence 52, Application US/09302629
; Patent No. 6316418
; GENERAL INFORMATION:
; APPLICANT: Gerald R. Crabtree
; APPLICANT: Schreiber, Stuart L.
; APPLICANT: Spencer, David M.
; APPLICANT: Wandless, Thomas J.
; APPLICANT: Belshaw, Peter
; TITLE OF INVENTION: Regulated Apoptosis
; NUMBER OF SEQUENCES: 81
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARIAD Pharmaceuticals, Inc.
; STREET: 26 Landsdowne Street
; CITY: Cambridge
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02139
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC/DOS/MS/DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:

```
  ,,;    APPLICATION NUMBER:  US/09/302,629
  ,,;    FILING DATE:
  ,,;    CLASSIFICATION:
  ,,;  PRIOR APPLICATION DATA:
  ,,;    APPLICATION NUMBER:  09/087,811
  ,,;    FILING DATE:
  ,,;  ATTORNEY/AGENT INFORMATION:
  ,,;    NAME: Figg, E. Anthony
  ,,;    REGISTRATION NUMBER: 27,195
  ,,;    REFERENCE/DOCKET NUMBER: 2054-108A
  ,,;  TELECOMMUNICATION INFORMATION:
  ,,;    TELEPHONE:  (202) 783-6040
  ,,;    TELEFAX:  (202) 783-6031
  ,;  INFORMATION FOR SEQ ID NO: 52:
  ,,;    SEQUENCE CHARACTERISTICS:
  ,,;    LENGTH:  6 amino acids
  ,,;    TYPE: amino acid
  ,,;    TOPOLOGY: linear
  ,;    MOLECULE TYPE: protein
  US-09-302-629-52

Query Match      79.2%;  Score 19;  DB 3;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 4.1e+05;
Matches     3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      2 FRH 4
          |||
Db      2 FRH 4

RESULT 56
US-09-526-738A-8
  ; Sequence 8, Application US/09526738A
  ; Patent No. 6630584
  ; GENERAL INFORMATION:
  ; APPLICANT: RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DVELOPMENT
  ; APPLICANT: LTD.
  ; TITLE OF INVENTION: SINGLE CHAIN  ANTIBODY AGAINST MUTANT P53
  ; FILE REFERENCE: 1196336
  ; CURRENT APPLICATION NUMBER: US/09/526,738A
  ; CURRENT FILING DATE: 2000-03-16
  ; NUMBER OF SEQ ID NOS: 9
  ; SOFTWARE: PatentIn version 3.1
  ; SEQ ID NO 8
  ;   LENGTH: 6
  ;   TYPE: PRT
  ;   ORGANISM: Humanus
  US-09-526-738A-8

Query Match      79.2%;  Score 19;  DB 4;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 4.1e+05;
Matches     3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      2 FRH 4
          |||
Db      1 FRH 3

RESULT 57
US-08-875-533-57
  ; Sequence 57, Application US/08875533
  ; Patent No. 6254870
  ; GENERAL INFORMATION:
  ; APPLICANT:
  ; TITLE OF INVENTION:  No. 6254870el c-MPL Ligands
  ; NUMBER OF SEQUENCES: 73
  ; COMPUTER READABLE FORM:
  ;   MEDIUM TYPE: Floppy disk
  ;   COMPUTER: IBM PC compatible
  ;   OPERATING SYSTEM: PC-DOS/MS-DOS
  ;   SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
  ; CURRENT APPLICATION DATA:
  ;   APPLICATION NUMBER: US/08/875,533
```

```
  ,,;    FILING DATE:
  ,,;    CLASSIFICATION:  514
  ,,;  PRIOR APPLICATION DATA:
  ,,;    APPLICATION NUMBER:  US 08/383,035
  ,,;    FILING DATE:  04-FEB-1995
  ,;  INFORMATION FOR SEQ ID NO:  57:
  ,,;    SEQUENCE CHARACTERISTICS:
  ,,;    LENGTH:  8 amino acids
  ,,;    TYPE: amino acid
  ,,;    STRANDEDNESS:
  ,,;    TOPOLOGY: linear
  ,;    MOLECULE TYPE: peptide
  US-08-875-533-57

Query Match      79.2%;  Score 19;  DB 3;  Length 8;
Best Local Similarity   75.0%;  Pred. No. 4.1e+05;
Matches     3;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy      1 EFRH 4
          ||
Db      1 EFHH 4

RESULT 58
US-09-464-152A-14
  ; Sequence 14, Application US/09464152A
  ; Patent No.6498020
  ; GENERAL INFORMATION:
  ; APPLICANT: Miroux, Bruno
  ; APPLICANT: Walker, John
  ; TITLE OF INVENTION: Fusion Proteins Comprising Coiled-Coil Structures Derived of Bovi
  ; TITLE OF INVENTION: ATPase Inhibitor Protein
  ; FILE REFERENCE: 3789/85128
  ; CURRENT APPLICATION NUMBER: US/09/464,152A
  ; CURRENT FILING DATE: 1999-12-27
  ; PRIOR APPLICATION NUMBER: PCT/GB98/02041
  ; PRIOR FILING DATE: 1998-07-10
  ; PRIOR APPLICATION NUMBER: GB971460.7
  ; PRIOR FILING DATE: 1997-07-11
  ; NUMBER OF SEQ ID NOS: 25
  ; SOFTWARE: PatentIn version 3.1
  ; SEQ ID NO 14
  ;   LENGTH: 8
  ;   TYPE: PRT
  ;   ORGANISM: Artificial sequence
  ;   FEATURE:
  ;   OTHER INFORMATION: Histidine tag
  US-09-464-152A-14

Query Match      79.2%;  Score 19;  DB 4;  Length 8;
Best Local Similarity   75.0%;  Pred. No. 4.1e+05;
Matches     3;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy      1 EFRH 4
          ||
Db      1 EFHH 4

RESULT 59
US-09-589-483-28
  ; Sequence 28, Application US/09589483
  ; Patent No. 6797488
  ; GENERAL INFORMATION:
  ; APPLICANT: Sukhatme, Vikas P.
  ; TITLE OF INVENTION: METHODS OF PRODUCING ANTI-ANGIOGENIC
  ; TITLE OF INVENTION: PROTEINS
  ; FILE REFERENCE: 1440.1031010
  ; CURRENT APPLICATION NUMBER: US/09/589,483
  ; CURRENT FILING DATE: 2000-06-07
  ; PRIOR APPLICATION NUMBER: US 60/108,536
  ; PRIOR FILING DATE: 1998-11-16
  ; PRIOR APPLICATION NUMBER: US 60/082,663
  ; PRIOR FILING DATE: 1998-04-22
```

```
  ;   PRIOR APPLICATION NUMBER: US 60/067,888
  ;   PRIOR FILING DATE: 1997-12-08
  ;   PRIOR APPLICATION NUMBER: PCT/US98/25892
  ;   PRIOR FILING DATE: 1998-12-08
  ;   NUMBER OF SEQ ID NOS: 34
  ;   SOFTWARE: FastSEQ for Windows Version 4.0
  ;   SEQ ID NO 28
  ;     LENGTH: 8
  ;     TYPE: PRT
  ;     ORGANISM: Artificial Sequence
  ;     FEATURE:
  ;     OTHER INFORMATION: Leader peptide on protein produced by eukaryotic
  ;     OTHER INFORMATION: yeast expression system pPICZaA
US-09-589-483-28

Query Match             79.2%;  Score 19;  DB 4;  Length 8;
Best Local Similarity   75.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative   0;  Mismatches   1;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
                |||
Db          1 EFHH 4


RESULT 60
US-08-134-198E-12
  ;   Sequence 12, Application US/08134198E
  ;   Patent No. 6190885
  ;   GENERAL INFORMATION:
  ;     APPLICANT: CANCER RESEARCH FUND
  ;     APPLICANT: OF CONTRA COSTA
  ;     APPLICANT: PETERSON, JERRY A.
  ;     APPLICANT: LAROCCA, DAVID J.
  ;     TITLE OF INVENTION: FUSION PROTEIN CONTAINING HMFG
  ;     NUMBER OF SEQUENCES: 42
  ;     CORRESPONDENCE ADDRESS:
  ;       ADDRESSEE: Pretty, Schroeder & Poplawski
  ;       STREET: 444 South Flower Street, Suite 1900
  ;       CITY: Los Angeles
  ;       STATE: California
  ;       COUNTRY: USA
  ;       ZIP: 90071
  ;     COMPUTER READABLE FORM:
  ;       MEDIUM TYPE: 3.5" Floppy disk
  ;       COMPUTER: IBM PC compatible
  ;       OPERATING SYSTEM: PC-DOS/MS-DOS
  ;       SOFTWARE: PatentIn Release #1.0,
  ;       SOFTWARE: Version #1.25
  ;     CURRENT APPLICATION DATA:
  ;       APPLICATION NUMBER: US/08/134,198E
  ;       FILING DATE: October 8, 1993
  ;       CLASSIFICATION: 530
  ;     ATTORNEY/AGENT INFORMATION:
  ;       NAME: Amzel, Viviana
  ;       REGISTRATION NUMBER: 30,930
  ;       REFERENCE/DOCKET NUMBER: P66 38208 (CRFC-003C)
  ;     TELECOMMUNICATION INFORMATION:
  ;       TELEPHONE: (213) 622-7700
  ;       TELEFAX: (213) 489-4210
  ;   INFORMATION FOR SEQ ID NO: 12:
  ;     SEQUENCE CHARACTERISTICS:
  ;       LENGTH: 9
  ;       TYPE: amino acid
  ;       STRANDEDNESS:
  ;       TOPOLOGY: linear
  ;     MOLECULE TYPE: peptide
US-08-134-198E-12

Query Match             79.2%;  Score 19;  DB 3;  Length 9;
Best Local Similarity   75.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative   0;  Mismatches   1;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
```

```
Db          1 EFHH 4


RESULT 61
US-09-502-600-117
  ;   Sequence 117, Application US/09502600A
  ;   Patent No. 6294344
  ;   GENERAL INFORMATION:
  ;     APPLICANT: O'Brien, Timothy J.
  ;     TITLE OF INVENTION: Compositions and Methods for the Early Diagnosis of
  ;     TITLE OF INVENTION: Ovarian Cancer
  ;     FILE REFERENCE: D6223CIP-C
  ;     CURRENT FILING DATE: 2000-02-11
  ;     CURRENT APPLICATION NUMBER: US/09/502,600A
  ;     PRIOR APPLICATION NUMBER: 09/039,211
  ;     PRIOR FILING DATE: 03-14-1998
  ;     NUMBER OF SEQ ID NOS: 136
  ;   SEQ ID NO 117
  ;     LENGTH: 9
  ;     TYPE: PRT
  ;     ORGANISM: Homo sapiens
  ;     FEATURE:
  ;     OTHER INFORMATION: Residues 99-107 of the SCCE protein
US-09-502-600-117

Query Match             79.2%;  Score 19;  DB 3;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          2 FRH 4
                |||
Db          1 FRH 3


RESULT 62
US-09-149-476-663
  ;   Sequence 663, Application US/0914947 6
  ;   Patent No. 6420526
  ;   GENERAL INFORMATION:
  ;     APPLICANT: Rosen et al.
  ;     TITLE OF INVENTION: 186 Human Secreted proteins
  ;     FILE REFERENCE: P2002P1
  ;     CURRENT APPLICATION NUMBER: US/09/149,476
  ;     CURRENT FILING DATE: 1998-09-08
  ;     EARLIER APPLICATION NUMBER: PCT/US98/04493
  ;     EARLIER FILING DATE: 1998-03-06
  ;     EARLIER APPLICATION NUMBER: 60/040,162
  ;     EARLIER FILING DATE: 1997-03-07
  ;     EARLIER APPLICATION NUMBER: 60/040,333
  ;     EARLIER FILING DATE: 1997-03-07
  ;     EARLIER APPLICATION NUMBER: 60/038,621
  ;     EARLIER FILING DATE: 1997-03-07
  ;     EARLIER APPLICATION NUMBER: 60/040,626
  ;     EARLIER FILING DATE: 1997-03-07
  ;     EARLIER APPLICATION NUMBER: 60/040,334
  ;     EARLIER FILING DATE: 1997-03-07
  ;     EARLIER APPLICATION NUMBER: 60/040,336
  ;     EARLIER FILING DATE: 1997-03-07
  ;     EARLIER APPLICATION NUMBER: 60/040,163
  ;     EARLIER FILING DATE: 1997-03-07
  ;     EARLIER APPLICATION NUMBER: 60/047,600
  ;     EARLIER FILING DATE: 1997-05-23
  ;     EARLIER APPLICATION NUMBER: 60/047,615
  ;     EARLIER FILING DATE: 1997-05-23
  ;     EARLIER APPLICATION NUMBER: 60/047,597
  ;     EARLIER FILING DATE: 1997-05-23
  ;     EARLIER APPLICATION NUMBER: 60/047,502
  ;     EARLIER FILING DATE: 1997-05-23
  ;     EARLIER APPLICATION NUMBER: 60/047,633
  ;     EARLIER FILING DATE: 1997-05-23
  ;     EARLIER APPLICATION NUMBER: 60/047,583
  ;     EARLIER FILING DATE: 1997-05-23
```

EARLIER APPLICATION NUMBER: 60/047,617
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,618
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,503
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,592
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,581
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,584
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,500
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,587
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,492
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,598
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,613
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,582
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,596
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,612
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,632
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,601
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/043,580
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,568
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,314
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,569
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,311
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,671
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,674
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,669
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,312
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,313
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,672
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,315
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/048,974
EARLIER FILING DATE: 1997-06-06
EARLIER APPLICATION NUMBER: 60/056,886
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,877
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,889
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,893
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,630
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,878
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,662
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,872

EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,882
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,637
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,903
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,888
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,879
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,880
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,894
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,911
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,636
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,874
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,910
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,864
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,631
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,845
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,892
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/057,761
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/047,595
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,599
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,588
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,585
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,586
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,590
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,594
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,589
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,593
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/047,614
EARLIER FILING DATE: 1997-05-23
EARLIER APPLICATION NUMBER: 60/043,578
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/047,501
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/043,670
EARLIER FILING DATE: 1997-04-11
EARLIER APPLICATION NUMBER: 60/056,632
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,664
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,876
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,881
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,909
EARLIER FILING DATE: 1997-08-22
EARLIER APPLICATION NUMBER: 60/056,875
EARLIER FILING DATE: 1997-08-22

; EARLIER APPLICATION NUMBER: 60/056,862
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,887
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,908
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/048,964
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/057,650
; EARLIER FILING DATE: 1997-09-05
; EARLIER APPLICATION NUMBER: 60/056,884
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/057,669
; EARLIER FILING DATE: 1997-09-05
; EARLIER APPLICATION NUMBER: 60/049,610
; EARLIER FILING DATE: 1997-06-13
; EARLIER APPLICATION NUMBER: 60/061,060
; EARLIER FILING DATE: 1997-10-02

Query Match              79.2%;   Score 19;  DB 4;  Length 9;
Best Local Similarity  100.0%;    Pred. No. 4.1e+05;
Matches    3;  Conservative    0;  Mismatches   0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              |||
Db          5 FRH 7

RESULT 63
US-09-918-243-117
; Sequence 117, Application US/09918243
; Patent No. 6627403
; GENERAL INFORMATION:
; APPLICANT: O'Brien, Timothy J.
; APPLICANT: Cannon, Martin J.
; APPLICANT: Santin, Alessandro
; TITLE OF INVENTION: Methods for the early diagnosis of ovarian cancer
; FILE REFERENCE: D6223CIP/C/D/CIP
; CURRENT APPLICATION NUMBER: US/09/918,243
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US
; PRIOR FILING DATE: 2001-07-13
; NUMBER OF SEQ ID NOS: 136
; SEQ ID NO 117
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CHAIN
; OTHER INFORMATION: Residues 99-107 of the SCCE protein
US-09-918-243-117

Query Match              79.2%;   Score 19;  DB 4;  Length 9;
Best Local Similarity  100.0%;    Pred. No. 4.1e+05;
Matches    3;  Conservative    0;  Mismatches   0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              |||
Db          1 FRH 3

RESULT 64
US-09-601-729-103
; Sequence 103, Application US/09601729
; Patent No. 6683052
; GENERAL INFORMATION:
; APPLICANT: THIAM, KADER
; APPLICANT: AURIAULT, CLAUDE
; APPLICANT: GRAS-MASSE, HELENE
; APPLICANT: LOING, ESTELLE
; APPLICANT: VERWAERDE, CLAUDIE
; APPLICANT: GUILLET, JEAN GERARD
; TITLE OF INVENTION: LIPOPEPTIDES CONTAINING AN INTERFERON FRAGMENT AND USES

; TITLE OF INVENTION: THEREOF IN PHARMACEUTICAL COMPOSITIONS
; FILE REFERENCE: USB-97-AU-IN
; CURRENT APPLICATION NUMBER: US/09/601,729
; CURRENT FILING DATE: 2000-11-20
; PRIOR APPLICATION NUMBER: PCT/FR99/00259
; PRIOR FILING DATE: 1999-02-05
; PRIOR APPLICATION NUMBER: 98 01439
; PRIOR FILING DATE: 1998-02-06
; NUMBER OF SEQ ID NOS: 281
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 103
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-09-601-729-103

Query Match              79.2%;   Score 19;  DB 4;  Length 9;
Best Local Similarity  100.0%;    Pred. No. 4.1e+05;
Matches    3;  Conservative    0;  Mismatches   0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              |||
Db          3 FRH 5

RESULT 65
PCT-US95-16415-30
; Sequence 30, Application PC/TUS951615
; GENERAL INFORMATION:
; APPLICANT: The Scripps Research Institute
; TITLE OF INVENTION: IN VIVO ACTIVATION OF TUMOR-SPECIFIC
; TITLE OF INVENTION: CYTOTOXIC T CELLS
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: The Scripps Research Institute
; STREET: 10666 North Torrey Pines Road, TPC-8
; CITY: La Jolla
; STATE: California
; COUNTRY: US
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/16415
; FILING DATE: 13-DEC-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/355,558
; FILING DATE: 14-DEC-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Logan, April C.
; REGISTRATION NUMBER: 33,950
; REFERENCE/DOCKET NUMBER: 433.1PC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 554-2937
; TELEFAX: (619) 554-6312
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
PCT-US95-16415-30

Query Match              79.2%;   Score 19;  DB 5;  Length 9;
Best Local Similarity  100.0%;    Pred. No. 4.1e+05;
Matches    3;  Conservative    0;  Mismatches   0;  Indels    0;  Gaps    0;

```
Qy        2 FRH 4
            |||
Db        3 FRH 5

RESULT 66
5514558-10
;Patent No. 5514558
;APPLICANT: CERIANI, ROBERTO L.;PETERSON, JERRY A.;
;LAROCCA, DAVID J.;
;TITLE OF INVENTION: HIGHLY SENSITIVE AND SPECIFIC SOLID-PHASE
;COMPETITIVE ASSAY UTILIZING A FUSION PROTEIN
;     NUMBER OF SEQUENCES: 11
;     CURRENT APPLICATION DATA:
;        APPLICATION NUMBER: US/08/129,540
;        FILING DATE: 30-SEP-1993
;     PRIOR APPLICATION DATA:
;        APPLICATION NUMBER: 46,103
;        FILING DATE: 08-APR-1993
;        APPLICATION NUMBER: 473,673
;        FILING DATE: 02-FEB-1990
;SEQ ID NO:10:
;     LENGTH: 9
5514558-10

Query Match      79.2%;  Score 19;  DB 6;  Length 9;
Best Local Similarity   75.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy        1 EFRH 4
            |||
Db        1 EFHH 4

RESULT 67
5514558-10
;Patent No. 5514558
;APPLICANT: CERIANI, ROBERTO L.;PETERSON, JERRY A.;
;LAROCCA, DAVID J.;
;TITLE OF INVENTION: HIGHLY SENSITIVE AND SPECIFIC SOLID-PHASE
;COMPETITIVE ASSAY UTILIZING A FUSION PROTEIN
;     NUMBER OF SEQUENCES: 11
;     CURRENT APPLICATION DATA:
;        APPLICATION NUMBER: US/08/129,540
;        FILING DATE: 30-SEP-1993
;     PRIOR APPLICATION DATA:
;        APPLICATION NUMBER: 46,103
;        FILING DATE: 08-APR-1993
;        APPLICATION NUMBER: 473,673
;        FILING DATE: 02-FEB-1990
;SEQ ID NO:10:
;     LENGTH: 9
5514558-10

Query Match      79.2%;  Score 19;  DB 6;  Length 9;
Best Local Similarity   75.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy        1 EFRH 4
            |||
Db        1 EFHH 4

RESULT 68
US-08-338-634-19
; Sequence 19, Application US/08338634
; Patent No. 5679641
; GENERAL INFORMATION:
;     TITLE OF INVENTION: Peptides of human p53 protein for use
;     TITLE OF INVENTION: in human T cell response inducing compositions, and
;     TITLE OF INVENTION: human p53 protein-specific cytotoxic T-lymphocytes.
;     NUMBER OF SEQUENCES: 39
;     CORRESPONDENCE ADDRESS:
;        ADDRESSEE: Hoffmann & Baron
;        STREET: 350 Jericho Turnpike
;        CITY: Jericho
;        STATE: New York
;        COUNTRY: United States of America
;        ZIP: 11758
;     COMPUTER READABLE FORM:
;        MEDIUM TYPE: Floppy disk
;        COMPUTER: IBM PC compatible
;        OPERATING SYSTEM: PC-DOS/MS-DOS
;        SOFTWARE: ASCII
;     CURRENT APPLICATION DATA:
;        APPLICATION NUMBER: US/08/338,634
;        FILING DATE: 06-February-1995
;     PRIOR APPLICATION DATA:
;        APPLICATION NUMBER: PCT/NL93/00102
;        FILING DATE: 18-May-1993
;     ATTORNEY/AGENT INFORMATION:
;        NAME: Baron, Ronald J.
;        REGISTRATION NUMBER: 29,281
;        REFERENCE/DOCKET NUMBER: 294-26
;     TELECOMMUNICATION INFORMATION:
;        TELEPHONE: (516) 822-3550
;        TELEFAX: (516) 822-3582
;INFORMATION FOR SEQ ID NO: 19:
;     SEQUENCE CHARACTERISTICS:
;        LENGTH: 10 amino acids
;        TYPE: amino acid
;        STRANDEDNESS: unknown
;        TOPOLOGY: unknown
;     MOLECULE TYPE: peptide
;     HYPOTHETICAL: NO
US-08-338-634-19

Query Match      79.2%;     Score 19;  DB 1;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        2 FRH 4
            |||
Db        5 FRH 7

RESULT 69
US-08-637-759B-417
; Sequence 417, Application US/08637759B
; Patent No. 5876931
; GENERAL INFORMATION:
;     APPLICANT: David William Holden
;     TITLE OF INVENTION: Identification of Genes
;     NUMBER OF SEQUENCES: 501
;     CORRESPONDENCE ADDRESS:
;        ADDRESSEE: Patrea L. Pabst
;        STREET: 2800 One Atlantic Center
;        STREET: 1201 West Peachtree Street
;        CITY: Atlanta
;        STATE: Georgia
;        COUNTRY: USA
;        ZIP: 30309-3450
;     COMPUTER READABLE FORM:
;        MEDIUM TYPE: Floppy disk
;        COMPUTER: IBM PC compatible
;        OPERATING SYSTEM: PC-DOS/MS-DOS
;        SOFTWARE: PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;        APPLICATION NUMBER: US/08/637,759B
;        FILING DATE: 03-MAY-1996
;        CLASSIFICATION: 435
;     PRIOR APPLICATION DATA:
;        APPLICATION NUMBER: PCT/GB95/02875
;        FILING DATE: 11-DEC-1995
```

```
;         CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
;         NAME: Pabst, Patrea L.
;         REGISTRATION NUMBER: 31,284
;         REFERENCE/DOCKET NUMBER: RPMS 101
; TELECOMMUNICATION INFORMATION:
;         TELEPHONE: (404) 873-8794
;         TELEFAX: (404) 873-8795
; INFORMATION FOR SEQ ID NO: 417:
;         SEQUENCE CHARACTERISTICS:
;         LENGTH: 10 amino acids
;         TYPE: amino acid
;         STRANDEDNESS: single
;         TOPOLOGY: linear
;         MOLECULE TYPE: protein
;         HYPOTHETICAL: NO
US-08-637-759B-417

Query Match             79.2%;  Score 19;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              |||
Db          6 FRH 8

RESULT 70
US-08-556-597-171
; Sequence 171, Application US/08556597
; Patent No. 5877155
; GENERAL INFORMATION:
;         APPLICANT: Miller, Jonathan L.
;         APPLICANT: Lyle, Vicki A.
;         TITLE OF INVENTION: MIMOTOPES AND ANTI-MIMOTOPES OF
;         TITLE OF INVENTION: HUMAN PLATELET GLYCOPROTEIN Ib/IX
;         NUMBER OF SEQUENCES: 173
;         CORRESPONDENCE ADDRESS:
;         ADDRESSEE: Nixon, Hargrave, Devans & Doyle LLP
;         STREET: Clinton Square, P.O. Box 1051
;         CITY: Rochester
;         STATE: New York
;         COUNTRY: USA
;         ZIP: 14603
;         COMPUTER READABLE FORM:
;         MEDIUM TYPE: Floppy disk
;         COMPUTER: IBM PC compatible
;         OPERATING SYSTEM: PC-DOS/MS-DOS
;         SOFTWARE: PatentIn Release #1.0, Version #1.30
;         CURRENT APPLICATION DATA:
;         APPLICATION NUMBER: US/08/556,597
;         FILING DATE:
;         CLASSIFICATION: 530
;         PRIOR APPLICATION DATA:
;         APPLICATION NUMBER: US 08/406,330
;         FILING DATE: 17-MAR-1995
;         ATTORNEY/AGENT INFORMATION:
;         NAME: Timian, Susan J.
;         REGISTRATION NUMBER: 34,103
;         REFERENCE/DOCKET NUMBER: 20884/101
;         TELECOMMUNICATION INFORMATION:
;         TELEPHONE: (716) 263-1636
;         TELEFAX: (716) 263-1600
; INFORMATION FOR SEQ ID NO: 171:
;         SEQUENCE CHARACTERISTICS:
;         LENGTH: 10 amino acids
;         TYPE: amino acid
;         STRANDEDNESS: single
;         TOPOLOGY: linear
;         MOLECULE TYPE: peptide
US-08-556-597-171

Query Match             79.2%;  Score 19;  DB 2;  Length 10;


Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              |||
Db          4 FRH 6

RESULT 71
US-08-434-664-1
; Sequence 1, Application US/08434664
; Patent No. 5879917
; GENERAL INFORMATION:
;         APPLICANT: ESSIGMANN, JOHN M.
;         APPLICANT: CROY, ROBERT G.
;         APPLICANT: YAREMA, KEVIN J.
;         APPLICANT: TREIBER, DANIEL K.
;         APPLICANT: CHEN, ZHENGHUAN
;         APPLICANT: MORNINGSTAR, MARSHALL
;         APPLICANT: ZHAI, XIAOGUAN
;         TITLE OF INVENTION: PROGRAMMABLE GENOTOXIC AGENTS AND USES
;         TITLE OF INVENTION: THEREFOR
;         NUMBER OF SEQUENCES: 2
;         CORRESPONDENCE ADDRESS:
;         ADDRESSEE: PATENT ADMINISTRATOR, TESTA, HURWITZ &
;         ADDRESSEE: THIBEAULT
;         STREET: 53 STATE STREET
;         CITY: BOSTON
;         STATE: MA
;         COUNTRY: USA
;         ZIP: 02109
;         COMPUTER READABLE FORM:
;         MEDIUM TYPE: Floppy disk
;         COMPUTER: IBM PC compatible
;         OPERATING SYSTEM: PC-DOS/MS-DOS
;         SOFTWARE: PatentIn Release #1.0, Version #1.25
;         CURRENT APPLICATION DATA:
;         APPLICATION NUMBER: US/08/434,664
;         FILING DATE:
;         CLASSIFICATION: 514
;         ATTORNEY/AGENT INFORMATION:
;         NAME: FENTON, GILLIAN M.
;         REGISTRATION NUMBER: 36,508
;         REFERENCE/DOCKET NUMBER: MIT-018
;         TELECOMMUNICATION INFORMATION:
;         TELEPHONE: (617) 248-7000
;         TELEFAX: (617) 248-7100
; INFORMATION FOR SEQ ID NO: 1:
;         SEQUENCE CHARACTERISTICS:
;         LENGTH: 10 amino acids
;         TYPE: amino acid
;         STRANDEDNESS: single
;         TOPOLOGY: linear
;         MOLECULE TYPE: peptide
US-08-434-664-1

Query Match             79.2%;  Score 19;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              |||
Db          2 FRH 4

RESULT 72
US-08-239-428A-1
; Sequence 1, Application US/08239428A
; Patent No. 5882941
; GENERAL INFORMATION:
;         APPLICANT: ESSIGMANN, JOHN M.
;         APPLICANT: CROY, ROBERT G.
;         APPLICANT: YAREMA, KEVIN J.
```

```
; APPLICANT: TREIBER, DANIEL K.
; APPLICANT: CHEN, ZHENGHUAN
; APPLICANT: MORNINGSTAR, MARSHALL
; APPLICANT: ZHAI, XIAOGUAN
; TITLE OF INVENTION: PROGRAMMABLE GENOTOXIC AGENTS AND USES
; TITLE OF INVENTION: THEREFOR
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PATENT ADMINISTRATOR, TESTA, HURWITZ &
; ADDRESSEE: THIBEAULT
; STREET: 53 STATE STREET
; CITY: BOSTON
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/239,428A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: FENTON, GILLIAN M.
; REGISTRATION NUMBER: 36,508
; REFERENCE/DOCKET NUMBER: MIT-018
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 248-7000
; TELEFAX: (617) 248-7100
; MOLECULE TYPE: peptide
US-08-239-428A-1
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-239-428A-1

Query Match       79.2%;  Score 19;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
Matches   3;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy          2 FRH 4
              |||
Db          2 FRH 4

RESULT 73
US-08-871-355A-417
; Sequence 417, Application US/08871355A
; Patent No. 6015669
; GENERAL INFORMATION:
; APPLICANT: David William Holden
; TITLE OF INVENTION: Identification of Genes
; NUMBER OF SEQUENCES: 501
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Patrea L. Pabst
; STREET: 2800 One Atlantic Center
; STREET: 1201 West Peachtree Street
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30309-3450
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/871,355A
; FILING DATE: 09-JUN-1997
```

```
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB95/02875
; FILING DATE: 11-DEC-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Pabst, Patrea L.
; REGISTRATION NUMBER: 31,284
; REFERENCE/DOCKET NUMBER: RPMS 101 CON
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404) 873-8794
; TELEFAX: (404) 873-8795
; INFORMATION FOR SEQ ID NO: 417:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
US-08-871-355A-417

Query Match       79.2%;  Score 19;  DB 3;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
Matches   3;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy          2 FRH 4
              |||
Db          6 FRH 8

RESULT 74
US-09-201-945-417
; Sequence 417, Application US/09201945
; Patent No. 6342215
; GENERAL INFORMATION:
; APPLICANT: David William Holden
; TITLE OF INVENTION: Identification of Genes
; NUMBER OF SEQUENCES: 501
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Patrea L. Pabst
; STREET: 2800 One Atlantic Center
; STREET: 1201 West Peachtree Street
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30309-3450
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/201,945
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/637,759
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Pabst, Patrea L.
; REGISTRATION NUMBER: 31,284
; REFERENCE/DOCKET NUMBER: RPMS 101
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404) 873-8794
; TELEFAX: (404) 873-8795
; INFORMATION FOR SEQ ID NO: 417:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
US-09-201-945-417

Query Match     79.2%;   Score 19;   DB 3;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 2.6e+02;
Matches   3;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy      2 FRH 4
         |||
Db      6 FRH 8

RESULT 75
US-09-103-671-1
; Sequence 1, Application US/09103671
; Patent No. 6500669
; GENERAL INFORMATION:
; APPLICANT: Essigmann, John
; APPLICANT: Yarema, Kevin
; APPLICANT: Morningstar, Marshall
; APPLICANT: Croy, Robert
; TITLE OF INVENTION: Programmable Genotoxic Agents and Uses Therefor
; FILE REFERENCE: MIT-018CP2
; CURRENT APPLICATION NUMBER: US/09/103,671
; CURRENT FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: US 08/239,428
; PRIOR FILING DATE: 1994-05-04
; PRIOR APPLICATION NUMBER: US 08/434,664
; PRIOR FILING DATE: 1995-05-04
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: EP240-Cys peptide
US-09-103-671-1

Query Match     79.2%;   Score 19;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 2.6e+02;
Matches   3;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy      2 FRH 4
         |||
Db      2 FRH 4

RESULT 76
US-09-724-961-12
; Sequence 12, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740

; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-12

Query Match     79.2%;   Score 19;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 2.6e+02;
Matches   3;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy      2 FRH 4
         |||
Db      1 FRH 3

RESULT 77
US-09-580-018-12
; Sequence 12, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-12

Query Match     79.2%;   Score 19;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 2.6e+02;
Matches   3;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy      2 FRH 4
         |||
Db      1 FRH 3

RESULT 78
US-09-724-551-12
; Sequence 12, Application US/09724551
; Patent No. 6787637
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/724,551
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/580,018
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28

```
;   NUMBER OF SEQ ID NOS: 77
;   SOFTWARE: PatentIn Ver. 2.1
;
;   SEQ ID NO 12
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;   OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;   OTHER INFORMATION: peptide)
US-09-724-551-12

Query Match          79.2%;   Score 19;  DB 4;  Length 10;
Best Local Similarity  100.0%;   Pred. No. 2.6e+02;
Matches       3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2  FRH 4
               |||
Db          1  FRH 3


RESULT 79
PCT-US95-05787-1
;   Sequence 1, Application PC/TUS9505787
;   GENERAL INFORMATION:
;   APPLICANT: ESSIGMANN, JOHN M.
;   APPLICANT: CROY, ROBERT G.
;   APPLICANT: YAREMA, KEVIN J.
;   APPLICANT: TREIBER, DANIEL K.
;   APPLICANT: CHEN, ZHENGHUAN
;   APPLICANT: MORNINGSTAR, MARSHALL
;   APPLICANT: ZHAI, XIAOGUAN
;   TITLE OF INVENTION: PROGRAMMABLE GENOTOXIC AGENTS AND USES
;   TITLE OF INVENTION: THEREFOR
;   NUMBER OF SEQUENCES: 2
;   CORRESPONDENCE ADDRESS:
;   ADDRESSEE: PATENT ADMINISTRATOR, TESTA, HURWITZ &
;   ADDRESSEE: THIBEAULT
;   STREET: 53 STATE STREET
;   CITY: BOSTON
;   STATE: MA
;   COUNTRY: USA
;   ZIP: 02109
;   COMPUTER READABLE FORM:
;   MEDIUM TYPE: Floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: PC-DOS/MS-DOS
;   SOFTWARE: PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: PCT/US95/05787
;   FILING DATE:
;   CLASSIFICATION:
;   ATTORNEY/AGENT INFORMATION:
;   NAME: FENTON, GILLIAN M.
;   REGISTRATION NUMBER: 36,508
;   REFERENCE/DOCKET NUMBER: MIT-018
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (617) 248-7000
;   TELEFAX: (617) 248-7100
;   INFORMATION FOR SEQ ID NO: 1:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 10 amino acids
;   TYPE: amino acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: peptide
PCT-US95-05787-1

Query Match          79.2%;   Score 19;  DB 5;  Length 10;
Best Local Similarity  100.0%;   Pred. No. 2.6e+02;
Matches       3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2  FRH 4
```

```
Db          2  FRH 4
               |||
               2  FRH 4


RESULT 80
US-09-020-065A-13
;   Sequence 13, Application US/09020065A
;   Patent No. 6346602
;   GENERAL INFORMATION:
;   APPLICANT: Townsend, Robert M.
;   APPLICANT: Korngold, Robert
;   TITLE OF INVENTION: Peptide Mimics of the Cytokine Receptor Common
;   TITLE OF INVENTION: Gamma Chain and Methods and Compositions for
;   TITLE OF INVENTION: Making and Using the Same
;   NUMBER OF SEQUENCES: 37
;   CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6346602ris LLP
;   STREET: One Liberty Place, 46th Floor
;   CITY: Philadelphia
;   STATE: Pennsylvania
;   COUNTRY: USA
;   ZIP: 19103
;   COMPUTER READABLE FORM:
;   MEDIUM TYPE: Floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: Windows NT
;   SOFTWARE: Wordperfect V. 8
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/09/020,065A
;   FILING DATE:
;   CLASSIFICATION: 530
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: US 60/036,941
;   FILING DATE: 07-FEB-1997
;   ATTORNEY/AGENT INFORMATION:
;   NAME: DeLuca, Mark
;   REGISTRATION NUMBER: 33,229
;   REFERENCE/DOCKET NUMBER: TJU-2291
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 215-568-3100
;   TELEFAX: 215-568-3439
;   INFORMATION FOR SEQ ID NO: 13:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 8 amino acids
;   TYPE: amino acid
;   TOPOLOGY: both
;   MOLECULE TYPE: peptide
US-09-020-065A-13

Query Match          75.0%;   Score 18;  DB 3;  Length 8;
Best Local Similarity   50.0%;   Pred. No. 4.1e+05;
Matches       2;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1  EFRH 4
               :|:||
Db          1  DYRH 4


RESULT 81
US-09-809-517A-5
;   Sequence 5, Application US/09809517A
;   Patent No. 6753136
;   GENERAL INFORMATION:
;   APPLICANT: Lohning, Corinna
;   TITLE OF INVENTION: No. 6753136e1 methods for displaying (poly)peptides/proteins on b
;   TITLE OF INVENTION: particles via disulfide bonds
;   FILE REFERENCE: MORPHO/11
;   CURRENT APPLICATION NUMBER: US/09/809,517A
;   CURRENT FILING DATE: 2001-03-15
;   PRIOR APPLICATION NUMBER: EP 99114072.4
;   PRIOR FILING DATE: 1999-07-20
;   PRIOR APPLICATION NUMBER: EP 00103551.8
;   PRIOR FILING DATE: 2000-02-18
```

; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
; LENGTH: 9
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic module
US-09-809-517A-5

Query Match      75.0%;   Score 18;   DB 4;   Length 9;
Best Local Similarity   75.0%;   Pred. No. 4.1e+05;
Matches   3;   Conservative   0;   Mismatches   1;   Indels   0;   Gaps   0;

Qy   1 EFRH 4
       |||
Db   1 EFSH 4

RESULT 82
US-08-555-579-2
; Sequence 2, Application US/08555579
; Patent No. 5763225
; GENERAL INFORMATION:
; APPLICANT: Rechsteiner, Martin
; APPLICANT: Yoo, Yung
; APPLICANT: Rote, Kevin
; TITLE OF INVENTION: Synthesis of Peptides as Cloned
; TITLE OF INVENTION: Ubiquitin Extensions
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P. O. Box 4433
; CITY: Houston
; STATE: TX
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/555,579
; FILING DATE: Concurrently herewith
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sertich, Gary J.
; REGISTRATION NUMBER: 34,430
; REFERENCE/DOCKET NUMBER: UTAH:003--1)SER
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000
; TELEFAX: (512) 474-7577
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
US-08-555-579-2

Query Match      75.0%;   Score 18;   DB 1;   Length 10;
Best Local Similarity   75.0%;   Pred. No. 4.3e+02;
Matches   3;   Conservative   0;   Mismatches   1;   Indels   0;   Gaps   0;

Qy   1 EFRH 4
       |||
Db   2 EFMH 5

RESULT 83
US-08-159-339A-88
; Sequence 88, Application US/08159339A

; Patent No. 6037135
; GENERAL INFORMATION:
; APPLICANT: Kubo, Ralph T.
; APPLICANT: Grey, Howard M.
; APPLICANT: Sette, Alessandro
; APPLICANT: Celis, Esteban
; TITLE OF INVENTION: HLA Binding peptides and Their
; TITLE OF INVENTION: Uses
; NUMBER OF SEQUENCES: 1254
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/159,339A
; FILING DATE: 29-NOV-1993
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/926,666
; FILING DATE: 07-AUG-1992
; APPLICATION NUMBER: US 08/027,746
; FILING DATE: 05-MAR-1993
; APPLICATION NUMBER: US 08/103,396
; FILING DATE: 06-AUG-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Ellen Lauver
; REGISTRATION NUMBER: 32,762
; REFERENCE/DOCKET NUMBER: 018623-005030US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; TELEX:
; INFORMATION FOR SEQ ID NO: 88:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-159-339A-88

Query Match      75.0%;   Score 18;   DB 3;   Length 10;
Best Local Similarity   75.0%;   Pred. No. 4.3e+02;
Matches   3;   Conservative   0;   Mismatches   1;   Indels   0;   Gaps   0;

Qy   1 EFRH 4
       |||
Db   6 ELRH 9

RESULT 84
US-09-406-781-2
; Sequence 2, Application US/09406781
; Patent No. 6306663
; GENERAL INFORMATION:
; APPLICANT: Kenten, John
; APPLICANT: Roberts, Steven
; TITLE OF INVENTION: CONTROLLING PROTEIN LEVELS IN EUCARYOTIC ORGANISMS
; FILE REFERENCE: 2757-3
; CURRENT APPLICATION NUMBER: US/09/406,781
; CURRENT FILING DATE: 1999-09-28
; EARLIER APPLICATION NUMBER: 60/119,851
; EARLIER FILING DATE: 1999-02-12
; NUMBER OF SEQ ID NOS: 67
; SOFTWARE: PatentIn Ver. 2.1

```
; SEQ ID NO 2
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: PEST example
; OTHER INFORMATION: sequence
US-09-406-781-2

Query Match         75.0%;  Score 18;  DB 3;  Length 10;
Best Local Similarity  75.0%;  Pred. No. 4.3e+02;
Matches  3;  Conservative  0;  Mismatches  1;  Indels  0;  Gaps  0;

Qy     1 EFRH 4
         |||
Db     2 EFMH 5

RESULT 85
US-09-468-738A-5
; Sequence 5, Application US/09468738A
; Patent No. 6312933
; GENERAL INFORMATION:
; APPLICANT: Kimoto, No. 6312933ihiro
; APPLICANT: Yamamoto, Hiroaki
; APPLICANT: Mitsuhashi, Kazuya
; TITLE OF INVENTION: NOVEL CARBONYL REDUCTASE, METHOD FOR PRODUCING SAID ENZYME, DNA
; TITLE OF INVENTION: ENCODING SAID ENZYME, AND METHOD FOR PRODUCING ALCOHOL USING SAI
; TITLE OF INVENTION: ENZYME
; FILE REFERENCE: 06501-050001
; CURRENT APPLICATION NUMBER: US/09/468,738A
; CURRENT FILING DATE: 1999-12-21
; PRIOR APPLICATION NUMBER: JP 1999-171160
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: JP 1998-363130
; PRIOR FILING DATE: 1998-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.0, reformatted using WordPerfect 5.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Kluyveromyces aestuarii
US-09-468-738A-5

Query Match         75.0%;  Score 18;  DB 3;  Length 10;
Best Local Similarity  75.0%;  Pred. No. 4.3e+02;
Matches  3;  Conservative  0;  Mismatches  1;  Indels  0;  Gaps  0;

Qy     1 EFRH 4
         |||
Db     5 EFAH 8

RESULT 86
US-09-020-065A-30
; Sequence 30, Application US/09020065A
; Patent No. 6346602
; GENERAL INFORMATION:
; APPLICANT: Townsend, Robert M.
; APPLICANT: Korngold, Robert
; TITLE OF INVENTION: Peptide Mimics of the Cytokine Receptor Common
; TITLE OF INVENTION: Gamma Chain and Methods and Compositions for
; TITLE OF INVENTION: Making and Using the Same
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6346602ris LLP
; STREET: One Liberty Place, 46th Floor
; CITY: Philadelphia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
```

```
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Wordperfect V. 8
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/020,065A
; FILING DATE:
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,941
; FILING DATE: 07-FEB-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLuca, Mark
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-2291
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 amino acids
; TYPE: amino acid
; TOPOLOGY: circular
; MOLECULE TYPE: peptide
US-09-020-065A-30

Query Match         75.0%;  Score 18;  DB 3;  Length 10;
Best Local Similarity  50.0%;  Pred. No. 4.3e+02;
Matches  2;  Conservative  2;  Mismatches  0;  Indels  0;  Gaps  0;

Qy     1 EFRH 4
         ::||
Db     2 DYRH 5

RESULT 87
US-09-940-019-5
; Sequence 5, Application US/09940019
; Patent No. 6416986
; GENERAL INFORMATION:
; APPLICANT: Kimoto, No. 6416986ihiro
; APPLICANT: Yamamoto, Hiroaki
; APPLICANT: Mitsuhashi, Kazuya
; TITLE OF INVENTION: NOVEL CARBONYL REDUCTASE, METHOD FOR PRODUCING SAID ENZYME, DNA
; TITLE OF INVENTION: ENCODING SAID ENZYME, AND METHOD FOR PRODUCING ALCOHOL USING SAI
; TITLE OF INVENTION: ENZYME
; FILE REFERENCE: 06501-050001
; CURRENT APPLICATION NUMBER: US/09/940,019
; CURRENT FILING DATE: 2001-08-27
; PRIOR APPLICATION NUMBER: 09/468,738
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: JP 1998-363130
; PRIOR FILING DATE: 1998-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.0, reformatted using WordPerfect 5.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Kluyveromyces aestuarii
US-09-940-019-5

Query Match         75.0%;  Score 18;  DB 4;  Length 10;
Best Local Similarity  75.0%;  Pred. No. 4.3e+02;
Matches  3;  Conservative  0;  Mismatches  1;  Indels  0;  Gaps  0;

Qy     1 EFRH 4
         |||
Db     5 EFAH 8

RESULT 88
US-09-940-037A-5
; Sequence 5, Application US/09940037A
; Patent No. 6485948
```

; GENERAL INFORMATION:
; APPLICANT: Kimoto, No. 6485948ihiro
; APPLICANT: Yamamoto, Hiroaki
; APPLICANT: Mitsuhashi, Kazuya
; TITLE OF INVENTION: NOVEL CARBONYL REDUCTASE, METHOD FOR PRODUCING SAID ENZYME, DNA
; TITLE OF INVENTION: ENCODING SAID ENZYME, AND METHOD FOR PRODUCING ALCOHOL USING SAI
; TITLE OF INVENTION: ENZYME
; FILE REFERENCE: 06501-050001
; CURRENT APPLICATION NUMBER: US/09/940,037A
; CURRENT FILING DATE: 2000-08-27
; PRIOR APPLICATION NUMBER: 09/468,738
; PRIOR FILING DATE: 1999-12-21
; PRIOR APPLICATION NUMBER: JP 1998-363130
; PRIOR FILING DATE: 1998-12-21
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: Patentin Ver. 2.0, reformatted using WordPerfect 5.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Kluyveromyces aestuarii
US-09-940-037A-5

Query Match   75.0%;   Score 18;   DB 4;   Length 10;
Best Local Similarity   75.0%;   Pred. No. 4.3e+02;
Matches   3;   Conservative   0;   Mismatches   1;   Indels   0;   Gaps   0;

Qy   1 EFRH 4
      | | |
Db   5 EFAH 8

RESULT 89
US-09-880-132-2
; Sequence 2, Application US/09880132
; Patent No. 6559280
; GENERAL INFORMATION:
; APPLICANT: Kenten, John
; APPLICANT: Roberts, Steven
; TITLE OF INVENTION: CONTROLLING PROTEIN LEVELS IN EUCARYOTIC ORGANISMS
; FILE REFERENCE: 2757-6
; CURRENT APPLICATION NUMBER: US/09/880,132
; CURRENT FILING DATE: 2001-06-14
; PRIOR APPLICATION NUMBER: 09/406,781
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: 60/119,851
; PRIOR FILING DATE: 1999-02-12
; NUMBER OF SEQ ID NOS: 67
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 2
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: PEST example
; OTHER INFORMATION: sequence
US-09-880-132-2

Query Match   75.0%;   Score 18;   DB 4;   Length 10;
Best Local Similarity   75.0%;   Pred. No. 4.3e+02;
Matches   3;   Conservative   0;   Mismatches   1;   Indels   0;   Gaps   0;

Qy   1 EFRH 4
      | | |
Db   2 EPMH 5

RESULT 90
US-08-134-231C-37
; Sequence 37, Application US/08134231C
; Patent No. 6562596
; GENERAL INFORMATION:
; APPLICANT: Silbiger, Scott M.
;       Koski, Raymond A.

---

; TITLE OF INVENTION: Tissue Inhibitor Metalloproteinase Type
;       Three (TIMP-3) Composition and Methods
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett & Dunner
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: District of Columbia
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/134,231C
; FILING DATE: 06-Oct-1993
; CLASSIFICATION: <Unknown>
; INFORMATION FOR SEQ ID NO: 37:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 5 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 37:
US-08-134-231C-37

Query Match   70.8%;   Score 17;   DB 4;   Length 5;
Best Local Similarity   75.0%;   Pred. No. 4.1e+05;
Matches   3;   Conservative   0;   Mismatches   1;   Indels   0;   Gaps   0;

Qy   1 EFRH 4
      | | |
Db   2 EFGH 5

RESULT 91
US-08-728-160-37
; Sequence 37, Application US/08728160
; Patent No. 6683155
; GENERAL INFORMATION:
; APPLICANT: Silbiger, Scott M.
; APPLICANT: Koski, Raymond A.
; TITLE OF INVENTION: Tissue Inhibitor Metalloproteinase Type
; TITLE OF INVENTION: Three (TIMP-3) Composition and Methods
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc./Patent Operations/KMP
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: California
; COUNTRY: USA
; ZIP: 91320-1789
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/728,160
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/134,231
; FILING DATE:
; INFORMATION FOR SEQ ID NO: 37:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 5 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear

```
;   MOLECULE TYPE: protein
US-08-728-160-37

Query Match       70.8%;    Score 17;  DB 4;  Length 5;
Best Local Similarity   75.0%;  Pred. No. 4.1e+05;
Matches   3;  Conservative   0;  Mismatches   1;  Indels   0;  Gaps   0;

Qy    1 EFRH 4
        |||
Db    2 EFGH 5

RESULT 92
US-09-460-676B-3
; Sequence 3, Application US/09460676B
; Patent No. 6653532
; GENERAL INFORMATION:
; APPLICANT: Raap, Maik
; APPLICANT: Heyer, Arnd G.
; TITLE OF INVENTION: MEANS AND METHODS FOR INFLUENCING THE
; TITLE OF INVENTION: FLOWERING BEHAVIOUR OF PLANTS
; FILE REFERENCE: 23232.0001
; CURRENT APPLICATION NUMBER: US/09/460,676B
; CURRENT FILING DATE: 1999-12-14
; PRIOR APPLICATION NUMBER: DE 19857654.4
; PRIOR FILING DATE: 1998-12-14
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Arabidopsis thaliana
US-09-460-676B-3

Query Match       70.8%;    Score 17;  DB 4;  Length 8;
Best Local Similarity   50.0%;  Pred. No. 4.1e+05;
Matches   2;  Conservative   2;  Mismatches   2;  Indels   0;  Gaps   0;

Qy    1 EFRH 4
        |::|
Db    3 EYQH 6

RESULT 93
US-08-199-508-57
; Sequence 57, Application US/08199508
; Patent No. 5717058
; GENERAL INFORMATION:
; APPLICANT: Matthews, Maura-Ann H.
; APPLICANT: Stetler, Gary L.
; APPLICANT: Anthony-Cahill, Spencer J.
; APPLICANT: Anderson, David C.
; TITLE OF INVENTION: Modulators of Gene Expression
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Somatogen, Inc.
; STREET: 5797 Central Avenue
; CITY: Boulder
; STATE: Colorado
; ZIP: 80301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.4 Mb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: System 7.0.1
; SOFTWARE: Microsoft Word 5.0a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/199,508
; FILING DATE: February 18, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/021,536
; FILING DATE: February 23, 1993
; ATTORNEY/AGENT INFORMATION:
```

```
; NAME: No. 571705Bak, Henry P.
; REGISTRATION NUMBER: 33200
; REFERENCE/DOCKET NUMBER: 121 CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 303-541-3322
; TELEFAX: 303-444-3013
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10
; TYPE: amino acid
; TOPOLOGY: unknown to applicant
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
US-08-199-508-57

Query Match       70.8%;    Score 17;  DB 1;  Length 10;
Best Local Similarity   75.0%;  Pred. No. 7.3e+02;
Matches   3;  Conservative   0;  Mismatches   1;  Indels   0;  Gaps   0;

Qy    1 EFRH 4
        || |
Db    4 EFLH 7

RESULT 94
US-08-441-871-2
; Sequence 2, Application US/08441871
; Patent No. 5846765
; GENERAL INFORMATION:
; APPLICANT: Matthews, David J.
; APPLICANT: Wells, James A.
; APPLICANT: Zoller, Mark J.
; TITLE OF INVENTION: Identification of No. 5846765el Substrates
; NUMBER OF SEQUENCES: 152
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/441,871
; FILING DATE: 16-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/418928
; FILING DATE: 05-APR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/161692
; FILING DATE: 03-DEC-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/864452
; FILING DATE: 06-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/09133
; FILING DATE: 03-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/743614
; FILING DATE: 09-AUG-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/715300
; FILING DATE: 14-JUN-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/683400
; FILING DATE: 10-APR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/621667
```

;    FILING DATE:   03-DEC-1990
;  ATTORNEY/AGENT INFORMATION:
;    NAME:  Winter, Daryl B.
;    REGISTRATION NUMBER:  32,637
;    REFERENCE/DOCKET NUMBER:  645P5C2D1
;  TELECOMMUNICATION INFORMATION:
;    TELEPHONE:  415/225-1249
;    TELEFAX:  415/952-9881
;    TELEX:  910/371-7168
;  INFORMATION FOR SEQ ID NO:  2:
;  SEQUENCE CHARACTERISTICS:
;    LENGTH:  4 amino acids
;    TYPE:  amino acid
;    TOPOLOGY:  linear
US-08-441-871-2

Query Match         66.7%;  Score 16;  DB 2;  Length 4;
Best Local Similarity  100.0%;  Pred. No. 4.1e+05;
Matches    3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFR 3
              |||
Db          2 EFR 4

RESULT 95
PCT-US93-01669-16
; Sequence 16, Application PCT/US9301669
;  GENERAL INFORMATION:
;    APPLICANT:  Trowbridge, Ian S.
;    APPLICANT:  Collawn, Jr., James F.
;    APPLICANT:  Tainer, John A.
;    APPLICANT:  Kuhn, Leslie A.
;    TITLE OF INVENTION:  RECEPTOR INTERNALIZATION SIGNALS
;  NUMBER OF SEQUENCES:  57
;  CORRESPONDENCE ADDRESS:
;    ADDRESSEE:  Spensley Horn Jubas & Lubitz
;    STREET:  1880 Century Park East, Suite 500
;    CITY:  Los Angeles
;    STATE:  California
;    COUNTRY:  USA
;    ZIP:  90067
;  COMPUTER READABLE FORM:
;    MEDIUM TYPE:  Floppy disk
;    COMPUTER:  IBM PC compatible
;    OPERATING SYSTEM:  PC-DOS/MS-DOS
;    SOFTWARE:  PatentIn Release #1.0, Version #1.25
;  CURRENT APPLICATION DATA:
;    APPLICATION NUMBER:  PCT/US93/01669
;    FILING DATE:  01-MAR-1993
;  CLASSIFICATION:
;  PRIOR APPLICATION DATA:
;    APPLICATION NUMBER:  US/07/844,852
;    FILING DATE:  03-MAR-1992
;  ATTORNEY/AGENT INFORMATION:
;    NAME:  Wetherell, Jr. Ph.D., John R.
;    REGISTRATION NUMBER:  31,678
;    REFERENCE/DOCKET NUMBER:  PD-1636
;  TELECOMMUNICATION INFORMATION:
;    TELEPHONE:  (619) 455-5100
;    TELEFAX:  (619) 455-5110
;  INFORMATION FOR SEQ ID NO:  16:
;  SEQUENCE CHARACTERISTICS:
;    LENGTH:  4 amino acids
;    TYPE:  amino acid
;    TOPOLOGY:  unknown
;  MOLECULE TYPE:  peptide
PCT-US93-01669-16

Query Match         66.7%;  Score 16;  DB 5;  Length 4;
Best Local Similarity   66.7%;  Pred. No. 4.1e+05;
Matches    2;  Conservative   1;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          2 FRH 4
              :||
Db          1 YRH 3

RESULT 96
US-09-260-190-2
; Sequence 2, Application US/09260190
; Patent No. 6096713
;  GENERAL INFORMATION:
;    APPLICANT:  Green, Lawrence R.
;    APPLICANT:  Blaecki, John W.
;    TITLE OF INVENTION:  Pharmaceutical Angiostatic Dipeptide
;    TITLE OF INVENTION:  Compositions and Methods of Use Thereof
;  NUMBER OF SEQUENCES:  7
;  CORRESPONDENCE ADDRESS:
;    ADDRESSEE:  Townsend and Townsend and Crew LLP
;    STREET:  Two Embarcadero Center, Eighth Floor
;    CITY:  San Francisco
;    STATE:  California
;    COUNTRY:  USA
;    ZIP:  94111-3834
;  COMPUTER READABLE FORM:
;    MEDIUM TYPE:  Floppy disk
;    COMPUTER:  IBM PC compatible
;    OPERATING SYSTEM:  PC-DOS/MS-DOS
;    SOFTWARE:  PatentIn Release #1.0, Version #1.30
;  CURRENT APPLICATION DATA:
;    APPLICATION NUMBER:  US/09/260,190
;    FILING DATE:  01-MAR-1999
;    CLASSIFICATION:  514
;  PRIOR APPLICATION DATA:
;    APPLICATION NUMBER:  US 08/538,701
;    FILING DATE:  03-OCT-1995
;  PRIOR APPLICATION DATA:
;    APPLICATION NUMBER:  US 08/614,764
;    FILING DATE:  13-MAR-1996
;  ATTORNEY/AGENT INFORMATION:
;    NAME:  Powers, Margaret A.
;    REGISTRATION NUMBER:  39,804
;    REFERENCE/DOCKET NUMBER:  015542-002320US
;  TELECOMMUNICATION INFORMATION:
;    TELEPHONE:  (415) 576-0200
;    TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  2:
;  SEQUENCE CHARACTERISTICS:
;    LENGTH:  5 amino acids
;    TYPE:  amino acid
;    STRANDEDNESS:
;    TOPOLOGY:  linear
;  MOLECULE TYPE:  peptide
US-09-260-190-2

Query Match         66.7%;  Score 16;  DB 3;  Length 5;
Best Local Similarity   50.0%;  Pred. No. 4.1e+05;
Matches    2;  Conservative   2;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              |:::|
Db          1 EWKH 4

RESULT 97
US-09-029-267-15
; Sequence 15, Application US/09029267
; Patent No. 6107057
;  GENERAL INFORMATION:
;    APPLICANT:  Crawford, Kenneth
;    APPLICANT:  Zafor, Isabel
;    APPLICANT:  Innis, Michael
;    TITLE OF INVENTION:  Pichia Secretory Leader for Protein
;    TITLE OF INVENTION:  Expression
;  NUMBER OF SEQUENCES:  40

CORRESPONDENCE ADDRESS:
; ADDRESSEE: Chiron Corporation
; STREET: 4560 Horton Street
; CITY: Emeryville
; STATE: California
; COUNTRY: United States
; ZIP: 94608
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/029,267
; FILING DATE:
; CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
; NAME: Chung, Ling-Fong
; REGISTRATION NUMBER: 36,482
; REFERENCE/DOCKET NUMBER: 1165.100
TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 601-2704
; TELEFAX: (510) 655-3542
INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 5 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-029-267-15

Query Match    66.7%;  Score 16;  DB 3;  Length 5;
Best Local Similarity 100.0%;  Pred. No. 4.1e+05;
Matches  3;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy  1 EFR 3
       |||
Db  3 EFR 5

RESULT 98
US-09-794-927A-72
; Sequence 72, Application US/09794927A
; Patent No. 6727074
; GENERAL INFORMATION:
; APPLICANT: Gurney et al.
; TITLE OF INVENTION: Alzheimer's Disease Secretase, APP Substrates Therefor and Uses
; TITLE OF INVENTION: Therefor
; FILE REFERENCE: 29915/6280FG
; CURRENT APPLICATION NUMBER: US/09/794,927A
; CURRENT FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: 09/416,901
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/155,493
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 74
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 72
; LENGTH: 5
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-794-927A-72

Query Match    66.7%;  Score 16;  DB 4;  Length 5;

---

Best Local Similarity 100.0%;  Pred. No. 4.1e+05;
Matches  3;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy  1 EFR 3
       |||
Db  3 EFR 5

RESULT 99
US-09-795-847B-72
; Sequence 72, Application US/09795847B
; Patent No. 6753163
; GENERAL INFORMATION:
; APPLICANT: Gurney, Mark E.
; APPLICANT: Bienkowski, Michael J.
; APPLICANT: Heinrikson, Robert L.
; APPLICANT: Parodi, Luis A.
; APPLICANT: Yan, Riqiang
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR, AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 28341/6280DE
; CURRENT APPLICATION NUMBER: US/09/795,847B
; CURRENT FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 09/416,901
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/155,493
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 60/101,594
; PRIOR FILING DATE: 1998-09-24
; NUMBER OF SEQ ID NOS: 74
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 72
; LENGTH: 5
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-795-847B-72

Query Match    66.7%;  Score 16;  DB 4;  Length 5;
Best Local Similarity 100.0%;  Pred. No. 4.1e+05;
Matches  3;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy  1 EFR 3
       |||
Db  3 EFR 5

RESULT 100
US-09-869-414-72
; Sequence 72, Application US/09869414
; Patent No. 6790610
; GENERAL INFORMATION:
; APPLICANT: Beinkowski et al.
; TITLE OF INVENTION: ALZHEIMER'S DISEASE SECRETASE, APP SUBSTRATES THEREFOR, AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: 28341/6280M
; CURRENT APPLICATION NUMBER: US/09/869,414
; CURRENT FILING DATE: 2001-06-27
; PRIOR APPLICATION NUMBER: 09/416,901
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/155,493
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 09/404,133
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: PCT/US99/20881
; PRIOR FILING DATE: 1999-09-23
; PRIOR APPLICATION NUMBER: 60/101,594
; PRIOR FILING DATE: 1998-09-24

; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 72
;   LENGTH: 5
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-869-414-72

Query Match      66.7%;  Score 16;  DB 4;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 4.1e+05;
Matches      3;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 EFR 3
          |||
Db      3 EFR 5

Search completed: November  2, 2005, 09:42:33
Job time : 44 secs

Copyright  GenCore version 5.1.6
Copyright (c) 1993 - 2005  Compugen Ltd.

OM protein - protein search, using sw model

Run on:  November  2, 2005, 09:31:45 ; Search time 37 Seconds
(without alignments)
10.402 Million cell updates/sec

Title:          US-10-618-856-1
Perfect score:  24
Sequence:       1 EFRH 4

Scoring table:  BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched:  283416 seqs, 9216763 residues

Total number of hits satisfying chosen parameters:   1079

Minimum DB seq length:  4
Maximum DB seq length:  10

Post-processing:  Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database :  PIR_79.*
1:  pir1:*
2:  pir2:*
3:  pir3:*
4:  pir4:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match % | Length | DB | ID | Description |
|---|---|---|---|---|---|---|
| 1 | 13 | 54.2 | 8 | 2 | B45800 | serum albumin - do |
| 2 | 13 | 54.2 | 8 | 2 | PH1618 | Ig H chain V-D-J r |
| 3 | 13 | 54.2 | 8 | 2 | A25836 | L-serine ammonia-l |
| 4 | 13 | 54.2 | 9 | 2 | A31576 | xylose isomerase ( |
| 5 | 13 | 54.2 | 10 | 2 | PH1592 | Ig H chain V-D-J r |
| 6 | 11 | 45.8 | 5 | 2 | A44692 | fulicin - giant Af |
| 7 | 11 | 45.8 | 6 | 2 | A43129 | neuropeptide GNFFR |
| 8 | 11 | 45.8 | 8 | 2 | XGHUEU | urine glycopeptide |
| 9 | 11 | 45.8 | 9 | 2 | D28854 | fibrinopeptide B - |
| 10 | 11 | 45.8 | 9 | 2 | D58503 | translation elonga |
| 11 | 11 | 45.8 | 9 | 2 | S65433 | bradykinin - horn |
| 12 | 11 | 45.8 | 9 | 2 | S10920 | venom protein HR-3 |
| 13 | 11 | 45.8 | 9 | 2 | S77984 | cytochrome-c oxida |
| 14 | 11 | 45.8 | 9 | 2 | S66635 | alpha-2-macroglobu |
| 15 | 11 | 45.8 | 9 | 2 | A43065 | hydroxyproline-3-b |
| 16 | 11 | 45.8 | 9 | 2 | A26744 | bradykinin-like pe |
| 17 | 11 | 45.8 | 9 | 2 | A61057 | Thr-6 bradykinin - |
| 18 | 11 | 45.8 | 9 | 2 | A60579 | bradykinin-like pe |
| 19 | 11 | 45.8 | 9 | 2 | A61363 | bradykinin - commo |
| 20 | 11 | 45.8 | 9 | 2 | A61363 | bradykinin-like pe |
| 21 | 11 | 45.8 | 10 | 1 | GMROL2 | leucosulfakinin-II |
| 22 | 11 | 45.8 | 10 | 2 | S48182 | bacterioferritin - |
| 23 | 11 | 45.8 | 10 | 2 | PC2044 | beta-Kirilowin - M |
| 24 | 11 | 45.8 | 10 | 2 | A58365 | neuropeptide FFRFa |
| 25 | 11 | 45.8 | 10 | 2 | S30348 | clotting protein - |
| 26 | 11 | 45.8 | 10 | 2 | B60656 | leucosulfakinin II |
| 27 | 11 | 45.8 | 10 | 2 | D46285 | formaldehyde dehyd |
| 28 | 10 | 41.7 | 7 | 4 | I56695 | hypothetical L2 pr |
| 29 | 10 | 41.7 | 8 | 2 | S16324 | hypothetical prote |
| 30 | 10 | 41.7 | 8 | 2 | T14906 | hypothetical prote |
| 31 | 10 | 41.7 | 9 | 2 | PT0231 | Ig heavy chain CDR |
| 32 | 10 | 41.7 | 10 | 2 | S13224 | virG protein - Agr |
| 33 | 10 | 41.7 | 10 | 2 | A30823 | bothropstoxin - ja |
| 34 | 10 | 41.7 | 10 | 2 | A44871 | monodehydroascorba |
| 35 | 9 | 37.5 | 9 | 2 | PQ0783 | NADH2 dehydrogenas |
| 36 | 9 | 37.5 | 9 | 2 | JN0861 | peptidyl-dipeptida |
| 37 | 9 | 37.5 | 9 | 2 | S11024 | hydrogensulfite re |
| 38 | 9 | 37.5 | 9 | 2 | C36730 | hutU protein - Kle |
| 39 | 9 | 37.5 | 10 | 1 | RHPGG | gonadoliberin - pi |
| 40 | 9 | 37.5 | 10 | 1 | RHSHG | gonadoliberin - sh |
| 41 | 9 | 37.5 | 10 | 2 | A61126 | gonadoliberin - sp |
| 42 | 9 | 37.5 | 10 | 1 | RHAQ1 | gonadoliberin I - |
| 43 | 9 | 37.5 | 10 | 1 | RHAQ2 | gonadoliberin II - |
| 44 | 9 | 37.5 | 10 | 1 | RHLMGS | gonadoliberin - se |
| 45 | 9 | 37.5 | 10 | 2 | A43405 | 6-phosphofructo-2- |
| 46 | 9 | 37.5 | 10 | 2 | S39392 | calpain (EC 3.4.22 |
| 47 | 9 | 37.5 | 10 | 2 | B46030 | gonadoliberin II - |
| 48 | 9 | 37.5 | 10 | 2 | S59625 | beta-galactosidase |
| 49 | 9 | 37.5 | 10 | 2 | PC4374 | telomeric and tetr |
| 50 | 9 | 37.5 | 10 | 2 | F41839 | ribosomal protein |
| 51 | 9 | 37.5 | 10 | 2 | A46030 | gonadoliberin I - |
| 52 | 9 | 37.5 | 10 | 2 | A21114 | gonadoliberin - ch |
| 53 | 9 | 37.5 | 9 | 2 | H37196 | bradykinin-potenti |
| 54 | 8 | 33.3 | 8 | 2 | A48360 | gamma subunit of P |
| 55 | 8 | 33.3 | 8 | 2 | I38888 | COI intron 16 prot |
| 56 | 8 | 33.3 | 8 | 2 | PL0140 | carbon-monoxide de |
| 57 | 8 | 33.3 | 8 | 2 | JQ1273 | neuropeptide Antho |
| 58 | 8 | 33.3 | 8 | 2 | PT0712 | T-cell receptor be |
| 59 | 8 | 33.3 | 8 | 2 | JN0860 | peptidyl-dipeptida |
| 60 | 8 | 33.3 | 8 | 2 | A32516 | cholecystokinin-5 |
| 61 | 8 | 33.3 | 8 | 2 | C41225 | copper resistance |
| 62 | 8 | 33.3 | 8 | 2 | S70154 | URF2 protein - Xan |
| 63 | 8 | 33.3 | 8 | 2 | B37325 | pap fimbrial regul |
| 64 | 8 | 33.3 | 8 | 2 | F22565 | R-phycoerythrin ga |
| 65 | 8 | 33.3 | 8 | 2 | T10954 | hypothetical prote |
| 66 | 8 | 33.3 | 8 | 2 | I40698 | biotin B - Citroba |
| 67 | 8 | 33.3 | 8 | 2 | A61419 | sarcosine dehydrog |
| 68 | 8 | 33.3 | 6 | 2 | I37027 | protamine P1 - gor |
| 69 | 8 | 33.3 | 6 | 2 | B56979 | collagen alpha 1(I |
| 70 | 8 | 33.3 | 6 | 2 | S78764 | ribosomal protein |
| 71 | 8 | 33.3 | 6 | 2 | A46474 | Fc epsilon RIIb - |
| 72 | 8 | 33.3 | 6 | 2 | PT0693 | T-cell receptor be |
| 73 | 8 | 33.3 | 6 | 2 | A41946 | T-cell receptor ga |
| 74 | 8 | 33.3 | 6 | 2 | S71349 | beta-crystallin B2 |
| 75 | 8 | 33.3 | 6 | 2 | PD0028 | pev-kinin 2 - pena |
| 76 | 8 | 33.3 | 6 | 1 | NYPG7 | hypothalamic hepta |
| 77 | 8 | 33.3 | 7 | 2 | PQ0663 | membrane protein - |
| 78 | 8 | 33.3 | 7 | 2 | B39127 | phosphotransferase |
| 79 | 8 | 33.3 | 7 | 2 | S42407 | gramicidin S synth |
| 80 | 8 | 33.3 | 7 | 2 | A28709 | phosphonoacetalden |
| 81 | 8 | 33.3 | 7 | 2 | PT0246 | Ig heavy chain CRD |
| 82 | 8 | 33.3 | 7 | 2 | PT0520 | T-cell receptor be |
| 83 | 8 | 33.3 | 7 | 2 | PT0665 | T-cell receptor be |
| 84 | 8 | 33.3 | 7 | 2 | A38081 | amine oxidase (cop |
| 85 | 8 | 33.3 | 8 | 2 | S29735 | polyphosphate-gluc |
| 86 | 8 | 33.3 | 8 | 2 | A15398 | choline oxidase (E |
| 87 | 8 | 33.3 | 8 | 2 | I46868 | alpha-myosin heavy |
| 88 | 8 | 33.3 | 8 | 2 | S08606 | hypothetical prote |
| 89 | 8 | 33.3 | 8 | 2 | PQ0012 | cholecystokinin - |
| 90 | 8 | 33.3 | 8 | 2 | A43001 | cholecystokinin - |
| 91 | 8 | 33.3 | 8 | 2 | A39892 | P element, P cytot |
| 92 | 8 | 33.3 | 8 | 2 | PT0368 | Ig gamma chain C r |
| 93 | 8 | 33.3 | 8 | 2 | B54823 | olfactory receptor |
| 94 | 8 | 33.3 | 8 | 2 | S66296 | Na+-transporting A |
| 95 | 8 | 33.3 | 8 | 2 | S37141 | rpBA protein - Erw |
| 96 | 8 | 33.3 | 8 | 2 | PT0030 | inulinase (EC 3.2. |
| 97 | 8 | 33.3 | 8 | 2 | JS0316 | leucokinin VI - Ma |
| 98 | 8 | 33.3 | 8 | 2 | JS0318 | leucokinin VIII |
| 99 | 8 | 33.3 | 8 | 2 | H41978 | calliFMRFamide 8 - |
| 100 | 8 | 33.3 | 8 | 2 | E47393 | neuropeptide calla |

ALIGNMENTS

RESULT 1
B45800
serum albumin - dog (fragment)
C;Species: Canis lupus familiaris (dog)
C;Date: 03-Jun-1993 #sequence_revision 03-Jun-1993 #text_change 31-Dec-1993
C;Accession: B45800
R;Carraway, R.E.; Cochrane, D.E.; Boucher, W.; Mitra, S.P.
J. Immunol. 143, 1680-1684, 1989
A;Title: Structures of histamine-releasing peptides formed by the action of acid proteas
A;Reference number: A45800; MUID:89341406; PMID:2474609
A;Accession: B45800
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-8 <CAR>

Query Match             54.2%;  Score 13;  DB 2;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              ||
Db          4 RH 5


RESULT 2
PH1618
Ig H chain V-D-J region (clone B-less 33) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 02-Jun-1994 #sequence_revision 02-Jun-1994 #text_change 17-Mar-1999
C;Accession: PH1618
R;Levinson, D.A.; Campos-Torres, J.; Leder, P.
J. Exp. Med. 178, 317-329, 1993
A;Title: Molecular characterization of transgene-induced immunodeficiency in B-less mice
A;Reference number: PH1580; MUID:93301609; PMID:8315387
A;Accession: PH1618
A;Molecule type: DNA
A;Residues: 1-8 <LEV>
A;Experimental source: bone marrow pre-B lymphocyte
C;Keywords: immunoglobulin

Query Match             54.2%;  Score 13;  DB 2;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              ||
Db          3 RH 4


RESULT 3
A25836
L-serine ammonia-lyase (EC 4.3.1.17) - Escherichia coli (fragment)
C;Species: Escherichia coli
C;Date: 24-Jan-1988 #sequence_revision 24-Jan-1988 #text_change 09-Jul-2004
C;Accession: A25836
R;Heincz, M.C.; McFall, E
J. Bacteriol. 123, 1163-1168, 1975
A;Title: N-terminal amino acid sequences of D-serine deaminases of wild-type and operato
A;Reference number: A25836; MUID:76005414; PMID:1099073
A;Contents: K12
A;Accession: A25836
A;Molecule type: protein
A;Residues: 1-8 <HEI>
A;Cross-references: UNIPROT:Q7M194
C;Keywords: ammonia-lyase; carbon-nitrogen lyase; carbon-oxygen lyase; hydro-lyase; seri

Query Match             54.2%;  Score 13;  DB 2;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              ||
Db          3 RH 4


RESULT 4
A31576
xylose isomerase (EC 5.3.1.5), intracellular - Streptomyces sp. (fragment)
C;Species: Streptomyces sp.
C;Date: 31-Mar-1990 #sequence_revision 31-Mar-1990 #text_change 09-Jul-2004
C;Accession: A31576
R;Pawar, H.S.; Kannan, K.; Srinivasan, M.C.; Vartak, H.G.
Biochem. Biophys. Res. Commun. 155, 411-417, 1988
A;Title: Purification and characterisation of glucose (xylose) isomerase from Chainia sp
A;Reference number: A31576; MUID:88326335; PMID:3415697
A;Contents: Chainia sp. NCL 82-5-1
A;Accession: A31576
A;Molecule type: protein
A;Residues: 1-9 <PAW>
A;Cross-references: UNIPROT:P19149
C;Keywords: intramolecular oxidoreductase; isomerase

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              ||
Db          6 RH 7


RESULT 5
PH1592
Ig H chain V-D-J region (wild-type clone 143) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 02-Jun-1994 #sequence_revision 02-Jun-1994 #text_change 17-Mar-1999
C;Accession: PH1592
R;Levinson, D.A.; Campos-Torres, J.; Leder, P.
J. Exp. Med. 178, 317-329, 1993
A;Title: Molecular characterization of transgene-induced immunodeficiency in B-less mice
A;Reference number: PH1580; MUID:93301609; PMID:8315387
A;Accession: PH1592
A;Molecule type: DNA
A;Residues: 1-10 <LEV>
A;Experimental source: bone marrow pre-B lymphocyte
C;Keywords: immunoglobulin

Query Match             54.2%;  Score 13;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 2.8e+03;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              ||
Db          1 RH 2


RESULT 6
A44692
fulicin - giant African snail
C;Species: Achatina fulica (giant African snail)
C;Date: 23-Mar-1995 #sequence_revision 05-Apr-1995 #text_change 09-Jul-2004
C;Accession: A44692
R;Ohta, N.; Kubota, I.; Takao, T.; Shimonishi, Y.; Yasuda-Kamatani, Y.; Minakata, H.; No
Biochem. Biophys. Res. Commun. 178, 486-493, 1991
A;Title: Fulicin, a novel neuropeptide containing a D-amino acid residue isolated from t
A;Reference number: A44692; MUID:91315471; PMID:1859408
A;Accession: A44692
A;Molecule type: protein
A;Residues: 1-5 <OHT>
A;Cross-references: UNIPROT:P35905
C;Keywords: amidated carboxyl end; D-amino acid; neuropeptide
F;2/Modified site: D-asparagine (Asn) #status experimental
F;5/Modified site: amidated carboxyl end (Val) #status experimental

Query Match          45.8%;    Score 11;    DB 2;    Length 5;
Best Local Similarity    100.0%;    Pred. No. 2.8e+05;
  Matches    2;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;

Qy        1 EF 2
            | |
Db        3 EF 4

RESULT 7
A43129
neuropeptide GNFFRFamide - tapeworm (Moniezia expansa)
C;Species: Moniezia expansa
C;Date: 10-Nov-1997 #sequence_revision 14-Nov-1997 #text_change 09-Jul-2004
R;Maule, A.; Shaw, C.; Halton, D.; Thim, L.
Biochem. Biophys. Res. Commun. 193, 1054-1060, 1993
A;Title: GNFFRFamide: A novel FMRFamide-immunoreactive peptide isolated from the sheep b
A;Reference number: A43129; MUID:93312289; PMID:8323531
A;Accession: A43129
A;Molecule type: protein
A;Residues: 1-6 <MAU>
A;Cross-references: UNIPROT:P41966
A;Keywords: amidated carboxyl end; neuropeptide
F;6/Modified site: amidated carboxyl end (Phe) #status predicted

Query Match          45.8%;    Score 11;    DB 2;    Length 6;
Best Local Similarity    100.0%;    Pred. No. 2.8e+05;
  Matches    2;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;

Qy        2 FR 3
            | |
Db        4 FR 5

RESULT 8
XGHUEU
urine glycopeptide - human
C;Species: Homo sapiens (man)
C;Date: 20-Jun-2000 #sequence_revision 20-Jun-2000 #text_change 16-Aug-2004
R;Lote, C.J.; Weiss, J.B.
Biochem. J. 123, 25P, 1971
A;Title: Identification in urine of a low-molecular-weight polar glycopeptide containing
A;Reference number: A03188; MUID:72062338; PMID:5126885
A;Accession: A03188
A;Molecule type: protein
A;Residues: 1-8 <LOT>
A;Cross-references: UNIPROT:P02729
C;Comment: The identity of the glycoprotein from which this peptide is derived is unknow
re has also been found (see PIR:XGHUE).
C;Keywords: glycoprotein
F;1/Binding site: carbohydrate (Cys) (covalent) #status experimental

Query Match          45.8%;    Score 11;    DB 2;    Length 8;
Best Local Similarity    50.0%;    Pred. No. 2.8e+05;
  Matches    2;    Conservative    0;    Mismatches    2;    Indels    0;    Gaps    0;

Qy        1 EFRH 4
            | |
Db        2 EHSH 5

RESULT 9
D28854
fibrinopeptide B - olive baboon
C;Species: Papio anubis, Papio hamadryas anubis (olive baboon)
C;Date: 19-May-1989 #sequence_revision 19-May-1989 #text_change 09-Jul-2004
R;Nakamura, S.; Takenaka, O.; Takahashi, K.
J. Biochem. 94, 1973-1978, 1983
A;Title: Fibrinopeptides A and B of baboons (Papio anubis, Papio hamadryas, and Theropit

A;Reference number: A91973; MUID:84161822; PMID:6423621
A;Accession: D28854
A;Molecule type: protein
A;Residues: 1-9 <NAK>
A;Cross-references: UNIPROT:P19344
C;Superfamily: fibrinogen beta chain; fibrinogen beta/gamma homology; fibrinogen disulfi

Query Match          45.8%;    Score 11;    DB 2;    Length 9;
Best Local Similarity    100.0%;    Pred. No. 2.8e+05;
  Matches    2;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;

Qy        2 FR 3
            | |
Db        6 FR 7

RESULT 10
D58503
translation elongation factor EF-Tu - unidentified bacterium (fragment)
C;Species: unidentified bacterium
C;Date: 07-Feb-1997 #sequence_revision 07-Feb-1997 #text_change 09-Jul-2004
C;Accession: D58503
R.Binette, J.P.; Binette, M.B.
submitted to the Protein Sequence Database, October 1996
A;Description: The proteins of kidney and gallbladder stones.
A;Reference number: A58501
A;Accession: D58503
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-9 <BIN>
A;Cross-references: UNIPROT:Q7M151
A;Experimental source: human bile and stones
C;Superfamily: translation elongation factor Tu; translation elongation factor Tu homolo
C;Keywords: GTP binding

Query Match          45.8%;    Score 11;    DB 2;    Length 9;
Best Local Similarity    100.0%;    Pred. No. 2.8e+05;
  Matches    2;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;

Qy        2 FR 3
            | |
Db        8 FR 9

RESULT 11
S65433
bradykinin - horn fly (fragment)
C;Species: Haematobia irritans (horn fly)
C;Date: 28-Oct-1996 #sequence_revision 13-Mar-1997 #text_change 13-Mar-1997
C;Accession: S65433
R;Wijfels, G.; Fitzgerald, C.; Gough, J.; Riding, G.; Elvin, C.; Kemp, D.; Willadsen, F
Eur. J. Biochem. 237, 414-423, 1996
A;Title: Cloning and characterisation of angiotensin-converting enzyme from the dipteran
A;Reference number: S65431; MUID:9215437; PMID:8647080
A;Accession: S65433
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-9 <WIJ>
A;Note: the source is designated as Haematobia irritans exigua

Query Match          45.8%;    Score 11;    DB 2;    Length 9;
Best Local Similarity    100.0%;    Pred. No. 2.8e+05;
  Matches    2;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;

Qy        2 FR 3
            | |
Db        8 FR 9

RESULT 12
S10920
venom protein HR-3 - oriental hornet (fragment)
C;Species: Vespa orientalis (oriental hornet)

C;Date: 29-Jan-1993 #sequence_revision 29-Jan-1993 #text_change 09-Jul-2004
C;Accession: S10920
R;Tuichibaev, M.U.; Akhmedova, N.U.; Kazakov, I.; Korneev, A.S.; Gagel'gans, A.I.
Biochemistry (N.Y.) 53, 183-190, 1988
A;Title: Low-molecular-weight peptides of venom of the giant hornet Vespa orientalis. St
A;Reference number: S06445
A;Accession: S10920
A;Molecule type: protein
A;Residues: 1-9 <TUI>
A;Cross-references: UNIPROT:Q7M471
C;Keywords: venom

Query Match      45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches     2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EF 2
          ||
Db      5 EF 6

RESULT 13
S77984
cytochrome-c oxidase (EC 1.9.3.1) chain VIa - bigeye tuna (fragment)
C;Species: Thunnus obesus (bigeye tuna)
C;Date: 17-Sep-1997 #sequence_revision 17-Sep-1997 #text_change 09-Jul-2004
C;Accession: S77984
R;Arnold, S.; Lee, J.; Kim, M.; Song, E.; Linder, D.; Lottspeich, F.; Kadenbach, B.
submitted to the Protein Sequence Database, June 1997
A;Reference number: S77980
A;Accession: S77984
A;Molecule type: protein
A;Residues: 1-9 <ARN>
A;Cross-references: UNIPROT:P80975
A;Experimental source: heart
A;Genetics:
A;Genome: nuclear
C;Function:
C;Pathway: oxidative phosphorylation; respiratory chain
C;Keywords: electron transfer; membrane-associated complex; mitochondrial inner membrane

Query Match      45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches     2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EF 2
          ||
Db      5 EF 6

RESULT 14
S66635
alpha-2-macroglobulin isoform 1 - bovine (fragment)
C;Species: Bos primigenius indicus (zebu cattle)
C;Date: 15-Feb-1997 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004
C;Accession: S66635
R;Dolmer, K.; Jenner, L.B.; Jacobsen, L.; Andersen, G.R.; Koch, T.J.; Thirup, S.; Sottru
FEBS Lett. 372, 93-95, 1995
A;Title: Crystallisation and preliminary X-ray analysis of the receptor-binding domain o
A;Reference number: S66634; MUID:96032553; PMID:7556651
A;Accession: S66635
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-9 <DOL>
A;Cross-references: UNIPROT:Q7M2N8

Query Match      45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches     2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EF 2
          ||
Db      3 EF 4

RESULT 15
A43065
hydroxyproline-3-bradykinin - frog (Heleophryne purcelli)
C;Species: Heleophryne purcelli
C;Date: 07-Oct-1994 #sequence_revision 07-Oct-1994 #text_change 09-Jul-2004
C;Accession: A43065
R;Nakajima, T.; Yasuhara, T.; Erspamer, G.F.; Visser, J.
Experientia 35, 1133, 1979
A;Title: Occurrence of Hyp(3)-bradykinin in methanol extracts of the skin of the South A
A;Reference number: A43065; MUID:80024576; PMID:488255
A;Accession: A43065
A;Molecule type: protein
A;Residues: 1-9 <NAK>
A;Cross-references: UNIPROT:Q7LZI7
C;Keywords: bradykinin; hydroxyproline; skin
F;3/Modified site: hydroxyproline (Pro) #status experimental

Query Match      45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches     2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      2 FR 3
          ||
Db      8 FR 9

RESULT 16
A26744
bradykinin-like peptide - garden dagger wasp
N;Alternate names: Thr-6-bradykinin
C;Species: Megascolia flavifrons (garden dagger wasp)
C;Date: 08-Mar-1989 #sequence_revision 08-Mar-1989 #text_change 18-Aug-2000
C;Accession: A26744
R;Yasuhara, T.; Mantel, P.; Nakajima, T.; Piek, T.
Toxicon 25, 527-535, 1987
A;Title: Two kinins isolated from an extract of the venom reservoirs of the solitary wasp
A;Reference number: A94322; MUID:87293024; PMID:3617088
A;Accession: A26744
A;Molecule type: protein
A;Residues: 1-9 <YAS>
C;Superfamily: unassigned animal peptides

Query Match      45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches     2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      2 FR 3
          ||
Db      8 FR 9

RESULT 17
A61057
Thr-6 bradykinin - scoliid wasp (Colpa interrupta)
C;Species: Colpa interrupta
C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 18-Aug-2000
C;Accession: A61057
R;Piek, T.; Hue, B.; Mantel, P.; Nakajima, T.; Pelhate, M.; Yasuhara, T.
Comp. Biochem. Physiol. C 96, 157-162, 1990
A;Title: Threonine(6)-bradykinin in the venom of the wasp Colpa interrupta (F.) presynap
A;Reference number: A61057; MUID:91130217; PMID:1980872
A;Accession: A61057
A;Molecule type: protein
A;Residues: 1-9 <PIE>
C;Superfamily: unassigned animal peptides
C;Keywords: bradykinin; presynaptic neurotoxin; venom

Query Match      45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches     2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

```
Qy     2 FR 3
         | |
Db     8 FR 9

RESULT 18
A60579
bradykinin-like peptide - slider turtle
C;Species: Pseudemys scripta (slider)
C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 18-Aug-2000
C;Accession: A60579
R;Conlon, J.M.; Hicks, J.W.; Smith, D.D.
Endocrinology 126, 985-991, 1990
A;Title: Isolation and biological activity of a novel kinin ([Thr(6)]bradykinin) from th
A;Reference number: A60579; MUID:90126625; PMID:2298179
A;Accession: A60579
A;Molecule type: protein
A;Residues: 1-9 <CON>
C;Comment: This peptide increases aortic blood flow but, unlike bradykinin in mammalian
C;Superfamily: unassigned animal peptides
C;Keywords: plasma

Query Match             45.8%;  Score 11;  DB 2;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     2 FR 3
         | |
Db     8 FR 9

RESULT 19
A61363
bradykinin - common frog
C;Species: Rana temporaria (common frog)
C;Date: 09-Sep-1994 #sequence_revision 09-Sep-1994 #text_change 09-Jul-2004
C;Accession: A61363
R;Anastasi, A.; Erspamer, V.; Bertaccini, G.
Comp. Biochem. Physiol. A 14, 43-52, 1965
A;Title: Occurrence of bradykinin in the skin of Rana temporaria.
A;Reference number: A61363
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-9 <ANA>
A;Cross-references: UNIPROT:Q7LZJ8
C;Superfamily: unassigned animal peptides
C;Keywords: skin

Query Match             45.8%;  Score 11;  DB 2;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     2 FR 3
         | |
Db     8 FR 9

RESULT 20
A61358
bradykinin-like peptide I - Japanese pond frog
C;Species: Rana nigromaculata (Japanese pond frog)
C;Date: 09-Sep-1994 #sequence_revision 09-Sep-1994 #text_change 09-Jul-2004
C;Accession: A61358
R;Nakajima, T.
Chem. Pharm. Bull. 16, 769-770, 1968
A;Title: Occurrence of a new active peptide on smooth muscle and bradykinin in the skin
A;Reference number: A61358; MUID:68412013; PMID:5677638
A;Accession: A61358
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-9 <NAK>
A;Cross-references: UNIPROT:Q7LZ54
C;Superfamily: unassigned animal peptides
C;Keywords: skin

Query Match             45.8%;  Score 11;  DB 2;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     2 FR 3
         | |
Db     8 FR 9

RESULT 21
GMROL2
leucosulfakinin-II - Madeira cockroach
N;Alternate names: LSK-II
C;Species: Leucophaea maderae (Madeira cockroach)
C;Date: 31-Dec-1988 #sequence_revision 31-Dec-1988 #text_change 09-Jul-2004
C;Accession: A26335
R;Nachman, R.J.; Holman, G.M.; Cook, B.J.; Haddon, W.F.; Ling, N.
Biochem. Biophys. Res. Commun. 140, 357-364, 1986
A;Title: Leucosulfakinin-II, a blocked sulfated insect neuropeptide with homology to cho
A;Reference number: A26335; MUID:87048769; PMID:378455
A;Accession: A26335
A;Molecule type: protein
A;Residues: 1-10 <NAC>
A;Cross-references: UNIPROT:P09039
C;Comment: This peptide was isolated from head extracts. It stimulates muscle contractio
C;Superfamily: gastrin
C;Keywords: amidated carboxyl end; neuropeptide; pyroglutamic acid; sulfoprotein
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
F;5/Binding site: sulfate (Tyr) (covalent) #status experimental
F;10/Modified site: amidated carboxyl end (Phe) #status experimental

Query Match             45.8%;  Score 11;  DB 1;  Length 10;
  Best Local Similarity    25.0%;  Pred. No. 8.5e+03;
  Matches    1;  Conservative    2;  Mismatches    2;  Indels    1;  Gaps    0;

Qy     1 EFRH 4
         :: |
Db     4 DYGH 7

RESULT 22
S48182
bacterioferritin - Rhodobacter capsulatus
C;Species: Rhodobacter capsulatus
C;Date: 15-Jul-1995 #sequence_revision 19-Oct-1995 #text_change 07-May-1999
C;Accession: S48182
R;Ringeling, P.L.; Davy, S.L.; Monkara, F.A.; Hunt, C.; Dickson, D.P.E.; McEwan, A.G.; t
Eur. J. Biochem. 223, 847-855, 1994
A;Title: Iron metabolism in Rhodobacter capsulatus. Characterisation of bacterioferritin
A;Reference number: S48182; MUID:94333389; PMID:8055962
A;Accession: S48182
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-10 <RIN>

Query Match             45.8%;  Score 11;  DB 2;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 8.5e+03;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     1 EF 2
         | |
Db     9 EF 10

RESULT 23
PC2044
beta-Kirilowin - Mongolian snake-gourd (fragment)
C;Species: Trichosanthes kirilowii (Mongolian snake-gourd)
C;Date: 14-Jul-1994 #sequence_revision 14-Jul-1994 #text_change 09-Jul-2004
C;Accession: PC2044
```

R;Dong, T.X.; Ng, T.B.; Yeung, H.W.; Wong, R.N.S.
Biochem. Biophys. Res. Commun. 199, 387-393, 1994
A;Title: Isolation and characterization of a novel ribosome-inactivating protein, beta-k
A;Accession: PC2044
A;Reference number: PC2044; MUID:94168605; PMID:8123040
A;Molecule type: protein
A;Residues: 1-10 <DON>
A;Cross-references: UNIPROT:Q7M1I6
A;Experimental source: seed
C;Comment: This protein exhibited strong abortifacient activity, and is a ribosome inact
C;Keywords: seed

Query Match             45.8%;   Score 11;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 8.5e+03;
Matches    2;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

Qy      2 FR 3
          ||
Db      5 FR 6

RESULT 24
A58365
neuropeptide FFRFamide - blue mussel
N;Alternate names: FMRFamide-related decapeptide; Mytilus FFRFamide
C;Species: Mytilus edulis (blue mussel)
C;Date: 20-Nov-1996 #sequence_revision 22-Nov-1996 #text_change 09-Jul-2004
C;Accession: A58365
R;Fujisawa, Y.; Ikeda, T.; Nomoto, K.; Yasuda-Kamatani, Y.; Minakata, H.; Kenny, P.T.M.;
Comp. Biochem. Physiol. C 102, 91-95, 1992
A;Title: The FMRFamide-related decapeptide of Mytilus contains a D-amino acid residue.
A;Reference number: A58365; MUID:93047882; PMID:1358533
A;Accession: A58365
A;Molecule type: protein
A;Residues: 1-10 <FUJ>
A;Cross-references: UNIPROT:P42560
A;Experimental source: anterior byssus retractor muscle
C;Keywords: amidated carboxyl end; D-amino acid; neuropeptide
C;Modified site: D-leucine (Leu) #status experimental
F;2/Modified site: amidated carboxyl end (Phe) #status experimental

Query Match             45.8%;   Score 11;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 8.5e+03;
Matches    2;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

Qy      2 FR 3
          ||
Db      8 FR 9

RESULT 25
S30348
clotting protein - signal crayfish
C;Species: Pacifastacus leniusculus (signal crayfish)
C;Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 09-Jul-2004
C;Accession: S30348
R;Kopacek, P.; Hall, M.; Soederhaell, K.
Eur. J. Biochem. 213, 591-597, 1993
A;Title: Characterization of a clotting protein, isolated from plasma of the freshwater
A;Reference number: S30348; MUID:93238739; PMID:8097463
A;Accession: S30348
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-10 <KOP>
A;Cross-references: UNIPROT:P81070; UNIPROT:Q9UAR3

Query Match             45.8%;   Score 11;  DB 2;  Length 10;
Best Local Similarity   25.0%;   Pred. No. 8.5e+03;
Matches    1;   Conservative    1;   Mismatches    3;   Indels    0;   Gaps    0;

Qy      1 EFRH 4
          |:::|
Db      6 EYQY 9

RESULT 26
B60656
leucosulfakinin II, non-sulfated - American cockroach
C;Species: Periplaneta americana (American cockroach)
C;Date: 14-May-1993 #sequence_revision 14-May-1993 #text_change
C;Accession: B60656
R;Veenstra, J.A.
Neuropeptides 14, 145-149, 1989
A;Title: Isolation and structure of two gastrin/CCK-like neuropeptides from the American
A;Reference number: A60656; MUID:90137190; PMID:2615921
A;Accession: B60656
A;Molecule type: protein
A;Residues: 1-10 <VEE>
A;Cross-references: UNIPROT:P09039
C;Keywords: amidated carboxyl end; neuropeptide; pyroglutamic acid
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
F;10/Modified site: amidated carboxyl end (Phe) #status experimental

Query Match             45.8%;   Score 11;  DB 2;  Length 10;
Best Local Similarity   25.0%;   Pred. No. 8.5e+03;
Matches    1;   Conservative    2;   Mismatches    2;   Indels    1;   Gaps    0;

Qy      1 EFRH 4
          ::|
Db      4 DYGH 7

RESULT 27
D46285
formaldehyde dehydrogenase (glutathione) (EC 1.2.1.1) class III low activity form - Atla
C;Species: Gadus morhua (Atlantic cod)
C;Date: 19-Nov-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C;Accession: D46285
R;Danielsson, O.; Jornvall, H.
Proc. Natl. Acad. Sci. U.S.A. 89, 9247-9251, 1992
A;Title: "Enzymogenesis": classical liver alcohol dehydrogenase origin from the glutathi
A;Reference number: A46285; MUID:93028441; PMID:1409630
A;Accession: D46285
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-10 <DAN>
A;Cross-references: UNIPROT:Q9PSQ8
A;Note: sequence extracted from NCBI backbone (NCBIP:116272)
C;Keywords: NAD; oxidoreductase

Query Match             45.8%;   Score 11;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 8.5e+03;
Matches    2;   Conservative    0;   Mismatches    0;   Indels    0;   Gaps    0;

Qy      1 EF 2
          ||
Db      2 EF 3

RESULT 28
I56695
hypothetical L2 protein (mistranslated) - human papillomavirus type 16 (fragment)
C;Species: human papillomavirus type 16
C;Date: 18-Feb-2000 #sequence_revision 18-Feb-2000 #text_change 18-Feb-2000
C;Accession: I56695
R;Schneider-Maunoury, S.; Croissant, O.; Orth, G.
J. Virol. 61, 3295-3298, 1987
A;Title: Integration of human papillomavirus type 16 DNA sequences: a possible early eve
A;Reference number: I56695; MUID:87311896; PMID:3041049
A;Accession: I56695
A;Status: translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-7 <SCH>
A;Cross-references: GB:M30709; NID:g190253; PIDN:AAA65995.1; PID:g953616
C;Comment: This is the hypothetical translation of a viral sequence integrated into the
C;Comment: It is translated in an incorrect, -1, reading frame of the L2 protein.

RESULT 29
S16324
hypothetical protein 2 - Arabidopsis thaliana
C;Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 21-Nov-1993 #sequence_revision 12-May-1995 #text_change 21-Jul-2000
C;Accession: S16324
R;Ruberti, I.; Sessa, G.; Lucchetti, S.; Morelli, G.
EMBO J. 10, 1787-1791, 1991
A;Title: A novel class of plant proteins containing a homeodomain with a closely linked
A;Reference number: S16323; MUID:91266907; PMID:1675603
A;Accession: S16324
A;Status: translation not shown
A;Molecule type: mRNA
A;Residues: 1-8 <RUB>
A;Cross-references: EMBL:X58821; NID:g16327; PIDN:CAA41624.1; PID:g579259

Query Match             41.7%;  Score 10;  DB 4;  Length 7;
Best Local Similarity   33.3%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              :|:
Db          3 YRY 5

RESULT 30
T14906
hypothetical protein - parsley
C;Species: Petroselinum crispum (parsley)
C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 20-Sep-1999
C;Accession: T14906
R;Feldbrugge, M.; Sprenger, M.; Dinkelbach, M.; Yazaki, K.; Harter, K.; Weisshaar, B.
Plant Cell 6, 1607-1621, 1994
A;Title: Functional analysis of a light-responsive plant bZIP transcriptional regulator.
A;Reference number: 218259; MUID:95128172; PMID:7827494
A;Accession: T14906
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-8 <FEL>
A;Cross-references: EMBL:S75395; NID:g913201; PID:e194245

Query Match             41.7%;  Score 10;  DB 2;  Length 8;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFR 3
              |:|
Db          2 EYK 4

RESULT 31
PT0231
Ig heavy chain CDR3 region (clone 1-118B) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
C;Accession: PT0231
R;Yamada, M.; Wasserman, R.; Reichard, B.A.; Shane, S.; Caton, A.J.; Rovera, G.
J. Exp. Med. 173, 395-407, 1991
A;Title: Preferential utilization of specific immunoglobulin heavy chain diversity and J
A;Reference number: PT0222; MUID:91108337; PMID:1899102
A;Accession: PT0231
A;Molecule type: DNA
A;Residues: 1-9 <YAM>
A;Experimental source: B lymphocyte
C;Keywords: heterotetramer; immunoglobulin

Query Match             41.7%;  Score 10;  DB 2;  Length 9;
Best Local Similarity   33.3%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              :|
Db          1 YTH 3

RESULT 32
S13224
virG protein - Agrobacterium sp. (fragment)
C;Species: Agrobacterium sp.
C;Date: 19-Mar-1997 #sequence_revision 01-Aug-1997 #text_change 09-Jul-2004
C;Accession: S13224
R;Tamamoto, S.; Aoyama, T.; Takanami, M.; Oka, A.
J. Mol. Biol. 215, 537-547, 1990
A;Title: Binding of the regulatory protein VirG to the phased signal sequences upstream
A;Reference number: S13224; MUID:91039316; PMID:2231718
A;Accession: S13224
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-10 <TAM>
A;Cross-references: UNIPROT:Q7M0P7

Query Match             41.7%;  Score 10;  DB 2;  Length 10;
Best Local Similarity   50.0%;  Pred. No. 1.5e+04;
Matches    1;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              :|
Db          2 KH 3

RESULT 33
A30823
bothropstoxin - jararacussu (fragment)
C;Species: Bothrops jararacussu (jararacussu)
C;Date: 01-Dec-1989 #sequence_revision 01-Dec-1989 #text_change 09-Jul-2004
C;Accession: A30823
R;Homsi-Brandeburgo, M.I.; Queiroz, L.S.; Santo-Neto, H.; Rodrigues-Simioni, L.; Giglio,
Toxicon 26, 615-627, 1988
A;Title: Fractionation of Bothrops jararacussu snake venom: partial chemical characteriz
A;Reference number: A30823; MUID:89020120; PMID:3176051
A;Accession: A30823
A;Molecule type: protein
A;Residues: 1-10 <HOM>
A;Cross-references: UNIPROT:Q7LZ25

Query Match             41.7%;  Score 10;  DB 2;  Length 10;
Best Local Similarity   25.0%;  Pred. No. 1.5e+04;
Matches    1;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              :|
Db          4 ZLGH 7

RESULT 34
A44871
monodehydroascorbate reductase (NADH2) (EC 1.6.5.4) - soybean (fragment)
C;Species: Glycine max (soybean)
C;Date: 31-Mar-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C;Accession: A44871
R;Dalton, D.A.; Langeberg, L.; Robbins, M.
Arch. Biochem. Biophys. 292, 281-286, 1992
A;Title: Purification and characterization of monodehydroascorbate reductase from soybean
A;Reference number: A44871; MUID:92088257; PMID:1727643
A;Accession: A44871
A;Status: preliminary

A;Molecule type: protein
A;Residues:1-10 <DAL>
A;Cross-references: UNIPROT:Q9S926
A;Experimental source: root nodules, cv. Williams
A;Note: sequence extracted from NCBI backbone (NCBIP:71052)
C;Keywords: oxidoreductase

Query Match     41.7%;   Score 10;   DB 2;   Length 10;
Best Local Similarity   33.3%;   Pred. No. 1.5e+04;
Matches   1;   Conservative   2;   Mismatches   0;   Indels   0;   Gaps   0;

Qy    2 FRH 4
        | ::
Db    4 FKY 6

RESULT 35
PQ0783
NADH2 dehydrogenase (EC 1.6.99.3) 30K chain - fava bean mitochondrion (fragment)
N;Alternate names: complex I 30K chain; NADH-ubiquinone reductase 30K chain
C;Species: mitochondrion Vicia faba (fava bean)
C;Date: 03-May-1994 #sequence_revision 07-Oct-1994 #text_change 09-Jul-2004
C;Accession: PQ0783
R;Leterme, S.; Boutry, M.
Plant Physiol. 102, 435-443, 1993
A;Title: Purification and preliminary characterization of mitochondrial complex I (NADH:
A;Reference number: PQ0775; MUID:94151437; PMID:8108509
A;Molecule type: protein
A;Accession: PQ0783
A;Molecule type: protein
A;Residues:1-10 <LET>
A;Cross-references: UNIPROT:Q7M2G0
C;Comment: Complex I, mitochondrial NADH-ubiquinone reductase, is the first of the th
ranging from 5K to 75K.
C;Comment: This enzyme catalyzes electron transfer from endogenous NADH to ubiquinone by
C;Genetics: mitochondrion
C;Genome: mitochondrion
C;Keywords: electron transfer; mitochondrion; oxidoreductase

Query Match     41.7%;   Score 10;   DB 2;   Length 10;
Best Local Similarity   50.0%;   Pred. No. 1.5e+04;
Matches   1;   Conservative   1;   Mismatches   0;   Indels   0;   Gaps   0;

Qy    3 RH 4
        :|
Db    6 KH 7

RESULT 36
JN0861
peptidyl-dipeptidase A inhibitory peptide C111 - striped bonito
C;Species: Sarda orientalis (striped bonito)
C;Date: 10-Mar-1994 #sequence_revision 10-Mar-1994 #text_change 07-May-1999
C;Accession: JN0861
R;Matsumura, N.; Fujii, M.; Takeda, Y.; Shimizu, T.
Biosci. Biotechnol. Biochem. 57, 1743-1744, 1993
A;Title: Isolation and characterization of angiotensin I-converting enzyme inhibitory pe
A;Reference number: JN0859; MUID:94080036; PMID:7764272
A;Accession: JN0861
A;Molecule type: protein
A;Residues:1-6 <MAT>
A;Experimental source: liver
C;Comment: The carboxyl end is essential for the protein's expression of angiotensin I-c
C;Superfamily: bradykinin-potentiating peptide
C;Keywords: angiotensin-converting enzyme inhibitor

Query Match     37.5%;   Score 9;   DB 2;   Length 6;
Best Local Similarity   33.3%;   Pred. No. 2.8e+05;
Matches   1;   Conservative   1;   Mismatches   1;   Indels   0;   Gaps   0;

Qy    2 FRH 4
        |
Db    3 YPH 5

RESULT 37
S11024
hydrogensulfite reductase (EC 1.8.99.3) chain 1 - Desulfovibrio thermophilus (fragment)
N;Alternate names: bisulfite reductase; desulfofuscidin
C;Species: Desulfovibrio thermophilus
C;Date: 19-Mar-1997 #sequence_revision 30-Jan-1998 #text_change 30-Jan-1998
C;Accession: S11024
R;Fauque, G.; Lino, A.R.; Czechowski, M.; Kang, L.; DerVartanian, D.V.; Moura, J.J.G.; L
Biochim. Biophys. Acta 1040, 112-118, 1990
A;Title: Purification and characterization of bisulfite reductase (desulfofuscidin) from
A;Reference number: S11024; MUID:90335276; PMID:2165817
A;Accession: S11024
A;Molecule type: protein
A;Residues: 1-6 <FAU>
C;Keywords: oxidoreductase

Query Match     37.5%;   Score 9;   DB 2;   Length 6;
Best Local Similarity   33.3%;   Pred. No. 2.8e+05;
Matches   1;   Conservative   2;   Mismatches   2;   Indels   0;   Gaps   0;

Qy    1 EFR 3
        :|:
Db    4 KFK 6

RESULT 38
C36730
hutU protein - Klebsiella pneumoniae (fragment)
C;Species: Klebsiella pneumoniae
C;Date: 19-Apr-1991 #sequence_revision 19-Apr-1991 #text_change 08-Oct-1999
C;Accession: C36730
R;Schwacha, A.; Bender, R.A.
J. Bacteriol. 172, 5477-5481, 1990
A;Title: Nucleotide sequence of the gene encoding the repressor for the histidine utiliz
A;Reference number: A36730; MUID:9036B611; PMID:2203754
A;Accession: C36730
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-9 <SCH>
A;Cross-references: GB:M34604; NID:g149203; PIDN:AAA25076.1; PID:g149206

Query Match     37.5%;   Score 9;   DB 2;   Length 9;
Best Local Similarity   33.3%;   Pred. No. 2.8e+05;
Matches   1;   Conservative   2;   Mismatches   2;   Indels   0;   Gaps   0;

Qy    1 EFR 3
        :|
Db    5 KYR 7

RESULT 39
RHPGG
gonadoliberin - pig
C;Species: Sus scrofa domestica (domestic pig)
C;Date: 13-Jul-1981 #sequence_revision 13-Jul-1981 #text_change 18-Mar-1997
C;Accession: A01411
R;Baba, Y.; Matsuo, H.; Schally, A.V.
Biochem. Biophys. Res. Commun. 44, 459-463, 1971
A;Title: Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the
A;Reference number: A90172; MUID:72114303; PMID:4946067
A;Accession: A01411
A;Molecule type: protein
A;Residues: 1-10 <BAB>
R;Matsuo, H.; Arimura, A.; Nair, R.M.G.; Schally, A.V.
Biochem. Biophys. Res. Commun. 45, 822-827, 1971
A;Title: Synthesis of the porcine LH- and FSH-releasing hormone by the solid-phase metho
A;Reference number: A90176; MUID:72065376; PMID:4942726
A;Contents: annotation; synthesis
A;Note: the synthetic and natural hormones have the same physicochemical and biological
R;Baba, Y.; Arimura, A.; Schally, A.V.
Biochem. Biophys. Res. Commun. 45, 483-487, 1971
A;Title: On the tryptophan residue in porcine LH and FSH-releasing hormone.

A;Reference number: A90175; MUID:72117544; PMID:4946275
A;Contents: annotation
A;Note: Trp-3 appears to be essential for biological activity
C;Comment: This hypothalamic hormone stimulates the secretion of both luteinizing and fo
C;Superfamily: gonadoliberin
C;Keywords: amidated carboxyl end; hormone; hypothalamus; pyroglutamic acid
F;1/Modified site: pyroglutamic acid (Gln) #status experimental
F;10/Modified site: amidated carboxyl end (Gly) #status experimental

```
Query Match     37.5%;   Score 9;   DB 1; Length 10;
Best Local Similarity   50.0%;   Pred. No. 2.6e+04;
Matches    1; Conservative   1; Mismatches   0; Indels   0; Gaps   0;

Qy      3 RH 4
          :|
Db      1 QH 2
```

RESULT 40
RHSHG
gonadoliberin - sheep
C;Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)
C;Date: 31-Dec-1991 #sequence_revision 18-Mar-1997
C;Accession: A93780; A01411
R;Burgus, R.; Butcher, M.; Amoss, M.; Ling, N.; Monahan, M.; Rivier, J.; Fellows, R.; Bl
Proc. Natl. Acad. Sci. U.S.A. 69, 278-282, 1972
A;Title: Primary structure of the ovine hypothalamic luteinizing hormone-releasing facto
A;Reference number: A93780; MUID:72094314; PMID:4550508
A;Accession: A93780
A;Molecule type: protein
A;Residues: 1-10 <BUR>
C;Comment: This hypothalamic hormone stimulates the secretion of both luteinizing and fo
C;Superfamily: gonadoliberin
C;Keywords: amidated carboxyl end; hormone; hypothalamus; pyroglutamic acid
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
F;10/Modified site: amidated carboxyl end (Gly) #status experimental
A;Note: the natural and synthetic hormones have the same biological activity

```
Query Match     37.5%;   Score 9;   DB 1; Length 10;
Best Local Similarity   50.0%;   Pred. No. 2.6e+04;
Matches    1; Conservative   1; Mismatches   0; Indels   0; Gaps   0;

Qy      3 RH 4
          :|
Db      1 QH 2
```

RESULT 41
A61126
gonadoliberin - spotted ratfish
N;Alternate names: gonadotropin-releasing hormone
C;Species: Hydrolagus colliei (spotted ratfish)
C;Date: 26-May-1994 #sequence_revision 26-May-1994 #text_change 09-Jul-2004
C;Accession: A61126
R;Lovejoy, D.A.; Sherwood, N.M.; Fischer, W.H.; Jackson, B.C.; Rivier, J.E.; Lee, T.
Gen. Comp. Endocrinol. 82, 152-161, 1991
A;Title: Primary structure of gonadotropin-releasing hormone from the brain of a holocep
A;Reference number: A61126; MUID:91340067; PMID:1678723
A;Accession: A61126
A;Molecule type: protein
A;Residues: 1-10 <LOV>
A;Cross-references: UNIPROT:P37043
A;Experimental source: brain
C;Superfamily: gonadoliberin
C;Keywords: amidated carboxyl end; brain; hormone; pyroglutamic acid
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
F;10/Modified site: amidated carboxyl end (Gly) #status experimental

```
Query Match     37.5%;   Score 9;   DB 1; Length 10;
Best Local Similarity   50.0%;   Pred. No. 2.6e+04;
Matches    1; Conservative   1; Mismatches   0; Indels   0; Gaps   0;

Qy      3 RH 4
          :|
Db      1 QH 2
```

RESULT 42
RHAQ1
gonadoliberin I - American alligator
N;Alternate names: gonadotropin-releasing hormone I
C;Species: Alligator mississippiensis (American alligator)
C;Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 09-Jul-2004
C;Accession: A60066
R;Lovejoy, D.A.; Fischer, W.H.; Parker, D.B.; McRory, J.E.; Park, M.; Lance, V.; Swanson
Regul. Pept. 33, 105-116, 1991
A;Title: Primary structure of two forms of gonadotropin-releasing hormone from brains of
A;Reference number: A60066; MUID:91352338; PMID:1882082
A;Accession: A60066
A;Molecule type: protein
A;Residues: 1-10 <LOV>
A;Cross-references: UNIPROT:P37041
C;Superfamily: gonadoliberin
C;Keywords: amidated carboxyl end; hormone; hypothalamus; pyroglutamic acid
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
F;10/Modified site: amidated carboxyl end (Gly) #status experimental

```
Query Match     37.5%;   Score 9;   DB 1; Length 10;
Best Local Similarity   50.0%;   Pred. No. 2.6e+04;
Matches    1; Conservative   1; Mismatches   0; Indels   0; Gaps   0;

Qy      3 RH 4
          :|
Db      1 QH 2
```

RESULT 43
RHAQ2
gonadoliberin II - American alligator
N;Alternate names: gonadotropin-releasing hormone II
C;Species: Alligator mississippiensis (American alligator)
C;Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 09-Jul-2004
C;Accession: B60066
R;Lovejoy, D.A.; Fischer, W.H.; Parker, D.B.; McRory, J.E.; Park, M.; Lance, V.; Swanson
Regul. Pept. 33, 105-116, 1991
A;Title: Primary structure of two forms of gonadotropin-releasing hormone from brains of
A;Reference number: A60066; MUID:91352338; PMID:1882082
A;Accession: B60066
A;Molecule type: protein
A;Residues: 1-10 <LOV>
A;Cross-references: UNIPROT:P37043
C;Superfamily: gonadoliberin
C;Keywords: amidated carboxyl end; hormone; hypothalamus; pyroglutamic acid
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
F;10/Modified site: amidated carboxyl end (Gly) #status experimental

```
Query Match     37.5%;   Score 9;   DB 1; Length 10;
Best Local Similarity   50.0%;   Pred. No. 2.6e+04;
Matches    1; Conservative   1; Mismatches   0; Indels   0; Gaps   0;

Qy      3 RH 4
          :|
Db      1 QH 2
```

RESULT 44
RHLMGS
gonadoliberin - sea lamprey
N;Alternate names: gonadotropin releasing hormone (GnRH)
C;Species: Petromyzon marinus (sea lamprey)
C;Date: 17-Mar-1987 #sequence_revision 17-Mar-1987 #text_change 09-Jul-2004
C;Accession: A01412
R;Sherwood, N.M.; Sower, S.A.; Marshak, D.R.; Fraser, B.A.; Brownstein, M.J.
J. Biol. Chem. 261, 4812-4819, 1986
A;Title: Primary structure of gonadotropin-releasing hormone from lamprey brain.
A;Reference number: A01412; MUID:86168192; PMID:3514603

A;Accession: A01412
A;Molecule type: protein
A;Residues: 1-10 <SHE>
A;Cross-references: UNIPROT:P04378
C;Comment: This hormone was isolated from the brain.
C;Superfamily: gonadoliberin
C;Keywords: amidated carboxyl end; hormone; pyroglutamic acid
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
F;10/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match    37.5%;  Score 9;  DB 1;  Length 10;
Best Local Similarity  50.0%;  Pred. No. 2.6e+04;
Matches   1;  Conservative   1;  Mismatches   0;  Indels   0;  Gaps   0;

Qy    3 RH 4
        :|
Db    1 QH 2

RESULT 45
A43405
6-phosphofructo-2-kinase (EC 2.7.1.105) / fructose-2,6-bisphosphate 2-phosphatase (EC 3.
C;Species: Bos primigenius taurus (cattle)
C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C;Accession: A43405
R;Ventura, F.; Rosa, J.L.; Ambrosio, S.; Pilkis, S.J.; Bartrons, R.
J. Biol. Chem. 267, 17939-17943, 1992
A;Title: Bovine brain 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Evidence for
A;Reference number: A43405; MUID:92388154; PMID:1325453
A;Accession: A43405
A;Molecule type: protein
A;Residues: 1-10 <VEN>
A;Cross-references: UNIPROT:Q7M3I3
C;Superfamily: 6-phosphofructo-2-kinase / fructose-2,6-bisphosphate 2-phosphatase; phosp
C;Keywords: phosphoric monoester hydrolase; phosphotransferase

Query Match    37.5%;  Score 9;  DB 2;  Length 10;
Best Local Similarity  50.0%;  Pred. No. 2.6e+04;
Matches   1;  Conservative   1;  Mismatches   0;  Indels   0;  Gaps   0;

Qy    3 RH 4
        :|
Db    4 QH 5

RESULT 46
S39392
calpain (EC 3.4.22.17) II light chain - pig (fragment)
C;Species: Sus scrofa domestica (domestic pig)
C;Date: 18-Feb-1994 #sequence_revision 24-Jul-1998 #text_change 29-Sep-1999
C;Accession: S39392
R;Crawford, C.; Brown, N.R.; Willis, A.C.
Biochem. J. 296, 135-142, 1993
A;Title: Studies of the active site of m-calpain and the interaction with calpastatin.
A;Reference number: S39391; MUID:94071815; PMID:8250833
A;Accession: S39392
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-10 <CRA>
A;Superfamily: calpain small chain; calmodulin repeat homology
C;Superfamily: cysteine proteinase; EF hand; hydrolase

Query Match    37.5%;  Score 9;  DB 2;  Length 10;
Best Local Similarity  66.7%;  Pred. No. 2.6e+04;
Matches   2;  Conservative   0;  Mismatches   1;  Indels   0;  Gaps   0;

Qy    1 EFR 3
        |  |
Db    6 EVR 8

RESULT 47
B46030
gonadoliberin II - spiny dogfish
N;Alternate names: gonadotropin-releasing hormone
C;Species: Squalus acanthias (spiny dogfish)
C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 09-Jul-2004
C;Accession: B46030
R;Lovejoy, D.A.; Fischer, W.H.; Ngamvongchon, S.; Craig, A.G.; Nahorniak, C.S.; Peter, R
Proc. Natl. Acad. Sci. U.S.A. 89, 6373-6377, 1992
A;Title: Distinct sequence of gonadotropin-releasing hormone (GnRH) in dogfish brain pro
A;Reference number: A46030; MUID:92335300; PMID:1631133
A;Accession: B46030
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-10 <LOV>
A;Cross-references: UNIPROT:P37043
C;Superfamily: gonadoliberin
C;Keywords: hormone; pyroglutamic acid
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

Query Match    37.5%;  Score 9;  DB 2;  Length 10;
Best Local Similarity  50.0%;  Pred. No. 2.6e+04;
Matches   1;  Conservative   1;  Mismatches   0;  Indels   0;  Gaps   0;

Qy    3 RH 4
        :|
Db    1 QH 2

RESULT 48
S59625
beta-galactosidase alpha chain - Escherichia coli (fragment)
C;Species: Escherichia coli
C;Date: 20-Jul-1996 #sequence_revision 13-Mar-1997 #text_change 07-May-1999
C;Accession: S59625
R;Calugaru, S.V.; Hall, B.G.; Sinnott, M.L.
Biochem. J. 312, 281-286, 1995
A;Title: Catalysis by the large subunit of the second beta-galactosidase of Escherichia
A;Reference number: S59625; MUID:96077156; PMID:7492325
A;Accession: S59625
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-10 <CAL>

Query Match    37.5%;  Score 9;  DB 2;  Length 10;
Best Local Similarity  50.0%;  Pred. No. 2.6e+04;
Matches   1;  Conservative   1;  Mismatches   0;  Indels   0;  Gaps   0;

Qy    3 RH 4
        :|
Db    8 QH 9

RESULT 49
PC4374
telomeric and tetraplex DNA binding protein qTBP42 IV - rat (fragment)
C;Species: Rattus norvegicus (Norway rat)
C;Date: 28-Oct-1997 #sequence_revision 28-Oct-1997 #text_change 07-May-1999
C;Accession: PC4374
R;Sarig, G.; Weisman-Shomer, P.; Fry, M.
Biochem. Biophys. Res. Commun. 237, 617-623, 1997
A;Title: Telomeric and tetraplex DNA binding properties of qTBP42: A homologue of the CA
A;Reference number: PC4371; MUID:97445086; PMID:9299414
A;Accession: PC4374
A;Molecule type: protein
A;Residues: 1-10 <SAR>
C;Comment: This protein binds either strand of the telomeric DNA as well as unimolecular

Query Match    37.5%;  Score 9;  DB 2;  Length 10;
Best Local Similarity  66.7%;  Pred. No. 2.6e+04;
Matches   2;  Conservative   0;  Mismatches   1;  Indels   0;  Gaps   0;

Qy    1 EFR 3
        |  |
Db    7 EHR 9

RESULT 50
F41839
ribosomal protein L16 - Acholeplasma laidlawii (fragment)
C;Species: Acholeplasma laidlawii
C;Date: 12-Mar-1993 #sequence_revision 12-Mar-1993 #text_change 09-Jul-2004
C;Accession: F41839
R;Lim, P.O.; Sears, B.B.
J. Bacteriol. 174, 2606-2611, 1992
A;Title: Evolutionary relationships of a plant-pathogenic mycoplasmalike organism and Ac
A;Reference number: A41839; MUID:92210505; PMID:1556079
A;Accession: F41839
A;Status: preliminary; translation not shown
A;Molecule type: DNA
A;Residues: 1-10 <LIM>
A;Cross-references: UNIPROT:P29221; GB:M74471
C;Genetics:
A;Gene: rpl16
C;Keywords: protein biosynthesis; ribosome

Query Match             37.5%;  Score 9;  DB 2;  Length 10;
Best Local Similarity   33.3%;  Pred. No. 2.6e+04;
  Matches    1;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EPR 3
                ::|
Db          8 KYR 10


RESULT 51
A46030
gonadoliberin I - spiny dogfish
N;Alternate names: gonadotropin-releasing hormone
C;Species: Squalus acanthias (spiny dogfish)
C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 09-Jul-2004
C;Accession: A46030
R;Lovejoy, D.A.; Fischer, W.H.; Ngamvongchon, S.; Craig, A.G.; Nahorniak, C.S.; Peter, R
Proc. Natl. Acad. Sci. U.S.A. 89, 6373-6377, 1992
A;Title: Distinct sequence of gonadotropin-releasing hormone (GnRH) in dogfish brain pro
A;Reference number: A46030; MUID:92335300; PMID:1631133
A;Accession: A46030
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-10 <LOV>
A;Cross-references: UNIPROT:P27429
C;Keywords: hormone; pyroglutamic acid
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

Query Match             37.5%;  Score 9;  DB 2;  Length 10;
Best Local Similarity   50.0%;  Pred. No. 2.6e+04;
  Matches    1;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
                ::|
Db          1 QH 2


RESULT 52
A21114
gonadoliberin - chum salmon
C;Species: Oncorhynchus keta (chum salmon)
C;Date: 10-Aug-1990 #sequence_revision 10-Aug-1990 #text_change 09-Jul-2004
C;Accession: A21114
R;Sherwood, N.; Biden, L.; Brownstein, M.; Spiess, J.; Rivier, J.; Vale, W.
Proc. Natl. Acad. Sci. U.S.A. 80, 2794-2798, 1983
A;Title: Characterization of a teleost gonadotropin-releasing hormone.
A;Reference number: A21114; MUID:83195140; PMID:6341999
A;Accession: A21114
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-10 <SHE>
A;Cross-references: UNIPROT:P20367

Query Match             37.5%;  Score 9;  DB 2;  Length 10;
Best Local Similarity   50.0%;  Pred. No. 2.6e+04;
  Matches    1;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
                ::|
Db          1 QH 2


RESULT 53
H37196
bradykinin-potentiating peptide 8 - island jararaca
C;Species: Bothrops insularis (island jararaca)
C;Date: 14-Feb-1992 #sequence_revision 01-Dec-1992 #text_change 09-Jul-2004
C;Accession: H37196
R;Cintra, A.C.O.; Vieira, C.A.; Giglio, J.R.
J. Protein Chem. 9, 221-227, 1990
A;Title: Primary structure and biological activity of bradykinin potentiating peptides f
A;Reference number: A37196; MUID:90351557; PMID:2386615
A;Accession: H37196
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-10 <CIN>
A;Cross-references: UNIPROT:P30426
C;Keywords: pyroglutamic acid
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

Query Match             37.5%;  Score 9;  DB 2;  Length 10;
Best Local Similarity   50.0%;  Pred. No. 2.6e+04;
  Matches    1;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
                :|
Db          4 QH 5


RESULT 54
A48360
gamma subunit of Protein A - Methylosinus trichosporium (fragment)
C;Species: Methylosinus trichosporium
C;Date: 19-Nov-1993 #sequence_revision 18-Nov-1994 #text_change 08-Oct-1999
C;Accession: A48360
R;Cardy, D.L.; Laidler, V.; Salmond, G.P.; Murrell, J.C.
Arch. Microbiol. 156, 477-483, 1991
A;Title: The methane monooxygenase gene cluster of Methylosinus trichosporium: cloning a
A;Reference number: A48360; MUID:92153031; PMID:1785954
A;Contents: OB3b
A;Accession: A48360
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-4 <CAR>
A;Cross-references: GB:S81887; NID:g245213; PIDN:AAB21391.1; PID:g245214
A;Note: sequence extracted from NCBI backbone (NCBIN:81887; NCBIP:81912)

Query Match             33.3%;  Score 8;  DB 2;  Length 4;
Best Local Similarity  100.0%;  Pred. No. 2.8e+05;
  Matches    1;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          4 H 4
              |
Db          1 H 1


RESULT 55
I38888
COI intron 16 protein - Podospora anserina mitochondrion
C;Species: mitochondrion Podospora anserina
C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 07-Dec-1999
C;Accession: I38888
R;Cummings, D.J.; Michel, F.; McNally, K.L.
Curr. Genet. 16, 381-406, 1989
A;Title: DNA sequence analysis of the 24.5 kilobase pair cytochrome oxidase subunit I mi

A;Reference number: A48327; MUID:90124722; PMID:2558809
A;Accession: I38888
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-4 <CUM>
A;Cross-references: GB:X55026; GB:M30937; GB:M61734
C;Genetics:
A;Genome: mitochondrion
A;Genetic code: SGC3
C;Keywords: mitochondrion

Query Match     33.3%;    Score 8;    DB 2;    Length 4;
Best Local Similarity   100.0%;   Pred. No. 2.8e+05;
Matches     1;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy     4 H 4
         | |
Db     4 H 4

RESULT 56
PL0140
carbon-monoxide dehydrogenase (EC 1.2.99.2) large chain - Pseudomonas carboxydohydrogena
C;Species: Pseudomonas carboxydohydrogena
C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004
C;Accession: PL0140
R;Kraut, M.; Hugendieck, I.; Herwig, S.; Meyer, O.
Arch. Microbiol. 152, 335-341, 1989
A;Title: Homology and distribution of CO dehydrogenase structural genes in carboxydotrop
A;Reference number: PL0138; MUID:90055678; PMID:2818128
A;Accession: PL0140
A;Molecule type: protein
A;Residues: 1-4 <KRA>
A;Cross-references: UNIPROT:P19916
C;Comment: Carbon-monoxide dehydrogenase consists of three polypeptide chains: large, me
C;Keywords: oxidoreductase

Query Match     33.3%;    Score 8;    DB 2;    Length 4;
Best Local Similarity   100.0%;   Pred. No. 2.8e+05;
Matches     1;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy     4 H 4
         | |
Db     4 H 4

RESULT 57
JQ1273
neuropeptide Antho-KAamide - sea anemone (Anthopleura elegantissima)
C;Species: Anthopleura elegantissima
C;Date: 31-Mar-1992 #sequence_revision 04-Dec-1992 #text_change 09-Jul-2004
C;Accession: JQ1273
R;Nothacker, H.P.; Rinehart, K.L.; Grimmelikhuijzen, C.J.P.
Biochem. Biophys. Res. Commun. 179, 1205-1211, 1991
A;Title: Isolation of L-3-phenyllactyl-Phe-Lys-Ala-NH2 (Antho-KAamide), a novel neuropep
A;Reference number: JQ1273; MUID:92028852; PMID:1681803
A;Accession: JQ1273
A;Molecule type: protein
A;Residues: 1-4 <NOT>
A;Cross-references: UNIPROT:P58705
C;Comment: The carboxyl-terminal amide probably arises from cleavage of a following glyc
C;Keywords: amidated carboxyl end; neuropeptide; phenyllactylation
F;1/Modified site: L-3-phenyllactic acid (Phe) #status experimental
F;4/Modified site: amidated carboxyl end (Ala) #status experimental

Query Match     33.3%;    Score 8;    DB 2;    Length 4;
Best Local Similarity    50.0%;   Pred. No. 2.8e+05;
Matches     1;  Conservative   1;  Mismatches   0;  Indels   0;  Gaps   0;

Qy     2 FR 3
         |:
Db     2 FK 3

RESULT 58
PT0712
T-cell receptor beta chain V-D-J region (121-3BC) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 09-Jul-2004
C;Genetics:
R;Feeney, A.J.
J. Exp. Med. 174, 115-124, 1991
A;Title: Junctional sequences of fetal T cell receptor beta chains have few N regions.
A;Reference number: PT0509; MUID:91277601; PMID:1711558
A;Accession: PT0649
A;Status: translation not shown
A;Molecule type: mRNA
A;Residues: 1-4 <FEE>
A;Cross-references: UNIPROT:O18345; UNIPROT:Q8BT14; UNIPROT:Q8CHG3; UNIPROT:Q64512; UNIPF
A;Experimental source: day 4 postnatal thymus, strain BALB/c, 121-3BC
A;Accession: PT0712
A;Status: translation not shown
A;Molecule type: DNA
A;Residues: 1-4 <FE2>
A;Experimental source: newborn thymus, strain BALB/c, 165-3B
C;Keywords: T-cell receptor

Query Match     33.3%;    Score 8;    DB 2;    Length 4;
Best Local Similarity   100.0%;   Pred. No. 2.8e+05;
Matches     1;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy     4 H 4
         | |
Db     4 H 4

RESULT 59
JN0860
peptidyl-dipeptidase A inhibitory peptide C107 - striped bonito
C;Species: Sarda orientalis (striped bonito)
C;Date: 10-Mar-1994 #sequence_revision 10-Mar-1994 #text_change 07-May-1999
C;Accession: JN0860
R;Matsumura, N.; Fujii, M.; Takeda, Y.; Shimizu, T.
Biosci. Biotechnol. Biochem. 57, 1743-1744, 1993
A;Title: Isolation and characterization of angiotensin I-converting enzyme inhibitory pe
A;Reference number: JN0859; MUID:94080036; PMID:7764272
A;Accession: JN0860
A;Molecule type: protein
A;Residues: 1-5 <MAT>
A;Experimental source: intestine
C;Comment: The carboxyl-terminus is essential for the protein's expression of angiotensi
C;Superfamily: bradykinin-potentiating peptide
C;Keywords: angiotensin-converting enzyme inhibitor

Query Match     33.3%;    Score 8;    DB 2;    Length 5;
Best Local Similarity   100.0%;   Pred. No. 2.8e+05;
Matches     1;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy     4 H 4
         | |
Db     4 H 4

RESULT 60
A32516
cholecystokinin-5 - dog
N;Alternate names: CCK-5
C;Species: Canis lupus familiaris (dog)
C;Date: 18-Oct-1989 #sequence_revision 18-Oct-1989 #text_change 18-Aug-2000
C;Accession: A32516
R;Shively, J.; Reeve Jr., J.R.; Eysselein, V.E.; Vigna, S.R.; Ben-Avram, C.; Walsh, J.H.
Am. J. Physiol. 252, G272-G275, 1987
A;Title: CCK-5: sequence analysis of a small cholecystokinin from canine brain and intes
A;Reference number: A32516; MUID:87153871; PMID:3826354
A;Accession: A32516
A;Molecule type: protein

A;Residues: 1-5 <SHI>
C;Comment: This peptide corresponds to the five carboxyl-terminal residues of cholecysto
C;Superfamily: gastrin
C;Keywords: amidated carboxyl end; neuropeptide
F;5/Modified site: amidated carboxyl end (Phe) #status experimental

```
Query Match              33.3%;  Score 8;  DB 2;  Length 5;
Best Local Similarity    50.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative  1;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EF 2
          :|
Db    4 DF 5
```

RESULT 61
C41225
copper resistance protein - Pseudomonas syringae pv. tomato (fragment)
C;Species: Pseudomonas syringae pv. tomato
C;Date: 19-Jun-1992 #sequence_revision 24-Jun-1993
C;Accession: C41225
R;Cha, J.S.; Cooksey, D.A.
Proc. Natl. Acad. Sci. U.S.A. 88, 8915-8919, 1991
A;Title: Copper resistance in Pseudomonas syringae mediated by periplasmic and outer mem
A;Reference number: A41225; MUID:92020961; PMID:1924351
A;Accession: C41225
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-5 <CHA>

```
Query Match              33.3%;  Score 8;  DB 2;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    4 H 4
          |
Db    1 H 1
```

RESULT 62
S70154
URF2 protein - Xanthomonas sp.
C;Species: Xanthomonas sp.
C;Date: 15-Feb-1997 #sequence_revision 13-Mar-1997 #text_change 08-Oct-1999
C;Accession: S70154
R;Kholodii, G.Y.; Mindlin, S.Z.; Bass, I.A.; Yurieva, O.V.; Minakhina, S.V.; Nikiforov,
Mol. Microbiol. 17, 1189-1200, 1995
A;Title: Four genes, two ends, and a res region are involved in transposition of Tn5053:
A;Reference number: S70140; MUID:96130850; PMID:8594337
A;Accession: S70154
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-5 <KHO>
A;Cross-references: EMBL:L40585; NID:g710572; PIDN:AAA98329.1; PID:g735909
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, May 1995

```
Query Match              33.3%;  Score 8;  DB 2;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    4 H 4
          |
Db    5 H 5
```

RESULT 63
B37325
pap fimbrial regulatory protein papI - Escherichia coli (fragment)
C;Species: Escherichia coli
C;Date: 11-Sep-1992 #sequence_revision 11-Sep-1992 #text_change 23-Mar-1993
C;Accession: B37325
R;Braaten, B.A.; Blyn, L.B.; Skinner, B.S.; Low, D.A.
J. Bacteriol. 173, 1789-1800, 1991

A;Title: Evidence for a methylation-blocking factor (mbf) locus involved in pap pilus ex
A;Reference number: A37325; MUID:9154136; PMID:1671857
A;Accession: B37325
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-5 <BRA>
A;Cross-references: GB:M63747

```
Query Match              33.3%;  Score 8;  DB 2;  Length 5;
Best Local Similarity    50.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative  1;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EF 2
          :|
Db    3 EY 4
```

RESULT 64
F22565
R-phycoerythrin gamma-A chain - red alga (Gastroclonium coulteri) (fragment)
C;Species: Gastroclonium coulteri
C;Date: 07-Mar-1988 #sequence_revision 07-Mar-1988 #text_change 23-Mar-1993
C;Accession: F22565
R;Klotz, A.V.; Glazer, A.N.
J. Biol. Chem. 260, 4856-4863, 1985
A;Title: Characterization of the bilin attachment sites in R-phycoerythrin.
A;Reference number: A22565; MUID:85182601; PMID:3886644
A;Accession: F22565
A;Molecule type: protein
A;Residues: 1-5 <KLO>

```
Query Match              33.3%;  Score 8;  DB 2;  Length 5;
Best Local Similarity    50.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative  1;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    2 FR 3
          :|
Db    4 YR 5
```

RESULT 65
T10954
hypothetical protein 3 - spring vetch
C;Species: Vicia sativa (spring vetch, tare)
C;Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 16-Jul-1999
C;Accession: T10954
R;Christiansen, A.; Hansen, A.C.; Vijn, I.; Pallisgard, N.; Larsen, K.; Yang, W.C.; Bis:
submitted to the EMBL Data Library, December 1995
A;Description: A novel type of DNA binding protein interacts with a conserved sequence
A;Reference number: Z17228
A;Accession: T10954
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-5 <CHR>
A;Cross-references: EMBL:X95995; NID:g1160633; PID:e225862

```
Query Match              33.3%;  Score 8;  DB 2;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    4 H 4
          |
Db    4 H 4
```

RESULT 66
I40698
biotin B - Citrobacter freundii (fragment)
C;Species: Citrobacter freundii
C;Date: 12-Aug-1996 #sequence_revision 12-Aug-1996 #text_change 09-Jul-2004
C;Accession: I40698
R;Shiuan, D.; Campbell, A.
Gene 67, 203-211, 1988

A;Title: Transcriptional regulation and gene arrangement of Escherichia coli, Citrobacte
A;Reference number: I40697; MUID:89006280; PMID:2971595
A;Accession: I40698
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-5 <RES>
A;Cross-references: UNIPROT:P12997; GB:M21922; NID:g144434

Query Match             33.3%;  Score 8;  DB 2;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    4 H 4
         |
Db    3 H 3

RESULT 67
A61419
sarcosine dehydrogenase (EC 1.5.99.1) - Pseudomonas sp. (strain WRF) (fragment)
C;Species: Pseudomonas sp.
C;Date: 07-Oct-1994 #sequence_revision 07-Oct-1994 #text_change 07-May-1999
C;Accession: A61419
R;Pinto, J.T.; Friisell, W.R.
Arch. Biochem. Biophys. 169, 483-491, 1975
A;Title: Characterization of the peptide-bound flavin of a bacterial sarcosine dehydroge
A;Reference number: A61419; MUID:76038634; PMID:241294
A;Molecule type: protein
A;Residues: 1-6 <PIN>
C;Keywords: FAD; flavoprotein; oxidoreductase; phosphoprotein
F;6/Modified site: 3'-FAD-histidine (His) #status experimental

Query Match             33.3%;  Score 8;  DB 2;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    4 H 4
         |
Db    6 H 6

RESULT 68
I37027
protamine P1 - gorilla (fragment)
C;Species: Gorilla gorilla (gorilla)
C;Date: 04-Oct-1996 #sequence_revision 04-Oct-1996 #text_change 21-Jul-2000
C;Accession: I37027
R;Queralt, R.; Oliva, R.
Gene 133, 197-204, 1993
A;Title: Identification of conserved potential regulatory sequences of the protamine-enc
A;Reference number: I37013; MUID:94040810; PMID:8224908
A;Accession: I37027
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-6 <RES>
A;Cross-references: EMBL:Z12145; NID:g22910; PIDN:CAA78129.1; PID:g579612

Query Match             33.3%;  Score 8;  DB 2;  Length 6;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    2 FR 3

Db    4 YR 5

RESULT 69
B56979
collagen alpha 1(II) chain - bovine (fragment)
N;Alternate names: collagen alpha 3(XI) chain
C;Species: Bos primigenius taurus (cattle)
C;Date: 03-Oct-1995 #sequence_revision 03-Oct-1995 #text_change 03-Oct-1995

C;Accession: B56979
R;Wu, J.J.; Eyre, D.R.
J. Biol. Chem. 270, 18865-18870, 1995
A;Title: Structural analysis of cross-linking domains in cartilage type XI collagen. Ins
A;Reference number: A56978; MUID:95370194; PMID:7642541
A;Accession: B56979
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-6 <WUA>
A;Note: the residue designated "X" is modified Lysine in collagen 1(II) some cross-linke

Query Match             33.3%;  Score 8;  DB 2;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    4 H 4
         |
Db    5 H 5

RESULT 70
S78764
ribosomal protein MRP-S23, mitochondrial - bovine (fragment)
C;Species: Bos primigenius taurus (cattle)
C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 20-Sep-1999
C;Accession: S78764
R;Graack, H.R.
submitted to the Protein Sequence Database, July 1999
A;Reference number: S78760
A;Accession: S78764
A;Molecule type: protein
A;Residues: 1-6 <GRA>
C;Keywords: mitochondrion
F;1-6/Product: ribosomal protein MRP-S23 (fragment) #status experimental <MAT>

Query Match             33.3%;  Score 8;  DB 2;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    4 H 4
         |
Db    2 H 2

RESULT 71
A46474
Fc epsilon RIIb - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 18-Jun-1993 #sequence_revision 18-Nov-1994 #text_change 11-Apr-1995
C;Accession: A46474
R;Richards, M.L.; Katz, D.H.; Liu, F.T.
J. Immunol. 147, 1067-1074, 1991
A;Title: Complete genomic sequence of the murine low affinity Fc receptor for IgE. Demons
A;Reference number: A46474; MUID:91318149; PMID:1861070
A;Accession: A46474
A;Status: preliminary; not compared with conceptual translation
A;Molecule type: nucleic acid
A;Residues: 1-6 <RIC>
A;Experimental source: BALB C, splenic B cells
A;Note: sequence extracted from NCBI backbone (NCBIP:45428)

Query Match             33.3%;  Score 8;  DB 2;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    4 H 4
         |
Db    4 H 4

RESULT 72
PT0693
T-cell receptor beta chain V-D-J region (154-1A) - mouse (fragment)

C;Species: Mus musculus (house mouse)
C;Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 30-May-1997
C;Accession: PT0693
R;Feeney, A.J.
J. Exp. Med. 174, 115-124, 1991
A;Title: Junctional sequences of fetal T cell receptor beta chains have few N regions.
A;Reference number: PT0509; MUID:91277601; PMID:1711558
A;Accession: PT0693
A;Status: translation not shown
A;Molecule type: DNA
A;Residues: 1-6 <FEE>
A;Experimental source: day 18 fetal thymus, strain BALB/c
C;Keywords: T-cell receptor

Query Match    33.3%;  Score 8;  DB 2;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    4 H 4
        |
Db    6 H 6

RESULT 73
A41946
T-cell receptor gamma chain (1t.22) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 07-May-1999
C;Accession: A41946
R;Whetsell, M.; Mosley, R.L.; Whetsell, L.; Schaefer, F.V.; Miller, K.S.; Klein, J.R.
Mol Cell. Biol. 11, 5902-5909, 1991
A;Title: Rearrangement and junctional-site sequence analyses of T-cell receptor gamma ge
A;Reference number: A41946; MUID:92049316; PMID:1658619
A;Accession: A41946
A;Status: Preliminary; not compared with conceptual translation
A;Molecule type: DNA
A;Residues: 1-6 <WHE>
C;Keywords: T-cell receptor

Query Match    33.3%;  Score 8;  DB 2;  Length 6;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative  0;  Mismatches  1;  Indels  0;  Gaps  0;

Qy    2 FR 3
        : |
Db    1 YR 2

RESULT 74
S71349
beta-crystallin B2 - rat (fragment)
C;Species: Rattus norvegicus (Norway rat)
C;Date: 29-Jan-1998 #sequence_revision 06-Feb-1998 #text_change 07-May-1999
C;Accession: S71349
R;Dirks, R.P.H.; Kraft, H.J.; van Genesen, S.T.; Klok, E.J.; Pfundt, R.; Schoenmakers, J
Eur. J. Biochem. 239, 23-32, 1996
A;Title: The cooperation between two silencers creates an enhancer element that controls
A;Reference number: S71349; MUID:96305362; PMID:8706714
A;Accession: S71349
A;Status: translation not shown
A;Molecule type: DNA
A;Residues: 1-6 <DIR>
A;Cross-references: EMBL:X83671
A;Experimental source: strain Wistar; lens epithelial cells
C;Genetics:
A;Gene: CRYBB2

Query Match    33.3%;  Score 8;  DB 2;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    4 H 4
        |

Db    5 H 5

RESULT 75
PD0028
pev-kinin 2 - penaeid shrimp (Penaeus vannamei) (fragment)
C;Species: Penaeus vannamei
C;Date: 21-Aug-1998 #sequence_revision 21-Aug-1998 #text_change 19-May-2000
C;Accession: PD0028
R;Nieto, J.; Veelaert, D.; Derua, R.; Waelkens, E.; Cerstiaens, A.; Coast, G.; Devreese,
Biochem. Biophys. Res. Commun. 248, 406-411, 1998
A;Title: Identification of one tachykinin- and two kinin-related peptides in the brain o
A;Reference number: PD0027; MUID:98342103; PMID:9675150
A;Accession: PD0028
A;Molecule type: protein
A;Residues: 1-6 <NIE>
C;Comment: This peptide belongs to myotropic neuropeptides.

Query Match    33.3%;  Score 8;  DB 2;  Length 6;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative  1;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EF 2
        : |
Db    1 DF 2

RESULT 76
NYPG7
hypothalamic heptapeptide - pig
C;Species: Sus scrofa domestica (domestic pig)
C;Date: 01-Sep-1981 #sequence_revision 01-Sep-1981 #text_change 09-Jul-2004
C;Accession: A01417
R;Chang, R.C.C.; Huang, W.Y.; Arimura, A.; Redding, T.W.; Coy, D.H.; Safran, M.; Kong,
Horm. Metab. Res. 13, 228-232, 1981
A;Title: Isolation, structure and synthesis of a heptapeptide with in vitro ACTH-releasi
A;Reference number: A01417; MUID:81213980; PMID:6263778
A;Accession: A01417
A;Molecule type: protein
A;Residues: 1-7 <CHA>
A;Cross-references: UNIPROT:P01153
C;Superfamily: hypothalamic heptapeptide
C;Keywords: hypothalamus

Query Match    33.3%;  Score 8;  DB 1;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    4 H 4
        |
Db    4 H 4

RESULT 77
PQ0663
membrane protein - porcine epidemic diarrhea virus (isolate Belgian CV777) (fragment)
C;Species: porcine epidemic diarrhea virus
C;Date: 14-Jul-1994 #sequence_revision 14-Jul-1994 #text_change 08-Oct-1999
C;Accession: PQ0663
R;Bridgen, A.; Duarte, M.; Tobler, K.; Laude, H.; Ackermann, M.
J. Gen. Virol. 74, 1795-1804, 1993
A;Title: Sequence determination of the nucleocapsid protein gene of the porcine epidemic
issible gastroenteritis virus.
A;Reference number: JQ2191; MUID:93389433; PMID:8397280
A;Accession: PQ0663
A;Molecule type: mRNA
A;Residues: 1-7 <BRI>
A;Cross-references: GB:Z14976; NID:g311650; PIDN:CAA78699.1; PID:g584083
C;Comment: This virus is coronavirus related to human coronavirus 229E.
C;Keywords: membrane protein

Query Match    33.3%;  Score 8;  DB 2;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;

Qy    4 H 4
        |

Matches       1;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

```
Qy    4 H 4
            |
Db    5 H 5
```

RESULT 78
B39127
phosphotransferase system enzyme II (EC 2.7.1.69) - Escherichia coli (fragment)
C;Species: Escherichia coli
C;Date: 27-Nov-1991 #sequence_revision 27-Nov-1991 #text_change 08-Oct-1999
C;Accession: B39127
R;Hardesty, C.; Ferran, C.; DiRienzo, J.M.
J. Bacteriol. 173, 449-456, 1991
A;Title: Plasmid-mediated sucrose metabolism in Escherichia coli: characterization of so
rin.
A;Reference number: A39127; MUID:91100329; PMID:1846143
A;Accession: B39127
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-7 <HAR>
A;Cross-references: GB:M38416; NID:g155142; PIDN:AAA98418.1; PID:g155144
C;Keywords: phosphotransferase

Query Match             33.3%;  Score 8;  DB 2;  Length 7;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches       1;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

```
Qy    1 EF 2
            :|
Db    2 DF 3
```

RESULT 79
S42407
gramicidin S synthetase component II - Bacillus brevis (fragment)
C;Species: Bacillus brevis
C;Date: 20-Oct-1994 #sequence_revision 12-Apr-1996 #text_change 12-Apr-1996
C;Accession: S42407
R;Stein, T.; Vater, J.; Kruft, V.; Wittmann-Liebold, B.; Franke, P.; Panico, M.; Mc Dowe
FEBS Lett. 340, 39-44, 1994
A;Title: Detection of 4'-phosphopantetheine at the thioester binding site for L-valine o
A;Reference number: S42407; MUID:94164305; PMID:819405
A;Accession: S42407
A;Molecule type: protein
A;Residues: 1-7 <STE>

Query Match             33.3%;  Score 8;  DB 2;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches       1;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

```
Qy    4 H 4
            |
Db    4 H 4
```

RESULT 80
A28709
phosphonoacetaldehyde hydrolase - Bacillus cereus (fragment)
C;Species: Bacillus cereus
C;Date: 22-Aug-1988 #sequence_revision 22-Aug-1988 #text_change 30-Sep-1993
C;Accession: A28709
R;Olsen, D.B.; Hepburn, T.W.; Moos, M.; Mariano, P.S.; Dunaway-Mariano, D.
Biochemistry 27, 2229-2234, 1988
A;Title: Investigation of the Bacillus cereus phosphonoacetaldehyde hydrolase. Evidence
idue.
A;Reference number: A28709; MUID:88241058; PMID:3112206
A;Accession: A28709
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-7 <OLS>

Query Match             33.3%;  Score 8;  DB 2;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches       1;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

```
Qy    4 H 4
            |
Db    5 H 5
```

RESULT 81
PT0246
Ig heavy chain CRD3 region (clone 2-103D) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 16-Aug-1996
C;Accession: PT0246
R;Yamada, M.; Wasserman, R.; Reichard, B.A.; Shane, S.; Caton, A.J.; Rovera, G.
J. Exp. Med. 173, 395-407, 1991
A;Title: Preferential utilization of specific immunoglobulin heavy chain diversity and jo
A;Reference number: PT0222; MUID:91108337; PMID:1899102
A;Accession: PT0246
A;Molecule type: DNA
A;Residues: 1-7 <YAM>
A;Experimental source: B lymphocyte
C;Keywords: heterotetramer; immunoglobulin

Query Match             33.3%;  Score 8;  DB 2;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches       1;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

```
Qy    4 H 4
            |
Db    1 H 1
```

RESULT 82
PT0520
T-cell receptor beta chain V-D-J region (100-4F) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 30-May-1997
C;Accession: PT0520
R;Feeney, A.J.
J. Exp. Med. 174, 115-124, 1991
A;Title: Junctional sequences of fetal T cell receptor beta chains have few N regions.
A;Reference number: PT0509; MUID:91277601; PMID:1711558
A;Accession: PT0520
A;Status: translation not shown
A;Molecule type: mRNA
A;Residues: 1-7 <FEE>
A;Experimental source: adult thymus, strain BALB/c
C;Keywords: T-cell receptor

Query Match             33.3%;  Score 8;  DB 2;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 2.8e+05;
Matches       1;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

```
Qy    4 H 4
            |
Db    7 H 7
```

RESULT 83
PT0665
T-cell receptor beta chain V-D-J region (121-3BM) - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 30-May-1997
C;Accession: PT0665
R;Feeney, A.J.
J. Exp. Med. 174, 115-124, 1991
A;Title: Junctional sequences of fetal T cell receptor beta chains have few N regions.
A;Reference number: PT0509; MUID:91277601; PMID:1711558
A;Accession: PT0665
A;Status: translation not shown
A;Molecule type: mRNA

A;Residues: 1-7 <FEE>
A;Experimental source: day 4 postnatal thymus, strain BALB/c
C;Keywords: T-cell receptor

Query Match             33.3%;  Score 8;  DB 2;  Length 7;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative   1;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        1 EF 2
            :|
Db        6 DF 7

RESULT 84
A38081
amine oxidase (copper-containing) (EC 1.4.3.6) - yeast (Pichia angusta) (fragment)
C;Species: Pichia angusta
C;Date: 31-Dec-1993 #sequence_revision 03-Feb-1994 #text_change 20-Apr-2000
A;Accession: A38081
R;Mu, D.; Janes, S.M.; Smith, A.J.; Brown, D.E.; Dooley, D.M.; Klinman, J.P.
J. Biol. Chem. 267, 7979-7982, 1992
A;Title: Tyrosine codon corresponds to topa quinone at the active site of copper amine o
A;Reference number: A38081; MUID:92235001; PMID:1569055
A;Accession: A38081
A;Molecule type: protein
A;Residues: 1-7 <MUA>
C;Keywords: copper; oxidoreductase; quinoprotein; topaquinone
F;4/Modified site: topaquinone (Tyr) #status experimental

Query Match             33.3%;  Score 8;  DB 2;  Length 7;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative   1;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        1 EF 2
            |:
Db        5 EY 6

RESULT 85
S29735
polyphosphate-glucose phosphotransferase (EC 2.7.1.63) - Propionibacterium freudenreichi
C;Species: Propionibacterium freudenreichii subsp. shermanii
C;Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 03-Jun-2002
A;Accession: S29735
R;Phillips, N.F.B.; Horn, P.J.; Wood, H.G.
Arch. Biochem. Biophys. 300, 309-319, 1993
A;Title: The polyphosphate- and ATP-dependent glucokinase from Propionibacterium sherman
A;Reference number: S29735; MUID:93143332; PMID:8380966
A;Accession: S29735
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-7 <PHI>
C;Keywords: phosphotransferase

Query Match             33.3%;  Score 8;  DB 2;  Length 7;
Best Local Similarity  100.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        4 H 4
            |
Db        2 H 2

RESULT 86
A15398
choline oxidase (EC 1.1.3.17) - Alcaligenes sp. (tentative sequence) (fragment)
C;Species: Alcaligenes sp.
C;Date: 05-Jun-1987 #sequence_revision 05-Jun-1987 #text_change 09-Jul-2004
A;Accession: A15398
R;Ohta-Fukuyama, M.; Miyake, Y.; Emi, S.; Yamano, T.
J. Biochem. 88, 197-203, 1980
A;Title: Identification and properties of the prosthetic group of choline oxidase from A
A;Reference number: A15398; MUID:81006769; PMID:6997283

A;Accession: A15398
A;Molecule type: protein
A;Residues: 1-7 <OHT>
A;Cross-references: UNIPROT:P16101
C;Keywords: oxidoreductase

Query Match             33.3%;  Score 8;  DB 2;  Length 7;
Best Local Similarity  100.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        4 H 4
            |
Db        5 H 5

RESULT 87
I46868
alpha-myosin heavy chain - rabbit (fragment)
C;Species: Oryctolagus cuniculus (domestic rabbit)
C;Date: 14-Feb-1997 #sequence_revision 14-Feb-1997 #text_change 09-Jul-2004
A;Accession: I46868
R;Friedman, D.J.; Umeda, P.K.; Sinha, A.M.; Hsu, H.
Proc. Natl. Acad. Sci. U.S.A. 81, 3044-3048, 1984
A;Title: Characterization of genomic clones specifying rabbit alpha- and beta-ventricula
A;Reference number: I46868; MUID:84221901; PMID:6328491
A;Accession: I46868
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-7 <FRI>
A;Cross-references: UNIPROT:Q28742; GB:K01698; NID:g165538; PIDN:AAA31415.1; PID:g165539

Query Match             33.3%;  Score 8;  DB 2;  Length 7;
Best Local Similarity  100.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        4 H 4
            |
Db        4 H 4

RESULT 88
S08606
hypothetical protein 2 estrogen receptor 5'-region - chicken
C;Species: Gallus gallus (chicken)
C;Date: 02-Dec-1993 #sequence_revision 10-Nov-1995 #text_change 16-Aug-2004
A;Accession: S08606
R;Krust, A.; Green, S.; Argos, P.; Kumar, V.; Walter, P.; Bornert, J.M.; Chambon, P.
EMBO J. 5, 891-897, 1986
A;Title: The chicken oestrogen receptor sequence: homology with v-erbA and the human oes
A;Reference number: S07192; MUID:86247578; PMID:3755102
A;Accession: S08606
A;Status: translation not shown
A;Molecule type: mRNA
A;Residues: 1-7 <KRU>
A;Cross-references: EMBL:X03805; NID:g63378; PIDN:CAA27432.1; PID:g584490

Query Match             33.3%;  Score 8;  DB 2;  Length 7;
Best Local Similarity  100.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        4 H 4
            |
Db        5 H 5

RESULT 89
PQ0012
cholecystokinin - southeastern quoll
N;Alternate names: CCK
C;Species: Dasyurus viverrinus (southeastern quoll)
C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004
A;Accession: PQ0012
R;Fan, Z.W.; Eng, J.; Shaw, G.; Yalow, R.S.

Peptides 9, 429-431, 1988
A;Title: Cholecystokinin octapeptide purified from brains of Australian marsupials.
A;Reference number: PQ0012; MUID:88234141; PMID:3375140
A;Accession: PQ0012
A;Molecule type: protein
A;Residues: 1-8 <FAN>
A;Cross-references: UNIPROT:P30369
C;Superfamily: gastrin
C;Keywords: amidated carboxyl end; hormone; neuropeptide; sulfoprotein
F;2/Binding site: sulfate (Tyr) (covalent) #status predicted
F;8/Modified site: amidated carboxyl end (Phe) #status predicted

Query Match             33.3%;  Score  8;  DB 2;  Length 8;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps   0;

Qy          5 FK 6
              |:
Db          5 FK 6

RESULT 92
PT0368
Ig gamma chain C region (gamma-1) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 31-Mar-1992 #sequence_revision 31-Mar-1992 #text_change 16-Aug-1996
C;Accession: PT0368
R;Milili, M.; Fougereau, M.; Guglielmi, P.; Schiff, C.
Mol. Immunol. 28, 753-761, 1991
A;Title: Early occurrence of immunoglobulin isotype switching in human fetal liver.
A;Reference number: PT0368; MUID:9112348; PMID:1906981
A;Accession: PT0368
A;Molecule type: mRNA
A;Residues: 1-8 <MIL>
A;Experimental source: fetal liver
C;Keywords: immunoglobulin

Query Match             33.3%;  Score  8;  DB 2;  Length 8;
Best Local Similarity  100.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps   0;

Qy          4 H 4
              |
Db          2 H 2

RESULT 93
B54823
olfactory receptor I7 - western wild mouse (fragment)
C;Species: Mus spretus (western wild mouse)
C;Date: 28-Apr-1995 #sequence_revision 28-Apr-1995 #text_change 17-Mar-1999
C;Accession: B54823
R;Chess, A.; Simon, I.; Cedar, H.; Axel, R.
Cell 78, 823-834, 1994
A;Title: Allelic inactivation regulates olfactory receptor gene expression.
A;Reference number: A54823; MUID:94373818; PMID:8087849
A;Accession: B54823
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-8 <CHE>

Query Match             33.3%;  Score  8;  DB 2;  Length 8;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps   0;

Qy          1 EFRH 4
              |  ||
Db          2 ERRN 5

RESULT 94
S66296
Na+-transporting ATP synthase (EC 3.6.1.-) chain c - Acetobacterium woodii (fragment)
N;Alternate names: ATPase chain c
C;Species: Acetobacterium woodii
C;Date: 19-Mar-1997 #sequence_revision 06-Jun-1997 #text_change 07-May-1999
C;Accession: S66296
R;Reidlinger, J.; Mueller, V.
Eur. J. Biochem. 223, 275-283, 1994
A;Title: Purification of ATP synthase from Acetobacterium woodii and identification as a
A;Reference number: S45648; MUID:94307271; PMID:8033902
A;Accession: S66296
A;Molecule type: protein
A;Residues: 1-8 <REI>
A;Experimental source: DSM 1030
C;Keywords: hydrolase

Query Match             33.3%;  Score  8;  DB 2;  Length 8;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps   0;

Qy          2 FR 3

---

RESULT 90
A43001
cholecystokinin - tammar wallaby
N;Alternate names: CCK
C;Species: Macropus eugenii (tammar wallaby)
C;Date: 30-Oct-1992 #sequence_revision 30-Oct-1992 #text_change 09-Jul-2004
C;Accession: A43001; PQ0012
R;Fan, Z.W.; Eng, J.; Shaw, G.; Yalow, R.S.
Peptides 9, 429-431, 1988
A;Title: Cholecystokinin octapeptide purified from brains of Australian marsupials.
A;Reference number: PQ0012; MUID:88234141; PMID:3375140
A;Accession: A43001
A;Molecule type: protein
A;Residues: 1-8 <FAN>
C;Superfamily: gastrin
C;Keywords: amidated carboxyl end; hormone; neuropeptide; sulfoprotein
F;2/Binding site: sulfate (Tyr) (covalent) #status predicted
F;8/Modified site: amidated carboxyl end (Phe) #status predicted

Query Match             33.3%;  Score  8;  DB 2;  Length 8;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps   0;

Qy          1 EF 2
              :|
Db          7 DF 8

RESULT 91
A39892
P element, P cytotype-determining - fruit fly (Drosophila melanogaster) (fragment)
C;Species: Drosophila melanogaster
C;Date: 24-Jan-1992 #sequence_revision 24-Jan-1992 #text_change 16-Feb-1997
C;Accession: A39892
R;Nitasaka, E.; Mukai, T.; Yamazaki, T.
Proc. Natl. Acad. Sci. U.S.A. 84, 7605-7608, 1987
A;Title: Repressor of P elements in Drosophila melanogaster: cytotype determination by a
A;Reference number: A39892
A;Accession: A39892
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-8 <NIT>
C;Genetics:
C;Gene: FlyBase:P-element
A;Cross-references: FlyBase:FBgn0003055

Query Match             33.3%;  Score  8;  DB 2;  Length 8;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches    1;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps   0;

Qy          1 EF 2
              :|
Db          7 DF 8

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
F;8/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match             33.3%;  Score 8;  DB 2;  Length 8;
Best Local Similarity  100.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      4 H 4
        :|
Db      5 H 5

RESULT 98
JS0318
leucokinin VIII - Madeira cockroach
C;Species: Leucophaea maderae (Madeira cockroach)
C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004
C;Accession: JS0318
R;Holman, G.M.; Cook, B.J.; Nachman, R.J.
Comp. Biochem. Physiol. C 88, 31-34, 1987
A;Title: Isolation, primary structure and synthesis of leucokinins VII and VIII: the fin
A;Reference number: JS0318
A;Accession: JS0318
A;Molecule type: protein
A;Residues: 1-8 <HOL>
A;Cross-references: UNIPROT:P19990
C;Comment: Leucokinins, a family of cephalomyotropic peptides, stimulate contractile act
C;Keywords: amidated carboxyl end; cephalomyotropic peptide
F;8/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match             33.3%;  Score 8;  DB 2;  Length 8;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative   1;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 EF 2
        :|
Db      3 DF 4

RESULT 99
H41978
calliFMRFamide 8 - bluebottle fly (Calliphora vomitoria)
C;Species: Calliphora vomitoria
C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C;Accession: H41978
R;Duve, H.; Johnsen, A.H.; Sewell, J.C.; Scott, A.G.; Orchard, I.; Rehfeld, J.F.; Thorpe
Proc. Natl. Acad. Sci. U.S.A. 89, 2326-2330, 1992
A;Title: Isolation, structure, and activity of -Phe-Met-Arg-Phe-NH-2 neuropeptides (desi
A;Reference number: A41978; MUID:9219611; PMID:1549595
A;Accession: H41978
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-8 <DUV>
A;Cross-references: UNIPROT:P41863
C;Keywords: amidated carboxyl end; neuropeptide
F;8/Modified site: amidated carboxyl end (Phe) #status experimental

Query Match             33.3%;  Score 8;  DB 2;  Length 8;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative   1;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 EF 2
        :|
Db      4 DF 5

RESULT 100
E47393
neuropeptide callatostatin 5 - bluebottle fly (Calliphora vomitoria)
C;Species: Calliphora vomitoria
C;Date: 16-Feb-1994 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C;Accession: E47393
R;Duve, H.; Johnsen, A.H.; Scott, A.G.; Yu, C.G.; Yagi, K.J.; Tobe, S.S.; Thorpe, A.

---

Qy      1 EF 2
        :|
Db      5 DF 6

RESULT 95
S37141
rpsA protein - Erwinia chrysanthemi
C;Species: Erwinia chrysanthemi
C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 09-Jul-2004
C;Accession: S37141
R;Douillie, A.; Toussaint, A.; Faelen, M.
submitted to the EMBL Data Library, August 1993
A;Description: Identification of the integration host factor genes of E. chrysanthemi.
A;Reference number: S37139
A;Accession: S37141
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-8 <DOU>
A;Cross-references: UNIPROT:P37985; EMBL:X74750; NID:g399669; PIDN:CAA52769.1; PID:g5811

Query Match             33.3%;  Score 8;  DB 2;  Length 8;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative   1;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      2 FR 3
        :|:
Db      2 FK 3

RESULT 96
PT0030
inulinase (EC 3.2.1.7) - Aspergillus ficuum (fragment)
N;Alternate names: inulase
C;Species: Aspergillus ficuum
C;Date: 31-Dec-1990 #sequence_revision 31-Dec-1990 #text_change 09-Jul-2004
C;Accession: PT0030
R;Ettalibi, M.; Baratti, J.C.
Agric. Biol. Chem. 54, 61-68, 1990
A;Title: Molecular and kinetic properties of Aspergillus ficuum inulinases.
A;Reference number: PT0030; MUID:90344234; PMID:1368526
A;Accession: PT0030
A;Molecule type: protein
A;Residues: 1-8 <ETT>
A;Cross-references: UNIPROT:Q7M4U4
C;Keywords: glycosidase; hydrolase; polysaccharide degradation

Query Match             33.3%;  Score 8;  DB 2;  Length 8;
Best Local Similarity   50.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative   1;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      2 FR 3
        :|
Db      7 YR 8

RESULT 97
JS0316
leucokinin VI - Madeira cockroach
C;Species: Leucophaea maderae (Madeira cockroach)
C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 09-Jul-2004
C;Accession: JS0316
R;Holman, G.M.; Cook, B.J.; Nachman, R.J.
Comp. Biochem. Physiol. C 88, 27-30, 1987
A;Title: Isolation, primary structure, and synthesis of leucokinins V and VI: myotropic
A;Reference number: JS0316
A;Accession: JS0316
A;Molecule type: protein
A;Residues: 1-8 <HOL>
A;Cross-references: UNIPROT:P19988
C;Comment: Leucokinins, a family of cephalomyotropic peptides, stimulate contractile act
C;Keywords: amidated carboxyl end; cephalomyotropic peptide; pyroglutamic acid

Proc. Natl. Acad. Sci. U.S.A. 90, 2456-2460, 1993
A;Title: Callatostatins: neuropeptides from the blowfly Calliphora vomitoria with sequen
A;Reference number: A47393; MUID:93211980; PMID:8460157
A;Accession: E47393
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-8 <DUV>
A;Cross-references: UNIPROT:P41841
A;Experimental source: whole flies
A;Note: sequence extracted from NCBI backbone (NCBIP:128482)

Query Match          33.3%;  Score  8;  DB 2;  Length 8;
Best Local Similarity  50.0%;  Pred. No. 2.8e+05;
Matches   1;  Conservative  1;  Mismatches  0;  Indels  0;  Gaps  0;

Qy      1 EF 2
            :|
Db      5 DF 6

Search completed: November  2, 2005, 09:41:47
Job time : 41 secs

OM protein - protein search, using sw model

Copyright     GenCore version 5.1.6
(c) 1993 - 2005 Compugen Ltd.

Run on:        November  2, 2005, 09:31:04 ; Search time 167 Seconds
                                            (without alignments)
                                            12.265 Million cell updates/sec

Title:         US-10-618-856-1
Perfect score: 24
Sequence:      1 BFRH 4

Scoring table: BLOSUM62
               Gapop 10.0 , Gapext 0.5

Searched:      1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters:     2541

Minimum DB seq length: 4
Maximum DB seq length: 10

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 100 summaries

Database :     UniProt 03:*
               1: uniprot_sprot:*
               2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | % Query Match | Length | DB | ID | Description |
|---|---|---|---|---|---|---|
| 1 | 17 | 70.8 | 10 | 2 | Q63056 | Q63056 rattus norv |
| 2 | 16 | 66.7 | 10 | 2 | Q8TGB8 | Q8TGB8 pleurotus o |
| 3 | 16 | 66.7 | 10 | 2 | Q7WUG1 | Q7WUG1 pseudomonas |
| 4 | 14 | 58.3 | 8 | 2 | O13591 | O13591 saccharomyc |
| 5 | 13 | 54.2 | 8 | 2 | Q9Y4J4 | Q9Y4J4 homo sapien |
| 6 | 13 | 54.2 | 8 | 2 | Q28866 | Q28866 megaptera n |
| 7 | 13 | 54.2 | 8 | 2 | Q9GMH3 | Q9GMH3 lagenorhync |
| 8 | 13 | 54.2 | 8 | 2 | Q9TT78 | Q9TT78 canis famil |
| 9 | 13 | 54.2 | 8 | 2 | Q7M194 | Q7M194 escherichia |
| 10 | 13 | 54.2 | 8 | 2 | Q84156 | Q84156 orf virus. |
| 11 | 13 | 54.2 | 9 | 1 | BS43_SERPL | BS43 SERPL serratia pl |
| 12 | 13 | 54.2 | 9 | 1 | NEUX_HUMAN | NEUX_HUMAN xenopus lae |
| 13 | 13 | 54.2 | 9 | 1 | XYLA_STRS8 | XYLA_STRS8 streptomyce |
| 14 | 13 | 54.2 | 9 | 2 | Q8MJN1 | Q8MJN1 cebuella py |
| 15 | 13 | 54.2 | 9 | 2 | Q8MJN2 | Q8MJN2 callithrix |
| 16 | 13 | 54.2 | 9 | 2 | Q8MJN3 | Q8MJN3 callimico g |
| 17 | 13 | 54.2 | 9 | 2 | Q8MJN4 | Q8MJN4 leontopithe |
| 18 | 13 | 54.2 | 9 | 2 | Q8MJN5 | Q8MJN5 saguinus fu |
| 19 | 13 | 54.2 | 9 | 2 | Q8MJN6 | Q8MJN6 aotus azara |
| 20 | 13 | 54.2 | 9 | 2 | Q8MJN7 | Q8MJN7 saimiri sci |
| 21 | 13 | 54.2 | 9 | 2 | Q8MJN8 | Q8MJN8 cebus apell |
| 22 | 13 | 54.2 | 9 | 2 | Q8MJN9 | Q8MJN9 ateles fusc |
| 23 | 13 | 54.2 | 9 | 2 | Q7JIS3 | Q7JIS3 lagenorhync |
| 24 | 13 | 54.2 | 9 | 2 | Q7JIS4 | Q7JIS4 lagenorhync |
| 25 | 13 | 54.2 | 9 | 2 | Q7JIS5 | Q7JIS5 lagenorhync |
| 26 | 13 | 54.2 | 9 | 2 | Q7JIS6 | Q7JIS6 lagenorhync |
| 27 | 13 | 54.2 | 9 | 2 | Q7JIS7 | Q7JIS7 lagenorhync |
| 28 | 13 | 54.2 | 9 | 2 | Q7JIS8 | Q7JIS8 lagenorhync |
| 29 | 13 | 54.2 | 9 | 2 | Q7JIS9 | Q7JIS9 lagenorhync |
| 30 | 13 | 54.2 | 9 | 2 | Q7JIT0 | Q7JIT0 lagenorhync |
| 31 | 13 | 54.2 | 9 | 2 | Q7JIT1 | Q7JIT1 lagenorhync |
| 32 | 13 | 54.2 | 9 | 2 | Q7JIT1 | Q7jit1 lagenorhync |
| 33 | 13 | 54.2 | 9 | 2 | Q9GJV1 | Q9gjv1 lagenorhync |
| 34 | 13 | 54.2 | 9 | 2 | Q9GJV2 | Q9gjv2 lagenorhync |
| 35 | 13 | 54.2 | 9 | 2 | Q9GJV3 | Q9gjv3 lagenorhync |
| 36 | 13 | 54.2 | 9 | 2 | Q9TT77 | Q9tt77 bos taurus |
| 37 | 13 | 54.2 | 9 | 2 | Q9R7H9 | Q9r7h9 haemophilus |
| 38 | 13 | 54.2 | 10 | 2 | Q8N6B1 | Q8n6b1 homo sapien |
| 39 | 13 | 54.2 | 10 | 2 | Q6LCI4 | Q61c14 homo sapien |
| 40 | 13 | 54.2 | 10 | 2 | Q6IG13 | Q61g13 bos taurus |
| 41 | 13 | 54.2 | 10 | 2 | Q958J8 | Q958j8 rana muscos |
| 42 | 13 | 54.2 | 10 | 2 | O54217 | O54217 staphylococ |
| 43 | 12 | 50.0 | 7 | 2 | O99182 | O99182 gnatholebia |
| 44 | 12 | 50.0 | 9 | 1 | OXYT_OCTVU | P80027 octopus vul |
| 45 | 12 | 50.0 | 9 | 2 | Q7RE58 | Q7re58 plasmodium |
| 46 | 12 | 50.0 | 9 | 2 | Q6JDL5 | Q6jd15 canis famil |
| 47 | 12 | 50.0 | 10 | 2 | Q8HUB4 | Q8hub4 anomobryum |
| 48 | 12 | 50.0 | 10 | 2 | Q8QE18 | Q8qe18 human immun |
| 49 | 11 | 45.8 | 5 | 1 | EI03_LITRU | P82099 litoria rub |
| 50 | 11 | 45.8 | 5 | 1 | RE21_LITRU | P82071 litoria rub |
| 51 | 11 | 45.8 | 5 | 1 | RE31_LITRU | P82072 litoria rub |
| 52 | 11 | 45.8 | 6 | 1 | FARP_MONEX | P41966 moniezia ex |
| 53 | 11 | 45.8 | 7 | 1 | FAFI_ASCSU | P31889 ascaris suu |
| 54 | 11 | 45.8 | 7 | 2 | O98866 | O98866 spinacia ol |
| 55 | 11 | 45.8 | 8 | 1 | GLUR_HUMAN | P02729 homo sapien |
| 56 | 11 | 45.8 | 8 | 1 | PPK3_PERAM | P82618 periplaneta |
| 57 | 11 | 45.8 | 8 | 2 | Q15901 | Q15901 homo sapien |
| 58 | 11 | 45.8 | 8 | 2 | Q34909 | Q34909 locusta mig |
| 59 | 11 | 45.8 | 8 | 2 | Q6Y2F2 | Q6y2f2 citrus sine |
| 60 | 11 | 45.8 | 8 | 2 | Q6LDQ5 | Q6ldq5 rhodobacter |
| 61 | 11 | 45.8 | 8 | 2 | Q9R3X0 | Q9r3x0 planktothri |
| 62 | 11 | 45.8 | 8 | 2 | Q9ERD2 | Q9erd2 mus musculu |
| 63 | 11 | 45.8 | 8 | 2 | Q90ZV5 | Q90zv5 fulica leuc |
| 64 | 11 | 45.8 | 8 | 2 | Q6VMC6 | Q6vmc6 serilophus |
| 65 | 11 | 45.8 | 9 | 1 | BRK1_RANNI | Q71z54 rana nigrom |
| 66 | 11 | 45.8 | 9 | 1 | COXE_THUOB | P80975 thunnus obe |
| 67 | 11 | 45.8 | 9 | 1 | FIBB_PAPAN | P19344 papio anubi |
| 68 | 11 | 45.8 | 9 | 1 | KNL3_BOMVA | P83058 bombina var |
| 69 | 11 | 45.8 | 9 | 1 | KNL3_CYPDO | P83659 cyphononyx |
| 70 | 11 | 45.8 | 9 | 1 | NEUU_CAVPO | P34966 cavia porce |
| 71 | 11 | 45.8 | 9 | 1 | NSK1_SARBU | P41492 sarcophaga |
| 72 | 11 | 45.8 | 9 | 2 | Q7M471 | Q7m471 vespa orien |
| 73 | 11 | 45.8 | 9 | 2 | Q7M2N8 | Q7m2n8 bos indicus |
| 74 | 11 | 45.8 | 9 | 2 | Q8MEM3 | Q8mem3 howittia tr |
| 75 | 11 | 45.8 | 9 | 2 | Q8S3C6 | Q8s3c6 glycine max |
| 76 | 11 | 45.8 | 9 | 2 | Q7M151 | Q7m151 unidentifie |
| 77 | 11 | 45.8 | 9 | 2 | Q67605 | Q67605 squash leaf |
| 78 | 11 | 45.8 | 9 | 2 | Q67606 | Q67606 squash leaf |
| 79 | 11 | 45.8 | 9 | 2 | Q88953 | Q88953 vaccinia vi |
| 80 | 11 | 45.8 | 9 | 2 | Q7LZI7 | Q71z17 heleophryne |
| 81 | 11 | 45.8 | 9 | 2 | Q7LZJ8 | Q7lzj8 rana tempor |
| 82 | 11 | 45.8 | 9 | 2 | Q7SX77 | Q7sx77 geochelone |
| 83 | 11 | 45.8 | 9 | 2 | Q9PRJ4 | Q9prj4 lepisosteus |
| 84 | 11 | 45.8 | 9 | 2 | Q85599 | Q85599 moloney mur |
| 85 | 11 | 45.8 | 10 | 1 | FARP_MYTED | P42560 mytilus edu |
| 86 | 11 | 45.8 | 10 | 1 | LSK2_LEUMA | P67802 leucophaea |
| 87 | 11 | 45.8 | 10 | 1 | LSK2_PERAM | P30095 periplaneta |
| 88 | 11 | 45.8 | 10 | 1 | UPA9_HUMAN | Q96qt9 homo sapien |
| 89 | 11 | 45.8 | 10 | 2 | Q96QT9 | Q7z5a2 homo sapien |
| 90 | 11 | 45.8 | 10 | 2 | Q7Z5A2 | P82217 homo sapien |
| 91 | 11 | 45.8 | 10 | 2 | P82217 | Q8sha8 bombyx mori |
| 92 | 11 | 45.8 | 10 | 2 | Q8SHA8 | Q96041 rhampholeon |
| 93 | 11 | 45.8 | 10 | 2 | Q96041 | Q85bv6 oenothera b |
| 94 | 11 | 45.8 | 10 | 2 | Q85BV6 | Q85v67 eucalyptus |
| 95 | 11 | 45.8 | 10 | 2 | Q85V67 | Q76vi9 eucalyptus |
| 96 | 11 | 45.8 | 10 | 2 | Q76VI9 | Q6kc69 lactococcus |
| 97 | 11 | 45.8 | 10 | 2 | Q6KC69 | Q7m1i6 eucalyptus |
| 98 | 11 | 45.8 | 10 | 2 | Q7M1I6 | Q93u2 trichosanth |
| 99 | 11 | 45.8 | 10 | 2 | Q93U2 | Q6jl97 escherichia |
| 100 | 11 | 45.8 | 10 | 2 | Q6JL97 | Q6j197 neiseria g |

ALIGNMENTS

RESULT 1
Q63056
ID   Q63056          PRELIMINARY;       PRT;    10 AA.
AC   Q63056;
DT   01-NOV-1996 (TrEMBLrel. 01, Created)
DT   01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Rat asialoglycoprotein receptor (ASGP) (Fragment).
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Liver;
RX   MEDLINE=87026895; PubMed=2945599;
RA   Watts C.;
RT   "Isolation and expression of cDNA clones for a rat liver
RT   asialoglycoprotein receptor.";
RL   Biosci. Rep. 6:527-534(1986).
DR   EMBL; M21739; AAA40763.1; -.
DR   GO; GO:0004872; F:receptor activity; IEA.
KW   Receptor.
FT   NON_TER          1      1
SQ   SEQUENCE   10 AA;   1312 MW;  56ADE0CAB6CB5AA3 CRC64;

Query Match             70.8%;  Score 17;  DB 2;  Length 10;
Best Local Similarity   50.0%;  Pred. No. 1.9e+03;
Matches    2;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          | :|:|
Db      7 DFQH 10


RESULT 2
Q8TG88
ID   Q8TG88          PRELIMINARY;       PRT;    10 AA.
AC   Q8TG88;
DT   01-JUN-2002 (TrEMBLrel. 21, Created)
DT   01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Manganese peroxidase (Fragment).
GN   Name=mrp3;
OS   Pleurotus ostreatus (Oyster mushroom) (White-rot fungus).
OC   Eukaryota; Fungi; Basidiomycota; Hymenomycetes; Homobasidiomycetes;
OC   Agaricales; Pleurotaceae; Pleurotus.
OX   NCBI_TaxID=5322;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=Florida 6;
RX   MEDLINE=22034998; PubMed=12039783;
RX   DOI=10.1128/AEM.68.6.3156-3158.2002;
RA   Cohen R., Yarden O., Hadar Y.;
RT   "Lignocellulose Affects Mn(2+) Regulation of Peroxidase Transcript
RT   Levels in Solid-State Cultures of Pleurotus ostreatus.";
RL   Appl. Environ. Microbiol. 68:3156-3158(2002).
DR   EMBL; AF435445; AAM08267.1; -.
DR   GO; GO:0004601; F:peroxidase activity; IEA.
KW   Peroxidase.
FT   NON_TER          10     10
SQ   SEQUENCE   10 AA;   1166 MW;  CC9D0CA5B9C1E339 CRC64;

Query Match             66.7%;  Score 16;  DB 2;  Length 10;
Best Local Similarity   66.7%;  Pred. No. 3.3e+03;
Matches    2;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      2 FRH 4
          |:|
Db      3 FKH 5


RESULT 3
Q7WUG1
ID   Q7WUG1          PRELIMINARY;       PRT;    10 AA.
AC   Q7WUG1;
DT   01-OCT-2003 (TrEMBLrel. 25, Created)
DT   01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE   Probable ATP-binding component of ABC transporter (Fragment).
OS   Pseudomonas fluorescens.
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
OC   Pseudomonadaceae; Pseudomonas.
OX   NCBI_TaxID=294;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=CHA0;
RA   Pechy-Tarr M., Bottiglieri M., Bang Lejbolle K., Gigot-Bonnefoy C.,
RA   Keel C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AY341911; AAQ17034.1; -.
DR   GO; GO:0005524; F:ATP binding; IEA.
KW   ATP-binding.
FT   NON_TER          1      1
SQ   SEQUENCE   10 AA;   1262 MW;  08EF18CB11B8773B CRC64;

Query Match             66.7%;  Score 16;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 3.3e+03;
Matches    3;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFR 3
          | | |
Db      7 EFR 9


RESULT 4
O13591
ID   O13591          PRELIMINARY;       PRT;    8 AA.
AC   O13591;
DT   01-JAN-1998 (TrEMBLrel. 05, Created)
DT   01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   ORF YNL337w (Fragment).
OS   Saccharomyces cerevisiae (Baker's yeast).
OC   Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC   Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=4932;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Obermaier B., Piravandi E., Rinke M.;
RL   Submitted (MAY-1996) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   SEQUENCE FROM N.A.
RA   MIPS;
RL   Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; Z71612; CAA96271.2; -.
FT   NON_TER          1      1
SQ   SEQUENCE   8 AA;   1005 MW;  5CA441E449C9C720 CRC64;

Query Match             58.3%;  Score 14;  DB 2;  Length 8;
Best Local Similarity   66.7%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy      2 FRH 4
          | |
Db      4 FNH 6


RESULT 5
Q9Y4J4
ID   Q9Y4J4          PRELIMINARY;       PRT;    8 AA.
AC   Q9Y4J4;
DT   01-NOV-1999 (TrEMBLrel. 12, Created)
DT   01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)

```
DE   Runt/82nt/MTG8 protein (Fragment).
GN   Name=runt/82nt/MTG8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=95002916; PubMed=7919324;
RA   Tighe J.E., Calabi F.;
RT   "Alternative, out-of-frame runt/MTG8 transcripts are encoded by the
RT   derivative (8) chromosome in the t(8;21) of acute myeloid leukemia
RT   M2.";
RL   Blood 84:2115-2121(1994).
DR   EMBL; S74092; AAD14144.1; -.
FT   NON_TER       8      8
SQ   SEQUENCE   8 AA;  1067 MW;  20F414044B17244B CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 8;
Best Local Similarity   100.0%;            Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              |  |
Db          7 RH 8


RESULT 6
Q28866
ID   Q28866     PRELIMINARY;       PRT;    8 AA.
AC   Q28866;
DT   01-NOV-1996 (TrEMBLrel. 01, Created)
DT   01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT   01-MAY-1999 (TrEMBLrel. 10, Last annotation update)
DE   Actin protein (Fragment).
GN   Name=actin;
OS   Megaptera novaeangliae (Humpback whale).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Mysticeti;
OC   Balaenopteridae; Megaptera.
OX   NCBI_TaxID=9773;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=94285813; PubMed=7912407;
RA   Palumbi S.R., Baker C.S.;
RT   "Contrasting population structure from nuclear intron sequences and
RT   mtDNA of humpback whales.";
RL   Mol. Biol. Evol. 11:426-435(1994).
DR   EMBL; S73467; AAD14118.1; -.
FT   NON_TER       8      8
SQ   SEQUENCE   8 AA;  906 MW;  69C866D1F4177408 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 8;
Best Local Similarity   100.0%;            Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              |  |
Db          4 RH 5


RESULT 7
Q9GMH3
ID   Q9GMH3     PRELIMINARY;       PRT;    8 AA.
AC   Q9GMH3;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-MAR-2001 (TrEMBLrel. 16, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus obscurus (Dusky dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC   Lagenorhynchus.
```

```
OX   NCBI_TaxID=27611;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140833; AAF98686.1; -.
FT   NON_TER       1      1
FT   NON_TER       8      8
SQ   SEQUENCE   8 AA;  962 MW;  5BD1F41774D862C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 8;
Best Local Similarity   100.0%;            Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              |  |
Db          6 RH 7


RESULT 8
Q9TT78
ID   Q9TT78     PRELIMINARY;       PRT;    8 AA.
AC   Q9TT78;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE   Thymidylate synthase (Fragment).
OS   Canis familiaris (Dog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
OX   NCBI_TaxID=9615;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=21015404; PubMed=11130975;
RA   Brouillette J.A., Andrew J.R., Venta P.J.;
RT   "Estimate of nucleotide diversity in dogs with a pool-and-sequence
RT   method.";
RL   Mamm. Genome 11:1079-1086(2000).
DR   EMBL; AF202073; AAF20918.1; -.
FT   NON_TER       1      1
FT   NON_TER       8      8
SQ   SEQUENCE   8 AA;  899 MW;  6731A1E059CAA867 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 8;
Best Local Similarity   50.0%;             Pred. No. 1.6e+06;
Matches    2;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              : | |
Db          3 DFIH 6


RESULT 9
Q7M194
ID   Q7M194     PRELIMINARY;       PRT;    8 AA.
AC   Q7M194;
DT   01-MAR-2004 (TrEMBLrel. 26, Created)
DT   01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE   L-serine ammonia-lyase (EC 4.3.1.17) (Fragment).
OS   Escherichia coli.
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=562;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=76005414; PubMed=1099073;
RA   Heincz M.C., McFall E.;
RT   "N-terminal amino acid sequences of D-serine deaminases of wild-type
RT   and operator-constitutive strains of Escherichia coli K-12.";
RL   J. Bacteriol. 123:1163-1168(1975).
DR   PIR; A25836; A25836.
DR   GO; GO:0003941; F:L-serine ammonia-lyase activity; IEA.
```

```
FT   NON_TER      8     8
SQ   SEQUENCE     8 AA;  906 MW;  F7B1F40865BB05B6 CRC64;

Query Match            54.2%;  Score 13;  DB 2;  Length 8;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy   3 RH 4
       ||
Db   6 RH 7

RESULT 10
Q84156
ID   Q84156;           PRELIMINARY;         PRT;      8 AA.
AC   Q84156;
DT   01-NOV-1996 (TrEMBLrel. 01, Created)
DT   01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT   01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE   Similar to Vaccinia virus (Fragment).
OS   Orf virus.
OC   Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
OC   Parapoxvirus.
OX   NCBI_TaxID=10258;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=96010242; PubMed=7571439;
RA   Mercer A.A., Lyttle D.J., Whelan E.M., Fleming S.B., Sullivan J.T.;
RT   "The establishment of a genetic map of orf virus reveals a pattern of
RT   genomic organization that is highly conserved among divergent
RT   poxviruses.";
RL   Virology 212:698-704(1995).
DR   EMBL; U30336; AAA86400.1; -.
FT   NON_TER      8     8
SQ   SEQUENCE     8 AA;  1091 MW;  E24411A441F40446 CRC64;

Query Match            54.2%;  Score 13;  DB 2;  Length 8;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy   3 RH 4
       ||
Db   3 RH 4

RESULT 11
P79940
ID   P79940;           PRELIMINARY;         PRT;      8 AA.
AC   P79940;
DT   01-MAY-1997 (TrEMBLrel. 03, Created)
DT   01-MAY-1997 (TrEMBLrel. 03, Last sequence update)
DT   01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE   XMeis1-4 protein (Fragment).
OS   Xenopus laevis (African clawed frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae;
OC   Xenopodinae; Xenopus.
OX   NCBI_TaxID=8355;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=97202105; PubMed=9049632;
RA   Steelman S., Moskow J.J., Muzynski K., North C., Druck T.,
RA   Montgomery J.C., Huebner K., Daar I.O., Buchberg A.M.;
RT   "Identification of a conserved family of Meis1-related homeobox
RT   genes.";
RL   Genome Res. 7:142-156(1997).
DR   EMBL; U68389; AAB19199.1; -.
DR   TRANSFAC; T03410; -.
FT   NON_TER      1     1
SQ   SEQUENCE     8 AA;  1187 MW;  278B51F37B11F40B CRC64;

Query Match            54.2%;  Score 13;  DB 2;  Length 8;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy   3 RH 4
       ||
Db   2 RH 3

RESULT 12
BS43_SERPL
ID   BS43_SERPL        STANDARD;            PRT;      9 AA.
AC   P83375;
DT   28-FEB-2003 (Rel. 41, Created)
DT   28-FEB-2003 (Rel. 41, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Bacteriocin serracin P 43 kDa subunit (Fragment).
OS   Serratia plymuthica.
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Serratia.
OX   NCBI_TaxID=82996;
RN   [1]
RP   SEQUENCE, AND FUNCTION.
RC   STRAIN=J7;
RX   MEDLINE=22293561; PubMed=12406768;
RA   Jabrane A., Sabri A., Compere P., Jacques P., Vandenberghe I.,
RA   Van Beumen J., Thonart P.;
RT   "Characterization of serracin P, a phage-tail-like bacteriocin, and
RT   its activity against Erwinia amylovora, the fire blight pathogen.";
RL   Appl. Environ. Microbiol. 68:5704-5710(2002).
CC   -!- FUNCTION: Major component of a prophage tail sheath (Probable).
CC   -!- FUNCTION: Antibacterial activity against Gram-negative bacterium
CC       E.amylovora.
KW   Antibiotic; Bacteriocin; Direct protein sequencing.
FT   NON_TER      9     9
SQ   SEQUENCE     9 AA;  1095 MW;  1E66D412C871E1FB CRC64;

Query Match            54.2%;  Score 13;  DB 1;  Length 9;
Best Local Similarity  25.0%;  Pred. No. 1.6e+06;
Matches    1;  Conservative  2;  Mismatches  2;  Indels  1;  Gaps  0;

Qy   1 EFRH 4
       :||
Db   1 DYHH 4

RESULT 13
NEUX_HUMAN
ID   NEUX_HUMAN        STANDARD;            PRT;      9 AA.
AC   P04277;
DT   20-MAR-1987 (Rel. 04, Created)
DT   20-MAR-1987 (Rel. 04, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Neurotensin-related peptide (NRP) (Kinetensin).
OS   Homo sapiens (Human).
OS   Bos taurus (Bovine), and
OS   Oryctolagus cuniculus (Rabbit).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606, 9913, 9986;
RN   [1]
RP   SEQUENCE.
RC   SPECIES=Human;
RX   MEDLINE=86242180; PubMed=3087352;
RA   Mogard M.H., Kobayashi R., Chen C.F., Lee T.D., Reeve J.R. Jr.,
RA   Shively J.E., Walsh J.H.;
RT   "The amino acid sequence of kinetensin, a novel peptide isolated from
RT   pepsin-treated human plasma: homology with human serum albumin,
RT   neurotensin and angiotensin.";
RL   Biochem. Biophys. Res. Commun. 136:983-988(1986).
RN   [2]
RP   SEQUENCE.
RC   SPECIES=Bovine, Human, and Rabbit;
RX   MEDLINE=87194805; PubMed=2437111;
RA   Carraway R.E., Mitra S.P., Cochrane D.E.;
```

RT   "Structure of a biologically active neurotensin-related peptide
RT   obtained from pepsin-treated albumin(s).";
RL   J. Biol. Chem. 262:5968-5973(1987).
CC   -!- FUNCTION: Regulation of fat digestion, lipid absorption, and blood
CC       flow (Potential).
DR   PIR; A38885; ABBOS.
DR   GO; GO:0005576; C:extracellular; NAS.
DR   GO; GO:0005179; F:hormone activity; NAS.
DR   GO; GO:0007599; P:hemostasis; IDA.
DR   GO; GO:0006629; P:lipid metabolism; NAS.
KW   Direct protein sequencing; Hormone.
SQ   SEQUENCE   9 AA;   1172 MW;   C804DB4761F4140D CRC64;

Query Match             54.2%;  Score 13;  DB 1;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              ||
Db          4 RH 5

RESULT 14
XYLA_STRS8
ID   XYLA_STRS8              STANDARD;      PRT;         9 AA.
AC   P19149;
DT   01-NOV-1990 (Rel. 16, Created)
DT   01-NOV-1990 (Rel. 16, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Xylose isomerase (EC 5.3.1.5) (Fragment).
GN   Name=xylA;
OS   Streptomyces sp. (strain NCL 82-5-1).
OC   Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
OC   Streptomycineae; Streptomycetaceae; Streptomyces.
OX   NCBI_TaxID=72593;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=88326335; PubMed=3415697;
RA   Pawar H.S., Srinivasan M.C., Vartak H.G.;
RT   "Purification and characterisation of glucose (xylose) isomerase from
RT   Chainia sp. (NCL 82-5-1).";
RL   Biochem. Biophys. Res. Commun. 155:411-417(1988).
CC   -!- FUNCTION: Involved in D-xylose catabolism.
CC   -!- CATALYTIC ACTIVITY: D-xylose = D-xylulose.
CC   -!- COFACTOR: Binds 2 magnesium ions per subunit (Potential).
CC   -!- SUBUNIT: Homotetramer.
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic.
CC   -!- SIMILARITY: Belongs to the xylose isomerase family.
DR   PIR; A31576; A31576.
DR   HAMAP; MF_00455; -; 1.
DR   InterPro; IPR001998; Xylose_isom.
DR   PROSITE; PS00172; XYLOSE_ISOMERASE_1; PARTIAL.
DR   PROSITE; PS00173; XYLOSE_ISOMERASE_2; PARTIAL.
KW   Direct protein sequencing; Isomerase; Magnesium; Metal-binding;
KW   Pentose shunt; Xylose metabolism.
FT   NON_TER       9      9
SQ   SEQUENCE   9 AA;   983 MW;   F64BA1EDC5BB7DD1 CRC64;

Query Match             54.2%;  Score 13;  DB 1;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              ||
Db          1 RH 2

RESULT 15
Q8MJN1
ID   Q8MJN1              PRELIMINARY;      PRT;         9 AA.
AC   Q8MJN1;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)

DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   Heparin-binding EGF-like growth factor (Fragment).
OS   Cebuella pygmaea (Pygmy marmoset) (Callithrix pygmaea).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Platyrrhini; Callitrichidae; Callithrix.
OX   NCBI_TaxID=9493;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA   Singer S.S., Schmitz J., Schwiegk C., Zischler H.;
RT   "Molecular cladistic markers in New World monkey phylogeny
RT   (Platyrrhini, Primates).";
RL   Mol. Phylogenet. Evol. 26:490-501(2003).
DR   EMBL; AF368167; AAN01111.1; -.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE   9 AA;   1135 MW;   38754409C6972728 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   66.7%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              ||
Db          6 FRY 8

RESULT 16
Q8MJN2
ID   Q8MJN2              PRELIMINARY;      PRT;         9 AA.
AC   Q8MJN2;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   Heparin-binding EGF-like growth factor (Fragment).
OS   Callithrix jacchus (Common marmoset).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Platyrrhini; Callitrichidae; Callithrix.
OX   NCBI_TaxID=9483;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA   Singer S.S., Schmitz J., Schwiegk C., Zischler H.;
RT   "Molecular cladistic markers in New World monkey phylogeny
RT   (Platyrrhini, Primates).";
RL   Mol. Phylogenet. Evol. 26:490-501(2003).
DR   EMBL; AF368166; AAN01110.1; -.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE   9 AA;   1135 MW;   38754409C6972728 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   66.7%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              ||
Db          6 FRY 8

RESULT 17
Q8MJN3
ID   Q8MJN3              PRELIMINARY;      PRT;         9 AA.
AC   Q8MJN3;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   Heparin-binding EGF-like growth factor (Fragment).
OS   Callimico goeldii (Goeldi's marmoset).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Platyrrhini; Callitrichidae; Callimico.
OX   NCBI_TaxID=9495;
RN   [1]

```
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA   Singer S.S., Schmitz J., Schwiegk C., Zischler H.;
RT   "Molecular cladistic markers in New World monkey phylogeny
RT   (Platyrrhini, Primates).";
RL   Mol. Phylogenet. Evol. 26:490-501(2003).
DR   EMBL; AF368165; AAN01109.1; -.
FT   NON_TER         1      1
FT   NON_TER         9      9
SQ   SEQUENCE    9 AA;   1135 MW;  38754409C6972728 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   66.7%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              ||:|
Db          6 FRY 8

RESULT 18
Q8MJN4
ID   Q8MJN4      PRELIMINARY;      PRT;    9 AA.
AC   Q8MJN4;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   Heparin-binding EGF-like growth factor (Fragment).
OS   Leontopithecus rosalia (Golden lion tamarin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Platyrrhini; Callitrichidae;
OC   Leontopithecus.
OX   NCBI_TaxID=30588;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA   Singer S.S., Schmitz J., Schwiegk C., Zischler H.;
RT   "Molecular cladistic markers in New World monkey phylogeny
RT   (Platyrrhini, Primates).";
RL   Mol. Phylogenet. Evol. 26:490-501(2003).
DR   EMBL; AF368164; AAN01108.1; -.
FT   NON_TER         1      1
FT   NON_TER         9      9
SQ   SEQUENCE    9 AA;   1135 MW;  38754409C6972728 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   66.7%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              ||:|
Db          6 FRY 8

RESULT 19
Q8MJN5
ID   Q8MJN5      PRELIMINARY;      PRT;    9 AA.
AC   Q8MJN5;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   Heparin-binding EGF-like growth factor (Fragment).
OS   Saguinus fuscicollis (Brown-headed tamarin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Platyrrhini; Callitrichidae; Saguinus.
OX   NCBI_TaxID=9487;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA   Singer S.S., Schmitz J., Schwiegk C., Zischler H.;
RT   "Molecular cladistic markers in New World monkey phylogeny
RT   (Platyrrhini, Primates).";
RL   Mol. Phylogenet. Evol. 26:490-501(2003).
```

```
DR   EMBL; AF368163; AAN01107.1; -.
FT   NON_TER         1      1
FT   NON_TER         9      9
SQ   SEQUENCE    9 AA;   1135 MW;  38754409C6972728 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   66.7%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              ||:|
Db          6 FRY 8

RESULT 20
Q8MJN6
ID   Q8MJN6      PRELIMINARY;      PRT;    9 AA.
AC   Q8MJN6;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Heparin-binding EGF-like growth factor (Fragment).
OS   Aotus azarai (Southern owl monkey) (Aocus azarae).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Platyrrhini; Cebidae; Aotinae; Aotus.
OX   NCBI_TaxID=30591;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA   Singer S.S., Schmitz J., Schwiegk C., Zischler H.;
RT   "Molecular cladistic markers in New World monkey phylogeny
RT   (Platyrrhini, Primates).";
RL   Mol. Phylogenet. Evol. 26:490-501(2003).
DR   EMBL; AF368162; AAN01106.1; -.
FT   NON_TER         1      1
FT   NON_TER         9      9
SQ   SEQUENCE    9 AA;   1135 MW;  38754409C6972728 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   66.7%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              ||:|
Db          6 FRY 8

RESULT 21
Q8MJN7
ID   Q8MJN7      PRELIMINARY;      PRT;    9 AA.
AC   Q8MJN7;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   Heparin-binding EGF-like growth factor (Fragment).
OS   Saimiri sciureus (Common squirrel monkey).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Platyrrhini; Cebidae; Cebinae; Saimiri.
OX   NCBI_TaxID=9521;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA   Singer S.S., Schmitz J., Schwiegk C., Zischler H.;
RT   "Molecular cladistic markers in New World monkey phylogeny
RT   (Platyrrhini, Primates).";
RL   Mol. Phylogenet. Evol. 26:490-501(2003).
DR   EMBL; AF368161; AAN01105.1; -.
FT   NON_TER         1      1
FT   NON_TER         9      9
SQ   SEQUENCE    9 AA;   1135 MW;  38754409C6972728 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   66.7%;  Pred. No. 1.6e+06;
```

```
Matches       2;  Conservative    1;  Mismatches    0;  Indels   0;  Gaps   0;

Qy          2  FRH  4
               ||:
Db          6  FRY  8

RESULT 22
Q8MJN8
ID   Q8MJN8               PRELIMINARY;            PRT;       9 AA.
AC   Q8MJN8;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   Heparin-binding EGF-like growth factor (Fragment).
OS   Cebus apella (Brown-capped capuchin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Platyrrhini; Cebidae; Cebinae; Cebus.
OX   NCBI_TaxID=9515;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA   Singer S.S., Schmitz J., Schwiegk C., Zischler H.;
RT   "Molecular cladistic markers in New World monkey phylogeny
RT   (Platyrrhini, Primates).";
RL   Mol. Phylogenet. Evol. 26:490-501(2003).
DR   EMBL; AF368160; AAN01104.1; -.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE    9 AA;   1135 MW;  38754409C6972728 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   66.7%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    2;  Mismatches    1;  Indels   0;  Gaps   0;

Qy          2  FRH  4
               ||:
Db          6  FRY  8

RESULT 23
Q8MJN9
ID   Q8MJN9               PRELIMINARY;            PRT;       9 AA.
AC   Q8MJN9;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   Heparin-binding EGF-like growth factor (Fragment).
OS   Ateles fusciceps (Brown-headed spider monkey).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Platyrrhini; Cebidae; Atelinae; Ateles.
OX   NCBI_TaxID=9508;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22531646; PubMed=12644406; DOI=10.1016/S1055-7903(02)00312-3;
RA   Singer S.S., Schmitz J., Schwiegk C., Zischler H.;
RT   "Molecular cladistic markers in New World monkey phylogeny
RT   (Platyrrhini, Primates).";
RL   Mol. Phylogenet. Evol. 26:490-501(2003).
DR   EMBL; AF368159; AAN01103.1; -.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE    9 AA;   1135 MW;  38754409C6972728 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   66.7%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    2;  Mismatches    1;  Indels   0;  Gaps   0;

Qy          2  FRH  4
               ||:
Db          6  FRY  8


RESULT 24
Q7JIS3
ID   Q7JIS3               PRELIMINARY;            PRT;       9 AA.
AC   Q7JIS3;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus obscurus (Dusky dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC   Lagenorhynchus.
OX   NCBI_TaxID=27611;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140832; AAF98685.1; -.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE    9 AA;   1049 MW;  1D0EF41774086 2C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels   0;  Gaps   0;

Qy          3  RH  4
               ||
Db          7  RH  8

RESULT 25
Q7JIS4
ID   Q7JIS4               PRELIMINARY;            PRT;       9 AA.
AC   Q7JIS4;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus obliquidens (Pacific white-sided dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC   Lagenorhynchus.
OX   NCBI_TaxID=90247;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140830; AAF98683.1; -.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE    9 AA;   1049 MW;  1D0EF41774086 2C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels   0;  Gaps   0;

Qy          3  RH  4
               ||
Db          7  RH  8

RESULT 26
Q7JIS5
ID   Q7JIS5               PRELIMINARY;            PRT;       9 AA.
AC   Q7JIS5;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus obliquidens (Pacific white-sided dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
```

```
OC   Lagenorhynchus.
OX   NCBI_TaxID=90247;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140829; AAF98682.1; -.
FT   NON_TER          1      1
FT   NON_TER          9      9
SQ   SEQUENCE   9 AA;  1049 MW;  1D0EF41774O862C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   100.0%;           Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              | |
Db          7 RH 8

RESULT 27
Q7JIS6
ID   Q7JIS6;
AC   Q7JIS6;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus obliquidens (Pacific white-sided dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC   Lagenorhynchus.
OX   NCBI_TaxID=90247;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140828; AAF98681.1; -.
FT   NON_TER          1      1
FT   NON_TER          9      9
SQ   SEQUENCE   9 AA;  1049 MW;  1D0EF41774O862C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   100.0%;           Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              | |
Db          7 RH 8

RESULT 28
Q7JIS7
ID   Q7JIS7;
AC   Q7JIS7;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus obliquidens (Pacific white-sided dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC   Lagenorhynchus.
OX   NCBI_TaxID=90247;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140827; AAF98680.1; -.
FT   NON_TER          1      1
FT   NON_TER          9      9
SQ   SEQUENCE   9 AA;  1049 MW;  1D0EF41774O862C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   100.0%;           Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              | |
Db          7 RH 8

RESULT 29
Q7JIS8
ID   Q7JIS8;
AC   Q7JIS8;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus obliquidens (Pacific white-sided dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC   Lagenorhynchus.
OX   NCBI_TaxID=90247;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140826; AAF98679.1; -.
FT   NON_TER          1      1
FT   NON_TER          9      9
SQ   SEQUENCE   9 AA;  1049 MW;  1D0EF41774O862C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   100.0%;           Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              | |
Db          7 RH 8

RESULT 30
Q7JIS9
ID   Q7JIS9;
AC   Q7JIS9;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus acutus (Atlantic white-sided dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC   Lagenorhynchus.
OX   NCBI_TaxID=90246;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140824; AAF98677.1; -.
FT   NON_TER          1      1
FT   NON_TER          9      9
SQ   SEQUENCE   9 AA;  1049 MW;  1D0EF41774O862C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   100.0%;           Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              | |
Db          7 RH 8

RESULT 31
Q7JIT0
```

```
ID   Q7JIT0      PRELIMINARY;      PRT;    9 AA.
AC   Q7JIT0;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus acutus (Atlantic white-sided dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC   Lagenorhynchus.
OX   NCBI_TaxID=90246;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140823; AAF98676.1; -.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE   9 AA;  1049 MW;  1D0EF41774086 2C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              ||
Db          7 RH 8

RESULT 32
Q7JIT1
ID   Q7JIT1      PRELIMINARY;      PRT;    9 AA.
AC   Q7JIT1;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus acutus (Atlantic white-sided dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC   Lagenorhynchus.
OX   NCBI_TaxID=90246;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140822; AAF98675.1; -.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE   9 AA;  1049 MW;  1D0EF41774086 2C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              ||
Db          7 RH 8

RESULT 33
Q9GJV1
ID   Q9GJV1      PRELIMINARY;      PRT;    9 AA.
AC   Q9GJV1;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-MAR-2001 (TrEMBLrel. 16, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus acutus (Atlantic white-sided dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC   Lagenorhynchus.
OX   NCBI_TaxID=90246;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140825; AAF98678.1; -.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE   9 AA;  1049 MW;  1D0EF41774086 2C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              ||
Db          7 RH 8

RESULT 34
Q9GJV2
ID   Q9GJV2      PRELIMINARY;      PRT;    9 AA.
AC   Q9GJV2;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-MAR-2001 (TrEMBLrel. 16, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus obliquidens (Pacific white-sided dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC   Lagenorhynchus.
OX   NCBI_TaxID=90247;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140831; AAF98684.1; -.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE   9 AA;  1049 MW;  1D0EF41774086 2C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 RH 4
              ||
Db          7 RH 8

RESULT 35
Q9GJV3
ID   Q9GJV3      PRELIMINARY;      PRT;    9 AA.
AC   Q9GJV3;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-MAR-2001 (TrEMBLrel. 16, Last annotation update)
DE   Actin (Fragment).
OS   Lagenorhynchus obscurus (Dusky dolphin).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Cetacea; Odontoceti; Delphinidae;
OC   Lagenorhynchus.
OX   NCBI_TaxID=27611;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Hare M.P., Cipriano F., Palumbi S.R.;
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF140834; AAF98687.1; -.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE   9 AA;  1049 MW;  1D0EF41774086 2C0 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
```

Matches           2;   Conservative       0;   Mismatches       0;   Indels       0;   Gaps      0;

Qy      3 RH 4
               ||
Db      7 RH 8

RESULT 36
Q9TT77
ID   Q9TT77;                    PRELIMINARY;          PRT;        9 AA.
AC   Q9TT77;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE   Wilm's tumor protein 1 (Fragment).
GN   Name=WT1;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC   Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=21015404; PubMed=11130975;
RA   Brouillette J.A., Andrew J.R., Venta P.J.;
RT   "Estimate of nucleotide diversity in dogs with a pool-and-sequence
RT   method.";
RL   Mamm. Genome 11:1079-1086(2000).
DR   EMBL; AF202074; AAF20919.1; -.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE    9 AA;   1231 MW;  58DDF41416D1F403 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      3 RH 4
               ||
Db      3 RH 4

RESULT 37
Q9R7H9
ID   Q9R7H9;                    PRELIMINARY;          PRT;        9 AA.
AC   Q9R7H9;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE   Lipoprotein (Fragment).
GN   Name=nlpD;
OS   Haemophilus influenzae.
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Pasteurellales;
OC   Pasteurellaceae; Haemophilus.
OX   NCBI_TaxID=727;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=98083063; PubMed=9422600;
RA   Martin K., Morlin G., Smith A., Nordyke A., Eisenstark A., Golomb M.;
RT   "The tryptophanase gene cluster of Haemophilus influenzae type b:
RT   evidence for horizontal gene transfer.";
RL   J. Bacteriol. 180:107-118(1998).
DR   EMBL; AF003252; AAB96582.1; -.
FT   NON_TER       1      1
SQ   SEQUENCE    9 AA;   1152 MW;  35A017673B4412D7 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      3 RH 4
               ||
Db      8 RH 9

RESULT 38
Q8N6B1
ID   Q8N6B1                     PRELIMINARY;          PRT;       10 AA.
AC   Q8N6B1;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE   Capacitative calcium channel protein Trp1 (Fragment).
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Late pregnancy myometrium;
RX   MEDLINE=22181008; PubMed=12193412;
RA   Yang M., Gupta A., Shlykov S.G., Corrigan B., Tsujimoto S.,
RA   Sanborn B.M.;
RT   "Multiple Trp isoforms implicated in capacitative calcium entry are
RT   expressed in human pregnant myometrium and myometrial cells.";
RL   Biol. Reprod. 67:988-994(2002).
DR   EMBL; AF483646; AAM97861.1; -.
FT   NON_TER       1      1
SQ   SEQUENCE   10 AA;   1336 MW;  0DD0C0B401F40724 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 1.7e+04;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      3 RH 4
               ||
Db      5 RH 6

RESULT 39
Q6LCI4
ID   Q6LCI4                     PRELIMINARY;          PRT;       10 AA.
AC   Q6LCI4;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Na+-phosphate cotransporter type II (Fragment).
GN   Name=NPT2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=93317607; PubMed=8327470;
RA   Magagnin S., Werner A., Markovich D., Sorribas V., Stange G.,
RA   Biber J., Murer H.;
RT   "Expression cloning of human and rat renal cortex Na/Pi cotransport.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5979-5983(1993).
RN   [2]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=96293539; PubMed=8693007; DOI=10.1073/pnas.93.14.7409;
RA   Hartmann C.M., Hewson A.S., Kos C.H., Hilfiker H., Soumounou Y.,
RA   Murer H., Tenenhouse H.S.;
RT   "Structure of murine and human renal type II Na+-phosphate
RT   cotransporter genes (Npt2 and NPT2).";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:7409-7414(1996).
DR   EMBL; U56682; AAD14854.1; -.
FT   NON_TER       1      1
FT   NON_TER      10     10
SQ   SEQUENCE   10 AA;   1221 MW;  3F555CCAB1B40AA8 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 10;
Best Local Similarity   66.7%;  Pred. No. 1.7e+04;
  Matches    2;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

```
Qy          1 EFR 3
              :||
Db          7 DFR 9

RESULT 40
Q6IG13
ID   Q6IG13              PRELIMINARY;       PRT;    10 AA.
AC   Q6IG13;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   RTN1-Cw (Fragment).
GN   Name=RTN1;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC   Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22715887; PubMed=12832288;
RA   Oertle T., Klinger M., Stuermer C.A., Schwab M.E.;
RT   "A reticular rhapsody: phylogenic evolution and nomenclature of the
RT   RTN/Nogo gene family.";
RL   FASEB J. 17:1238-1247(2003).
-!-  MISCELLANEOUS: The sequence shown here is derived from an
     EMBL/GenBank/DDBJ third party annotation (TPA) entry.
DR   EMBL; BK003968; DAA02043.1; -.
DR   InterPro; IPR001951; Histone_H4.
DR   PROSITE; PS00047; HISTONE_H4; UNKNOWN_1.
FT   NON_TER       1      1
SQ   SEQUENCE     10 AA;   1136 MW;  317406F4033DD867 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 10;
Best Local Similarity  100.0%;  Pred. No. 1.7e+04;
Matches    2; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy          3 RH 4
              |||
Db          7 RH 8

RESULT 41
Q958J8
ID   Q958J8              PRELIMINARY;       PRT;    10 AA.
AC   Q958J8;
DT   01-DEC-2001 (TrEMBLrel. 19, Created)
DT   01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Cytochrome c oxidase subunit I (Fragment).
GN   Name=COI;
OS   Rana muscosa.
OG   Mitochondrion.
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; Rana.
OX   NCBI_TaxID=160500;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=21184280; PubMed=11286498; DOI=10.1006/mpev.2000.0908;
RA   Macey J.R., Strasburg J.L., Brisson J.A., Vredenburg V.T.,
RA   Jennings M., Larson A.;
RT   "Molecular phylogenetics of western North American frogs of the Rana
RT   boylii species group.";
RL   Mol. Phylogenet. Evol. 19:131-143(2001).
DR   EMBL; AF314026; AAK56898.1; -.
DR   GO; GO:0005739; C:mitochondrion; IEA.
KW   Mitochondrion.
FT   NON_TER      10     10
SQ   SEQUENCE     10 AA;   1335 MW;  C0D380C9D371F1A9 CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 10;
Best Local Similarity   66.7%;  Pred. No. 1.7e+04;
```

```
Matches    2; Conservative   0; Mismatches   1; Indels   0; Gaps   0;

Qy          2 FRH 4
              |||
Db          3 FTH 5

RESULT 42
O54217
ID   O54217              PRELIMINARY;       PRT;    10 AA.
AC   O54217;
DT   01-JUN-1998 (TrEMBLrel. 06, Created)
DT   01-JUN-1998 (TrEMBLrel. 06, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Transposase (Fragment).
GN   Name=tnpl;
OS   Staphylococcus epidermidis.
OG   Plasmid pCH01.
OC   Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX   NCBI_TaxID=1282;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=BN 280;
RX   MEDLINE=98394975; PubMed=9726851;
RA   Heidrich C., Pag U., Josten M., Metzger J., Jack R.W., Bierbaum G.,
RA   Jung G., Sahl H.G.;
RT   "Isolation, characterization and sequence of the novel lantibiotic
RT   epicidin 280 and its biosynthetic gene cluster.";
RL   Appl. Environ. Microbiol. 64:3140-3146(1998).
DR   EMBL; Y14023; CAA74345.1; -.
KW   Plasmid.
FT   NON_TER      10     10
SQ   SEQUENCE     10 AA;   1453 MW;  05A0EFD32B4409DB CRC64;

Query Match             54.2%;  Score 13;  DB 2;  Length 10;
Best Local Similarity   66.7%;  Pred. No. 1.7e+04;
Matches    2; Conservative   0; Mismatches   1; Indels   0; Gaps   0;

Qy          1 EFR 3
              :||
Db          8 QFR 10

RESULT 43
O99182
ID   O99182              PRELIMINARY;       PRT;    7 AA.
AC   O99182;
DT   01-MAY-1999 (TrEMBLrel. 10, Created)
DT   01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Cytochrome oxidase I (Fragment).
GN   Name=COI;
OS   Gnatholebias zonatus.
OG   Mitochondrion.
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC   Acanthomorpha; Acanthopterygii; Percomorpha; Atherinomorpha;
OC   Cyprinodontiformes; Aplocheilidae; Rivulinae; Gnatholebias.
OX   NCBI_TaxID=135316;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=20072928; PubMed=10603257; DOI=10.1006/mpev.1999.0656;
RA   Murphy W.J., Thomerson J.E., Collier G.E.;
RT   "Phylogeny of the Neotropical killifish family Rivulidae
RT   (Cyprinodontiformes, Aplocheiloidei) inferred from mitochondrial DNA
RT   sequences.";
RL   Mol. Phylogenet. Evol. 13:289-301(1999).
DR   EMBL; AF002591; AAD01074.1; -.
DR   GO; GO:0005739; C:mitochondrion; IEA.
KW   Mitochondrion.
FT   NON_TER       1      1
SQ   SEQUENCE      7 AA;    899 MW;  672721F6CB572030 CRC64;
```

```
Query Match                50.0%;   Score 12; DB 2; Length 7;
Best Local Similarity      33.3%;   Pred. No. 1.6e+06;
Matches     1; Conservative    2; Mismatches    0;  Indels    0;  Gaps    0;

Qy    2 FRH 4
        ::|
Db    3 YQH 5

RESULT 44
OXYT_OCTVU
ID   OXYT_OCTVU    STANDARD;     PRT;    9 AA.
AC   P80027;
DT   01-MAR-1992 (Rel. 21, Created)
DT   01-MAR-1992 (Rel. 21, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Cephalotocin.
OS   Octopus vulgaris (Octopus).
OC   Eukaryota; Metazoa; Mollusca; Cephalopoda; Coleoidea; Neocoleoidea;
OC   Octopodiformes; Octopoda; Incirrata; Octopodidae; Octopus.
OX   NCBI_TaxID=6645;
RN   [1]
RP   SEQUENCE.
RC   TISSUE=Nerve endings;
RX   MEDLINE=92270139; PubMed=1589145; DOI=10.1016/0304-3940(92)90514-8;
RA   Reich G.;
RT   "A new peptide of the oxytocin/vasopressin family isolated from nerves
RT   of the cephalopod Octopus vulgaris.";
RL   Neurosci. Lett. 134:191-194(1992).
-!- FUNCTION: Has a role in the neurosecretory system of the vena
     cava.
-!- SUBCELLULAR LOCATION: Secreted.
-!- SIMILARITY: Belongs to the vasopressin/oxytocin family.
DR   InterPro; IPR000981; Neuhyp_horm.
DR   Pfam; PF00220; Hormone 4; 1.
DR   PROSITE; PS00264; NEUROHYPOPHYS_HORM; 1.
KW   Amidation; Direct protein sequencing; Hormone.
FT   DISULFID     1      6
FT   MOD_RES      9      9       Glycine amide.
SQ   SEQUENCE    9 AA;  1072 MW;  17FF476EB45409DB CRC64;

Query Match                50.0%;   Score 12; DB 1; Length 9;
Best Local Similarity      66.7%;   Pred. No. 1.6e+06;
Matches     2; Conservative    1; Mismatches    0;  Indels    0;  Gaps    0;

Qy    2 FRH 4
        |:
Db    3 FRN 5

RESULT 45
Q7RE58
ID   Q7RE58        PRELIMINARY;  PRT;    9 AA.
AC   Q7RE58;
DT   01-MAR-2004 (TrEMBLrel. 26, Created)
DT   01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE   Hypothetical protein.
GN   Name=PY05210;
OS   Plasmodium yoelii yoelii.
OC   Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX   NCBI_TaxID=73239;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=17XNL;
RX   PubMed=12368865; DOI=10.1038/nature01099;
RA   Carlton J.M., Angiuoli S.V., Suh B.B., Kooij T.W., Pertea M.,
RA   Silva J.C., Ermolaeva M.D., Allen J.E., Selengut J.D., Koo H.L.,
RA   Peterson J.D., Pop M., Kosack D.S., Shumway M.F., Bidwell S.L.,
RA   Shallom S.J., van Aken S.E., Riedmuller S.B., Feldblyum T.V.,
RA   Cho J.K., Quackenbush J., Sedegah M., Shoaibi A., Cummings L.M.,
RA   Florens L., Yates F.R. III, Raine J.D., Sinden R.E., Harris M.A.,
RA   Cunningham D.A., Preiser P.R., Bergman L.W., Vaidya A.B.,
```

```
RA   van Lin L.H., Janse C.J., Waters A.P., Smith H.O., White O.R.,
RA   Salzberg S.L., Venter J.C., Fraser C.M., Hoffman S.L., Gardner M.J.,
RA   Carucci D.J.;
RT   "Genome sequence and comparative analysis of the model rodent malaria
RT   parasite Plasmodium yoelii yoelii.";
RL   Nature 419:512-519(2002).
-!- CAUTION: The sequence shown here is derived from an
    EMBL/GenBank/DDBJ whole genome shotgun (WGS) entry which is
    preliminary data.
DR   EMBL; AABL01001641; EAA17207.1; -.
KW   Hypothetical protein.
SQ   SEQUENCE    9 AA;  1131 MW;  6178E9CB13387734 CRC64;

Query Match                50.0%;   Score 12; DB 2; Length 9;
Best Local Similarity      50.0%;   Pred. No. 1.6e+06;
Matches     2; Conservative    1; Mismatches    1;  Indels    0;  Gaps    0;

Qy    1 EFRH 4
        |||
Db    6 EFHN 9

RESULT 46
Q6JDL5
ID   Q6JDL5        PRELIMINARY;  PRT;    9 AA.
AC   Q6JDL5;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Ectonucleotide pyrophosphatase/phosphodiesterase 1 (Fragment).
GN   Name=ENPP1;
OS   Canis familiaris (Dog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
OX   NCBI_TaxID=9615;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   PubMed=15233990; DOI=10.1016/j.ygeno.2004.04.001;
RA   Housley D.J.E., Ritzert E., Venta P.J.;
RT   "Comparative radiation hybrid map of canine chromosome 1 incorporating
RT   SNP and indel polymorphisms.";
RL   Genomics 84:248-264(2004).
DR   EMBL; AY514708; AAT44554.1; -.
FT   NON_TER      1      1
FT   NON_TER      9      9
SQ   SEQUENCE    9 AA;  1051 MW;  5DB6240B05A76447 CRC64;

Query Match                50.0%;   Score 12; DB 2; Length 9;
Best Local Similarity      50.0%;   Pred. No. 1.6e+06;
Matches     2; Conservative    1; Mismatches    1;  Indels    0;  Gaps    0;

Qy    1 EFRH 4
        | :|
Db    6 ERKH 9

RESULT 47
Q8HUB4
ID   Q8HUB4        PRELIMINARY;  PRT;    10 AA.
AC   Q8HUB4;
DT   01-MAR-2003 (TrEMBLrel. 23, Created)
DT   01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Ribosomal protein L16 (Fragment).
GN   Name=rpl16;
OS   Anomobryum julaceum.
OG   Chloroplast.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Bryophyta;
OC   Bryopsida; Bryidae; Bryales; Bryaceae; Anomobryum.
OX   NCBI_TaxID=67232;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Pedersen N., Cox C.J., Hedenas L.;
```

```
RT   "Phylogeny of the Moss Family Bryaceae Inferred from Chloroplast DNA
RT   Sequences and Morphology.";
RL   Syst. Bot. 28:471-482(2003).
DR   EMBL; AF546765; AAN62980.1; -.
DR   GO; GO:0009507; C:chloroplast; IEA.
DR   GO; GO:0003735; F:structural constituent of ribosome; IEA.
KW   Chloroplast; Ribosomal protein.
FT   NON_TER       1      1
FT   NON_TER      10     10
SQ   SEQUENCE   10 AA;   1326 MW;  6314C32409C321B4 CRC64;

Query Match             50.0%;  Score 12;  DB 2;  Length 10;
 Best Local Similarity   66.7%;  Pred. No. 3e+04;
 Matches    2;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 EFR 3
              :||
Db          5 KFR 7


RESULT 48
Q8QE18
ID   Q8QE18      PRELIMINARY;      PRT;    10 AA.
AC   Q8QE18;
DT   01-JUN-2002 (TrEMBLrel. 21, Created)
DT   01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT   01-JUN-2002 (TrEMBLrel. 24, Last annotation update)
DE   Truncated envelope glycoprotein (Fragment).
GN   Name=env;
OS   Human immunodeficiency virus 1.
OC   Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX   NCBI_TaxID=11676;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=22961413; PubMed=14601597; DOI=10.1089/088922203322493139;
RA   Masharsky A.E., Klimov N.A., Kozlov A.P.;
RT   "Molecular cloning and analysis of full-length genome of HIV type 1
RT   strains prevalent in countries of the former Soviet Union.";
RL   AIDS Res. Hum. Retroviruses 19:933-939(2003).
DR   EMBL; AF413977; AAL78427.1; -.
DR   GO; GO:0019031; C:viral envelope; IEA.
KW   Envelope protein.
FT   NON_TER       1      1
SQ   SEQUENCE   10 AA;   1274 MW;  A9FD6CCB54326D6 CRC64;

Query Match             50.0%;  Score 12;  DB 2;  Length 10;
 Best Local Similarity   33.3%;  Pred. No. 3e+04;
 Matches    1;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              :|
Db          7 YQH 9


RESULT 49
EI03_LITRU
ID   EI03_LITRU   STANDARD;      PRT;     5 AA.
AC   P82099;
DT   28-FEB-2003 (Rel. 41, Created)
DT   28-FEB-2003 (Rel. 41, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Electrin 3.
OS   Litoria rubella (Desert tree frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;
OC   Pelodryadinae; Litoria.
OX   NCBI_TaxID=104895;
RN   [1]
RP   SEQUENCE.
RC   TISSUE=Skin secretion;
RA   Wabnitz P.A., Bowie J.H., Tyler M.J., Wallace J.C.;
RT   "Peptides from the skin glands of the Australian buzzing tree frog
RT   Litori electrica. Comparison with the skin peptides from Litoria
```

```
RT   rubella.";
RL   Aust. J. Chem. 52:639-645(1999).
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Skin.
KW   Amidation; Amphibian defense peptide; Direct protein sequencing.
FT   MOD_RES       5      5       Methionine amide.
SQ   SEQUENCE    5 AA;   630 MW;  668761F2C9A00000 CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 5;
 Best Local Similarity   66.7%;  Pred. No. 1.6e+06;
 Matches    2;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 FRH 4
              |||
Db          1 FVH 3


RESULT 50
RE21_LITRU
ID   RE21_LITRU   STANDARD;      PRT;     5 AA.
AC   P82071;
DT   28-FEB-2003 (Rel. 41, Created)
DT   28-FEB-2003 (Rel. 41, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Rubellidin 2.1.
OS   Litoria rubella (Desert tree frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;
OC   Pelodryadinae; Litoria.
OX   NCBI_TaxID=104895;
RN   [1]
RP   SEQUENCE, AND MASS SPECTROMETRY.
RC   TISSUE=Skin secretion;
RA   Steinborner S.T., Wabnitz P.A., Waugh R.J., Bowie J.H., Gao C.;
RT   "The structure of new peptides from the Australin red tree frog
RT   'Litoria rubella'. The skin peptide profile as a probe for the study
RT   of evolutionary trends of amphibians.";
RL   Aust. J. Chem. 49:955-963(1996).
CC   -!- FUNCTION: Shows neither neuropeptide activity nor antibiotic
CC       activity.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Expressed by the skin dorsal glands.
CC   -!- MASS SPECTROMETRY: MW=626; METHOD=FAB; RANGE=1-5; NOTE=Ref.1.
KW   Amphibian defense peptide; Direct protein sequencing.
SQ   SEQUENCE    5 AA;   626 MW;  6DD9C9CB10300000 CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 5;
 Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
 Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EF 2
              ||
Db          2 EF 3


RESULT 51
RE31_LITRU
ID   RE31_LITRU   STANDARD;      PRT;     5 AA.
AC   P82072;
DT   28-FEB-2003 (Rel. 41, Created)
DT   28-FEB-2003 (Rel. 41, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Rubellidin 3.1.
OS   Litoria rubella (Desert tree frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;
OC   Pelodryadinae; Litoria.
OX   NCBI_TaxID=104895;
RN   [1]
RP   SEQUENCE, AND MASS SPECTROMETRY.
RC   TISSUE=Skin secretion;
RA   Steinborner S.T., Wabnitz P.A., Waugh R.J., Bowie J.H., Gao C.,
```

RA   Tyler M.J., Wallace J.C.;
RT   "The structure of new peptides from the Australian red tree frog
RT   'Litoria rubella'. The skin peptide profile as a probe for the study
RT   of evolutionary trends of amphibians.";
RL   Aust. J. Chem. 49:955-963(1996).
CC   -!- FUNCTION: Shows neither neuropeptide activity nor antibiotic
CC       activity.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Expressed by the skin dorsal glands.
CC   -!- MASS SPECTROMETRY: MW=655; METHOD=FAB; RANGE=1-5; NOTE=Ref.1.
KW   Amidation; Amphibian defense peptide; Direct protein sequencing.
FT   MOD_RES       5      5       Threonine amide.
SQ   SEQUENCE   5 AA;   656 MW;  71A9C9CB10300000 CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EF 2
              ||
Db          2 EF 3

RESULT 52
FARP_MONEX
ID   FARP_MONEX     STANDARD;      PRT;     6 AA.
AC   P41966;
DT   01-NOV-1995 (Rel. 32, Created)
DT   01-NOV-1995 (Rel. 32, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   FMRFamide-like neuropeptide GNFFRF-amide.
OS   Moniezia expansa (Sheep tapeworm).
OC   Eukaryota; Metazoa; Platyhelminthes; Cestoda; Eucestoda;
OC   Cyclophyllidea; Anoplocephalidae; Moniezia.
OX   NCBI_TaxID=28841;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=93312289; PubMed=8323531;
RA   Maule A.G., Shaw C., Halton D.W., Thim L.;
RT   "GNFFRFamide: a novel FMRFamide-immunoreactive peptide isolated from
RT   the sheep tapeworm, Moniezia expansa.";
RL   Biochem. Biophys. Res. Commun. 193:1054-1060(1993).
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- SIMILARITY: Belongs to the FARP (FMRFamide related peptide)
CC       family.
DR   PIR; A43129; A43129.
KW   Amidation; Direct protein sequencing; Neuropeptide.
FT   MOD_RES       6      6       Phenylalanine amide.
SQ   SEQUENCE   6 AA;   787 MW;  69D409C9C4481000 CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FR 3
              ||
Db          4 FR 5

RESULT 53
FAF1_ASCSU
ID   FAF1_ASCSU     STANDARD;      PRT;     7 AA.
AC   P31889;
DT   01-JUL-1993 (Rel. 26, Created)
DT   01-JUL-1993 (Rel. 26, Last sequence update)
DT   25-OCT-2004 (Rel. 45, Last annotation update)
DE   FMRFamide-like neuropeptide AF1.
OS   Ascaris suum (Pig roundworm) (Ascaris lumbricoides).
OC   Eukaryota; Metazoa; Nematoda; Chromadorea; Ascaridida; Ascaridoidea;
OC   Ascarididae; Ascaris.
OX   NCBI_TaxID=6253;
RN   [1]
RP   SEQUENCE.

RX   MEDLINE=90180465; PubMed=2627377;
RA   Cowden C., Stretton A.O.W., Davis R.E.;
RT   "AF1, a sequenced bioactive neuropeptide isolated from the nematode
RT   Ascaris suum.";
RL   Neuron 2:1465-1473(1989).
CC   -!- FUNCTION: Potent modulator of inhibitory motorneurons. Reduces the
CC       input resistance and blocks slow oscillatory potentials in these
CC       cells.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Found in the nerve cords and a variety of
CC       ganglia particularly in the anterior regions.
CC   -!- SIMILARITY: Belongs to the FARP (FMRFamide related peptide)
CC       family.
KW   Amidation; Direct protein sequencing; Neuropeptide.
FT   MOD_RES       7      7       Phenylalanine amide.
SQ   SEQUENCE   7 AA;   953 MW;  69D40059CB144350 CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EF 2
              ||
Db          3 EF 4

RESULT 54
O98866
ID   O98866         PRELIMINARY;    PRT;     7 AA.
AC   O98866;
DT   01-MAY-1999 (TrEMBLrel. 10, Created)
DT   01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Cytochrome b/f subunit IV (Fragment).
OS   Spinacia oleracea (Spinach).
OG   Chloroplast.
OC   Eukaryota; viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
OC   Caryophyllales; Amaranthaceae; Spinacia.
OX   NCBI_TaxID=3562;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=86120353; PubMed=3003688;
RA   Sijben-Mueller G., Hallick R.B., Alt J., Westhoff P., Herrmann R.G.;
RT   "Spinach plastid genes coding for initiation factor IF-1, ribosomal
RT   protein S11 and RNA polymerase alpha-subunit.";
RL   Nucleic Acids Res. 14:1029-1044(1986).
DR   EMBL; X03496; CAA27215.1; -.
DR   GO; GO:0009507; C:chloroplast; IEA.
KW   Chloroplast.
FT   NON_TER       1      1
SQ   SEQUENCE   7 AA;   907 MW;  644729D77409C420 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FR 3
              ||
Db          2 FR 3

RESULT 55
GLUR_HUMAN
ID   GLUR_HUMAN     STANDARD;      PRT;     8 AA.
AC   P02729;
DT   21-JUL-1986 (Rel. 01, Created)
DT   21-JUL-1986 (Rel. 01, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Urine glycopeptide.
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=72062338; PubMed=5126885;
RA   Lote C.J., Weiss J.B.;
RT   "Identification in urine of a low-molecular-weight highly polar
RT   glycopeptide containing cysteinyl-galactose.";
RL   Biochem. J. 123:25P-25P(1971).
CC   -!- FUNCTION: The identity of the glycoprotein from which this peptide
CC       is derived is unknown. No physiological function has been
CC       attributed. An erythrocyte membrane glycopeptide having a similar
CC       structure has also been found.
DR   PIR; A03188; XGHUEU.
DR   GO; GO:0005576; C:extracellular; NAS.
KW   Direct protein sequencing; Glycoprotein.
FT   CARBOHYD      1      1       S-linked (Gal...).
SQ   SEQUENCE   8 AA;   855 MW;   C2D87AA1F5B1EB1E CRC64;

Query Match        45.8%;  Score 11;  DB 1;  Length 8;
Best Local Similarity   50.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative   0;  Mismatches   2;  Indels   0;  Gaps   0;

Qy   1 EFRH 4
        |  |
Db   2 EHSH 5

RESULT 56
ID   PPK3_PERAM      STANDARD;      PRT;      8 AA.
PPK3_PERAM
AC   P82618;
DT   16-OCT-2001 (Rel. 40, Created)
DT   16-OCT-2001 (Rel. 40, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Pyrokinin-3 (Pea-PK-3) (FXPRL-amide).
OS   Periplaneta americana (American cockroach).
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blattoidea;
OC   Blattidae; Periplaneta.
OX   NCBI_TaxID=6978;
RN   [1]
RP   SEQUENCE, FUNCTION, AND MASS SPECTROMETRY.
RC   TISSUE=Retrocerebral complex;
RX   MEDLINE=99212469; PubMed=10196736; DOI=10.1016/S0965-1748(98)00117-9;
RA   Predel R., Kellner R., Nachman R.J., Holman G.M., Rapus J., Gaede G.;
RT   "Differential distribution of pyrokinin-isoforms in cerebral and
RT   abdominal neurohemal organs of the American cockroach.";
RL   Insect Biochem. Mol. Biol. 29:139-144(1999).
RN   [2]
RP   TISSUE SPECIFICITY.
RX   MEDLINE=20189894; PubMed=10723010;
RA   Predel R., Eckert M.;
RT   "Tagma-specific distribution of FXPRLamides in the nervous system of
RT   the American cockroach.";
RL   J. Comp. Neurol. 419:352-363(2000).
CC   -!- FUNCTION: Mediates visceral muscle contractile activity (myotropic
CC       activity).
CC   -!- TISSUE SPECIFICITY: Corpora cardiaca.
CC   -!- MASS SPECTROMETRY: MW=996.5; METHOD=MALDI; RANGE=1-8; NOTE=Ref.1.
CC   -!- SIMILARITY: Belongs to the pyrokinin family.
KW   Amidation; Direct protein sequencing; Neuropeptide; Pyrokinin.
FT   MOD_RES       8      8       Leucine amide.
SQ   SEQUENCE   8 AA;   997 MW;   0B34177409D772C7 CRC64;

Query Match        45.8%;  Score 11;  DB 1;  Length 8;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy   2 FR 3
        ||
Db   4 FR 5

RESULT 57
Q15901
ID   Q15901      PRELIMINARY;      PRT;      8 AA.
AC   Q15901;
DT   01-NOV-1996 (TrEMBLrel. 01, Created)
DT   01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT   01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE   Homo sapiens (clone XP7B11B) (Fragment).
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Placenta;
RA   Lee C.-C., Yazdani A., Wehnert M., Bailey J., Couch L., Xiong M.,
RA   Coolbaugh M.I., Chinault C.A., Baldini A., Lindsay E.A., Zhao Z.-Y.,
RA   Caskey C.T.H.;
RT   "Isolation of chromosome-specific genes by reciprocal probing of
RT   arrayed cDNAs and cosmid libraries.";
RL   Hum. Mol. Genet. 0:0-0(1995).
DR   EMBL; L32080; AAA73891.1; -.
FT   NON_TER       1      1
FT   NON_TER       8      8
SQ   SEQUENCE   8 AA;   860 MW;   37D728786767729CB CRC64;

Query Match        45.8%;  Score 11;  DB 2;  Length 8;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy   1 EF 2
        | |
Db   1 EF 2

RESULT 58
Q34909
ID   Q34909      PRELIMINARY;      PRT;      8 AA.
AC   Q34909;
DT   01-NOV-1996 (TrEMBLrel. 01, Created)
DT   01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Cytochrome b (Fragment).
OS   Locusta migratoria (Migratory locust).
OG   Mitochondrion.
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Orthopteroidea; Orthoptera; Caelifera; Acridomorpha;
OC   Acridoidea; Acrididae; Oedipodinae; Locusta.
OX   NCBI_TaxID=7004;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=88223478; PubMed=2836084;
RA   McCracken A., Uhlenbusch I., Gellissen G.;
RT   "Structure of the cloned Locusta migratoria mitochondrial genome:
RT   restriction mapping and sequence of its ND-1 (URF-1) gene.";
RL   Curr. Genet. 11:625-630(1987).
DR   EMBL; X05286; CAA28905.1; -.
DR   GO; GO:0005739; C:mitochondrion; IEA.
KW   Mitochondrion.
FT   NON_TER       1      1
FT   NON_TER       8      8
SQ   SEQUENCE   8 AA;   1019 MW;   F8E3723304B45B6 CRC64;

Query Match        45.8%;  Score 11;  DB 2;  Length 8;
Best Local Similarity   25.0%;  Pred. No. 1.6e+06;
Matches    1;  Conservative   2;  Mismatches   1;  Indels   0;  Gaps   0;

Qy   1 EFRH 4
        : :|
Db   5 KLKH 8

RESULT 59

```
Q6Y2F2
ID   Q6Y2F2          PRELIMINARY;      PRT;      8 AA.
AC   Q6Y2F2;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Vacuolar invertase (Fragment).
OS   Citrus sinensis (Sweet orange).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC   eurosids II; Sapindales; Rutaceae; Citrus.
OX   NCBI_TaxID=2711;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   An X., Zhang S., Xu C., Qin Q.;
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AY190016; AAO73818.1; -.
FT   NON_TER          8        8
SQ   SEQUENCE   8 AA;   1013 MW;  FE21E1FB4771AAA6 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 8;
Best Local Similarity  33.3%;  Pred. No. 1.6e+06;
Matches    1;  Conservative   1;  Mismatches   1;  Indels   0;  Gaps   0;

Qy          2 FRH 4
              :||
Db          5 YHH 7


RESULT 60
Q6LDQ5
ID   Q6LDQ5          PRELIMINARY;      PRT;      8 AA.
AC   Q6LDQ5;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Nitogen fixation protein (nifQ) (Fragment).
OS   Rhodobacter capsulatus (Rhodopseudomonas capsulata).
OC   Bacteria; Proteobacteria; Alphaproteobacteria; Rhodobacterales;
OC   Rhodobacteraceae; Rhodobacter.
OX   NCBI_TaxID=1061;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=89213944; PubMed=2708314;
RA   Moreno-Vivian C., Hennecke S., Puehler A., Klipp W.;
RT   "Open reading frame 5 (ORF5), encoding a ferredoxinlike protein, and
RT   nifQ are cotranscribed with nifE, nifN, nifX, and ORF4 in Rhodobacter
RT   capsultus.";
RL   J. Bacteriol. 171:2591-2598(1989).
DR   EMBL; M26323; AAA26145.1; -.
FT   NON_TER          1        1
SQ   SEQUENCE   8 AA;    890 MW;  2CC40DDDB0769CB CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 8;
Best Local Similarity 100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EF 2
              ||
Db          1 EF 2


RESULT 61
Q9R3X0
ID   Q9R3X0          PRELIMINARY;      PRT;      8 AA.
AC   Q9R3X0;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit
DE   (Fragment).
GN   Name=rbcL;
OS   Planktothrix rubescens.
OC   Bacteria; Cyanobacteria; Oscillatoriales; Planktothrix.
OX   NCBI_TaxID=59512;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=BC-Pla 9316, BC-Pla 9401, BC-Pla 9402, BC-Pla 9303, and
RC   BC-Pla 9307;
RX   MEDLINE=20005589; PubMed=10537197;
RA   Beard S.J., Handley B.A., Hayes P.K., Walsby A.E.;
RT   "The diversity of gas vesicle genes in Planktothrix rubescens from
RT   Lake Zurich.";
RL   Microbiology 145:2757-2768(1999).
DR   EMBL; AJ132249; CAB59537.1; -.
DR   EMBL; AJ132248; CAB59534.1; -.
FT   NON_TER          1        1
SQ   SEQUENCE   8 AA;    957 MW;  33D1AAA685BB19CB CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 8;
Best Local Similarity 100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EF 2
              ||
Db          1 EF 2


RESULT 62
Q9ERD2
ID   Q9ERD2          PRELIMINARY;      PRT;      8 AA.
AC   Q9ERD2;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Galactose-1-phosphate uridyl transferase (Fragment).
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=129/D3;
RA   Leslie N.D., Bai S.;
RL   Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF314226; AAG31161.1; -.
DR   GO; GO:0016740; F:transferase activity; IEA.
KW   Transferase.
FT   NON_TER          8        8
SQ   SEQUENCE   8 AA;    854 MW;  ECBDC409D1ADDDD6 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 8;
Best Local Similarity 100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          2 FR 3
              ||
Db          5 FR 6


RESULT 63
Q9OZV5
ID   Q9OZV5          PRELIMINARY;      PRT;      8 AA.
AC   Q9OZV5;
DT   01-DEC-2001 (TrEMBLrel. 19, Created)
DT   01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Adenylate kinase (Fragment).
OS   Fulica leucoptera.
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Archosauria; Aves; Neognathae; Gruiformes; Rallidae; Fulica.
OX   NCBI_TaxID=156758;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Shapiro L.H., Dumbacher J.P.;
RT   "Adenylate kinase intron 5: a new nuclear locus for avian
```

```
RT    systematics.";
RL    Auk 118:248-255(2001).
DR    EMBL; AF307898; AAK43537.1; -.
DR    GO; GO:0016301; F:kinase activity; IEA.
KW    Kinase.
FT    NON_TER          1      1
FT    NON_TER          8      8
SQ    SEQUENCE   8 AA;  994 MW;  9633B19CB1B1866 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EF 2
              ||
Db          4 EF 5

RESULT 64
Q6VMC6
ID   Q6VMC6        PRELIMINARY;         PRT;     8 AA.
AC   Q6VMC6;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Myoglobin (Fragment).
OS   Serilophus lunatus (silver-breasted broadbill).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Archosauria; Aves; Neognathae; Passeriformes; Eurylaimidae;
OC   Serilophus.
OX   NCBI_TaxID=239386;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Fieldsa J., Zuccon D., Irestedt M., Johansson U.S., Ericson P.G.P.;
RT   "Sapayoa aenigma: a New World representative of 'Old World
RT   suboscines'.";
RL   Proc. R. Soc. Lond. B, Biol. Sci. 0:0-0(2003).
DR   EMBL; AY338738; AAQ62892.1; -.
FT   NON_TER          1      1
FT   NON_TER          8      8
SQ   SEQUENCE   8 AA;  943 MW;  8109C1F2C865B046 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FR 3
              ||
Db          7 FR 8

RESULT 65
BRK1_RANNI
ID   BRK1_RANNI    STANDARD;         PRT;     9 AA.
AC   Q7LZ54;
DT   05-JUL-2004 (Rel. 44, Created)
DT   05-JUL-2004 (Rel. 44, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Bradykinin-like peptide I.
OS   Rana nigromaculata (Japanese pond frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; Rana.
OX   NCBI_TaxID=8409;
RN   [1]
RP   SEQUENCE.
RC   TISSUE=Skin;
RX   MEDLINE=68412013; PubMed=5677638;
RA   Nakajima T.;
RT   "Occurrence of a new active peptide on smooth muscle and bradykinin in
RT   the skin of Rana nigromaculata hallowell.";
RL   Chem. Pharm. Bull. 16:769-770(1968).
CC   -!- FUNCTION: Induces smooth muscle contraction.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- SIMILARITY: Belongs to the bradykinin family.
DR   PIR; A61358; A61358.
KW   Bradykinin; Direct protein sequencing; Vasodilator.
SQ   SEQUENCE   9 AA;  1017 MW;  368D771A9C86777 CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FR 3
              ||
Db          8 FR 9

RESULT 66
COXE_THUOB
ID   COXE_THUOB    STANDARD;         PRT;     9 AA.
AC   P80975;
DT   01-NOV-1997 (Rel. 35, Created)
DT   01-NOV-1997 (Rel. 35, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Cytochrome c oxidase polypeptide VIa (EC 1.9.3.1) (Fragment).
OS   Thunnus obesus (Bigeye tuna).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC   Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Scombroidei;
OC   Scombridae; Thunnus.
OX   NCBI_TaxID=8241;
RN   [1]
RP   SEQUENCE.
RC   TISSUE=Heart;
RX   MEDLINE=97454291; PubMed=9310366;
RA   Arnold S., Lee I., Kim M., Song E., Linder D., Lottspeich F.,
RA   Kadenbach B.;
RT   "The subunit structure of cytochrome-c oxidase from tuna heart and
RT   liver.";
RL   Eur. J. Biochem. 248:99-103(1997).
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- CATALYTIC ACTIVITY: 4 ferrocytochrome c + O(2) = 4 ferricytochrome
CC       c + 2 H(2)O.
CC   -!- SUBCELLULAR LOCATION: Mitochondrial inner membrane.
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase VIa family.
DR   PIR; S77984; S77984.
DR   InterPro; IPR001349; COX6A.
DR   PROSITE; PS01329; COX6A; PARTIAL.
KW   Direct protein sequencing; Inner membrane; Mitochondrion;
KW   Oxidoreductase.
FT   NON_TER          1      1
FT   NON_TER          9      9
SQ   SEQUENCE   9 AA;  1136 MW;  62E072C9CB0776DB CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EF 2
              ||
Db          5 EF 6

RESULT 67
FIBB_PAPAN
ID   FIBB_PAPAN    STANDARD;         PRT;     9 AA.
AC   P19344;
DT   01-NOV-1990 (Rel. 16, Created)
DT   01-NOV-1990 (Rel. 16, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Fibrinogen beta chain [Contains: Fibrinopeptide B] (Fragment).
GN   Name=FGB;
OS   Papio anubis (Olive baboon).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
OC   Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae;
OC   Cercopithecinae; Papio.
OX   NCBI_TaxID=9555;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=84161822; PubMed=6423621;
RA   Nakamura S., Takenaka O., Takahashi K.;
RT   "Fibrinopeptides A and B of baboons (Papio anubis, Papio hamadryas,
RT   and Theropithecus gelada): their amino acid sequences and evolutionary
RT   rates and a molecular phylogeny for the baboons.";
RL   J. Biochem. 94:1973-1978(1983).
CC   -!- FUNCTION: Fibrinogen has a double function: yielding monomers that
CC       polymerize into fibrin and acting as a cofactor in platelet
CC       aggregation.
CC   -!- SUBUNIT: Hexamer containing 2 sets of 3 nonidentical chains
CC       (alpha, beta and gamma), linked to each other by disulfide bonds.
CC   -!- PTM: Conversion of fibrinogen to fibrin is triggered by thrombin,
CC       which cleaves fibrinopeptides A and B from alpha and beta chains,
CC       and thus exposes the N-terminal polymerization sites responsible
CC       for the formation of the soft clot.
DR   PIR; D28854; D28854.
DR   InterPro; IPR002181; Fibrinogen_C.
DR   PROSITE; PS00514; FIBRIN_AG_C_DOMAIN; PARTIAL.
KW   Blood coagulation; Direct protein sequencing; Plasma.
FT   PEPTIDE       1      9       Fibrinopeptide B.
FT   NON_TER       1
FT   NON_TER       9
SQ   SEQUENCE   9 AA;  1076 MW;  DDFE6409C7287B06 CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      2  FR  3
           ||
Db      6  FR  7


RESULT 68
KNL3_BOMVA
ID   KNL3_BOMVA     STANDARD;     PRT;     9 AA.
AC   P83058;
DT   28-FEB-2003 (Rel. 41, Created)
DT   28-FEB-2003 (Rel. 41, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   [Thr6]bradykinin.
OS   Bombina variegata (Yellow-bellied toad).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Archeobatrachia; Bombinatoridae; Bombina.
OX   NCBI_TaxID=8348;
RN   [1]
RP   SEQUENCE, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Skin secretion;
RX   MEDLINE=22217713; PubMed=12230583;
RA   Chen T., Orr D.F., Bjourson A.J., McClean S., O'Rourke M., Hirst D.G.,
RA   Rao P., Shaw C.;
RT   "Novel bradykinins and their precursor cDNAs from European yellow-
RT   bellied toad (Bombina variegata) skin.";
RL   Eur. J. Biochem. 269:4693-4700(2002).
CC   -!- FUNCTION: Produces in vitro relaxation of intestinal smooth
CC       muscle and constriction of intestinal smooth muscle.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Skin.
CC   -!- SIMILARITY: Belongs to the bradykinin family.
KW   Amphibian defense peptide; Bradykinin; Direct protein sequencing;
KW   Vasodilator.
SQ   SEQUENCE   9 AA;  1074 MW;  3393D771A9C86777 CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      2  FR  3
           ||
Db      8  FR  9


RESULT 69
KNL3_CYPDO
ID   KNL3_CYPDO     STANDARD;     PRT;     9 AA.
AC   P83659;
DT   05-JUL-2004 (Rel. 44, Created)
DT   05-JUL-2004 (Rel. 44, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   [Thr6]bradykinin.
OS   Cyphononyx dorsalis (Spider wasp).
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Endopterygota; Hymenoptera; Apocrita; Aculeata; Vespoidea;
OC   Pompilidae; Cyphononyx.
OX   NCBI_TaxID=246266;
RN   [1]
RP   SEQUENCE, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Venom;
RX   MEDLINE=21203862; PubMed=11306139; DOI=10.1016/S0041-0101(00)00262-2;
RA   Konno K., Hisada M., Naoki H., Itagaki Y., Yasuhara T., Juliano M.A.,
RA   Juliano L., Palma M.S., Yamane T., Nakajima T.;
RT   "Isolation and sequence determination of peptides in the venom of the
RT   spider wasp (Cyphononyx dorsalis) guided by matrix-assisted laser
RT   desorption/ionization time of flight (MALDI-TOF) mass spectrometry.";
RL   Toxicon 39:1257-1260(2001).
CC   -!- FUNCTION: Produces in vitro relaxation of rat arterial smooth
CC       muscle and constriction of intestinal smooth muscle (By
CC       similarity).
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC   -!- MASS SPECTROMETRY: MW=1074.58; METHOD=MALDI; RANGE=1-9;
CC       NOTE=Ref.1.
CC   -!- SIMILARITY: Belongs to the bradykinin family.
DR   GO; GO:0005615; C:extracellular space; IDA.
DR   GO; GO:0045776; P:negative regulation of blood pressure; ISS.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contra. . .; ISS.
KW   Bradykinin; Direct protein sequencing; Vasodilator.
SQ   SEQUENCE   9 AA;  1074 MW;  3393D771A9C86777 CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      2  FR  3
           ||
Db      8  FR  9


RESULT 70
NEUU_CAVPO
ID   NEUU_CAVPO     STANDARD;     PRT;     9 AA.
AC   P34966;
DT   01-FEB-1994 (Rel. 28, Created)
DT   01-FEB-1994 (Rel. 28, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Neuromedin U-9 (NmU-9).
GN   Name=NMU;
OS   Cavia porcellus (Guinea pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Rodentia; Hystricognathi; Cavidae; Cavia.
OX   NCBI_TaxID=10141;
RN   [1]
RP   SEQUENCE.
RC   TISSUE=Small intestine;
RX   MEDLINE=90341105; PubMed=2281877; DOI=10.1016/0196-9781(90)90066-E;
RA   Murphy R., Turner C.A., Furness J.B., Parker L., Giraud A.;
RT   "Isolation and microsequence analysis of a novel form of neuromedin U
RT   from guinea pig small intestine.";
RL   Peptides 11:613-617(1990).
CC   -!- FUNCTION: Stimulates uterine smooth muscle contraction and causes
CC       selective vasoconstriction.
```

```
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- SIMILARITY: Belongs to the NmU family.
DR   InterPro; IPR008199; NMU.
DR   Pfam; PF02070; NMU; 1.
DR   PROSITE; PS00967; NMU; 1.
KW   Amidation; Direct protein sequencing; Hormone.
FT   MOD_RES       9      9       Asparagine amide.
SQ   SEQUENCE   9 AA;  1169 MW;  1ECF17409C729DB CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      2 FR 3
           ||
Db      5 FR 6

RESULT 71
NSK1_SARBU
ID   NSK1_SARBU    STANDARD;    PRT;    9 AA.
AC   P41492;
DT   01-NOV-1995 (Rel. 32, Created)
DT   01-NOV-1995 (Rel. 32, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Neosulfakinin-I (NEB-SK-I).
OS   Sarcophaga bullata (Grey flesh fly) (Neobellieria bullata).
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Oestroidea;
OC   Sarcophagidae; Sarcophaga.
OX   NCBI_TaxID=7385;
RN   [1]
RP   SEQUENCE.
RC   TISSUE=Head;
RX   MEDLINE=93083101; PubMed=1360367;
RA   Fonagy A., Schoofs L., Proost P., van Damme J., de Loof A.;
RT   "Isolation and primary structure of two sulfakinin-like peptides from
RT   the fleshfly, Neobellieria bullata.";
RL   Comp. Biochem. Physiol. 103C:135-142(1992).
CC   -!- FUNCTION: Myotropic peptide.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
DR   InterPro; IPR001651; Gastrin.
DR   PROSITE; PS00259; GASTRIN; 1.
KW   Amidation; Direct protein sequencing; Neuropeptide; Sulfation.
FT   MOD_RES       4      4       Sulfotyrosine (Potential).
FT   MOD_RES       9      9       Phenylalanine amide (Potential).
SQ   SEQUENCE   9 AA;  1187 MW;  8B0A0691E86B5AAA CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 9;
Best Local Similarity   25.0%;  Pred. No. 1.6e+06;
Matches    1;  Conservative    2;  Mismatches    2;  Indels    1;  Gaps    0;

Qy      1 EFRH 4
          :: |
Db      3 DYGH 6

RESULT 72
Q7M471
ID   Q7M471    PRELIMINARY;    PRT;    9 AA.
AC   Q7M471;
DT   01-MAR-2004 (TrEMBLrel. 26, Created)
DT   01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE   Venom protein HR-3 (Fragment).
OS   Vespa orientalis (Oriental hornet).
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Endopterygota; Hymenoptera; Apocrita; Aculeata; Vespoidea;
OC   Vespidae; Vespinae; Vespa.
OX   NCBI_TaxID=7447;
RN   [1]
RP   SEQUENCE.
RA   Tuichibaev M.U., Akhmedova N.U., Kazakov I., Korneev A.S.,
RA   Gagel'gans A.I.;
RT   "Low-molecular-weight peptides of venom of the giant hornet Vespa
RT   orientalis. Structure and function.";
RL   Biochemistry 53:183-190(1988).
DR   PIR; S10920; S10920.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE   9 AA;  1029 MW;  9C27C729CB11F2D5 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EF 2
          ||
Db      5 EF 6

RESULT 73
Q7M2N8
ID   Q7M2N8    PRELIMINARY;    PRT;    9 AA.
AC   Q7M2N8;
DT   01-MAR-2004 (TrEMBLrel. 26, Created)
DT   01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE   Alpha-2-macroglobulin isoform 1 (Fragment).
OS   Bos indicus (Zebu).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC   Bovinae; Bos.
OX   NCBI_TaxID=9915;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=96032553; PubMed=7556651; DOI=10.1016/0014-5793(95)00960-H;
RA   Dolmer K., Jenner L.B., Jacobsen L., Andersen G.R., Koch T.J.,
RA   Thirup S., Sottrup-Jensen L., Nyborg J.;
RT   "Crystallisation and preliminary X-ray analysis of the receptor-
RT   binding domain of human and bovine alpha(2)-macroglobulin.";
RL   FEBS Lett. 372:93-95(1995).
DR   PIR; S66635; S66635.
FT   NON_TER       1      1
FT   NON_TER       9      9
SQ   SEQUENCE   9 AA;  1095 MW;  87B02DD9D769CB1A CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EF 2
          ||
Db      3 EF 4

RESULT 74
Q8MEM3
ID   Q8MEM3    PRELIMINARY;    PRT;    9 AA.
AC   Q8MEM3;
DT   01-OCT-2002 (TrEMBLrel. 22, Created)
DT   01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Ribosomal protein 16 (Fragment).
GN   Name=rpl16;
OS   Howittia trilocularis.
OG   Chloroplast.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC   eurosids II; Malvales; Malvaceae; Malvoideae; Howittia.
OX   NCBI_TaxID=183372;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Pfeil B.E., Brubaker C.L., Craven L.A., Crisp M.D.;
RT   "Phylogeny of Hibiscus and the tribe Hibisceae (Malvaceae) using
```

RT    chloroplast DNA sequences of ndhF and the rpl16 intron.";
RL    Syst. Bot. 27:333-350(2002).
DR    EMBL; AF384615; AAM50387.1; -.
DR    GO; GO:0009507; C:chloroplast; IEA.
DR    GO; GO:0003735; F:structural constituent of ribosome; IEA.
KW    Chloroplast; Ribosomal protein.
FT    NON_TER       1      1
FT    NON_TER       9      9
SQ    SEQUENCE      9 AA;   1256 MW;  6351D32409D411B4 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        2 FR 3
            ||
Db        5 FR 6

RESULT 75
Q8S3C6
ID    Q8S3C6;               PRELIMINARY;       PRT;     9 AA.
AC    Q8S3C6;
DT    01-JUN-2002 (TrEMBLrel. 21, Created)
DT    01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT    01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE    SNF RAD 54-like protein (Fragment).
OS    Glycine max (Soybean).
OC    Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC    Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC    eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae; Glycine.
OX    NCBI_TaxID=3847;
RN    [1]
RP    SEQUENCE FROM N.A.
RX    MEDLINE=21258784; PubMed=11361330; DOI=10.1007/s004380000418;
RA    Meksem K., Ruben E., Hyten D., Triwitayakorn K., Lightfoot D.A.;
RT    "Conversion of AFLP bands into high-throughput DNA markers.";
RL    Mol. Genet. Genomics 265:207-214(2001).
RN    [2]
RP    SEQUENCE FROM N.A.
RA    Meksem K., Lightfoot D., Gibson P.;
RL    Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
DR    EMBL; AF489439; AAM14563.1; -.
FT    NON_TER       1      1
FT    NON_TER       9      9
SQ    SEQUENCE      9 AA;   1070 MW;  DC20A69735A2C699 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EF 2
            ||
Db        1 EF 2

RESULT 76
Q7M151
ID    Q7M151;               PRELIMINARY;       PRT;     9 AA.
AC    Q7M151;
DT    01-MAR-2004 (TrEMBLrel. 26, Created)
DT    01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT    01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE    Translation elongation factor EF-Tu (Fragment).
OS    unidentified bacterium.
OC    Bacteria; environmental samples.
OX    NCBI_TaxID=2338;
RN    [1]
RP    SEQUENCE.
RA    Binette J.P., Binette M.B.;
RL    Submitted (OCT-1996) to the PIR data bank.
DR    PIR; D58503; D58503.
FT    NON_TER       1      1


FT    NON_TER       9      9
SQ    SEQUENCE      9 AA;   1233 MW;  0E92DB59D6C7741B CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        2 FR 3
            ||
Db        8 FR 9

RESULT 77
Q67605
ID    Q67605;               PRELIMINARY;       PRT;     9 AA.
AC    Q67605;
DT    01-NOV-1996 (TrEMBLrel. 01, Created)
DT    01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT    01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE    AL1 protein (Fragment).
GN    Name=AL1;
OS    Squash leaf curl virus (SqLCV).
OC    Viruses; ssDNA viruses; Geminiviridae; Begomovirus.
OX    NCBI_TaxID=10829;
RN    [1]
RP    SEQUENCE FROM N.A.
RC    STRAIN=CV-R;
RX    MEDLINE=91082450; PubMed=1984669;
RA    Lazarowitz S.G.;
RT    "Molecular characterization of two bipartite geminiviruses causing
RT    squash leaf curl disease: role of viral replication and movement
RT    functions in determining host range.";
RL    Virology 180:70-80(1991).
DR    EMBL; M63155; AAA47823.1; -.
FT    NON_TER       9      9
SQ    SEQUENCE      9 AA;   1118 MW;  2B30D5B457645417 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        2 FR 3
            ||
Db        8 FR 9

RESULT 78
Q67606
ID    Q67606;               PRELIMINARY;       PRT;     9 AA.
AC    Q67606;
DT    01-NOV-1996 (TrEMBLrel. 01, Created)
DT    01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT    01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE    AL1 protein (Fragment).
GN    Name=AL1;
OS    Squash leaf curl virus (SqLCV).
OC    Viruses; ssDNA viruses; Geminiviridae; Begomovirus.
OX    NCBI_TaxID=10829;
RN    [1]
RP    SEQUENCE FROM N.A.
RC    STRAIN=CV-E;
RX    MEDLINE=91082450; PubMed=1984669;
RA    Lazarowitz S.G.;
RT    "Molecular characterization of two bipartite geminiviruses causing
RT    squash leaf curl disease: role of viral replication and movement
RT    functions in determining host range.";
RL    Virology 180:70-80(1991).
DR    EMBL; M63157; AAA47822.1; -.
FT    NON_TER       9      9
SQ    SEQUENCE      9 AA;   1118 MW;  2B30D5B457645417 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;

```
Matches     2; Conservative     0; Mismatches     0; Indels     0; Gaps     0;

Qy      2 FR      3
          | |
Db      8 FR      9

RESULT 79
Q88953
ID   Q88953          PRELIMINARY;      PRT;         9 AA.
AC   Q88953;
DT   01-NOV-1996 (TrEMBLrel. 01, Created)
DT   01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT   01-NOV-1998 (TrEMBLrel. 08, Last annotation update)
DE   Serpins (Fragment).
GN   Name=B13R/SPI-2;
OS   Vaccinia virus.
OC   Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
OC   Orthopoxvirus.
OX   NCBI_TaxID=10245;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=95133144; PubMed=7831769;
RA   Kettle S., Blake N.W., Law K.M., Smith G.L.;
RT   "Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5
RT   and 40K, intracellular polypeptides that do not affect virus virulence
RT   in a murine intranasal model.";
RL   Virology 206:136-147(1995).
DR   EMBL; S75133; AAC60736.1; -.
FT   NON_TER    1      1
SQ   SEQUENCE    9 AA;   1081 MW;   9B84D05B0409C05A CRC64;

Query Match     45.8%;   Score 11;   DB 2;   Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches     2; Conservative     0; Mismatches     0; Indels     0; Gaps     0;

Qy      2 FR      3
          | |
Db      4 FR      5

RESULT 80
Q7LZI7
ID   Q7LZI7          PRELIMINARY;      PRT;         9 AA.
AC   Q7LZI7;
DT   01-MAR-2004 (TrEMBLrel. 26, Created)
DT   01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE   Hydroxyproline-3-bradykinin.
OS   Heleophryne purcelli (Cape ghost frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Heleophrynidae;
OC   Heleophryne.
OX   NCBI_TaxID=31911;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Nakajima T., Yasuhara T., Erspamer G.F., Visser J.;
RT   "Occurrence of Hyp(3)-bradykinin in methanol extracts of the skin of
RT   the South African leptodactylid frog Heleophryne purcelli.";
RL   Experientia 35:1133-1133(1979).
DR   PIR; A43065; A43065.
SQ   SEQUENCE    9 AA;   1060 MW;   3393D775B9C86777 CRC64;

Query Match     45.8%;   Score 11;   DB 2;   Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches     2; Conservative     0; Mismatches     0; Indels     0; Gaps     0;

Qy      2 FR      3
          | |
Db      8 FR      9

RESULT 81


Q7LZJ8
ID   Q7LZJ8          PRELIMINARY;      PRT;         9 AA.
AC   Q7LZJ8;
DT   01-MAR-2004 (TrEMBLrel. 26, Created)
DT   01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE   Bradykinin.
OS   Rana temporaria (European common frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; Rana.
OX   NCBI_TaxID=8407;
RN   [1]
RP   SEQUENCE.
RA   Anastasi A., Erspamer V., Bertaccini G.;
RT   "Occurrence of bradykinin in the skin of Rana temporaria.";
RL   Comp. Biochem. Physiol. 14:43-52(1965).
DR   PIR; A61363; A61363.
SQ   SEQUENCE    9 AA;   1060 MW;   3393D775B9C86777 CRC64;

Query Match     45.8%;   Score 11;   DB 2;   Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches     2; Conservative     0; Mismatches     0; Indels     0; Gaps     0;

Qy      2 FR      3
          | |
Db      8 FR      9

RESULT 82
Q7SX77
ID   Q7SX77          PRELIMINARY;      PRT;         9 AA.
AC   Q7SX77;
DT   01-OCT-2003 (TrEMBLrel. 25, Created)
DT   01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Calmodulin (Fragment).
OS   Geochelone nigra (Galapagos giant tortoise).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Testudines; Cryptodira; Testudinoidea; Testudinidae; Geochelone.
OX   NCBI_TaxID=66189;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   PubMed=15062813; DOI=10.1016/j.ympev.2004.02.004;
RA   Caccone A., Gentile G., Burns C., Sezzi E., Bergman W., Ruelle M.,
RA   Saltonstall K., Powell J.R.;
RT   "Extreme difference in rate of mitochondrial and nuclear evolution in
RT   a large ectotherm, Galapagos tortoises.";
RL   Mol. Phylogenet. Evol. 31:794-798(2004).
DR   EMBL; AY101709; AAM47114.1; -.
DR   EMBL; AY101712; AAM47117.1; -.
FT   NON_TER    1      1
FT   NON_TER    9      9
SQ   SEQUENCE    9 AA;   1039 MW;   2E3D0769CAA041A8 CRC64;

Query Match     45.8%;   Score 11;   DB 2;   Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches     2; Conservative     0; Mismatches     0; Indels     0; Gaps     0;

Qy      1 EF      2
          | |
Db      8 EF      9

RESULT 83
Q9PRJ4
ID   Q9PRJ4          PRELIMINARY;      PRT;         9 AA.
AC   Q9PRJ4;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE   Bradykinin.
OS   Lepisosteus osseus (Long-nosed gar), and
OS   Amia calva (Bowfin).
```

OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Actinopterygii; Neopterygii; Semionotiformes; Lepisosteidae;
OC   Lepisosteus;
OX   NCBI_TaxID=34771, 7924;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=95380361; PubMed=7651903; DOI=10.1016/0196-9781(94)00202-H;
RA   Conlon J.M., Platzack B., Marra L.E., Youson J.H., Olson K.R.;
RT   "Isolation and biological activity of [Trp5]bradykinin from the plasma
RT   of the phylogenetically ancient fish, the bowfin and the longnosed
RT   gar.";
RL   Peptides 16:485-489(1995).
SQ   SEQUENCE   9 AA;  1099 MW;  3393D775A3786777 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FR 3
              ||
Db          8 FR 9

RESULT 84
Q85599
ID   Q85599      PRELIMINARY;      PRT;    9 AA.
AC   Q85599;
DT   01-NOV-1996 (TrEMBLrel. 01, Created)
DT   01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT   01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE   Moloney murine sarcoma virus (strain HT1) mos/env 3' junction.
DE   (Fragment).
OS   Moloney murine leukemia virus.
OC   Viruses; Retroid viruses; Retroviridae; Gammaretrovirus.
OX   NCBI_TaxID=11801;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=83164305; PubMed=6300424;
RA   Donoghue D.J., Hunter T.;
RT   "Recombination junctions of variants of Moloney murine sarcom virus:
RT   Generation and divergence of a mammalian transforming gene.";
RL   J. Virol 45:607-617(1983).
DR   EMBL; K03107; AAA46493.1; -.
FT   NON_TER       1      1
SQ   SEQUENCE   9 AA;  932 MW;  410B2DD86409CDD3 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 9;
Best Local Similarity  100.0%;  Pred. No. 1.6e+06;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FR 3
              ||
Db          4 FR 5

RESULT 85
FARP_MYTED
ID   FARP_MYTED     STANDARD;      PRT;   10 AA.
AC   P42560;
DT   01-NOV-1995 (Rel. 32, Created)
DT   01-NOV-1995 (Rel. 32, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   FMRFamide-like neuropeptide ALAGDHFFRF-amide.
OS   Mytilus edulis (Blue mussel).
OC   Eukaryota; Metazoa; Mollusca; Bivalvia; Pteriomorphia; Mytiloida;
OC   Mytiloidea; Mytilidae; Mytilus.
OX   NCBI_TaxID=6550;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=93047883; PubMed=1358534; DOI=10.1016/0742-8413(92)90104-F;
RA   Walker R.J.;
RT   "Neuroactive peptides with an RFamide or Famide carboxyl terminal.";
RL   Comp. Biochem. Physiol. 102C:213-222(1992).

CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- SIMILARITY: Belongs to the FARP (FMRFamide related peptide)
CC       family.
DR   PIR; A58365; A58365.
KW   Amidation; Direct protein sequencing; Neuropeptide.
FT   MOD_RES      10     10       Phenylalanine amide.
SQ   SEQUENCE   10 AA;  1180 MW;  C2F80CC9C1EAA87D CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 10;
Best Local Similarity  100.0%;  Pred. No. 5.1e+04;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FR 3
              ||
Db          8 FR 9

RESULT 86
LSK2_LEUMA
ID   LSK2_LEUMA     STANDARD;      PRT;   10 AA.
AC   P67802; P09039;
DT   01-NOV-1988 (Rel. 09, Created)
DT   01-FEB-1994 (Rel. 28, Last sequence update)
DT   25-OCT-2004 (Rel. 45, Last annotation update)
DE   Leucosulfakinin-II (LSK-II).
OS   Leucophaea maderae (Madeira cockroach).
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blaberoidea;
OC   Blaberidae; Leucophaea.
OX   NCBI_TaxID=6988;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=87048769; PubMed=3778455;
RA   Nachman R.J., Holman G.M., Cook B.J., Haddon W.F., Ling N.;
RT   "Leucosulfakinin-II, a blocked sulfated insect neuropeptide with
RT   homology to cholecystokinin and gastrin.";
RL   Biochem. Biophys. Res. Commun. 140:357-364(1986).
CC   -!- FUNCTION: Changes the frequency and amplitude of contractions of
CC       the cockroach hingut. Stimulates muscle contraction of hindgut.
CC   -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
DR   PIR; A26335; GMRO2.
DR   InterPro; IPR001651; Gastrin.
DR   PROSITE; PS00259; GASTRIN; 1.
KW   Amidation; Direct protein sequencing; Hormone;
KW   Pyrrolidone carboxylic acid; Sulfation.
FT   MOD_RES       1      1       Pyrrolidone carboxylic acid.
FT   MOD_RES       5      5       Sulfotyrosine.
FT   MOD_RES      10     10       Phenylalanine amide.
SQ   SEQUENCE   10 AA;  1255 MW;  9B4F5391E86B5AAA CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 10;
Best Local Similarity   25.0%;  Pred. No. 5.1e+04;
Matches    1;  Conservative    2;  Mismatches    0;  Indels    1;  Gaps    0;

Qy          1 EFRH 4
              ::|
Db          4 DYGH 7

RESULT 87
LSK2_PERAM
ID   LSK2_PERAM     STANDARD;      PRT;   10 AA.
AC   P67803; P09039;
DT   01-NOV-1988 (Rel. 09, Created)
DT   01-FEB-1994 (Rel. 28, Last sequence update)
DT   25-OCT-2004 (Rel. 45, Last annotation update)
DE   Leucosulfakinin-II (LSK-II).
OS   Periplaneta americana (American cockroach).
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blattoidea;
OC   Blattidae; Periplaneta.
OX   NCBI_TaxID=6978;
RN   [1]

```
RP   SEQUENCE.
RC   TISSUE=Corpora cardiaca;
RX   MEDLINE=90137190; PubMed=2615921; DOI=10.1016/0143-4179(89)90038-3;
RA   Veenstra J.A.;
RT   "Isolation and structure of two gastrin/CCK-like neuropeptides from
RT   the American cockroach homologous to the leucosulfakinins.";
RL   Neuropeptides 14:145-149(1989).
CC   -!- FUNCTION: Changes the frequency and amplitude of contractions of
CC       the cockroach hindgut. Stimulates muscle contraction of hindgut.
CC   -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.
DR   PIR; B60656; B60656.
DR   InterPro; IPR001651; Gastrin.
DR   PROSITE; PS00259; GASTRIN; 1.
KW   Amidation; Direct protein sequencing; Hormone;
KW   Pyrrolidone carboxylic acid.
FT   MOD_RES       1      1       Pyrrolidone carboxylic acid.
FT   MOD_RES      10     10       Phenylalanine amide.
SQ   SEQUENCE   10 AA;  1255 MW;  9B4F5391E86B5AAA CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 10;
Best Local Similarity   25.0%;  Pred. No. 5.1e+04;
Matches    2;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            :::
Db        4 DYGH 7

RESULT 88
UPA9_HUMAN
ID   UPA9_HUMAN     STANDARD;      PRT;     10 AA.
AC   P30095;
DT   01-APR-1993 (Rel. 25, Created)
DT   01-APR-1993 (Rel. 25, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Unknown protein from 2D-PAGE of plasma (Spot 35) (Fragment).
OS   Homo sapiens (Human)
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE.
RC   TISSUE=Plasma;
RX   MEDLINE=93092937; PubMed=1459097;
RA   Hughes G.J., Frutiger S., Paquet N., Ravier F., Pasquali C.,
RA   Sanchez J.-C., James R., Tissot J.-D., Bjellqvist B.,
RA   Hochstrasser D.F.;
RT   "Plasma protein map: an update by microsequencing.";
RL   Electrophoresis 13:707-714(1992).
CC   -!- MISCELLANEOUS: On the 2D-gel the determined pI of this unknown
CC       protein is 7.2, its MW is 15 kDa.
DR   SWISS-2DPAGE; P30095; HUMAN.
KW   Direct protein sequencing.
FT   NON_TER       1      1
FT   NON_TER      10     10
SQ   SEQUENCE   10 AA;  1233 MW;  37AD72BA09C681B7 CRC64;

Query Match             45.8%;  Score 11;  DB 1;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 5.1e+04;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        2 FR 3
            ||
Db        6 FR 7

RESULT 89
Q96QT9
ID   Q96QT9         PRELIMINARY;   PRT;     10 AA.
AC   Q96QT9;
DT   01-DEC-2001 (TrEMBLrel. 19, Created)
DT   01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT   01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
```

```
DE   Protein tyrosine phosphatase 1B (Fragment).
OS   Homo sapiens (Human)
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=21326081; PubMed=11316810; DOI=10.1074/jbc.M101354200;
RA   Fukada T., Tonks N.K.;
RT   "The reciprocal role of Egr-1 and Sp family proteins in regulation of
RT   the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein-
RT   tyrosine kinase.";
RL   J. Biol. Chem. 276:25512-25519(2001).
DR   EMBL; AY029236; AAK31734.1; -.
FT   NON_TER      10     10
SQ   SEQUENCE   10 AA;  1314 MW;  AC08E219CB133B16 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 5.1e+04;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EF 2
            ||
Db        6 EF 7

RESULT 90
Q7Z5A2
ID   Q7Z5A2         PRELIMINARY;   PRT;     10 AA.
AC   Q7Z5A2;
DT   01-OCT-2003 (TrEMBLrel. 25, Created)
DT   01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein.
OS   Homo sapiens (Human)
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   TISSUE=Testis;
RA   Fraisl P., Forss-Petter S., Berger J.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AJ577571; CAE12153.1; -.
KW   Hypothetical protein.
SQ   SEQUENCE   10 AA;  1086 MW;  622094D78676 9D4 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 5.1e+04;
Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        2 FR 3
            ||
Db        2 FR 3

RESULT 91
P82217
ID   P82217         PRELIMINARY;   PRT;     10 AA.
AC   P82217;
DT   01-OCT-2001 (TrEMBLrel. 18, Created)
DT   01-OCT-2001 (TrEMBLrel. 18, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Unknown protein from 2D-page (Fragment).
OS   Bombyx mori (Silk moth)
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia; Bombycoidea;
OC   Bombycidae; Bombyx.
OX   NCBI_TaxID=7091;
RN   [1]
RP   SEQUENCE.
RC   STRAIN=XINHANG X KEMING; TISSUE=Body wall, and Fat body;
RX   MEDLINE=21177481; PubMed=11280994;
```

RA    Zhong B.X.;
RT    "Protein database for several tissues derived from five instar of
RT    silkworm.";
RL    I Chuan Hsueh Pao 28:217-224(2001).
FT    NON_TER    10    10
SQ    SEQUENCE    10 AA;    1148 MW;    DC779AB32E451A9 CRC64;

Query Match    45.8%;    Score 11;    DB 2;    Length 10;
Best Local Similarity    100.0%;    Pred. No. 5.1e+04;
Matches    2;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;

Qy    1 EF 2
         ||
Db    2 EF 3

RESULT 92
Q8SHA8
ID    Q8SHA8    PRELIMINARY;    PRT;    10 AA.
AC    Q8SHA8;
DT    01-JUN-2002 (TrEMBLrel. 21, Created)
DT    01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE    Cytochrome c oxidase subunit I (Fragment).
GN    Name=COI;
OS    Rhampholeon spectrum (Spectral pygmy chameleon).
OG    Mitochondrion.
OC    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC    Lepidosauria; Squamata; Iguania; Acrodonta; Chamaeleonidae;
OC    Rhampholeon.
OX    NCBI_TaxID=179929;
RN    [1]
RP    SEQUENCE FROM N.A.
RX    MEDLINE=22169767; PubMed=12182400; DOI=10.1006/mpev.2001.1076;
RA    Townsend T., Larson A.;
RT    "Molecular phylogenetics and mitochondrial genomic evolution in the
RT    chamaeleonidae (Reptilia, Squamata).";
RL    Mol. Phylogenet. Evol. 23:22-36(2002).
RN    [2]
RP    SEQUENCE FROM N.A.
RA    Townsend T.M., Larson A.L.;
RL    Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.
DR    EMBL; AF448772; AAL90598.1; -.
DR    GO; GO:0005739; C:mitochondrion; IEA.
KW    Mitochondrion.
FT    NON_TER    10    10
SQ    SEQUENCE    10 AA;    1279 MW;    35BF8E27336409D7 CRC64;

Query Match    45.8%;    Score 11;    DB 2;    Length 10;
Best Local Similarity    100.0%;    Pred. No. 5.1e+04;
Matches    2;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;

Qy    2 FR 3
         ||
Db    4 FR 5

RESULT 93
Q96041
ID    Q96041    PRELIMINARY;    PRT;    10 AA.
AC    Q96041;
DT    01-FEB-1997 (TrEMBLrel. 02, Created)
DT    01-FEB-1997 (TrEMBLrel. 02, Last sequence update)
DT    01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE    NADH-ubiquinone oxidoreductase subunit 3 (Fragment).
GN    Name=nad3;
OS    Oenothera bertiana (Bertero's evening primrose).
OG    Mitochondrion.
OC    Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC    Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC    Myrtales; Onagraceae; Oenothera.
OX    NCBI_TaxID=3950;
RN    [1]

RP    SEQUENCE FROM N.A.
RX    MEDLINE=94019250; PubMed=8413195;
RA    Schuster W.;
RT    "Ribosomal protein gene rpl5 is cotranscribed with the nad3 gene in
RT    Oenothera mitochondria.";
RL    Mol. Gen. Genet. 240:445-449(1993).
DR    EMBL; X69553; CAA49285.1; -.
DR    GO; GO:0005739; C:mitochondrion; IEA.
KW    Mitochondrion; Ubiquinone.
FT    NON_TER    10    10
SQ    SEQUENCE    10 AA;    1097 MW;    723067B0476DD9CB CRC64;

Query Match    45.8%;    Score 11;    DB 2;    Length 10;
Best Local Similarity    100.0%;    Pred. No. 5.1e+04;
Matches    2;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;

Qy    1 EF 2
         ||
Db    3 EF 4

RESULT 94
Q85BV6
ID    Q85BV6    PRELIMINARY;    PRT;    10 AA.
AC    Q85BV6;
DT    01-JUN-2003 (TrEMBLrel. 24, Created)
DT    01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT    05-JUL-2003 (TrEMBLrel. 27, Last annotation update)
DE    Ribosomal protein L2 (Fragment).
GN    Name=rpl2;
OS    Eucalyptus grandis (Flooded gum).
OG    Chloroplast.
OC    Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC    Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC    Myrtales; Myrtaceae; Eucalyptus.
OX    NCBI_TaxID=71139;
RN    [1]
RP    SEQUENCE FROM N.A.
RA    Jones M.E., Shepherd M., Henry R.J., Delves A., Schoer L.;
RL    Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
DR    EMBL; AF502101; AAP30806.1; -.
DR    EMBL; AF502103; AAP30808.1; -.
DR    GO; GO:0009507; C:chloroplast; IEA.
DR    GO; GO:0003735; F:structural constituent of ribosome; IEA.
KW    Chloroplast; Ribosomal protein.
FT    NON_TER    1    1
SQ    SEQUENCE    10 AA;    1305 MW;    5387F0141409C057 CRC64;

Query Match    45.8%;    Score 11;    DB 2;    Length 10;
Best Local Similarity    100.0%;    Pred. No. 5.1e+04;
Matches    2;    Conservative    0;    Mismatches    0;    Indels    0;    Gaps    0;

Qy    2 FR 3
         ||
Db    5 FR 6

RESULT 95
Q85V67
ID    Q85V67    PRELIMINARY;    PRT;    10 AA.
AC    Q85V67;
DT    01-JUN-2003 (TrEMBLrel. 24, Created)
DT    01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE    Ribosomal protein L2 (Fragment).
GN    Name=rpl2;
OS    Eucalyptus grandis (Flooded gum).
OG    Chloroplast.
OC    Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC    Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC    Myrtales; Myrtaceae; Eucalyptus.
OX    NCBI_TaxID=71139;
RN    [1]

RP   SEQUENCE FROM N.A.
RA   Jones M.E., Shepherd M., Henry R.J., Delves A., Schoer L.;
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF502102; AAP30807.1; -.
DR   GO; GO:0009507; C:chloroplast; IEA.
DR   GO; GO:0003735; F:structural constituent of ribosome; IEA.
KW   Chloroplast; Ribosomal protein.
FT   NON_TER        1      1
SQ   SEQUENCE   10 AA;   1245 MW;  5387F0177409C057 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 5.1e+04;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FR 3
              ||
Db          5 FR 6

RESULT 96
Q76VI9
ID   Q76VI9            PRELIMINARY;       PRT;   10 AA.
AC   Q76VI9;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Lysin (Fragment).
GN   Name=lysA;
OS   Lactococcus delbrueckii bacteriophage LL-H.
OC   Viruses.
OX   NCBI_TaxID=12348;
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=96209253; PubMed=8633887;
RA   Mikkonen M., Dupont L., Alatossava T., Ritzenthaler P.;
RT   "Defective site-specific integration elements are present in the
RT   genome of virulent bacteriophage LL-H of Lactobacillus delbrueckii.";
RL   Appl. Environ. Microbiol. 62:1847-1851(1996).
RN   [2]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=94237431; PubMed=7514146; DOI=10.1016/0378-1097(94)90053-1;
RA   Mikkonen M., Vuoristo J., Alatossava T.;
RT   "Ribosome binding site consensus sequence of Lactobacillus delbrueckii
RT   subsp. lactis bacteriophage LL-H.";
RL   FEMS Microbiol. Lett. 116:315-320(1994).
RN   [3]
RP   SEQUENCE FROM N.A.
RX   MEDLINE=96064414; PubMed=8526515;
RA   Vasala A., Valkkila M., Caldentey J., Alatossava T.;
RT   "Genetic and biochemical characterization of the Lactobacillus
RT   delbrueckii subsp. lactis bacteriophage LL-H lysin.";
RL   Appl. Environ. Microbiol. 61:4004-4011(1995).
RN   [4]
RP   SEQUENCE FROM N.A.
RA   Mikkonen M., Dupont L., Alatossava T., Ritzenthaler P.;
RT   "Complex DNA rearrangements in the att-integration genome regions in
RT   related virulent and temperate phages of Lactobacillus delbrueckii.";
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; L42315; AAB06218.1; -.
FT   NON_TER        1      1
SQ   SEQUENCE   10 AA;   1162 MW;  926B8D41B2C9CB1A CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 5.1e+04;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EP 2
              ||
Db          4 EF 5

RESULT 97
Q6KC69

---

ID   Q6KC69            PRELIMINARY;       PRT;   10 AA.
AC   Q6KC69;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Putative glutamine synthetase (Fragment).
OS   Eucalyptus globulus subsp. globulus.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC   Myrtales; Myrtaceae; Eucalyptus.
OX   NCBI_TaxID=71271;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Pelosi A.;
RT   "Molecular and genetic studies into the formation of lateral roots in
RT   Eucalyptus and Arabidopsis.";
RL   Thesis (2002), Department of Biological Sciences, Monash University,
RL   Melbourne, Australia.
RN   [2]
RP   SEQUENCE FROM N.A.
RA   Hamill J.D.;
RL   Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AJ697760; CAG30778.1; -.
FT   NON_TER        1      1
FT   NON_TER       10     10
SQ   SEQUENCE   10 AA;   1218 MW;  C519C76AA339C05D CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 5.1e+04;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FR 3
              ||
Db          9 FR 10

RESULT 98
Q7M1I6
ID   Q7M1I6            PRELIMINARY;       PRT;   10 AA.
AC   Q7M1I6;
DT   01-MAR-2004 (TrEMBLrel. 26, Created)
DT   01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE   Beta-Kirilowin (Fragment).
OS   Trichosanthes kirilowii (Mongolian snake-gourd).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC   eurosids I; Cucurbitales; Cucurbitaceae; Trichosanthes.
OX   NCBI_TaxID=3677;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=94168605; PubMed=8123040;
RA   Dong T.X., Ng T.B., Yeung H.W., Wong R.N.S.;
RT   "Isolation and characterization of a novel ribosome-inactivating
RT   protein, beta-kirilowin, from the seeds of Trichosanthes kirilowii.";
RL   Biochem. Biophys. Res. Commun. 199:387-393(1994).
DR   PIR; PC2044; PC2044.
FT   NON_TER        1      1
FT   NON_TER       10     10
SQ   SEQUENCE   10 AA;   1105 MW;  1C7A31B73409C050 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 5.1e+04;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FR 3
              ||
Db          5 FR 6

RESULT 99
Q93UU2
ID   Q93UU2            PRELIMINARY;       PRT;   10 AA.

```
AC   Q93UU2;
DT   01-DEC-2001 (TrEMBLrel. 19, Created)
DT   01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT   01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE   Orf.
OS   Escherichia coli O157:H7.
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83334;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Miyamoto T., Ichioka N., Sasaki C., Kobayashi H., Honjoh K., Iio M.,
RA   Hatano S.;
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AB061018; BAB47190.1; -.
SQ   SEQUENCE   10 AA;  1236 MW;  DF344CBAB409D5A6 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 5.1e+04;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FR 3
              ||
Db          5 FR 6


RESULT 100
Q6JL97
ID   Q6JL97      PRELIMINARY;      PRT;    10 AA.
AC   Q6JL97;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   NuoL (Fragment).
GN   Name=nuoL;
OS   Neisseria gonorrhoeae.
OC   Bacteria; Proteobacteria; Betaproteobacteria; Neisseriales;
OC   Neisseriaceae; Neisseria.
OX   NCBI_TaxID=485;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=MS11;
RX   PubMed=15084227;
RA   Snyder L.A., Davies J.K., Saunders N.J.;
RT   "Microarray genomotyping of key experimental strains of Neisseria
RT   gonorrhoeae reveals gene complement diversity and five new neisserial
RT   genes associated with Minimal Mobile Elements.";
RL   BMC Genomics 5:23-23 (2004).
RN   [2]
RP   SEQUENCE FROM N.A.
RC   STRAIN=MS11;
RA   Snyder L.A.S., Davies J.K., Saunders N.J.;
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AY386266; AAS16521.1; -.
FT   NON_TER       1      1
SQ   SEQUENCE   10 AA;  1227 MW;  BACCBB286379D1A6 CRC64;

Query Match             45.8%;  Score 11;  DB 2;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 5.1e+04;
  Matches    2;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 FR 3
              ||
Db          9 FR 10


Search completed: November  2, 2005, 09:41:08
Job time : 176 secs
```

OM protein - protein search, using sw model

```
            GenCore version 5.1.6
    Copyright (c) 1993 - 2005 Compugen Ltd.
```

Run on:    November 2, 2005, 09:25:50 ; Search time 168 Seconds
                                        (without alignments)
                              9.953 Million cell updates/sec

Title:            US-10-618-856-1
Perfect score:    24
Sequence:         1 EFRH 4

Scoring table:    BLOSUM62
                  Gapop 10.0 , Gapext 0.5

Searched:         1865214 seqs, 418043040 residues

Total number of hits satisfying chosen parameters:    1865214

Minimum DB seq length:    0
Maximum DB seq length:    2000000000

Post-processing:  Minimum Match 0%
                  Maximum Match 100%
                  Listing first 45 summaries

Database :   Published Applications AA:*
```
 1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
 2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*
 3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
 4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*
 5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
 6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*
 7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
 8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
 9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:*
10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:*
11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*
12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*
14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*
15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*
16: /cgn2_6/ptodata/2/pubpaa/US10D_PUBCOMB.pep:*
17: /cgn2_6/ptodata/2/pubpaa/US10E_PUBCOMB.pep:*
18: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
19: /cgn2_6/ptodata/2/pubpaa/US11A_PUBCOMB.pep:*
20: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep:*
21: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
22: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*
```

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

## SUMMARIES

| Result No. | Score | % Query Match | Match Length | DB | ID | Description |
|---|---|---|---|---|---|---|
| 1 | 24 | 100.0 | 4 | 9 | US-09-808-037-1 | Sequence 1, Appli |
| 2 | 24 | 100.0 | 4 | 9 | US-09-975-932-8 | Sequence 8, Appli |
| 3 | 24 | 100.0 | 4 | 14 | US-10-084-380A-8 | Sequence 8, Appli |
| 4 | 24 | 100.0 | 4 | 14 | US-10-162-889-1 | Sequence 1, Appli |
| 5 | 24 | 100.0 | 4 | 15 | US-10-384-788-1 | Sequence 1, Appli |
| 6 | 24 | 100.0 | 4 | 15 | US-10-618-856-1 | Sequence 1, Appli |
| 7 | 24 | 100.0 | 4 | 17 | US-10-481-642-5 | Sequence 5, Appli |
| 8 | 24 | 100.0 | 4 | 17 | US-10-749-522-1 | Sequence 1, Appli |
| 9 | 24 | 100.0 | 4 | 18 | US-10-625-854-27 | Sequence 27, Appli |
| 10 | 24 | 100.0 | 4 | 20 | US-11-073-526-1 | Sequence 1, Appli |
| 11 | 24 | 100.0 | 5 | 18 | US-10-505-313-287 | Sequence 287, App |
| 12 | 24 | 100.0 | 5 | 18 | US-10-625-854-15 | Sequence 15, Appl |
| 13 | 24 | 100.0 | 5 | 18 | US-10-625-854-28 | Sequence 28, Appl |
| 14 | 24 | 100.0 | 6 | 9 | US-09-808-037-7 | Sequence 7, Appli |
| 15 | 24 | 100.0 | 6 | 9 | US-09-975-932-6 | Sequence 6, Appli |
| 16 | 24 | 100.0 | 6 | 14 | US-10-084-380A-6 | Sequence 6, Appli |
| 17 | 24 | 100.0 | 6 | 14 | US-10-162-889-7 | Sequence 7, Appli |
| 18 | 24 | 100.0 | 6 | 15 | US-10-384-788-7 | Sequence 7, Appli |
| 19 | 24 | 100.0 | 6 | 15 | US-10-618-856-7 | Sequence 75, Appl |
| 20 | 24 | 100.0 | 6 | 16 | US-10-622-087-75 | Sequence 84, Appl |
| 21 | 24 | 100.0 | 6 | 16 | US-10-622-087-84 | Sequence 85, Appl |
| 22 | 24 | 100.0 | 6 | 16 | US-10-622-087-85 | Sequence 88, Appl |
| 23 | 24 | 100.0 | 6 | 16 | US-10-622-087-88 | Sequence 90, Appl |
| 24 | 24 | 100.0 | 6 | 16 | US-10-622-087-90 | Sequence 101, App |
| 25 | 24 | 100.0 | 6 | 17 | US-10-749-522-7 | Sequence 285, App |
| 26 | 24 | 100.0 | 6 | 18 | US-10-810-881A-101 | Sequence 3, Appli |
| 27 | 24 | 100.0 | 6 | 18 | US-10-810-881A-111 | Sequence 16, Appl |
| 28 | 24 | 100.0 | 6 | 18 | US-10-505-313-285 | Sequence 29, Appl |
| 29 | 24 | 100.0 | 6 | 18 | US-10-625-854-3 | Sequence 7, Appl |
| 30 | 24 | 100.0 | 6 | 18 | US-10-625-854-16 | Sequence 5, Appli |
| 31 | 24 | 100.0 | 6 | 18 | US-10-625-854-29 | Sequence 8, Appli |
| 32 | 24 | 100.0 | 6 | 18 | US-10-625-854-41 | Sequence 4, Appli |
| 33 | 24 | 100.0 | 6 | 20 | US-11-073-526-7 | Sequence 5, Appli |
| 34 | 24 | 100.0 | 7 | 9 | US-09-867-847-5 | Sequence 17, Appl |
| 35 | 24 | 100.0 | 7 | 14 | US-10-337-970-8 | Sequence 30, Appl |
| 36 | 24 | 100.0 | 7 | 16 | US-10-481-954-4 | Sequence 42, Appl |
| 37 | 24 | 100.0 | 7 | 17 | US-10-825-958-5 | Sequence 5, Appli |
| 38 | 24 | 100.0 | 7 | 18 | US-10-810-881A-100 | Sequence 100, App |
| 39 | 24 | 100.0 | 7 | 18 | US-10-505-313-256 | Sequence 256, App |
| 40 | 24 | 100.0 | 7 | 18 | US-10-505-313-257 | Sequence 257, App |
| 41 | 24 | 100.0 | 7 | 18 | US-10-505-313-286 | Sequence 286, App |
| 42 | 24 | 100.0 | 7 | 18 | US-10-625-854-4 | Sequence 4, Appli |
| 43 | 24 | 100.0 | 7 | 18 | US-10-625-854-17 | Sequence 17, Appl |
| 44 | 24 | 100.0 | 7 | 18 | US-10-625-854-30 | Sequence 30, Appl |
| 45 | 24 | 100.0 | 7 | 18 | US-10-625-854-42 | Sequence 42, Appl |

## ALIGNMENTS

RESULT 1
US-09-808-037-1
```
; Sequence 1, Application US/09808037
; Patent No. US2002005231A1
; GENERAL INFORMATION:
;  APPLICANT: SOLOMON, Beka
;  APPLICANT: HANAN, Eilat
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR DIAGNOSIS OF
;  TITLE OF INVENTION: NEUROLOGICAL DISEASES AND DISORDERS
;  FILE REFERENCE: SOLOMON=2D
;  CURRENT APPLICATION NUMBER: US/09/808,037
;  CURRENT FILING DATE: 2001-03-15
;  PRIOR APPLICATION NUMBER: 09/629,971
;  PRIOR APPLICATION FILING DATE: 2000-07-31
;  PRIOR APPLICATION NUMBER: US 09/473,653
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: US 60/152,417
;  PRIOR FILING DATE: 1999-09-03
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;  LENGTH: 4
;  TYPE: PRT
;  ORGANISM: Artificial Sequence
;  FEATURE:
;  OTHER INFORMATION: synthetic peptide
US-09-808-037-1

  Query Match             100.0%;  Score 24;  DB 9;  Length 4;
  Best Local Similarity   100.0%;  Pred. No. 1.7e-06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
```

Db        1 EFRH 4

RESULT 2
US-09-975-932-8
; Sequence 8, Application US/0975932
; Publication No. US20020086847A1
; GENERAL INFORMATION:
;   APPLICANT: CHAIN, Daniel G.
;   TITLE OF INVENTION: RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,
;   TITLE OF INVENTION: DNA ENCODING AND METHODS OF USE THEREOF
;   FILE REFERENCE: CHAIN1B
;   CURRENT APPLICATION NUMBER: US/09/975,932
;   CURRENT FILING DATE: 2001-10-15
;   PRIOR APPLICATION NUMBER: 09/402,820
;   PRIOR FILING DATE: 1999-10-12
;   PRIOR APPLICATION NUMBER: PCT/US98/06900
;   PRIOR FILING DATE: 1998-04-09
;   PRIOR APPLICATION NUMBER: 60/041,850
;   PRIOR FILING DATE: 1997-04-09
;   NUMBER OF SEQ ID NOS: 8
;   SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-975-932-8

Query Match       100.0%;   Score 24;  DB 9; Length 4;
Best Local Similarity  100.0%;   Pred. No. 1.7e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy   1 EFRH 4
       ||||
Db   1 EFRH 4

RESULT 3
US-10-084-380A-8
; Sequence 8, Application US/10084380A
; Publication No. US20030073665A1
; GENERAL INFORMATION:
;   APPLICANT: Mindset Biopharmaceutical Inc.
;   APPLICANT: Chain, Daniel G.
;   TITLE OF INVENTION: Specific antibodies to amyloid beta peptide, pharmaceutical compc
;   TITLE OF INVENTION: and methods of use thereof
;   FILE REFERENCE: P-4815-US1
;   CURRENT APPLICATION NUMBER: US/10/084,380A
;   CURRENT FILING DATE: 2002-02-28
;   PRIOR APPLICATION NUMBER: 60/041,850
;   PRIOR FILING DATE: 1997-04-09
;   PRIOR APPLICATION NUMBER: 09/402,820
;   PRIOR FILING DATE: 1999-10-12
;   PRIOR APPLICATION NUMBER: pct/us98/06900
;   PRIOR FILING DATE: 1998-04-09
;   NUMBER OF SEQ ID NOS: 13
;   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: human
US-10-084-380A-8

Query Match       100.0%;   Score 24;  DB 14; Length 4;
Best Local Similarity  100.0%;   Pred. No. 1.7e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy   1 EFRH 4
       ||||
Db   1 EFRH 4

RESULT 4

US-10-162-889-1
; Sequence 1, Application US/10162889
; Publication No. US2003007725A1
; GENERAL INFORMATION:
;   APPLICANT: SOLOMON, Beka
;   APPLICANT: HANAN, Eilat
;   TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME
;   TITLE OF INVENTION: USEFUL IN DIAGNOSING
;   TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
;   FILE REFERENCE: SOLOMON-2B
;   CURRENT APPLICATION NUMBER: US/10/162,889
;   CURRENT FILING DATE: 2002-06-06
;   PRIOR APPLICATION NUMBER: US/09/629,971
;   PRIOR FILING DATE: 2000-07-31
;   PRIOR APPLICATION NUMBER: US 09/473,653
;   PRIOR FILING DATE: 1999-12-29
;   PRIOR APPLICATION NUMBER: US 60/152,417
;   PRIOR FILING DATE: 1999-09-03
;   NUMBER OF SEQ ID NOS: 29
;   SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic peptide
US-10-162-889-1

Query Match       100.0%;   Score 24;  DB 14; Length 4;
Best Local Similarity  100.0%;   Pred. No. 1.7e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy   1 EFRH 4
       ||||
Db   1 EFRH 4

RESULT 5
US-10-384-788-1
; Sequence 1, Application US/10384788
; Publication No. US20040013647A1
; GENERAL INFORMATION:
;   APPLICANT: SOLOMON, Beka
;   APPLICANT: FRENKEL, Dan
;   TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING A PLAQUE-FORMING DISEASE
;   FILE REFERENCE: SOLOMON-2D.2
;   CURRENT APPLICATION NUMBER: US/10/384,788
;   CURRENT FILING DATE: 2003-03-11
;   PRIOR APPLICATION NUMBER: 60/371,735
;   PRIOR FILING DATE: 2002-04-12
;   PRIOR APPLICATION NUMBER: 09/808,037
;   PRIOR FILING DATE: 2001-03-15
;   PRIOR APPLICATION NUMBER: 09/830,954
;   PRIOR FILING DATE: 2001-06-22
;   PRIOR APPLICATION NUMBER: 10/162,889
;   PRIOR FILING DATE: 2002-06-06
;   PRIOR APPLICATION NUMBER: 09/473,653
;   PRIOR FILING DATE: 1999-12-29
;   PRIOR APPLICATION NUMBER: 09/629,971
;   PRIOR FILING DATE: 2000-07-31
;   PRIOR APPLICATION NUMBER: 60/152,417
;   PRIOR FILING DATE: 1999-09-03
;   PRIOR APPLICATION NUMBER: PCT/IL00/00518
;   PRIOR FILING DATE: 2000-08-31
;   NUMBER OF SEQ ID NOS: 33
;   SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
;   LENGTH: 4
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic peptide
US-10-384-788-1

Query Match             100.0%;  Score 24;  DB 15;  Length 4;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 6
US-10-618-856-1
; Sequence 1, Application US/10618856
; Publication No. US20040052766A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; TITLE OF INVENTION: IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY TECHNOLOGY
; FILE REFERENCE: SOLOMON=2A
; CURRENT APPLICATION NUMBER: US/10/618,856
; CURRENT FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: US/09/473,653A
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.0
;
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-618-856-1

Query Match             100.0%;  Score 24;  DB 15;  Length 4;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 7
US-10-481-642-5
; Sequence 5, Application US/10481642
; Publication No. US20050053575A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; TITLE OF INVENTION: ANTIGENIC PRODUCT DISPLAYING MULTIPLE COPIES OF AN EPITOPE OF A D
; TITLE OF INVENTION: FORMING POLYPEPTIDE INVOLVED IN PLAQUE-FORMING DISEASES AND METH
; TITLE OF INVENTION: USING SAME
; FILE REFERENCE: SOLOMON=4.1A PCT
; CURRENT APPLICATION NUMBER: US/10/481,642
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.1
;
; SEQ ID NO 5
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-481-642-5

Query Match             100.0%;  Score 24;  DB 17;  Length 4;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 8
US-10-749-522-1
; Sequence 1, Application US/10749522
; Publication No. US20050089510A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIAG
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
; FILE REFERENCE: SOLOMON=2B
; CURRENT APPLICATION NUMBER: US/10/749,522
; CURRENT FILING DATE: 2004-01-02
; PRIOR APPLICATION NUMBER: US/09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
;
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-749-522-1

Query Match             100.0%;  Score 24;  DB 17;  Length 4;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 9
US-10-625-854-27
; Sequence 27, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
;
; SEQ ID NO 27
; LENGTH: 4
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-27

Query Match             100.0%;  Score 24;  DB 18;  Length 4;
Best Local Similarity  100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 10

US-11-073-526-1
; Sequence 1, Application US/11073526
; Publication No. US20050152878A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIAG
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
; FILE REFERENCE: SOLOMON=2C
; CURRENT APPLICATION NUMBER: US/11/073,526
; CURRENT FILING DATE: 2005-03-08
; PRIOR APPLICATION NUMBER: US/09/830,954
; PRIOR FILING DATE: 2001-08-07
; PRIOR APPLICATION NUMBER: PCT/IL00/00518
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic peptide
US-11-073-526-1

Query Match        100.0%;    Score 24;  DB 20;  Length 4;
Best Local Similarity 100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy   1 EFRH 4
         ||||
Db   1 EFRH 4

RESULT 11
US-10-505-313-287
; Sequence 287, Application US/10505313
; Publication No. US20050169925A1
; GENERAL INFORMATION:
; APPLICANT: F. Hoffmann-La Roche AG
; APPLICANT: MorphoSys AG
; TITLE OF INVENTION: Anti A-beta antibodies and their use
; FILE REFERENCE: F 2842 PCT
; CURRENT APPLICATION NUMBER: US/10/505,313
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: EP 02003844.4
; PRIOR FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 414
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 287
; LENGTH: 5
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic construct; peptide 3 A beta
US-10-505-313-287

Query Match        100.0%;    Score 24;  DB 18;  Length 5;
Best Local Similarity 100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy   1 EFRH 4
         ||||
Db   1 EFRH 4

RESULT 12
US-10-625-854-15
; Sequence 15, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 5
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-15

Query Match        100.0%;    Score 24;  DB 18;  Length 5;
Best Local Similarity 100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy   1 EFRH 4
         |||
Db   2 EFRH 5

RESULT 13
US-10-625-854-28
; Sequence 28, Application US/10625854
; Publication No. US20050175626A1
; GENERAL INFORMATION:
; APPLICANT: Delacourte, Andr
; APPLICANT: Sergeant, Nicolas
; TITLE OF INVENTION: Prevention, treatment and diagnosis of diseases associated with
; TITLE OF INVENTION: beta-amyloid formation and/or aggregation
; FILE REFERENCE: 11362.0039.NPUS01 (INNS039---)
; CURRENT APPLICATION NUMBER: US/10/625,854
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: European Patent Application No. 02447147.6
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/401,497
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 261
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28
; LENGTH: 5
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-625-854-28

Query Match        100.0%;    Score 24;  DB 18;  Length 5;
Best Local Similarity 100.0%;  Pred. No. 1.7e+06;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy   1 EFRH 4
         |||
Db   1 EFRH 4

RESULT 14
US-09-808-037-7
; Sequence 7, Application US/09808037
; Patent No. US20020052311A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR DIAGNOSIS OF
; TITLE OF INVENTION: NEUROLOGICAL DISEASES AND DISORDERS
; FILE REFERENCE: SOLOMON-2D
; CURRENT APPLICATION NUMBER: US/09/808,037
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic peptide
US-09-808-037-7

Query Match          100.0%;   Score 24;  DB 9;  Length 6;
Best Local Similarity 100.0%;   Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6


RESULT 15
US-09-975-932-6
; Sequence 6, Application US/09975932
; Publication No. US20020086847A1
; GENERAL INFORMATION:
;  APPLICANT: CHAIN, Daniel G.
;  TITLE OF INVENTION: RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,
;  TITLE OF INVENTION: DNA ENCODING AND METHODS OF USE THEREOF
;  FILE REFERENCE: CHAIN1B
;  CURRENT APPLICATION NUMBER: US/09/975,932
;  CURRENT FILING DATE: 2001-10-15
;  PRIOR APPLICATION NUMBER: 09/402,820
;  PRIOR FILING DATE: 1999-10-12
;  PRIOR APPLICATION NUMBER: PCT/US98/06900
;  PRIOR FILING DATE: 1998-04-09
;  PRIOR APPLICATION NUMBER: 60/041,850
;  PRIOR FILING DATE: 1997-04-09
;  NUMBER OF SEQ ID NOS: 8
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-975-932-6

Query Match          100.0%;   Score 24;  DB 9;  Length 6;
Best Local Similarity 100.0%;   Pred. No. 1.7e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6


Search completed: November  2, 2005, 09:35:19
Job time : 169 secs

OM protein - protein search, using sw model

```
              GenCore version 5.1.6
      Copyright (c) 1993 - 2005 Compugen Ltd.
```

Run on: November 2, 2005, 09:21:35 ; Search time 42 Seconds
(without alignments)
7.109 Million cell updates/sec

Title: US-10-618-856-1
Perfect score: 24
Sequence: 1 EFRH 4
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | % Query Match | Length | DB | ID | Description |
|---|---|---|---|---|---|---|
| 1 | 24 | 100.0 | 4 | 4 | US-09-579-012-24 | Sequence 24, Appl |
| 2 | 24 | 100.0 | 7 | 4 | US-09-579-012-25 | Sequence 25, Appl |
| 3 | 24 | 100.0 | 10 | 1 | US-08-371-930-12 | Sequence 12, Appl |
| 4 | 24 | 100.0 | 10 | 4 | US-09-724-961-5 | Sequence 5, Appli |
| 5 | 24 | 100.0 | 10 | 4 | US-09-724-961-6 | Sequence 6, Appli |
| 6 | 24 | 100.0 | 10 | 4 | US-09-724-961-7 | Sequence 7, Appli |
| 7 | 24 | 100.0 | 10 | 4 | US-09-724-961-8 | Sequence 8, Appli |
| 8 | 24 | 100.0 | 10 | 4 | US-09-724-961-9 | Sequence 9, Appli |
| 9 | 24 | 100.0 | 10 | 4 | US-09-724-961-10 | Sequence 10, Appl |
| 10 | 24 | 100.0 | 10 | 4 | US-09-724-961-11 | Sequence 11, Appl |
| 11 | 24 | 100.0 | 10 | 4 | US-09-580-018-5 | Sequence 5, Appli |
| 12 | 24 | 100.0 | 10 | 4 | US-09-580-018-6 | Sequence 6, Appli |
| 13 | 24 | 100.0 | 10 | 4 | US-09-580-018-7 | Sequence 7, Appli |
| 14 | 24 | 100.0 | 10 | 4 | US-09-580-018-8 | Sequence 8, Appli |
| 15 | 24 | 100.0 | 10 | 4 | US-09-580-018-9 | Sequence 9, Appli |
| 16 | 24 | 100.0 | 10 | 4 | US-09-580-018-10 | Sequence 10, Appl |
| 17 | 24 | 100.0 | 10 | 4 | US-09-580-018-11 | Sequence 11, Appl |
| 18 | 24 | 100.0 | 10 | 4 | US-09-724-551-5 | Sequence 5, Appli |
| 19 | 24 | 100.0 | 10 | 4 | US-09-724-551-6 | Sequence 6, Appli |
| 20 | 24 | 100.0 | 10 | 4 | US-09-724-551-7 | Sequence 7, Appli |
| 21 | 24 | 100.0 | 10 | 4 | US-09-724-551-8 | Sequence 8, Appli |
| 22 | 24 | 100.0 | 10 | 4 | US-09-724-551-9 | Sequence 9, Appli |
| 23 | 24 | 100.0 | 10 | 4 | US-09-724-551-10 | Sequence 10, Appl |
| 24 | 24 | 100.0 | 10 | 4 | US-09-724-551-11 | Sequence 11, Appl |
| 25 | 24 | 100.0 | 11 | 1 | US-08-352-179-23 | Sequence 23, Appl |
| 26 | 24 | 100.0 | 11 | 5 | PCT-US94-01712-12 | Sequence 12, Appl |
| 27 | 24 | 100.0 | 11 | 3 | US-09-264-709A-6 | Sequence 6, Appli |
| 28 | 24 | 100.0 | 12 | 5 | PCT-US94-07043A-2 | Sequence 2, Appli |
| 29 | 24 | 100.0 | 13 | 4 | US-09-723-384-2 | Sequence 2, Appl |
| 30 | 24 | 100.0 | 13 | 4 | US-09-724-961-72 | Sequence 72, Appl |
| 31 | 24 | 100.0 | 13 | 4 | US-09-724-552-2 | Sequence 2, Appl |
| 32 | 24 | 100.0 | 13 | 4 | US-09-580-018-72 | Sequence 72, Appl |
| 33 | 24 | 100.0 | 13 | 4 | US-09-723-927-2 | Sequence 2, Appli |
| 34 | 24 | 100.0 | 13 | 4 | US-09-724-489-2 | Sequence 2, Appli |
| 35 | 24 | 100.0 | 13 | 4 | US-09-724-477-2 | Sequence 2, Appli |
| 36 | 24 | 100.0 | 13 | 4 | US-09-723-762-2 | Sequence 2, Appli |
| 37 | 24 | 100.0 | 13 | 4 | US-09-201-430-2 | Sequence 2, Appli |
| 38 | 24 | 100.0 | 13 | 4 | US-09-724-551-72 | Sequence 72, Appl |
| 39 | 24 | 100.0 | 13 | 4 | US-10-815-353-2 | Sequence 2, Appli |
| 40 | 24 | 100.0 | 13 | 4 | US-10-816-529-2 | Sequence 2, Appli |
| 41 | 24 | 100.0 | 15 | 2 | US-08-609-090-1 | Sequence 1, Appli |
| 42 | 24 | 100.0 | 16 | 1 | US-08-302-808-10 | Sequence 10, Appl |
| 43 | 24 | 100.0 | 16 | 2 | US-08-659-984A-20 | Sequence 20, Appl |
| 44 | 24 | 100.0 | 16 | 2 | US-08-986-948-10 | Sequence 10, Appl |
| 45 | 24 | 100.0 | 16 | 3 | US-08-660-531-20 | Sequence 20, Appl |

ALIGNMENTS

RESULT 1
US-09-579-012-24
; Sequence 24, Application US/09579012
; Patent No. 6670195
; GENERAL INFORMATION:
; APPLICANT: Jorge GHISO
; APPLICANT: Ruben VIDAL
; APPLICANT: Blas FRANGIONE
; TITLE OF INVENTION: New Mutant Genes in Familial British Dementia and Familial Danish
; TITLE OF INVENTION: Dementia
; FILE REFERENCE: 32004-16277
; CURRENT APPLICATION NUMBER: US/09/579,012
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/136238
; PRIOR FILING DATE: 1999-05-26
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
; LENGTH: 4
; TYPE: PRT
; ORGANISM: consensus sequence
US-09-579-012-24

Query Match          100.0%;  Score 24;  DB 4;  Length 4;
Best Local Similarity 100.0%;  Pred. No. 4.1e+05;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

```
Qy   1 EFRH 4
         ||||
Db   1 EFRH 4
```

RESULT 2
US-09-579-012-25
; Sequence 25, Application US/09579012
; Patent No. 6670195
; GENERAL INFORMATION:
; APPLICANT: Jorge GHISO
; APPLICANT: Ruben VIDAL
; APPLICANT: Blas FRANGIONE
; TITLE OF INVENTION: New Mutant Genes in Familial British Dementia and Familial Danish
; TITLE OF INVENTION: Dementia
; FILE REFERENCE: 32004-16277
; CURRENT APPLICATION NUMBER: US/09/579,012
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/136238
; PRIOR FILING DATE: 1999-05-26
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25

; LENGTH: 7
; TYPE: PRT
; ORGANISM: epitope
US-09-579-012-25

Query Match      100.0%;  Score 24;  DB 4;  Length 7;
Best Local Similarity  100.0%;  Pred. No. 4.1e+05;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    3 EFRH 6

RESULT 3
US-08-371-930-12
; Sequence 12, Application US/08371930
; Patent No. 5578451
; GENERAL INFORMATION:
; APPLICANT: Nishimoto, Ikuo
; TITLE OF INVENTION: ALZHEIMER'S DISEASE THERAPEUTICS
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/371,930
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/019,208
; FILING DATE: February 18, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/154001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
US-08-371-930-12

Query Match      100.0%;  Score 24;  DB 1;  Length 10;
Best Local Similarity  100.0%;  Pred. No. 19;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    3 EFRH 6

RESULT 4
US-09-724-961-5
; Sequence 5, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-5

Query Match      100.0%;  Score 24;  DB 4;  Length 10;
Best Local Similarity  100.0%;  Pred. No. 19;
Matches   4;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy    1 EFRH 4
        ||||
Db    7 EFRH 10

RESULT 5
US-09-724-961-6
; Sequence 6, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 6
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid

```
; OTHER INFORMATION: peptide)
US-09-724-961-6

Query Match         100.0%;  Score 24; DB 4; Length 10;
Best Local Similarity 100.0%;  Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy     1 EFRH 4
         ||||
Db     6 EFRH 9

RESULT 6
US-09-724-961-7
; Sequence 7, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
;  APPLICANT: Schenk, Dale B.
;  APPLICANT: Bard, Frederique
;  APPLICANT: Vasquez, Nicki
;  APPLICANT: Yednock, Ted
;  TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;  FILE REFERENCE: 15270J-004750UC
;  CURRENT APPLICATION NUMBER: US/09/724,961
;  CURRENT FILING DATE: 2000-11-28
;  PRIOR APPLICATION NUMBER: US 09/580,015
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/322,289
;  PRIOR FILING DATE: 1999-05-28
;  PRIOR APPLICATION NUMBER: US 09/201,430
;  PRIOR FILING DATE: 1998-11-30
;  PRIOR APPLICATION NUMBER: WO PCT/US00/14810
;  PRIOR FILING DATE: 1998-11-30
;  PRIOR APPLICATION NUMBER: US 60/080,970
;  PRIOR FILING DATE: 1998-04-07
;  PRIOR APPLICATION NUMBER: US 60/067,740
;  PRIOR FILING DATE: 1997-12-02
;  NUMBER OF SEQ ID NOS: 77
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
;  LENGTH: 10
;  TYPE: PRT
;  ORGANISM: Artificial Sequence
;  FEATURE:
;  OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;  OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;  OTHER INFORMATION: peptide)
US-09-724-961-7

Query Match         100.0%;  Score 24; DB 4; Length 10;
Best Local Similarity 100.0%;  Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy     1 EFRH 4
         ||||
Db     5 EFRH 8

RESULT 7
US-09-724-961-8
; Sequence 8, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
;  APPLICANT: Schenk, Dale B.
;  APPLICANT: Bard, Frederique
;  APPLICANT: Vasquez, Nicki
;  APPLICANT: Yednock, Ted
;  TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;  FILE REFERENCE: 15270J-004750UC
;  CURRENT APPLICATION NUMBER: US/09/724,961
;  CURRENT FILING DATE: 2000-11-28
;  PRIOR APPLICATION NUMBER: US 09/580,015
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/322,289
;  PRIOR FILING DATE: 1999-05-28
;  PRIOR APPLICATION NUMBER: US 09/201,430
;  PRIOR FILING DATE: 1998-11-30
;  PRIOR APPLICATION NUMBER: WO PCT/US00/14810
;  PRIOR FILING DATE: 1998-11-30
;  PRIOR APPLICATION NUMBER: US 60/080,970
;  PRIOR FILING DATE: 1998-04-07
;  PRIOR APPLICATION NUMBER: US 60/067,740
;  PRIOR FILING DATE: 1997-12-02
;  NUMBER OF SEQ ID NOS: 77
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
;  LENGTH: 10
;  TYPE: PRT
;  ORGANISM: Artificial Sequence
;  FEATURE:
;  OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;  OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;  OTHER INFORMATION: peptide)
US-09-724-961-8

Query Match         100.0%;  Score 24; DB 4; Length 10;
Best Local Similarity 100.0%;  Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy     1 EFRH 4
         ||||
Db     4 EFRH 7

RESULT 8
US-09-724-961-9
; Sequence 9, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
;  APPLICANT: Schenk, Dale B.
;  APPLICANT: Bard, Frederique
;  APPLICANT: Vasquez, Nicki
;  APPLICANT: Yednock, Ted
;  TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;  FILE REFERENCE: 15270J-004750UC
;  CURRENT APPLICATION NUMBER: US/09/724,961
;  CURRENT FILING DATE: 2000-11-28
;  PRIOR APPLICATION NUMBER: US 09/580,015
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/322,289
;  PRIOR FILING DATE: 1999-05-28
;  PRIOR APPLICATION NUMBER: US 09/201,430
;  PRIOR FILING DATE: 1998-11-30
;  PRIOR APPLICATION NUMBER: WO PCT/US00/14810
;  PRIOR FILING DATE: 1998-11-30
;  PRIOR APPLICATION NUMBER: US 60/080,970
;  PRIOR FILING DATE: 1998-04-07
;  PRIOR APPLICATION NUMBER: US 60/067,740
;  PRIOR FILING DATE: 1997-12-02
;  NUMBER OF SEQ ID NOS: 77
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
;  LENGTH: 10
;  TYPE: PRT
;  ORGANISM: Artificial Sequence
;  FEATURE:
;  OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
;  OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
;  OTHER INFORMATION: peptide)
US-09-724-961-9

Query Match         100.0%;  Score 24; DB 4; Length 10;
Best Local Similarity 100.0%;  Pred. No. 19;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy     1 EFRH 4
```

```
Db          3 EFRH 6
            |||

RESULT 9
US-09-724-961-10
; Sequence 10, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-10

Query Match          100.0%;    Score 24;  DB 4;  Length 10;
Best Local Similarity 100.0%;    Pred. No. 19;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          2 EFRH 5

RESULT 10
US-09-724-961-11
; Sequence 11, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
```

```
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-11

Query Match          100.0%;    Score 24;  DB 4;  Length 10;
Best Local Similarity 100.0%;    Pred. No. 19;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 11
US-09-580-018-5
; Sequence 5, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-5

Query Match          100.0%;    Score 24;  DB 4;  Length 10;
Best Local Similarity 100.0%;    Pred. No. 19;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          7 EFRH 10

RESULT 12
US-09-580-018-6
; Sequence 6, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
```

```
                  GenCore version 5.1.6
          Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on:     November  2, 2005, 09:04:09 ; Search time 164 Seconds
                                         (without alignments)
                                9.433 Million cell updates/sec

Title:         US-10-618-856-1
Perfect score: 24
Sequence:      1 EFRH 4

Scoring table: BLOSUM62
               Gapop 10.0 , Gapext 0.5

Searched:      2105692 seqs, 38676381 residues

Total number of hits satisfying chosen parameters:     2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :  A_Geneseq_16Dec04:.*
        1:  geneseqp1980s:.*
        2:  geneseqp1990s:.*
        3:  geneseqp2000s:.*
        4:  geneseqp2001s:.*
        5:  geneseqp2002s:.*
        6:  geneseqp2003as:.*
        7:  geneseqp2003bs:.*
        8:  geneseqp2004s:.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

                         SUMMARIES
```

| Result No. | Score | Query Match | Length | DB | ID | Description |
|---|---|---|---|---|---|---|
| 1 | 24 | 100.0 | 4 | 2 | AAW70870 | Aaw70870 Beta-amyl |
| 2 | 24 | 100.0 | 4 | 6 | AAO16062 | Aao16062 Neurologi |
| 3 | 24 | 100.0 | 4 | 6 | ABP70744 | Abp70744 Antigenic |
| 4 | 24 | 100.0 | 4 | 7 | ADB75167 | Adb75167 Human amy |
| 5 | 24 | 100.0 | 4 | 7 | ADE36574 | Ade36574 Beta-amyl |
| 6 | 24 | 100.0 | 4 | 8 | ADJ88108 | Adj88108 Human bet |
| 7 | 24 | 100.0 | 4 | 8 | ADJ71364 | Adj71364 N-termina |
| 8 | 24 | 100.0 | 4 | 8 | ADJ71377 | Adj71377 N-termina |
| 9 | 24 | 100.0 | 4 | 8 | ADP90808 | Adp90808 Protein/p |
| 10 | 24 | 100.0 | 5 | 6 | ADA90172 | Ada90172 Anti-Abet |
| 11 | 24 | 100.0 | 5 | 8 | ADJ71378 | Adj71378 N-termina |
| 12 | 24 | 100.0 | 5 | 8 | ADJ71365 | Adj71365 N-termina |
| 13 | 24 | 100.0 | 5 | 8 | ADJ71352 | Adj71352 N-termina |
| 14 | 24 | 100.0 | 5 | 2 | AAW70868 | Aaw70868 Beta-amyl |
| 15 | 24 | 100.0 | 6 | 4 | AAB47109 | Aab47109 Epitope # |
| 16 | 24 | 100.0 | 6 | 6 | AAO16067 | Aao16067 Neurologi |
| 17 | 24 | 100.0 | 6 | 6 | ADA90170 | Ada90170 Anti-Abet |
| 18 | 24 | 100.0 | 6 | 7 | ADB75165 | Adb75165 Human amy |
| 19 | 24 | 100.0 | 6 | 8 | ADJ88114 | Adj88114 fd phage |
| 20 | 24 | 100.0 | 6 | 8 | ADJ71366 | Adj71366 N-termina |
| 21 | 24 | 100.0 | 6 | 8 | ADJ71379 | Adj71379 N-termina |
| 22 | 24 | 100.0 | 6 | 8 | ADJ71340 | Adj71340 N-termina |
| 23 | 24 | 100.0 | 6 | 8 | ADJ71353 | Adj71353 N-termina |
| 24 | 24 | 100.0 | 6 | 8 | ADK52251 | Adk52251 Human amy |
| 25 | 24 | 100.0 | 6 | 8 | ADK52264 | Adk52264 Guinea pi |
| 26 | 24 | 100.0 | 6 | 8 | ADK52261 | Adk52261 Rabbit am |
| 27 | 24 | 100.0 | 6 | 8 | ADK52260 | Adk52260 Primate a |
| 28 | 24 | 100.0 | 6 | 8 | ADK52266 | Adk52266 Amyloid b |
| 29 | 24 | 100.0 | 6 | 8 | ADQ82427 | Adq82427 N-termina |
| 30 | 24 | 100.0 | 6 | 8 | ADQ82432 | Adq82432 N-termina |
| 31 | 24 | 100.0 | 6 | 8 | ADQ82430 | Adq82430 N-termina |
| 32 | 24 | 100.0 | 6 | 8 | ADQ82433 | Adq82433 N-termina |
| 33 | 24 | 100.0 | 6 | 8 | ADQ82434 | Adq82434 N-termina |
| 34 | 24 | 100.0 | 6 | 8 | ADQ82436 | Adq82436 N-termina |
| 35 | 24 | 100.0 | 6 | 8 | ADQ82431 | Adq82431 N-termina |
| 36 | 24 | 100.0 | 6 | 8 | ADQ82423 | Adq82423 N-termina |
| 37 | 24 | 100.0 | 6 | 8 | ADQ82424 | Adq82424 N-termina |
| 38 | 24 | 100.0 | 6 | 8 | ADQ82428 | Adq82428 N-termina |
| 39 | 24 | 100.0 | 6 | 8 | ADQ82435 | Adq82435 N-termina |
| 40 | 24 | 100.0 | 6 | 8 | ADQ82429 | Adq82429 N-termina |
| 41 | 24 | 100.0 | 6 | 8 | ADQ82425 | Adq82425 N-termina |
| 42 | 24 | 100.0 | 6 | 8 | ADQ82422 | Adq82422 N-termina |
| 43 | 24 | 100.0 | 6 | 8 | ADQ82421 | Adq82421 N-termina |
| 44 | 24 | 100.0 | 6 | 8 | ADQ82437 | Adq82437 N-termina |
| 45 | 24 | 100.0 | 6 | 8 | ADQ82386 | Adq82386 Natural N |

```
                         ALIGNMENTS

RESULT 1
AAW70870
ID   AAW70870 standard; peptide; 4 AA.
XX
AC   AAW70870;
XX
DT   04-FEB-1999  (first entry)
XX
DE   Beta-amyloid peptide epitope.
XX
KW   Beta-amyloid precursor protein; beta-APP; beta-amyloid peptide; antibody;
KW   amyloid deposit; Alzheimer's disease.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO984955-A1.
XX
PD   15-OCT-1998.
XX
PF   09-APR-1998;  98WO-US006900.
XX
PR   09-APR-1997;  97US-0041850P.
XX
PA   (MIND-) MINDSET LTD.
PA   (MCIN/) MCINNIS P A.
XX
PI   Chain DG;
XX
DR   WPI; 1998-594476/50.
XX
PT   Preventing or inhibiting;progression of Alzheimer's Disease - comprises
PT   use of recombinant DNA encoding an antibody specific for the N- or C-
PT   terminus of an amyloid-beta peptide.
XX
PS   Example 1; Page 47; 58pp; English.
XX
CC   The present sequence represents a peptide epitope derived from beta-
CC   amyloid precursor protein peptide. The specification describes a method
CC   for prevention or inhibition of progression of Alzheimer's disease. The
CC   method comprises administering a composition comprising a recombinant DNA
CC   molecule containing a gene encoding a recombinant antibody end-specific
CC   for the N-terminus or the C-terminus of an amyloid-beta peptide, operably
CC   linked to a promoter which is expressed in the central nervous system.
CC   The recombinant antibody molecules prevent the accumulation of beta-
CC   amyloid peptides in the extracellular space, interstitial fluid and
CC   cerebrospinal fluid and the aggregation of such peptides into amyloid
CC   deposits in the brain. They also inhibit the progression of Alzheimer's
```

```
CC           disease by inhibiting the interaction of beta-amyloid peptides mediating
CC           Alzheimer's disease induced neurotoxicity and inhibiting the Alzheimer's
CC           disease induced complement activation and cytokine release involved in
CC           the inflammatory process
XX
SQ           Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 2;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy            1 EFRH 4
                |||
Db            1 EFRH 4

XX
SQ           Sequence 4 AA;

RESULT 2
AAO16062
ID   AAO16062 standard; peptide; 4 AA.
XX
AC   AAO16062;
XX
DT   27-FEB-2003  (first entry)
XX
DE   Neurological/CNS disease treatment method-related peptide #1.
XX
KW   Vaccine; gene therapy; neurological disease; CNS disorder;
KW   central nervous system disorder; olfactory system; Alzheimer's disease;
KW   Creutzfeld-Jakob disease; Huntington's chorea; Parkinson's disease;
KW   viral infection of the brain; brain tumour; lysosomal storage disease;
KW   multiple sclerosis.
XX
OS   Unidentified.
XX
PN   WO20027424 3-A2.
XX
PD   26-SEP-2002.
XX
PF   15-MAR-2002; 2002WO-US008042.
XX
PR   15-MAR-2001; 2001US-00808037.
XX
PA   (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
PA   (MCIN/) MCINNIS P.
XX
PI   Solomon B, Frenkel D;
XX
DR   WPI; 2003-040542/03.
XX
PT   Treating or diagnosing neurological diseases of the central nervous
PT   system, e.g. Alzheimer's disease, comprises displaying a polypeptide or
PT   diagnostic agent on viral display vehicle and introducing or detecting
PT   the display vehicle.
XX
PS   Example 9; Page 138; 214pp; English.
XX
CC   The invention comprises a method for treating a neurological disease or a
CC   central nervous system (CNS) disorder. The method involves displaying a
CC   therapeutic molecule capable of treating the neurological disease or CNS
CC   disorder on a viral display vehicle. The viral display vehicle is then
CC   introduced into the olfactory system of a subject to treat the disease or
CC   disorder. The method of the invention is useful for preventing, treating
CC   and diagnosing neurological diseases or CNS disorders, such as:
CC   Alzheimer's disease; Creutzfeld-Jakob disease; Huntington's chorea; viral
CC   infections of the brain; brain tumours; lysosomal storage diseases;
CC   Parkinson's disease; and multiple sclerosis. The present amino acid
CC   sequence represents a peptide which was used in the invention
XX
SQ           Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 6;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy            1 EFRH 4
                |||
Db            1 EFRH 4

RESULT 3
ABP70744
ID   ABP70744 standard; peptide; 4 AA.
XX
AC   ABP70744;
XX
DT   15-MAY-2003  (first entry)
XX
DE   Antigenic peptide, SEQ ID 5.
XX
KW   Nootropic; neuroprotective; antiinflammatory; vaccine; antigenic product;
KW   plaque-forming disease; Alzheimer's disease; SAA amyloidosis;
KW   hereditary Icelandic syndrome; senility; multiple myeloma;
KW   Creutzfeld-Jakob disease; Kuru; Gerstmann-Straussler-Scheinker disease;
KW   fatal familial insomnia; scrapie; bovine spongiform encephalitis;
KW   antigenic; multiantigen.
XX
OS   Synthetic.
XX
PN   WO2003000719-A2.
XX
PD   03-JAN-2003.
XX
PF   20-JUN-2002; 2002WO-US019567.
XX
PR   20-JUN-2001; 2001US-0299201P.
PR   12-APR-2002; 2002US-0371717P.
XX
PA   (UYRA-) UNIV RAMOT.
PA   (MCIN/) MCINNIS P.
XX
PI   Mcinnis P, Solomon B;
XX
DR   WPI; 2003-239139/23.
XX
PT   Antigenic product has dendritic polymer built on core molecule having
PT   terminal functional groups to which antigenic peptide that has epitope of
PT   deposit-forming polypeptide involved in plaque-forming disease is joined.
XX
PS   Claim 6; Page 44; 70pp; English.
XX
CC   The present invention relates to antigenic products (A), comprising a
CC   dendritic polymer built on a core molecule which is at least difunctional
CC   to provide branching and containing up to 16 terminal functional groups
CC   to which an antigenic peptide, that comprises an epitope of a deposit-
CC   forming polypeptide involved in plaque-forming disease, is joined by
CC   covalent bonds. The antigenic products are useful for eliciting an immune
CC   response against a deposit-forming polypeptide involved in a plaque-
CC   forming disease or disorder, e.g. Alzheimer's disease, SAA amyloidosis,
CC   hereditary Icelandic syndrome, senility, multiple myeloma, Creutzfeldt-
CC   Jakob disease, Kuru, Gerstmann-Straussler-Scheinker disease, fatal
CC   familial insomnia, scrapie or bovine spongiform encephalitis, by
CC   administering the antigenic product to a subject in need of it. The
CC   present sequence is one such antigenic peptide, which was used to
CC   illustrate the invention
XX
SQ           Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 6;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy            1 EFRH 4
                |||
Db            1 EFRH 4
```

RESULT 4
ADB75167
ID   ADB75167 standard; peptide; 4 AA.
XX
AC   ADB75167;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Human amyloid beta peptide SEQ ID NO:8.
XX
KW   antibody; amyloid beta peptide; amyloid beta; nootropic; neuroprotective;
KW   antibody therapy; Alzheimer's disease; mild cognitive impairment;
KW   cerebral amyloid angiopathy; congiophylic angiopathy; Down's syndrome;
KW   inclusion body myositis; neurotoxicity; beta amyloid precursor protein;
KW   APP; human.
XX
OS   Homo sapiens.
XX
PN   WO200307408l-Al.
XX
PD   12-SEP-2003.
XX
PF   21-OCT-2002; 2002WO-US031590.
XX
PR   28-FEB-2002; 2002US-00084380.
XX
PA   (MIND-) MINDSET BIOPHARMACEUTICALS USA INC.
XX
PI   Chain DG;
XX
DR   WPI; 2003-731651/69.
XX
PT   New antibody that is targeted to amyloid beta peptide, or its fragment,
PT   useful for treating a subject having Alzheimer's disease, or a disease or
PT   disorder characterized by amyloid beta deposition, e.g. cognitive
PT   impairment or dementia.
XX
PS   Disclosure; Page 60; 63pp; English.
XX
CC   The present invention describes an antibody that is targeted to amyloid
CC   beta peptide, or its fragment. Also described: (1) an antibody that is
CC   free-end specific and is targeted to: (a) the free N-terminus of amyloid
CC   beta-peptide; (b) the free N-terminus of amyloid beta-peptide, where the
CC   first amino acid of amyloid beta-peptide is aspartate; (c) the free N-
CC   terminus of N- and/or C-terminus-truncated amyloid beta-peptide fragment;
CC   (d) the free C-terminus of the amyloid beta-peptide Abeta1-39, Abeta1-40,
CC   Abeta1-41 or Abeta1-43; or (e) to the free C-terminus of N- and/or C-
CC   terminus-truncated amyloid beta-peptide fragment; (2) a single chain or
CC   artificial antibody that is free-end specific and is targeted to the free
CC   C-terminus of the amyloid beta-peptide Abeta1-42; and (3) a
CC   pharmaceutical composition comprising the antibody, and a carrier. The
CC   antibody targeted to amyloid beta peptide has nootropic and
CC   neuroprotective activities, and can be used in antibody therapy. The
CC   antibody or its fragment is used for manufacturing a medicament for
CC   treating a subject having Alzheimer's disease, or a disease or disorder
CC   characterized by amyloid beta deposition (e.g. mild cognitive impairment,
CC   cerebral amyloid angiopathy or congiophylic angiopathy, Alzheimer's
CC   disease associated with Down's syndrome, or inclusion body myositis), or
CC   for delaying, inhibiting or suppressing accumulation of amyloid beta
CC   peptide, or the neurotoxicity of amyloid beta peptide or its fragment.
CC   Amyloid beta peptide are derived from beta amyloid precursor protein
CC   (APP). The present sequence represents an amyloid beta peptide which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 7;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 5
ADE36574
ID   ADE36574 standard; peptide; 4 AA.
XX
AC   ADE36574;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Beta-amyloid (Abeta) peptide 3-6 SEQ ID NO:2.
XX
KW   immune response; beta-secretase cleavage site; amyloid precursor protein;
KW   APP; nootropic; neuroprotective; vaccine; passive immunisation;
KW   Alzheimer's disease.
XX
OS   Synthetic.
XX
PN   WO200307645s-A2.
XX
PD   18-SEP-2003.
XX
PF   04-MAR-2003; 2003WO-US006388.
XX
PR   05-MAR-2002; 2002US-0361344P.
XX
PA   (UYRA-) UNIV RAMOT AT TEL AVIV LTD.
PA   (MCIN/) MCINNIS P.
XX
PI   Solomon B;
XX
DR   WPI; 2003-865017/80.
XX
PT   Immunizing composition, useful for treating Alzheimer's disease by
PT   inhibiting processing of amyloid precursor protein, also antibodies for
PT   passive immunization.
XX
PS   Disclosure; SEQ ID NO 2; 76pp; English.
XX
CC   The present invention describes an immunising composition (A) comprising:
CC   (a) an antigenic product (I) which induces an immune response against the
CC   beta-secretase cleavage site of amyloid precursor protein (APP); and (b)
CC   a carrier, diluent, excipient, adjuvant or auxiliary. Also described: (1)
CC   a molecule (II) comprising the antigen-binding part of an antibody (Ab)
CC   directed against the beta-secretase cleavage site of APP; (2) a
CC   filamentous bacteriophage (FB) that displays (II), where this is a single
CC   -chain Ab, on its surface; and (3) a composition containing FB. (A) has
CC   nootropic and neuroprotective activities, and can be used in vaccines or
CC   passive immunisation. (A) inhibits the cleavage of APP and so prevents
CC   the formation of beta-amyloid. (A) can be used to induce an immune
CC   response against the beta-secretase cleavage site of APP, specifically
CC   for treatment and prevention of Alzheimer's disease. The molecule (II)
CC   that contains the antigen-binding part of an Ab directed against the
CC   cleavage site, or a filamentous phage that displays such an Ab (as a
CC   single-chain molecule) can be used similarly, for passive immunisation.
CC   The present sequence represents a beta-amyloid (Abeta) peptide which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 7;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 6
ADJ88108
ID   ADJ88108 standard; peptide; 4 AA.
XX

```
AC   ADJ8108;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human beta amyloid peptide anti-aggregating epitope.
XX
KW   Neurological disease; central nervous system; CNS disorder;
KW   plaque-forming disease; Alzheimer's disease; SAA amyloidosis;
KW   hereditary Icelandic syndrome; senility; multiple myeloma; scrapie;
KW   bovine spongiform encephalopathy; BSE; kuru; Creutzfeldt-Jakob disease;
KW   CJD; Gerstmann-Streussler-Sheinker disease; GSS; fatal familial insomnia;
KW   FFI; non-plaque-forming disease; Huntington's chorea; viral infection;
KW   brain tumour; lysosomal storage disease; neurodegeneration;
KW   multiple sclerosis; vaccine; beta amyloid peptide; epitope; beta AP;
KW   human.
XX
OS   Homo sapiens.
XX
PN   US2004013647-A1.
XX
PD   22-JAN-2004.
XX
PF   11-MAR-2003; 2003US-00384788.
XX
PR   03-SEP-1999;   99US-0152417P.
PR   29-DEC-1999;   99US-00473653.
PR   31-JUL-2000;   2000US-00629971.
PR   31-AUG-2000;   2000WO-IL000518.
PR   15-MAR-2001;   2001US-00808037.
PR   07-AUG-2001;   2001US-00830954.
PR   12-APR-2002;   2002US-0371735P.
PR   06-JUN-2002;   2002US-00162889.
XX
PA   (UYRA-) UNIV RAMOT AT TEL AVIV LTD.
XX
PI   Solomon B,  Frenkel D;
XX
DR   WPI; 2004-108188/11.
XX
PT   Treating neurological disease CNS e.g., Alzheimer's disease, by
PT   displaying therapeutic molecule capable of treating the disease on viral
PT   display vehicle which is then administered to subject through olfactory
PT   system.
XX
PS   Example 10; SEQ ID NO 1; 68pp; English.
XX
CC   The invention relates to a method of treating a neurological disease or
CC   disorder of the central nervous system (CNS). The method involves
CC   displaying a therapeutic molecule capable of treating the neurological
CC   disease or disorder of the CNS on a viral display vehicle and introducing
CC   the viral display vehicle displaying the therapeutic molecule to an
CC   olfactory system of the subject. The method is useful for treating a
CC   neurological disease or disorder of CNS such as a plaque-forming disease
CC   such as Alzheimer's disease, late onset Alzheimer's disease,
CC   presymptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic
CC   syndrome, senility, multiple myeloma, scrapie, bovine spongiform
CC   encephalopathy (BSE), kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-
CC   Streussler-Sheinker disease (GSS) or fatal familial insomnia (FFI). The
CC   method is also useful for treating a non plaque forming disease or
CC   disorder e.g. Huntington's chorea, viral infections of the brain, brain
CC   tumours, lysosomal storage diseases which cause neurodegeneration and are
CC   manifested by enzyme deficiencies and multiple sclerosis. The invention
CC   is also used in the preparation of vaccines. The present sequence is
CC   human beta amyloid peptide (beta AP) anti-aggregating epitope. This
CC   sequence is used to illustrate the method of the invention.
XX
SQ   Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy           1 EFRH 4
               ||||
Db           1 EFRH 4
```

```
RESULT 7
ADJ71364
ID   ADJ71364 standard; peptide; 4 AA.
XX
AC   ADJ71364;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 27.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A,  Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment or a therapeutic vaccine associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 4 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy           1 EFRH 4
               ||||
Db           1 EFRH 4
```

```
RESULT 8
ADJ71377
ID   ADJ71377 standard; peptide; 4 AA.
XX
AC   ADJ71377;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 40.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
```

```
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "Pyroglutamic acid"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 62; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 4 AA;

Query Match         100.0%;     Score 24;  DB 8;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        1 EFRH 4
            ||||
Db        1 EFRH 4

RESULT 9
ADP90808
ID   ADP90808 standard; peptide; 4 AA.
XX
AC   ADP90808;
XX
DT   09-SEP-2004  (first entry)
XX
DE   Protein/peptide labelling method-related affinity tag peptide #3.
XX
KW   protein labelling; peptide labelling;
KW   irreversible affinity tagging residue;
KW   reversible affinity tagging residue; high throughput screening assay;
KW   pharmaceutical agent; affinity tag.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   4
FT                   /note= "C-terminal amide"
XX
PN   WO2004051270-A2.
XX


PD   17-JUN-2004.
XX
PF   04-DEC-2003; 2003WO-EP013715.
XX
PR   05-DEC-2002; 2002GB-00028429.
XX
PA   (NOVS ) NOVARTIS AG.
PA   (NOVS ) NOVARTIS PHARMA GMBH.
XX
PI   Auer M, Meisner N, Seifert J;
XX
DR   WPI; 2004-480677/45.
XX
PT   Providing labeled target protein or target peptide by contacting chemical
PT   compound with affinity support, removing impurities in reaction mixture
PT   surrounding affinity support, cleaving or eluting chemical molecule from
PT   affinity support.
XX
PS   Claim 4; Page 70; 81pp; English.
XX
CC   The invention comprises a method for providing a labelled target
CC   protein/peptide. The method involves contacting a chemical compound with
CC   affinity support, removing impurities in the reaction mixture surrounding
CC   the affinity support to which the chemical molecule is bound, and
CC   cleaving or eluting the molecule from the affinity support to obtain
CC   irreversible or reversible affinity tagging residue, labelled target
CC   protein or labelled peptide. The method of the invention is useful for
CC   labelling a target protein/peptide or high throughput screening assay.
CC   The method of the invention is useful for identifying agents that
CC   modulate the activity or characteristics of a target protein/peptide -
CC   such agents are useful as pharmaceuticals. The present amino acid
CC   sequence represents an affinity tag peptide of the invention.
XX
SQ   Sequence 4 AA;

Query Match         100.0%;     Score 24;  DB 8;  Length 4;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        1 EFRH 4
            ||||
Db        1 EFRH 4

RESULT 10
ADA90172
ID   ADA90172 standard; peptide; 5 AA.
XX
AC   ADA90172;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Anti-Abeta antibody related amino acid sequence SEQ ID NO:287.
XX
KW   antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;
KW   nootropic; antiparkinsonian; gene therapy; amyloidogenesis;
KW   amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;
KW   Alzheimer's disease; motor neuropathy; Down's syndrome;
KW   Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;
KW   Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;
KW   neuronal disorder; aging.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070760-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-EP001759.
XX
PR   20-FEB-2002; 2002EP-00003844.
XX
```

```
PA   (HOFF ) HOFFMANN LA ROCHE & CO AG F.
PA   (MORP-) MORPHOSYS AG.
XX
PI   Bardroff M,  Bohrmann B,  Brockhaus M,  Huber W,  Kretzschmar T;
PI   Loehning C,  Loetscher H,  Nordstedt C,  Rothe C;
XX
DR   WPI; 2003-663848/62.
XX
PT   New antibody molecule capable of specifically recognizing two regions of
PT   the beta-A4 peptide, useful for diagnosing, preventing or treating
PT   diseases associated with amyloidogenesis or amyloid-plaque formation
PT   (e.g. dementia).
XX
PS   Disclosure; Page 265; 312pp; English.
XX
CC   The present invention describes an antibody molecule (I) capable of
CC   specifically recognising two regions of the beta-A4 peptide/Abeta4. The
CC   first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-
CC   Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the
CC   amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-
CC   Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule
CC   encoding (I); (2) a vector comprising the nucleic acid of (1); (3) a host
CC   cell comprising the vector of (2); (4) preparing (I), comprising
CC   culturing the host cell of (3) under conditions that allow synthesis of
CC   (I) and recovering (I) from the culture; (5) a composition comprising (I)
CC   or an antibody molecule produced by method (4); (6) a kit comprising (I),
CC   nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising
CC   (I); (8) testing the resulting Fab optimisation library by panning
CC   against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing
CC   of selected, optimised clones; (11) preparing a pharmaceutical
CC   composition, comprising optimisation of (I), and formulating the
CC   optimised antibody/antibody molecule with a carrier; and (12) a
CC   pharmaceutical composition prepared by method (8). (I) has
CC   neuroprotective, nootropic and antiparkinsonian activities, and can be
CC   used in gene therapy. The antibody molecule (I), nucleic acid molecule,
CC   vector or host is useful in preparing a pharmaceutical composition for
CC   the prevention and/or treatment of a disease associated with
CC   amyloidogenesis and/or amyloid-plaque formation. The antibody molecule
CC   may also be used in preparing a diagnostic composition for the detection
CC   of the disease mentioned above. The antibody is used for the
CC   disintegration of beta-amyloid plaques or for passive immunisation
CC   against beta-amyloid plaque formation. In particular, the disease is
CC   dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,
CC   Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with
CC   amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,
CC   amyotrophic lateral sclerosis or neuronal disorders related to aging. The
CC   present sequence is used in the exemplification of the present invention.
XX
SQ   Sequence 5 AA;

Query Match             100.0%;  Score 24;  DB 6;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 11
ADJ71378
ID   ADJ71378 standard; peptide; 5 AA.
XX
AC   ADJ71378;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 41.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
```

```
XX
FH   Key              Location/Qualifiers
FT   Modified-site    1
FT                    /note= "Pyroglutamic acid"
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A,  Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 62; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 5 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 12
ADJ71365
ID   ADJ71365 standard; peptide; 5 AA.
XX
AC   ADJ71365;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 28.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   WO2004013172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002EP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
```

```
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 5 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches   0;  Indels    0;  Gaps     0;

Qy          1 EFRH 4
              ||||
Db          1 EFRH 4

RESULT 13
ADJ71352
ID   ADJ71352 standard; peptide; 5 AA.
XX
AC   ADJ71352;
XX
DT   06-MAY-2004  (first entry)
XX
DE   N-terminal truncated beta-amyloid peptide, SEQ ID 15.
XX
KW   Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW   amyloid precursor protein; APP; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
FH   Key           Location/Qualifiers
FT   Modified-site 1
FT                 /note= "Optionally methylated"
XX
PN   WO200413172-A2.
XX
PD   12-FEB-2004.
XX
PF   18-JUL-2003; 2003WO-EP007833.
XX
PR   24-JUL-2002; 2002BP-00447147.
PR   06-AUG-2002; 2002US-0401497P.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Delacourte A, Sergeant N;
XX
DR   WPI; 2004-180423/17.
XX
PT   New beta-amyloid or amyloid precursor protein preparation, useful as a
PT   prophylactic vaccine or a therapeutic for preventing or treating a
PT   disease associated with beta-amyloid formation and/or aggregation, e.g.
PT   Alzheimer's disease.
XX
PS   Claim 4; Page 61; 104pp; English.
XX
CC   The present invention relates to preparations (I) comprising a beta-
CC   amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC   terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC   fragment. The beta-amyloid or APP preparations are useful for
CC   manufacturing a prophylactic vaccine or a therapeutic, or as a
CC   prophylactic vaccine for the prevention, or as a therapeutic for the
CC   treatment of a disease associated with beta-amyloid formation and/or
CC   aggregation, such as Alzheimer's disease.
XX
SQ   Sequence 5 AA;

Query Match             100.0%;  Score 24;  DB 8;  Length 5;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative    0;  Mismatches   0;  Indels    0;  Gaps     0;

Qy          1 EFRH 4
              |||
Db          2 EFRH 5

RESULT 14
AAW70868
ID   AAW70868 standard; peptide; 6 AA.
XX
AC   AAW70868;
XX
DT   04-FEB-1999  (first entry)
XX
DE   Beta-amyloid peptide to create a monoclonal antibody.
XX
KW   Beta-amyloid precursor protein; beta-APP; beta-amyloid peptide; antibody;
KW   amyloid deposit; Alzheimer's disease.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO984955-A1.
XX
PD   15-OCT-1998.
XX
PF   09-APR-1998;  98WO-US006900.
XX
PR   09-APR-1997;  97US-0041850P.
XX
PA   (MIND-) MINDSET LTD.
PA   (MCIN/) MCINNIS P A.
XX
PI   Chain DG;
XX
DR   WPI; 1998-594476/50.
XX
PT   Preventing or inhibiting progression of Alzheimer's Disease - comprises
PT   use of recombinant DNA encoding an antibody specific for the N- or C-
PT   terminus of an amyloid-beta peptide.
XX
PS   Example 1; Page 47; 58pp; English.
XX
CC   The present sequence represents a peptide derived from beta-amyloid
CC   precursor protein (beta-APP, see AAW70863). The peptide is a beta-amyloid
CC   peptide and is used to produce a monoclonal antibody. The specification
CC   describes a method for prevention or inhibition of progression of
CC   Alzheimer's disease. The method comprises administering a composition
CC   comprising a recombinant DNA molecule containing a gene encoding a
CC   recombinant antibody end-specific for the N-terminus or the C-terminus of
CC   an amyloid-beta peptide, operably linked to a promoter which is expressed
CC   in the central nervous system. The recombinant antibody molecules prevent
CC   the accumulation of beta-amyloid peptides in the extracellular space,
CC   interstitial fluid and cerebrospinal fluid and the aggregation of such
CC   peptides into amyloid deposits in the brain. They also inhibit the
CC   progression of Alzheimer's disease by inhibiting the interaction of beta-
CC   amyloid peptides mediating Alzheimer's disease induced neurotoxicity and
CC   inhibiting the Alzheimer's disease induced complement activation and
CC   cytokine release involved in the inflammatory process
XX
```

Db              3 EFRH 6
                  |||||
                3 EFRH 6

Search completed: November  2, 2005, 09:27:50
Job time : 167 secs

SQ    Sequence 6 AA;

Query Match          100.0%;  Score 24; DB 2; Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 15
AAB47109
ID   AAB47109 standard; peptide; 6 AA.
XX
AC   AAB47109;
XX
DT   04-JUN-2001  (first entry)
XX
DE   Epitope #1 used in treatment of plaque forming disease.
XX
KW   Human; prion protein; plaque forming disease; display vehicle; kuru;
KW   aggregating protein; amyloid plaque; brain; early onset; senility;
KW   Alzheimer's disease; late onset; pre-symptomatic; SAA amyloidosis;
KW   hereditary Icelandic syndrome; multiple myeloma; scrapie; BSE; CJD;
KW   bovine spongiform encephalopathy; Creutzfeldt-Jakob Disease; FFI;
KW   Gerstmann-Streussler-Sheinker Disease; GSS; fatal familial insomnia.
XX
OS   Synthetic.
XX
PN   WO200118169-A2.
XX
PD   15-MAR-2001.
XX
PF   31-AUG-2000; 2000WO-IL000518.
XX
PR   03-SEP-1999;    99US-0152417P.
PR   29-DEC-1999;    99US-00473653.
PR   31-JUL-2000;    2000US-00629971.
XX
PA   (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
XX
PI   Solomon B,  Frenkel D,  Hanan E;
XX
DR   WPI; 2001-244564/25.
XX
PT   Treating amyloidgenic disease such as Alzheimer's disease, BSE or CJD
PT   comprises presentation of plaque derived antigens or epitopes on a
PT   display vehicle, and introducing the vehicle into the recipient.
XX
PS   Example; Page 50; 120pp; English.
XX
CC   This peptide is based on the N-terminal fragment of beta-amyloid peptide
CC   (beta-AP) and was fused to the minor coat protein of fd phage. This
CC   peptide may be used in the method of the invention. The invention
CC   provides an agent for treating a plaque forming disease. The polypeptide
CC   is displayed on a display vehicle and is capable of eliciting antibodies
CC   capable of disaggregating the aggregating protein and/or of preventing
CC   aggregation of the aggregating protein. This reduces formation of amyloid
CC   plaques in the brain of victims of plaque forming diseases, e.g. early
CC   onset Alzheimer's disease, late onset Alzheimer's disease, pre-
CC   symptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic
CC   syndrome, senility, multiple myeloma, scrapie, bovine spongiform
CC   encephalopathy (BSE), kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann-
CC   Streussler-Sheinker Disease (GSS) and fatal familial insomnia (FFI)
XX
SQ    Sequence 6 AA;

Query Match          100.0%;  Score 24;  DB 4; Length 6;
Best Local Similarity   100.0%;  Pred. No. 1.8e+06;
Matches    4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 EFRH 4

```
          Copyright  GenCore version 5.1.6
          Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on:    November  2, 2005, 09:12:39 ; Search time 38 seconds
                        (without alignments)
                        10.128 Million cell updates/sec

Title:     US-10-618-856-1
Perfect score: 24
Sequence:  1 EFRH 4
Scoring table: BLOSUM62
           Gapop 10.0 , Gapext 0.5

Searched:  283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters:        283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :  PIR 79:*
            1: Pir1:*
            2: pir2:*
            3: pir3:*
            4: pir4:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.
```

SUMMARIES

| Result No. | Score | % Query Match | Match Length | DB | ID | Description |
|---|---|---|---|---|---|---|
| 1 | 24 | 100.0 | 39 | 2 | A48544 | neuropeptide F - b |
| 2 | 24 | 100.0 | 42 | 2 | PN0512 | beta-amyloid prote |
| 3 | 24 | 100.0 | 52 | 2 | C91112 | hypothetical prote |
| 4 | 24 | 100.0 | 57 | 2 | A60045 | Alzheimer's diseas |
| 5 | 24 | 100.0 | 57 | 2 | F60045 | Alzheimer's diseas |
| 6 | 24 | 100.0 | 57 | 2 | D60045 | Alzheimer's diseas |
| 7 | 24 | 100.0 | 57 | 2 | E60045 | Alzheimer's diseas |
| 8 | 24 | 100.0 | 57 | 2 | G60045 | Alzheimer's diseas |
| 9 | 24 | 100.0 | 57 | 2 | B60045 | Alzheimer's diseas |
| 10 | 24 | 100.0 | 57 | 2 | B89981 | truncated transpos |
| 11 | 24 | 100.0 | 82 | 2 | PQ0438 | Alzheimer's diseas |
| 12 | 24 | 100.0 | 84 | 2 | G96025 | hypothetical prote |
| 13 | 24 | 100.0 | 89 | 2 | C82331 | hypothetical prote |
| 14 | 24 | 100.0 | 91 | 2 | T16095 | hypothetical prote |
| 15 | 24 | 100.0 | 94 | 2 | B86195 | hypothetical prote |
| 16 | 24 | 100.0 | 97 | 1 | RCBP22 | abc2 protein - pha |
| 17 | 24 | 100.0 | 97 | 2 | H84901 | hypothetical prote |
| 18 | 24 | 100.0 | 106 | 2 | G72059 | conserved hypothet |
| 19 | 24 | 100.0 | 106 | 2 | D86563 | CT466 hypothetical |
| 20 | 24 | 100.0 | 116 | 2 | B89964 | truncated transpos |
| 21 | 24 | 100.0 | 123 | 2 | G95878 | probable TRm2011-2 |
| 22 | 24 | 100.0 | 132 | 2 | JQ0737 | RnpA protein - Mic |
| 23 | 24 | 100.0 | 133 | 2 | AH2580 | PTS system, IIA co |
| 24 | 24 | 100.0 | 133 | 2 | F97362 | PTS enzyme IIAB, m |
| 25 | 24 | 100.0 | 134 | 2 | B86720 | conserved hypothet |
| 26 | 24 | 100.0 | 136 | 2 | B56338 | phospholipase A2 ( |
| 27 | 24 | 100.0 | 136 | 2 | A87681 | conserved hypothet |
| 28 | 24 | 100.0 | 139 | 1 | F64502 | hypothetical prote |
| 29 | 24 | 100.0 | 141 | 2 | A99796 | hypothetical prote |
| 30 | 24 | 100.0 | 141 | 2 | G85662 | unknown protein pr |
| 31 | 24 | 100.0 | 141 | 2 | D85605 | unknown in ISEc8 [ |
| 32 | 24 | 100.0 | 141 | 2 | A99803 | hypothetical prote |
| 33 | 24 | 100.0 | 141 | 2 | E85611 | unknown protein in |
| 34 | 24 | 100.0 | 143 | 2 | F75475 | 3-dehydroquinate d |
| 35 | 24 | 100.0 | 145 | 2 | AD2740 | 3-dehydroquinate d |
| 36 | 24 | 100.0 | 148 | 2 | B69960 | 3-dehydroquinate d |
| 37 | 24 | 100.0 | 152 | 2 | D75367 | hypothetical prote |
| 38 | 24 | 100.0 | 155 | 2 | AC1187 | B. subtilis YdcK p |
| 39 | 24 | 100.0 | 155 | 2 | AB1545 | B. subtilis YdcK p |
| 40 | 24 | 100.0 | 156 | 2 | T02166 | cysteine proteinas |
| 41 | 24 | 100.0 | 162 | 2 | B97521 | 3-dehydroquinate d |
| 42 | 24 | 100.0 | 166 | 2 | A28127 | myosin light chain |
| 43 | 24 | 100.0 | 167 | 2 | T34963 | hypothetical prote |
| 44 | 24 | 100.0 | 176 | 2 | H72201 | conserved hypothet |
| 45 | 24 | 100.0 | 176 | 2 | D95322 | hypothetical prote |

ALIGNMENTS

```
RESULT 1
A48544
neuropeptide F - brown garden snail
C;Species: Helix aspersa (brown garden snail)
C;Date: 19-Nov-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C;Accession: A48544
R;Leung, P.S.; Shaw, C.; Maule, A.G.; Thim, L.; Johnston, C.F.; Irvine, G.B.
Regul. Pept. 41, 71-81, 1992
A;Title: The primary structure of neuropeptide F (NPF) from the garden snail, Helix asp
A;Reference number: A48544; MUID:93087780; PMID:1472263
A;Accession: A48544
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-39 <LEU>
A;Cross-references: UNIPROT:P41321
A;Experimental source: circumesophageal ganglia
A;Note: sequence extracted from NCBI backbone (NCBIP:120485)

Query Match        100.0%;   Score 24;  DB 2;  Length 39;
Best Local Similarity 100.0%;   Pred. No. 22;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy    1 EFRH 4
        ||||
Db   13 EFRH 16


RESULT 2
PN0512
beta-amyloid protein - guinea pig (fragment)
C;Species: Cavia porcellus (guinea pig)
C;Date: 31-Dec-1993 #sequence_revision 31-Dec-1993 #text_change 09-Jul-2004
C;Accession: PN0512
R;Shimohigashi, Y.; Matsumoto, H.; Takano, Y.; Saito, R.; Iwata, T.; Kamiya, H.; Ohno, :
Biochem. Biophys. Res. Commun. 193, 624-630, 1993
A;Title: Receptor-mediated specific biological activity of a beta-amyloid protein fragm
A;Reference number: PN0512; MUID:93290653; PMID:7685598
A;Accession: PN0512
A;Molecule type: protein
A;Residues: 1-42 <SHI>
A;Cross-references: UNIPROT:Q7M088
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase
C;Keywords: alternative splicing; amyloid

Query Match        100.0%;   Score 24;  DB 2;  Length 42;
Best Local Similarity 100.0%;   Pred. No. 24;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy   1 EFRH 4
       ||||
Db   3 EFRH 6
```

RESULT 3
C91112
hypothetical protein ECs3867 [imported] - Escherichia coli (strain O157:H7, substrain RI
C;Species: Escherichia coli
C;Date: 18-Jul-2001 #sequence_revision 09-Jul-2004
C;Accession: C91112
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-52 <HAY>
A;Cross-references: UNIPROT:Q8X2N9; GB:BA000007; PIDN:BAB37290.1; PID:g13363339; GSPDB:G
A;Experimental source: strain O157:H7, substrain RIMD 0509952
C;Genetics:
A;Gene: ECs3867

Query Match             100.0%;  Score 24;  DB 2;  Length 52;
Best Local Similarity   100.0%;  Pred. No. 29;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db         24 EFRH 27

RESULT 4
A60045
Alzheimer's disease amyloid beta/A4 protein precursor - dog (fragment)
C;Species: Canis lupus familiaris (dog)
C;Date: 01-Dec-1992 #sequence_revision 28-Jul-1995
C;Accession: A60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: A60045
A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: EMBL:X56125
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match             100.0%;  Score 24;  DB 2;  Length 57;
Best Local Similarity   100.0%;  Pred. No. 32;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          8 EFRH 11

RESULT 5
F60045
Alzheimer's disease amyloid beta/A4 protein precursor - pig (fragment)
C;Species: Sus scrofa domestica (domestic pig)
C;Date: 01-Dec-1992 #sequence_revision 13-Aug-1999
C;Accession: F60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: F60045
A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: EMBL:X56127; NID:g1895; PIDN:CAA39592.1; PID:g1896
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match             100.0%;  Score 24;  DB 2;  Length 57;
Best Local Similarity   100.0%;  Pred. No. 32;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          8 EFRH 11

RESULT 6
D60045
Alzheimer's disease amyloid beta/A4 protein precursor - bovine (fragment)
C;Species: Bos primigenius taurus (cattle)
C;Date: 01-Dec-1992 #sequence_revision 28-Jul-1995
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: D60045
A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: EMBL:X56124
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match             100.0%;  Score 24;  DB 2;  Length 57;
Best Local Similarity   100.0%;  Pred. No. 32;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          8 EFRH 11

RESULT 7
E60045
Alzheimer's disease amyloid beta/A4 protein precursor - sheep (fragment)
C;Species: Ovis sp. (sheep)
C;Date: 01-Dec-1992 #sequence_revision 28-Jul-1995
C;Accession: E60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: E60045
A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: EMBL:X56130
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match             100.0%;  Score 24;  DB 2;  Length 57;
Best Local Similarity   100.0%;  Pred. No. 32;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          8 EFRH 11

RESULT 8
G60045
Alzheimer's disease amyloid beta/A4 protein precursor - guinea pig (fragment)
C;Species: Cavia porcellus (guinea pig)
C;Date: 01-Dec-1992 #sequence_revision 28-Jul-1995
C;Accession: G60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: G60045
A;Molecule type: mRNA

A;Residues: 1-57 <JOH>
A;Cross-references: EMBL:X56126
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match       100.0%; Score 24; DB 2; Length 57;
Best Local Similarity  100.0%; Pred. No. 32;
Matches    4; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy    1 EFRH 4
        ||||
Db    8 EFRH 11
```

RESULT 9
B60045
Alzheimer's disease amyloid beta/A4 protein precursor - polar bear (fragment)
C;Species: Ursus maritimus (polar bear)
C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 09-Jul-2004
R;Accession: B60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: B60045
A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: UNIPROT:Q29149; EMBL:X56128; NID:g2165; PIDN:CAA39593.1; PID:g2166
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match       100.0%; Score 24; DB 2; Length 57;
Best Local Similarity  100.0%; Pred. No. 32;
Matches    4; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy    1 EFRH 4
        ||||
Db    8 EFRH 11
```

RESULT 10
B89981
truncated transposase [imported] - Staphylococcus aureus (strain N315)
C;Species: Staphylococcus aureus
C;Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 09-Jul-2004
C;Accession: B89981
R;Kuroda, M.; Ohta, T.; Uchiyama, I.; Baba, T.; Yuzawa, H.; Kobayashi, I.; Cui, L.; Oguc
ma, A.; Mizutani-Ui, Y.; Kobayashi, N.; Sawano, T.; Inoue, R.; Kaito, C.; Sekimizu, K.;
C.; Shiba, T.; Hattori, M.; Ogasawara, N.; Hayashi, H.; Hiramatsu, K.
Lancet 357, 1225-1240, 2001
A;Title: Whole genome sequencing of meticillin-resistant Staphylococcus aureus.
A;Reference number: A89758; MUID:21311952; PMID:11418146
A;Accession: B89981
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-57 <KUR>
A;Cross-references: UNIPROT:Q99SW5; GB:BA000018; PID:g13701716; PIDN:BAB43009.1; GSPDB:C
A;Experimental source: strain N315
C;Genetics:
A;Gene: truncated-tnp

Query Match       100.0%; Score 24; DB 2; Length 57;
Best Local Similarity  100.0%; Pred. No. 32;
Matches    4; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy    1 EFRH 4
        ||||
Db   30 EFRH 33
```

RESULT 11
PQ0438
Alzheimer's disease amyloid A4 protein precursor - rabbit (fragment)

C;Species: Oryctolagus cuniculus (domestic rabbit)
C;Date: 30-Sep-1993 #sequence_revision 19-Oct-1995 #text_change 19-Oct-1995
C;Accession: PQ0438; C60045
R;Davidson, J.S.; West, R.L.; Kotikalapudi, P.; Maroun, L.E.
Biochem. Biophys. Res. Commun. 188, 905-911, 1992
A;Title: Sequence and methylation in the beta/A4 region of the rabbit amyloid precursor
A;Reference number: PQ0438; MUID:93075180; PMID:1445331
A;Accession: PQ0438
A;Molecule type: DNA
A;Residues: 1-82 <DAV>
A;Cross-references: GB:M83558; GB:M83657
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog,
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: C60045
A;Molecule type: mRNA
A;Residues: 12-68 <JOH>
A;Cross-references: EMBL:X56129
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase i
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; Down's syndrome

Query Match       100.0%; Score 24; DB 2; Length 82;
Best Local Similarity  100.0%; Pred. No. 48;
Matches    4; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy    1 EFRH 4
        ||||
Db   19 EFRH 22
```

RESULT 12
G96025
hypothetical protein Smb20779 [imported] - Sinorhizobium meliloti (strain 1021) magaplas
C;Species: Sinorhizobium meliloti
C;Date: 24-Aug-2001 #sequence_revision 24-Aug-2001 #text_change 09-Jul-2004
A;Accession: G96025
R;Finan, T.M.; Weidner, S.; Wong, K.; Buhrmester, J.; Chain, P.; Vorholter, F.J.; Hernan
Proc. Natl. Acad. Sci. U.S.A. 98, 9889-9894, 2001
A;Title: The complete sequence of the 1,683-kb pSymB megaplasmid from the N2-fixing endo
A;Reference number: A95842; MUID:21396508; PMID:11481431
A;Accession: G96025
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-84 <KUR>
A;Cross-references: UNIPROT:Q92TN7; GB:AL591985; PIDN:CAC49871.1; PID:g15141359; GSPDB:G
A;Experimental source: strain 1021, megaplasmid pSymB
R;Galibert, F.; Finan, T.M.; Long, S.R.; Puhler, A.; Abola, P.; Ampe, F.; Barloy-Hubler,
pela, D.; Chain, P.; Cowie, A.; Davis, R.W.; Dreano, S.; Federspiel, N.A.; Fisher, R.F.
L.; Hyman, R.W.; Jones, T.
Science 293, 668-672, 2001
A;Authors: Kahn, D.; Kahn, M.L.; Kalman, S.; Keating, D.H.; Kiss, E.; Komp, C.; Lelaure,
hebault, P.; Vandenbol, M.; Vorholter, F.J.; Weidner, S.; Wells, D.H.; Wong, K.; Yeh, K.
A;Title: The composite genome of the legume symbiont Sinorhizobium meliloti.
A;Reference number: A96039; MUID:21368234; PMID:11474104
A;Contents: annotation
C;Genetics:
A;Gene: Smb20779
A;Genome: plasmid

Query Match       100.0%; Score 24; DB 2; Length 84;
Best Local Similarity  100.0%; Pred. No. 49;
Matches    4; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy    1 EFRH 4
        ||||
Db   15 EFRH 18
```

RESULT 13
C82331
hypothetical protein VC0383 [imported] - Vibrio cholerae (strain N16961 serogroup O1)
C;Species: Vibrio cholerae

C;Date: 18-Aug-2000 #sequence_revision 20-Aug-2000 #text_change 09-Jul-2004
C;Accession: C82331
R;Heidelberg, J.F.; Eisen, J.A.; Nelson, W.C.; Clayton, R.A.; Gwinn, M.L.; Dodson, R.J.;
chardson, D.; Ermolaeva, M.D.; Vamathevan, J.; Bass, S.; Qin, H.; Dragoi, I.; Sellers, E
l, R.R.; Mekalanos, J.J.; Venter, J.C.; Fraser, C.M.
Nature 406, 477-483, 2000
A;Title: DNA Sequence of both chromosomes of the cholera pathogen Vibrio cholerae.
A;Reference number: A82035; MUID:20406833; PMID:10952301
A;Accession: C82331
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-89 <HEI>
A;Cross-references: UNIPROT:Q9KUX5; GB:AE004126; GB:AE003852; NID:g9654802; PIDN:AAF9355
A;Experimental source: serogroup O1; strain N16961; biotype El Tor
C;Genetics:
C;Gene: VC0383
A;Map position: 1

Query Match          100.0%;  Score 24;  DB 2;  Length 89;
Best Local Similarity 100.0%;  Pred. No. 52;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 EFRH 4
          ||||
Db     45 EFRH 48


RESULT 14
T16095
hypothetical protein F18E9.6 - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 09-Jul-2004
C;Accession: T16095
R;Leimbach, D.
submitted to the EMBL Data Library, June 1995
A;Description: The sequence of C. elegans cosmid F18E9.
A;Reference number: Z18460
A;Accession: T16095
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-91 <LEI>
A;Cross-references: UNIPROT:Q19566; EMBL:U29614; NID:g868285; PID:g868290; PIDN:AAA68811
A;Experimental source: strain Bristol N2
C;Genetics:
A;Gene: CESP:F18E9.6

Query Match          100.0%;  Score 24;  DB 2;  Length 91;
Best Local Similarity 100.0%;  Pred. No. 53;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 EFRH 4
          ||||
Db     86 EFRH 89


RESULT 15
B86195
hypothetical protein [imported] - Arabidopsis thaliana
C;Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 09-Jul-2004
C;Accession: B86195
R;Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso,
Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.;
ansen, N.F.; Hughes, B.; Huizar, L.
Nature 408, 816-820, 2000
A;Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.
C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marziali,
Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.
A;Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon,
ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.
A;Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.
A;Reference number: A86141; MUID:21016719; PMID:11130712
A;Accession: B86195

---

A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-94 <STO>
A;Cross-references: UNIPROT:Q9LNE5; GB:AE005172; NID:g8810463; PIDN:AAF80124.1; GSPDB:GN
C;Genetics:
A;Map position: 1

Query Match          100.0%;  Score 24;  DB 2;  Length 94;
Best Local Similarity 100.0%;  Pred. No. 55;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 EFRH 4
          ||||
Db     31 EFRH 34


Search completed: November  2, 2005, 09:31:39
Job time : 41 secs

```
                    Copyright   GenCore version 5.1.6
                              (c) 1993 - 2005  Compugen Ltd.

OM protein - protein search, using sw model

Run on:   November  2, 2005, 09:04:29 ; Search time 177 Seconds
                                        (without alignments)
                                11.572 Million cell updates/sec

Title:         US-10-618-856-1
Perfect score: 24
Sequence:      1 EFRH 4

Scoring table: BLOSUM62
               Gapop 10.0 , Gapext 0.5

Searched:      1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters:      1612378

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :     UniProt_03:*
               1: uniprot_sprot:*
               2: uniprot_trembl:*

        Pred. No. is the number of results predicted by chance to have a
        score greater than or equal to the score of the result being printed,
        and is derived by analysis of the total score distribution.

                            SUMMARIES
```

| Result No. | Score | % Query Match | Length | DB | ID | Description |
|---|---|---|---|---|---|---|
| 1 | 24 | 100.0 | 25 | 2 | Q7R843 | Q7r843 plasmodium |
| 2 | 24 | 100.0 | 33 | 2 | Q9UC33 | Q9uc33 homo sapien |
| 3 | 24 | 100.0 | 38 | 2 | Q8CM52 | Q8cm52 staphylococc |
| 4 | 24 | 100.0 | 38 | 2 | Q8CN66 | Q8cn66 staphylococc |
| 5 | 24 | 100.0 | 38 | 2 | Q8CNR0 | Q8cnr0 staphylococc |
| 6 | 24 | 100.0 | 38 | 2 | Q8CNT8 | Q8cnt8 staphylococc |
| 7 | 24 | 100.0 | 38 | 2 | Q8CP00 | Q8cp00 staphylococc |
| 8 | 24 | 100.0 | 38 | 2 | Q8CPT7 | Q8cpt7 staphylococc |
| 9 | 24 | 100.0 | 38 | 2 | Q8CPX2 | Q8cpx2 staphylococc |
| 10 | 24 | 100.0 | 39 | 1 | NPF_HELAS | P41321 helix asper |
| 11 | 24 | 100.0 | 42 | 2 | Q7M088 | Q7m088 cavia porce |
| 12 | 24 | 100.0 | 43 | 2 | Q7UT20 | Q7ut20 rhodopirell |
| 13 | 24 | 100.0 | 45 | 2 | Q6V7T6 | Q6v7t6 burkholderi |
| 14 | 24 | 100.0 | 45 | 2 | Q8CQ63 | Q8cq63 staphylococc |
| 15 | 24 | 100.0 | 48 | 2 | Q8CN63 | Q8cn63 staphylococc |
| 16 | 24 | 100.0 | 52 | 2 | Q8WZ99 | Q8wz99 homo sapien |
| 17 | 24 | 100.0 | 52 | 2 | Q8X2N9 | Q8x2n9 escherichia |
| 18 | 24 | 100.0 | 54 | 2 | Q64RK3 | Q64rk3 bacteroides |
| 19 | 24 | 100.0 | 55 | 2 | Q7UGM8 | Q7ugm8 rhodopirell |
| 20 | 24 | 100.0 | 57 | 1 | A4_URSMA | Q29149 ursus marit |
| 21 | 24 | 100.0 | 57 | 2 | Q99SW5 | Q99sw5 staphylococc |
| 22 | 24 | 100.0 | 57 | 2 | Q8DGN4 | Q8dgn4 synechococc |
| 23 | 24 | 100.0 | 58 | 1 | A4_CANFA | Q28280 canis famil |
| 24 | 24 | 100.0 | 58 | 1 | A4_RABIT | Q28748 oryctolagus |
| 25 | 24 | 100.0 | 58 | 1 | A4_SHEEP | Q28757 ovis aries |
| 26 | 24 | 100.0 | 59 | 1 | A4_BOVIN | Q28053 bos taurus |
| 27 | 24 | 100.0 | 61 | 2 | Q63YH0 | Q63yh0 burkholderi |
| 28 | 24 | 100.0 | 62 | 2 | Q65802 | Q65802 bovine vira |
| 29 | 24 | 100.0 | 62 | 2 | Q65804 | Q65804 bovine vira |
| 30 | 24 | 100.0 | 62 | 2 | Q65805 | Q65805 bovine vira |
| 31 | 24 | 100.0 | 65 | 2 | Q6IIT6 | Q6iit6 drosophila |
| 32 | 24 | 100.0 | 67 | 2 | Q98LA2 | Q98la2 rhizobium l |
| 33 | 24 | 100.0 | 68 | 2 | O14885 | O14885 homo sapien |
| 34 | 24 | 100.0 | 69 | 2 | Q98MZ4 | Q98mz4 rhizobium l |
| 35 | 24 | 100.0 | 73 | 2 | Q8GX82 | Q8gx82 arabidopsis |
| 36 | 24 | 100.0 | 76 | 2 | Q87189 | Q87189 vibrio para |
| 37 | 24 | 100.0 | 77 | 2 | Q8DCK3 | Q8dck3 vibrio vuln |
| 38 | 24 | 100.0 | 80 | 2 | Q6LM57 | Q6lm57 photobacter |
| 39 | 24 | 100.0 | 80 | 2 | Q8GR41 | Q8gr41 enterococcu |
| 40 | 24 | 100.0 | 84 | 2 | Q7TCW4 | Q7tcw4 untyped hum |
| 41 | 24 | 100.0 | 88 | 2 | Q92TN7 | Q92tn7 rhizobium m |
| 42 | 24 | 100.0 | 88 | 2 | Q7MHA4 | Q7mha4 vibrio vuln |
| 43 | 24 | 100.0 | 89 | 2 | Q9KUX5 | Q9kux5 vibrio chol |
| 44 | 24 | 100.0 | 90 | 2 | Q8VZU1 | Q8vzu1 arabidopsis |
| 45 | 24 | 100.0 | 90 | 2 | Q8CMD7 | Q8cmd7 staphylococc |

```
                                ALIGNMENTS

RESULT 1
Q7R843
ID   Q7R843          PRELIMINARY;       PRT;       25 AA.
AC   Q7R843;
DT   01-MAR-2004 (TrEMBLrel. 26, Created)
DT   01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE   Hypothetical protein (Fragment).
GN   Name=PY07380;
OS   Plasmodium yoelii yoelii.
OC   Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX   NCBI_TaxID=73239;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=17XNL;
RX   PubMed=12368865; DOI=10.1038/nature01099;
RA   Carlton J.M., Angiuoli S.V., Suh B.B., Kooij T.W., Pertea M.,
RA   Salzberg S.L., Venter J.C., Fraser C.M., Hoffman S.L., Gardner M.J.,
RA   Carucci D.J.;
RA   Silva J.C., Ermolaeva M.D., Allen J.E., Selengut J.D., Koo H.L.,
RA   Peterson J.D., Pop M., Kosack D.S., Shumway M.F., Bidwell S.L.,
RA   Shallom S.J., van Aken S.E., Riedmuller S.B., Feldblyum T.V.,
RA   Cho J.K., Quackenbush J., Sedegah M., Shoaibi A., Cummings L.M.,
RA   Florens L., Yates F.R. III, Raine J.D., Sinden R.E., Harris M.A.,
RA   Cunningham D.A., Preiser P.R., Bergman L.W., Vaidya A.B.,
RA   van Lin L.H., Janse C.J., Waters A.P., Smith H.O. White O.R.,
RT   "Genome sequence and comparative analysis of the model rodent malaria
RT   parasite Plasmodium yoelii yoelii.";
RL   Nature 419:512-519(2002).
CC   -!- CAUTION: The sequence shown here is derived from an
CC       EMBL/GenBank/DDBJ whole genome shotgun (WGS) entry which is
CC       preliminary data.
DR   EMBL; AABL01002689; EAA19793.1; -.
KW   Hypothetical protein.
FT   NON_TER       1       1
SQ   SEQUENCE   25 AA;   3303 MW;  1A5AB86BD78F4422 CRC64;

        Query Match             100.0%;  Score 24; DB 2; Length 25;
        Best Local Similarity   100.0%;  Pred. No. 99;
        Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db         10 EFRH 13

RESULT 2
Q9UC33
ID   Q9UC33          PRELIMINARY;       PRT;       33 AA.
AC   Q9UC33;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE   Beta-amyloid peptide (Fragment).
```

OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   SEQUENCE
RX   MEDLINE=93024877; PubMed=1406936; DOI=10.1038/359325a0;
RA   Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D.,
RA   Sinha S., Schlossmacher M., Whaley J., Swindlehurst C.;
RT   "Isolation and quantification of soluble Alzheimer's beta-peptide from
RT   biological fluids.";
RL   Nature 359:325-327(1992).
DR   HSSP; Q16019; 1BA4.
DR   GO; GO:0016021; C:integral to membrane; IEA.
DR   GO; GO:0005488; F:binding; IEA.
DR   InterPro; IPR001255; Beta-APP.
DR   Pfam; PF03494; Beta-APP; 1.
DR   PRINTS; PR00204; BETAAMYLOID.
SQ   SEQUENCE   33 AA;   3674 MW;  B1DEFE2F4167ABD0 CRC64;

Query Match             100.0%;  Score 24;  DB 2; Length 33;
Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db          3 EFRH 6

RESULT 3
Q8CM52
ID   Q8CM52            PRELIMINARY;      PRT;    38 AA.
AC   Q8CM52;
DT   01-MAR-2003 (TrEMBLrel. 23, Created)
DT   01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT   01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE   Truncated transposase.
GN   OrderedLocusNames=SE0257;
OS   Staphylococcus epidermidis.
OC   Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX   NCBI_TaxID=1282;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=ATCC 12228;
RX   PubMed=12950922;
RA   Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA   Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA   Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT   "Genome-based analysis of virulence genes in a non-biofilm-forming
RT   Staphylococcus epidermidis strain (ATCC 12228).";
RL   Mol. Microbiol. 49:1577-1593(2003).
DR   EMBL; AE016744; AAO03854.1; -.
KW   Complete proteome.
SQ   SEQUENCE   38 AA;   4448 MW;  A40B39C53421AD0E CRC64;

Query Match             100.0%;  Score 24;  DB 2; Length 38;
Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db         30 EFRH 33

RESULT 4
Q8CN66
ID   Q8CN66            PRELIMINARY;      PRT;    38 AA.
AC   Q8CN66;
DT   01-MAR-2003 (TrEMBLrel. 23, Created)
DT   01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT   01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE   Truncated transposase.
GN   OrderedLocusNames=SE1982;

OS   Staphylococcus epidermidis.
OC   Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX   NCBI_TaxID=1282;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=ATCC 12228;
RX   PubMed=12950922;
RA   Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA   Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA   Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT   "Genome-based analysis of virulence genes in a non-biofilm-forming
RT   Staphylococcus epidermidis strain (ATCC 12228).";
RL   Mol. Microbiol. 49:1577-1593(2003).
DR   EMBL; AE016750; AAO05623.1; -.
KW   Complete proteome.
SQ   SEQUENCE   38 AA;   4458 MW;  8BDB217272BB9946 CRC64;

Query Match             100.0%;  Score 24;  DB 2; Length 38;
Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db         30 EFRH 33

RESULT 5
Q8CNR0
ID   Q8CNR0            PRELIMINARY;      PRT;    38 AA.
AC   Q8CNR0;
DT   01-MAR-2003 (TrEMBLrel. 23, Created)
DT   01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT   01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE   Truncated transposase.
GN   OrderedLocusNames=SE1539;
OS   Staphylococcus epidermidis.
OC   Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX   NCBI_TaxID=1282;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=ATCC 12228;
RX   PubMed=12950922;
RA   Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA   Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA   Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT   "Genome-based analysis of virulence genes in a non-biofilm-forming
RT   Staphylococcus epidermidis strain (ATCC 12228).";
RL   Mol. Microbiol. 49:1577-1593(2003).
DR   EMBL; AE016749; AAO05138.1; -.
KW   Complete proteome.
SQ   SEQUENCE   38 AA;   4434 MW;  A415C7SC6E85FC4B CRC64;

Query Match             100.0%;  Score 24;  DB 2; Length 38;
Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
              ||||
Db         30 EFRH 33

RESULT 6
Q8CNT8
ID   Q8CNT8            PRELIMINARY;      PRT;    38 AA.
AC   Q8CNT8;
DT   01-MAR-2003 (TrEMBLrel. 23, Created)
DT   01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT   01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE   Truncated transposase.
GN   OrderedLocusNames=SE1454;
OS   Staphylococcus epidermidis.
OC   Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX   NCBI_TaxID=1282;

RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=ATCC 12228;
RX   PubMed=12950922;
RA   Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA   Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA   Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT   "Genome-based analysis of virulence genes in a non-biofilm-forming
RT   Staphylococcus epidermidis strain (ATCC 12228).";
RL   Mol. Microbiol. 49:1577-1593(2003).
DR   EMBL; AE016748; AAO05053.1; -.
KW   Complete proteome.
SQ   SEQUENCE   38 AA;   4404 MW;   FE0B21726435EC91 CRC64;

Query Match             100.0%;  Score 24;  DB 2;  Length 38;
Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db     30 EFRH 33

RESULT 7
Q8CP00
ID   Q8CP00          PRELIMINARY;      PRT;    38 AA.
AC   Q8CP00;
DT   01-MAR-2003 (TrEMBLrel. 23, Created)
DT   01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT   01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE   Truncated transposase.
GN   OrderedLocusNames=SE1319;
OS   Staphylococcus epidermidis.
OC   Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX   NCBI_TaxID=1282;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=ATCC 12228;
RX   PubMed=12950922;
RA   Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA   Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA   Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT   "Genome-based analysis of virulence genes in a non-biofilm-forming
RT   Staphylococcus epidermidis strain (ATCC 12228).";
RL   Mol. Microbiol. 49:1577-1593(2003).
DR   EMBL; AE016748; AAO04918.1; -.
KW   Complete proteome.
SQ   SEQUENCE   38 AA;   4495 MW;   B1D109D5DC4F3B0E CRC64;

Query Match             100.0%;  Score 24;  DB 2;  Length 38;
Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db     30 EFRH 33

RESULT 8
Q8CPT7
ID   Q8CPT7          PRELIMINARY;      PRT;    38 AA.
AC   Q8CPT7;
DT   01-MAR-2003 (TrEMBLrel. 23, Created)
DT   01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT   01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE   Truncated transposase.
GN   OrderedLocusNames=SE0668;
OS   Staphylococcus epidermidis.
OC   Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX   NCBI_TaxID=1282;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=ATCC 12228;

RX   PubMed=12950922;
RA   Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA   Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA   Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT   "Genome-based analysis of virulence genes in a non-biofilm-forming
RT   Staphylococcus epidermidis strain (ATCC 12228).";
RL   Mol. Microbiol. 49:1577-1593(2003).
DR   EMBL; AE016746; AAO04265.1; -.
KW   Complete proteome.
SQ   SEQUENCE   38 AA;   4534 MW;   A40B3F052B90E80E CRC64;

Query Match             100.0%;  Score 24;  DB 2;  Length 38;
Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db     30 EFRH 33

RESULT 9
Q8CPX2
ID   Q8CPX2          PRELIMINARY;      PRT;    38 AA.
AC   Q8CPX2;
DT   01-MAR-2003 (TrEMBLrel. 23, Created)
DT   01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Truncated transposase.
GN   OrderedLocusNames=SE0590;
OS   Staphylococcus epidermidis.
OC   Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX   NCBI_TaxID=1282;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=ATCC 12228;
RX   PubMed=12950922;
RA   Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA   Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA   Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT   "Genome-based analysis of virulence genes in a non-biofilm-forming
RT   Staphylococcus epidermidis strain (ATCC 12228).";
RL   Mol. Microbiol. 49:1577-1593(2003).
DR   EMBL; AE016745; AAO04187.1; -.
KW   Complete proteome.
SQ   SEQUENCE   38 AA;   4395 MW;   A40B39DF8421AD0E CRC64;

Query Match             100.0%;  Score 24;  DB 2;  Length 38;
Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 EFRH 4
          ||||
Db     30 EFRH 33

RESULT 10
NPF_HELAS
ID   NPF_HELAS       STANDARD;         PRT;    39 AA.
AC   P41321;
DT   01-FEB-1995 (Rel. 31, Created)
DT   01-FEB-1995 (Rel. 31, Last sequence update)
DT   05-JUL-2004 (Rel. 44, Last annotation update)
DE   Neuropeptide F (NPF).
OS   Helix aspersa (Brown garden snail).
OC   Eukaryota; Metazoa; Mollusca; Gastropoda; Pulmonata; Stylommatophora;
OC   Sigmurethra; Helicoidea; Helicidae; Helix.
OX   NCBI_TaxID=6535;
RN   [1]
RP   SEQUENCE.
RC   TISSUE=Circumoesophageal ganglion;
RX   MEDLINE=93087780; PubMed=1472263; DOI=10.1016/0167-0115(92)90515-V;
RA   Leung P.S., Shaw C., Maule A.G., Thim L., Johnston C.F., Irvine G.B.;
RT   "The primary structure of neuropeptide F (NPF) from the garden snail,

```
RT   Helix aspersa.";
RL   Regul. Pept. 41:71-81(1992).
CC   -!- FUNCTION: May have an important physiological role in
CC       neuroregulation.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Neuronal somata and fibers.
CC   -!- SIMILARITY: Belongs to the NPY family.
DR   PIR; A48544; A48544.
DR   HSSP; P41967; 1K8V.
DR   InterPro; IPR001955; Pancreatic_hormn.
DR   Pfam; PF00159; Hormone_3; 1.
DR   PROSITE; PS00265; PANCREATIC_HORMONE_1; 1.
DR   PROSITE; PS50276; PANCREATIC_HORMONE_2; 1.
KW   Amidation; Direct protein sequencing; Neuropeptide.
FT   MOD_RES      39     39       Phenylalanine amide.
SQ   SEQUENCE   39 AA;   4855 MW;  4B54AA7414CAAE33 CRC64;

Query Match             100.0%;  Score 24;  DB 1;  Length 39;
Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            ||||
Db       13 EFRH 16

RESULT 11
Q7M088
ID   Q7M088         PRELIMINARY;     PRT;    42 AA.
AC   Q7M088;
DT   01-MAR-2004 (TrEMBLrel. 26, Created)
DT   01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE   Beta-amyloid protein (Fragment).
OS   Cavia porcellus (Guinea pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Rodentia; Hystricognathi; Caviidae; Cavia.
OX   NCBI_TaxID=10141;
RN   [1]
RP   SEQUENCE.
RX   MEDLINE=93290653; PubMed=7685598;
RA   Shimohigashi Y., Matsumoto H., Takano Y., Saito R., Iwata T.,
RA   Kamiya H., Ohno M.;
RT   "Receptor-mediated specific biological activity of a beta-amyloid
RT   protein fragment for NK-1 substance p receptors.";
RL   Biochem. Biophys. Res. Commun. 193:624-630(1993).
DR   PIR; PN0512; PN0512.
DR   HSSP; Q16019; 1IYT.
DR   GO; GO:0016021; C:integral to membrane; IEA.
DR   GO; GO:0005488; F:binding; IEA.
DR   InterPro; IPR001255; Beta-APP.
DR   Pfam; PF03494; Beta-APP; 1.
DR   PRINTS; PR00204; BETAAMYLOID.
FT   NON_TER       1      1
FT   NON_TER      42     42
SQ   SEQUENCE   42 AA;   4514 MW;  3AC85563D7858C37 CRC64;

Query Match             100.0%;  Score 24;  DB 2;  Length 42;
Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            ||||
Db        3 EFRH 6

RESULT 12
Q7UT20
ID   Q7UT20         PRELIMINARY;     PRT;    43 AA.
AC   Q7UT20;
DT   01-OCT-2003 (TrEMBLrel. 25, Created)
DT   01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
```

```
DE   Hypothetical protein.
GN   OrderedLocusNames=RB4166;
OS   Rhodopirellula baltica.
OC   Bacteria; Planctomycetes; Planctomycetacia; Planctomycetales;
OC   Planctomycetaceae; Pirellula.
OX   NCBI_TaxID=117;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=1;
RX   MEDLINE=22735913; PubMed=12835416; DOI=10.1073/pnas.1431443100;
RA   Gloeckner F.O., Kube M., Bauer M., Teeling H., Lombardot T.,
RA   Ludwig W., Gade D., Beck A., Borzym K., Heitmann K., Rabus R.,
RA   Schlesner H., Amann R., Reinhardt R.;
RT   "Complete genome sequence of the marine planctomycete Pirellula sp.
RT   strain 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:8298-8303(2003).
DR   EMBL; BX294140; CAD73621.1; -.
KW   Complete proteome; Hypothetical protein.
SQ   SEQUENCE   43 AA;   5428 MW;  3106E49E67D19882 CRC64;

Query Match             100.0%;  Score 24;  DB 2;  Length 43;
Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            ||||
Db       19 EFRH 22

RESULT 13
Q6V7T6
ID   Q6V7T6         PRELIMINARY;     PRT;    45 AA.
AC   Q6V7T6;
DT   05-JUL-2004 (TrEMBLrel. 27, Created)
DT   05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT   05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE   Gp6.
OS   Burkholderia cepacia phage Bcep22.
OC   Viruses; dsDNA viruses, no RNA stage; Caudovirales; Podoviridae.
OX   NCBI_TaxID=242527;
RN   [1]
RP   SEQUENCE FROM N.A.
RA   Summer E.J., Cordova M., Parkinson B.C., Fuller A.C., Kitsopoulos K.,
RA   Parks B., Rambo L., Rothwell S., Mebane L.M., Carlile T.M., No B.G.,
RA   Gonzalez C.M., Young R.F.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AY349011; AAQ54942.1; -.
SQ   SEQUENCE   45 AA;   5701 MW;  8C2B46B47A94BF9 CRC64;

Query Match             100.0%;  Score 24;  DB 2;  Length 45;
Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        1 EFRH 4
            ||||
Db        7 EFRH 10

RESULT 14
Q8CQ63
ID   Q8CQ63         PRELIMINARY;     PRT;    45 AA.
AC   Q8CQ63;
DT   01-MAR-2003 (TrEMBLrel. 23, Created)
DT   01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT   01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE   Truncated transposase.
GN   OrderedLocusNames=SE0355;
OS   Staphylococcus epidermidis.
OC   Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX   NCBI_TaxID=1282;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=ATCC 12228;
```

```
RX   PubMed=12950922;
RA   Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA   Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA   Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT   "Genome-based analysis of virulence genes in a non-biofilm-forming
RT   Staphylococcus epidermidis strain (ATCC 12228).";
RL   Mol. Microbiol. 49:1577-1593(2003).
DR   EMBL; AE016745; AAO03952.1; -.
KW   Complete proteome.
SQ   SEQUENCE   45 AA;   5238 MW;  7E3C1EB6774709DB CRC64;

Query Match             100.0%;  Score 24;  DB 2;  Length 45;
Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
                |||
Db         37 EFRH 40


RESULT 15
Q8CN63
ID   Q8CN63        PRELIMINARY;      PRT;     48 AA.
AC   Q8CN63;
DT   01-MAR-2003 (TrEMBLrel. 23, Created)
DT   01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT   01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE   Truncated transposase.
GN   OrderedLocusNames=SE1990;
OS   Staphylococcus epidermidis.
OC   Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX   NCBI_TaxID=1282;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=ATCC 12228;
RX   PubMed=12950922;
RA   Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA   Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA   Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT   "Genome-based analysis of virulence genes in a non-biofilm-forming
RT   Staphylococcus epidermidis strain (ATCC 12228).";
RL   Mol. Microbiol. 49:1577-1593(2003).
DR   EMBL; AE016750; AAO05631.1; -.
KW   Complete proteome.
SQ   SEQUENCE   48 AA;   5719 MW;  62AF02B5272219C7 CRC64;

Query Match             100.0%;  Score 24;  DB 2;  Length 48;
Best Local Similarity   100.0%;  Pred. No. 1.9e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EFRH 4
                |||
Db         40 EFRH 43


Search completed: November  2, 2005, 09:30:56
Job time : 182 secs
```